{"version": "v2.0", "data": [{"id": "3708949_1_0", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_1_1", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_1_2", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_1_3", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_1_4", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_1_5", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What are the drugs used in the treatment in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_1_6", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the dosage of the treatment in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_1_7", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the frequency of the treatment in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_1_8", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the route of the treatment in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_1_9", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "How long has elapsed from the treatment to the occurence of the event in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_1_10", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "How long did the treatment last in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_1_11", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What is the disorder targeted by the treatment in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_1_12", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "What are the drugs used in combination in parenteral amiodarone (2300 mg in 3 days) and other measures?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_3_13", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_3_14", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_3_15", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_3_16", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_3_17", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_3_18", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What are the drugs used in the treatment in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_3_19", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the dosage of the treatment in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_3_20", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the frequency of the treatment in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_3_21", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the route of the treatment in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_3_22", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "How long has elapsed from the treatment to the occurence of the event in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_3_23", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "How long did the treatment last in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_3_24", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What is the disorder targeted by the treatment in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_3_25", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "What are the drugs used in combination in low dose methotrexate weekly over a 10-month period?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_6_26", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the age of the subject in patients with renal impairment?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1422497_6_27", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the gender of the subject in patients with renal impairment?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1422497_6_28", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the number of subjects in patients with renal impairment?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1422497_6_29", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the race of the subject in patients with renal impairment?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1422497_6_30", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the disorder of the subject in patients with renal impairment?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1422497_6_31", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What are the drugs used in the treatment in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1422497_6_32", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the dosage of the treatment in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_6_33", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the frequency of the treatment in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1422497_6_34", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the route of the treatment in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1422497_6_35", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_6_36", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "How long did the treatment last in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1422497_6_37", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What is the disorder targeted by the treatment in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_6_38", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "What are the drugs used in combination in alum irrigation; monitoring of serum aluminum levels?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10082597_3_39", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the age of the subject in A 44-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_3_40", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the gender of the subject in A 44-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_3_41", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the number of subjects in A 44-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_3_42", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the race of the subject in A 44-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_3_43", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the disorder of the subject in A 44-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_3_44", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What are the drugs used in the treatment in naproxen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_3_45", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the dosage of the treatment in naproxen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_3_46", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the frequency of the treatment in naproxen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_3_47", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the route of the treatment in naproxen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_3_48", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "How long has elapsed from the treatment to the occurence of the event in naproxen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_3_49", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "How long did the treatment last in naproxen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_3_50", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What is the disorder targeted by the treatment in naproxen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_3_51", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "What are the drugs used in combination in naproxen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_1_52", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the age of the subject in a middle-aged man who suffered from chronic sinusitis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_1_53", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the gender of the subject in a middle-aged man who suffered from chronic sinusitis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_1_54", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the number of subjects in a middle-aged man who suffered from chronic sinusitis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_1_55", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the race of the subject in a middle-aged man who suffered from chronic sinusitis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_1_56", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the disorder of the subject in a middle-aged man who suffered from chronic sinusitis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_1_57", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What are the drugs used in the treatment in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_1_58", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the dosage of the treatment in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_1_59", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the frequency of the treatment in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_1_60", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the route of the treatment in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_1_61", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "How long has elapsed from the treatment to the occurence of the event in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_1_62", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "How long did the treatment last in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_1_63", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What is the disorder targeted by the treatment in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_1_64", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "What are the drugs used in combination in pseudoephedrine daily for one year?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_1_65", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the age of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_1_66", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the gender of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_1_67", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the number of subjects in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_1_68", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the race of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_1_69", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the disorder of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_1_70", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_1_71", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_1_72", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_1_73", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_1_74", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_1_75", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_1_76", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_1_77", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_4_78", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the age of the subject in this patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14742791_4_79", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the gender of the subject in this patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14742791_4_80", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the number of subjects in this patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14742791_4_81", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the race of the subject in this patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14742791_4_82", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the disorder of the subject in this patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14742791_4_83", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What are the drugs used in the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_4_84", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the dosage of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_4_85", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the frequency of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_4_86", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the route of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_4_87", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "How long has elapsed from the treatment to the occurence of the event in pantoprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_4_88", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "How long did the treatment last in pantoprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_4_89", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What is the disorder targeted by the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_4_90", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "What are the drugs used in combination in pantoprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_11_91", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the age of the subject in fetus?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8442800_11_92", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the gender of the subject in fetus?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_11_93", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the number of subjects in fetus?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_11_94", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the race of the subject in fetus?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_11_95", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the disorder of the subject in fetus?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_11_96", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What are the drugs used in the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8442800_11_97", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the dosage of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_11_98", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the frequency of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_11_99", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the route of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_11_100", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_11_101", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "How long did the treatment last in disulfiram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_11_102", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What is the disorder targeted by the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_11_103", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "What are the drugs used in combination in disulfiram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_4_104", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the age of the subject in 2-16% of patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_4_105", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the gender of the subject in 2-16% of patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_4_106", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the number of subjects in 2-16% of patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_4_107", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the race of the subject in 2-16% of patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_4_108", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the disorder of the subject in 2-16% of patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_4_109", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_4_110", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_4_111", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_4_112", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_4_113", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_4_114", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_4_115", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_4_116", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_2_117", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What are the drugs used in the treatment in statin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_2_118", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What is the dosage of the treatment in statin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_2_119", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What is the frequency of the treatment in statin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_2_120", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What is the route of the treatment in statin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_2_121", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in statin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_2_122", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "How long did the treatment last in statin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_2_123", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What is the disorder targeted by the treatment in statin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_2_124", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "What are the drugs used in combination in statin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_1_125", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_1_126", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_1_127", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_1_128", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_1_129", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_1_130", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_1_131", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_1_132", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_1_133", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What are the drugs used in the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12166705_1_134", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What is the dosage of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_1_135", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What is the frequency of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_1_136", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What is the route of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_1_137", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_1_138", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "How long did the treatment last in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_1_139", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What is the disorder targeted by the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12166705_1_140", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "What are the drugs used in combination in Mitomycin-C?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_1_141", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What are the drugs used in the treatment in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_1_142", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What is the dosage of the treatment in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_1_143", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What is the frequency of the treatment in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_1_144", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What is the route of the treatment in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_1_145", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "How long has elapsed from the treatment to the occurence of the event in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_1_146", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "How long did the treatment last in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_1_147", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What is the disorder targeted by the treatment in propylthiouracil (PTU)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_1_148", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "What are the drugs used in combination in propylthiouracil (PTU)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_1_149", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_1_150", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_1_151", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_1_152", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_1_153", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_1_154", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What are the drugs used in the treatment in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_1_155", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the dosage of the treatment in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_1_156", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the frequency of the treatment in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_1_157", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the route of the treatment in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_1_158", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_1_159", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "How long did the treatment last in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_1_160", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What is the disorder targeted by the treatment in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_1_161", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "What are the drugs used in combination in chronic diphenylhydantoin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_3_162", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the age of the subject in a patient with systemic lupus erythematosus and tubulointerstitial renal disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3359700_3_163", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the gender of the subject in a patient with systemic lupus erythematosus and tubulointerstitial renal disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3359700_3_164", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the number of subjects in a patient with systemic lupus erythematosus and tubulointerstitial renal disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3359700_3_165", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the race of the subject in a patient with systemic lupus erythematosus and tubulointerstitial renal disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3359700_3_166", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the disorder of the subject in a patient with systemic lupus erythematosus and tubulointerstitial renal disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3359700_3_167", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What are the drugs used in the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_3_168", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the dosage of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_3_169", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the frequency of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_3_170", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the route of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_3_171", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine A?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_3_172", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "How long did the treatment last in cyclosporine A?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_3_173", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What is the disorder targeted by the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_3_174", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "What are the drugs used in combination in cyclosporine A?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_2_175", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What are the drugs used in the treatment in AZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_2_176", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the dosage of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_2_177", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the frequency of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_2_178", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the route of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_2_179", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "How long has elapsed from the treatment to the occurence of the event in AZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_2_180", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "How long did the treatment last in AZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_2_181", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the disorder targeted by the treatment in AZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_2_182", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What are the drugs used in combination in AZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3693034_1_183", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What are the drugs used in the treatment in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3693034_1_184", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What is the dosage of the treatment in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3693034_1_185", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What is the frequency of the treatment in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3693034_1_186", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What is the route of the treatment in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3693034_1_187", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "How long has elapsed from the treatment to the occurence of the event in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3693034_1_188", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "How long did the treatment last in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3693034_1_189", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What is the disorder targeted by the treatment in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3693034_1_190", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "What are the drugs used in combination in 19 days of treatment with 5-fluorocytosine and amphotericin B?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_4_191", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What are the drugs used in the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_4_192", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What is the dosage of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_4_193", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What is the frequency of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_4_194", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What is the route of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_4_195", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "How long has elapsed from the treatment to the occurence of the event in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_4_196", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "How long did the treatment last in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_4_197", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What is the disorder targeted by the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_4_198", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "What are the drugs used in combination in phenylpropanolamine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_1_199", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the age of the subject in A 61-year-old woman with no apparent risk factors for liver injury?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_1_200", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the gender of the subject in A 61-year-old woman with no apparent risk factors for liver injury?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_1_201", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the number of subjects in A 61-year-old woman with no apparent risk factors for liver injury?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_1_202", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the race of the subject in A 61-year-old woman with no apparent risk factors for liver injury?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_1_203", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the disorder of the subject in A 61-year-old woman with no apparent risk factors for liver injury?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_1_204", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What are the drugs used in the treatment in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_1_205", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the dosage of the treatment in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_1_206", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the frequency of the treatment in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_1_207", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the route of the treatment in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_1_208", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "How long has elapsed from the treatment to the occurence of the event in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_1_209", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "How long did the treatment last in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_1_210", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What is the disorder targeted by the treatment in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_1_211", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "What are the drugs used in combination in one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_4_212", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the age of the subject in a patient suffering from acute hemorrhagic gastritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_4_213", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the gender of the subject in a patient suffering from acute hemorrhagic gastritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_4_214", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the number of subjects in a patient suffering from acute hemorrhagic gastritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_4_215", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the race of the subject in a patient suffering from acute hemorrhagic gastritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_4_216", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the disorder of the subject in a patient suffering from acute hemorrhagic gastritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_4_217", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What are the drugs used in the treatment in AZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_4_218", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the dosage of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_4_219", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the frequency of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_4_220", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the route of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_4_221", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "How long has elapsed from the treatment to the occurence of the event in AZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_4_222", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "How long did the treatment last in AZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_4_223", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What is the disorder targeted by the treatment in AZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_4_224", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "What are the drugs used in combination in AZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_1_225", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the age of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_1_226", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the gender of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16192734_1_227", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the number of subjects in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_1_228", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the race of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_1_229", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the disorder of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16192734_1_230", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What are the drugs used in the treatment in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_1_231", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the dosage of the treatment in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_1_232", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the frequency of the treatment in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_1_233", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the route of the treatment in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_1_234", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "How long has elapsed from the treatment to the occurence of the event in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_1_235", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "How long did the treatment last in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_1_236", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What is the disorder targeted by the treatment in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_1_237", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "What are the drugs used in combination in tocolysis with oral ritodrine hydrochloride?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_238", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the age of the subject in normal male volunteers?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "536470_2_239", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the gender of the subject in normal male volunteers?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "536470_2_240", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the number of subjects in normal male volunteers?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "536470_2_241", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the race of the subject in normal male volunteers?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "536470_2_242", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the disorder of the subject in normal male volunteers?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "536470_2_243", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "536470_2_244", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_245", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_246", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "536470_2_247", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_248", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_249", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_250", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_251", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the age of the subject in a patient with a renal tubular defect?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "536470_2_252", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the gender of the subject in a patient with a renal tubular defect?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "536470_2_253", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the number of subjects in a patient with a renal tubular defect?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "536470_2_254", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the race of the subject in a patient with a renal tubular defect?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "536470_2_255", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the disorder of the subject in a patient with a renal tubular defect?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "536470_2_256", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What are the drugs used in the treatment in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "536470_2_257", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the dosage of the treatment in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_258", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the frequency of the treatment in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_259", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the route of the treatment in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "536470_2_260", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "How long has elapsed from the treatment to the occurence of the event in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_261", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "How long did the treatment last in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_262", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What is the disorder targeted by the treatment in sulindac?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_263", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "What are the drugs used in combination in sulindac?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8912599_7_264", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_7_265", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_7_266", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_7_267", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_7_268", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_7_269", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_7_270", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_7_271", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_2_272", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the age of the subject in an acromegalic patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_2_273", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the gender of the subject in an acromegalic patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_2_274", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the number of subjects in an acromegalic patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_2_275", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the race of the subject in an acromegalic patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_2_276", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the disorder of the subject in an acromegalic patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_2_277", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What are the drugs used in the treatment in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_2_278", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the dosage of the treatment in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_2_279", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the frequency of the treatment in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_2_280", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the route of the treatment in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_2_281", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "How long has elapsed from the treatment to the occurence of the event in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_2_282", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "How long did the treatment last in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_2_283", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What is the disorder targeted by the treatment in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_2_284", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "What are the drugs used in combination in pegvisomant and octreotide long-acting repeatable?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_2_285", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7978578_2_286", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7978578_2_287", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7978578_2_288", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7978578_2_289", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7978578_2_290", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What are the drugs used in the treatment in promethazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7978578_2_291", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the dosage of the treatment in promethazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_2_292", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the frequency of the treatment in promethazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7978578_2_293", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the route of the treatment in promethazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7978578_2_294", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "How long has elapsed from the treatment to the occurence of the event in promethazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_2_295", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "How long did the treatment last in promethazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7978578_2_296", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What is the disorder targeted by the treatment in promethazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7978578_2_297", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "What are the drugs used in combination in promethazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_3_298", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the age of the subject in patients 1 and 3,?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_3_299", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the gender of the subject in patients 1 and 3,?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_3_300", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the number of subjects in patients 1 and 3,?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18425523_3_301", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the race of the subject in patients 1 and 3,?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_3_302", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the disorder of the subject in patients 1 and 3,?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_3_303", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What are the drugs used in the treatment in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_3_304", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the dosage of the treatment in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_3_305", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the frequency of the treatment in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_3_306", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the route of the treatment in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_3_307", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "How long has elapsed from the treatment to the occurence of the event in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_3_308", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "How long did the treatment last in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_3_309", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What is the disorder targeted by the treatment in ranibizumab injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_3_310", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "What are the drugs used in combination in ranibizumab injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_5_311", "context": "Priapism associated with zuclopenthixol.", "question": "What are the drugs used in the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_5_312", "context": "Priapism associated with zuclopenthixol.", "question": "What is the dosage of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_5_313", "context": "Priapism associated with zuclopenthixol.", "question": "What is the frequency of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_5_314", "context": "Priapism associated with zuclopenthixol.", "question": "What is the route of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_5_315", "context": "Priapism associated with zuclopenthixol.", "question": "How long has elapsed from the treatment to the occurence of the event in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_5_316", "context": "Priapism associated with zuclopenthixol.", "question": "How long did the treatment last in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_5_317", "context": "Priapism associated with zuclopenthixol.", "question": "What is the disorder targeted by the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_5_318", "context": "Priapism associated with zuclopenthixol.", "question": "What are the drugs used in combination in zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_3_319", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What are the drugs used in the treatment in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12488741_3_320", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What is the dosage of the treatment in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_3_321", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What is the frequency of the treatment in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_3_322", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What is the route of the treatment in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_3_323", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_3_324", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "How long did the treatment last in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_3_325", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What is the disorder targeted by the treatment in metronidazole therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_3_326", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "What are the drugs used in combination in metronidazole therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_3_327", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What are the drugs used in the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_3_328", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What is the dosage of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_3_329", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What is the frequency of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_3_330", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What is the route of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_3_331", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "How long has elapsed from the treatment to the occurence of the event in rifabutin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_3_332", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "How long did the treatment last in rifabutin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_3_333", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What is the disorder targeted by the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_3_334", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "What are the drugs used in combination in rifabutin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_3_335", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the age of the subject in a child?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_3_336", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the gender of the subject in a child?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_3_337", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the number of subjects in a child?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_3_338", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the race of the subject in a child?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_3_339", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the disorder of the subject in a child?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_3_340", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What are the drugs used in the treatment in calcineurin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_3_341", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the dosage of the treatment in calcineurin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_3_342", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the frequency of the treatment in calcineurin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_3_343", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the route of the treatment in calcineurin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_3_344", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "How long has elapsed from the treatment to the occurence of the event in calcineurin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_3_345", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "How long did the treatment last in calcineurin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_3_346", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What is the disorder targeted by the treatment in calcineurin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_3_347", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "What are the drugs used in combination in calcineurin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_4_348", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the age of the subject in a male patient with psoriasis and hypertension?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_4_349", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the gender of the subject in a male patient with psoriasis and hypertension?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14684937_4_350", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the number of subjects in a male patient with psoriasis and hypertension?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_4_351", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the race of the subject in a male patient with psoriasis and hypertension?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_4_352", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the disorder of the subject in a male patient with psoriasis and hypertension?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_4_353", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What are the drugs used in the treatment in thiazide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_4_354", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the dosage of the treatment in thiazide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_4_355", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the frequency of the treatment in thiazide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_4_356", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the route of the treatment in thiazide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_4_357", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "How long has elapsed from the treatment to the occurence of the event in thiazide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_4_358", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "How long did the treatment last in thiazide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_4_359", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What is the disorder targeted by the treatment in thiazide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_4_360", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "What are the drugs used in combination in thiazide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_3_361", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What are the drugs used in the treatment in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_3_362", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What is the dosage of the treatment in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_3_363", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What is the frequency of the treatment in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_3_364", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What is the route of the treatment in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_3_365", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "How long has elapsed from the treatment to the occurence of the event in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_3_366", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "How long did the treatment last in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_3_367", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What is the disorder targeted by the treatment in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_3_368", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "What are the drugs used in combination in calcium hydroxylapatite injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_3_369", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What are the drugs used in the treatment in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_3_370", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What is the dosage of the treatment in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_3_371", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What is the frequency of the treatment in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_3_372", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What is the route of the treatment in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_3_373", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "How long has elapsed from the treatment to the occurence of the event in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_3_374", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "How long did the treatment last in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_3_375", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What is the disorder targeted by the treatment in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_3_376", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "What are the drugs used in combination in MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3868420_1_377", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the age of the subject in a patient with alveolar hydatid disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3868420_1_378", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the gender of the subject in a patient with alveolar hydatid disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3868420_1_379", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the number of subjects in a patient with alveolar hydatid disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3868420_1_380", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the race of the subject in a patient with alveolar hydatid disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3868420_1_381", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the disorder of the subject in a patient with alveolar hydatid disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3868420_1_382", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What are the drugs used in the treatment in mebendazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3868420_1_383", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the dosage of the treatment in mebendazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3868420_1_384", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the frequency of the treatment in mebendazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3868420_1_385", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the route of the treatment in mebendazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3868420_1_386", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "How long has elapsed from the treatment to the occurence of the event in mebendazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3868420_1_387", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "How long did the treatment last in mebendazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3868420_1_388", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What is the disorder targeted by the treatment in mebendazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3868420_1_389", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "What are the drugs used in combination in mebendazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_1_390", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the age of the subject in approximately 0.67% of patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_1_391", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the gender of the subject in approximately 0.67% of patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_1_392", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the number of subjects in approximately 0.67% of patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3174043_1_393", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the race of the subject in approximately 0.67% of patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_1_394", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the disorder of the subject in approximately 0.67% of patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_1_395", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What are the drugs used in the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_1_396", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the dosage of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_1_397", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the frequency of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_1_398", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the route of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_1_399", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "How long has elapsed from the treatment to the occurence of the event in Niacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_1_400", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "How long did the treatment last in Niacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_1_401", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What is the disorder targeted by the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_1_402", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "What are the drugs used in combination in Niacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6854698_1_403", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the age of the subject in tuberculosis patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6854698_1_404", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the gender of the subject in tuberculosis patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6854698_1_405", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the number of subjects in tuberculosis patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6854698_1_406", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the race of the subject in tuberculosis patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6854698_1_407", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the disorder of the subject in tuberculosis patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6854698_1_408", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What are the drugs used in the treatment in isoniazid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6854698_1_409", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the dosage of the treatment in isoniazid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6854698_1_410", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the frequency of the treatment in isoniazid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6854698_1_411", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the route of the treatment in isoniazid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6854698_1_412", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "How long has elapsed from the treatment to the occurence of the event in isoniazid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6854698_1_413", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "How long did the treatment last in isoniazid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6854698_1_414", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What is the disorder targeted by the treatment in isoniazid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6854698_1_415", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "What are the drugs used in combination in isoniazid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_2_416", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What are the drugs used in the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_2_417", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What is the dosage of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_2_418", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What is the frequency of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_2_419", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What is the route of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_2_420", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "How long has elapsed from the treatment to the occurence of the event in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_2_421", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "How long did the treatment last in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_2_422", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What is the disorder targeted by the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_2_423", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "What are the drugs used in combination in zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14766993_2_424", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14766993_2_425", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14766993_2_426", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14766993_2_427", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14766993_2_428", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14766993_2_429", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14766993_2_430", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14766993_2_431", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14766993_2_432", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14766993_2_433", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14766993_2_434", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14766993_2_435", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14766993_2_436", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17167851_1_437", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the age of the subject in three cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17167851_1_438", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the gender of the subject in three cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17167851_1_439", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the number of subjects in three cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17167851_1_440", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the race of the subject in three cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17167851_1_441", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the disorder of the subject in three cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17167851_1_442", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What are the drugs used in the treatment in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17167851_1_443", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the dosage of the treatment in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_1_444", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the frequency of the treatment in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_1_445", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the route of the treatment in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_1_446", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "How long has elapsed from the treatment to the occurence of the event in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_1_447", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "How long did the treatment last in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_1_448", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What is the disorder targeted by the treatment in cyproterone acetate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_1_449", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "What are the drugs used in combination in cyproterone acetate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_1_450", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What are the drugs used in the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_1_451", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What is the dosage of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_1_452", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What is the frequency of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_1_453", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What is the route of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_1_454", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_1_455", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "How long did the treatment last in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_1_456", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What is the disorder targeted by the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_1_457", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "What are the drugs used in combination in intrathecal methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_2_458", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What are the drugs used in the treatment in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_2_459", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What is the dosage of the treatment in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_2_460", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What is the frequency of the treatment in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_2_461", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What is the route of the treatment in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_2_462", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "How long has elapsed from the treatment to the occurence of the event in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_2_463", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "How long did the treatment last in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_2_464", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What is the disorder targeted by the treatment in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_2_465", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "What are the drugs used in combination in Isonicotinic acid hydrazide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_5_466", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the age of the subject in one case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_5_467", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the gender of the subject in one case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_5_468", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the number of subjects in one case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_5_469", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the race of the subject in one case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_5_470", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the disorder of the subject in one case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_5_471", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What are the drugs used in the treatment in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_5_472", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the dosage of the treatment in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_5_473", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the frequency of the treatment in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_5_474", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the route of the treatment in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_5_475", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "How long has elapsed from the treatment to the occurence of the event in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_5_476", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "How long did the treatment last in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_5_477", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What is the disorder targeted by the treatment in pulse therapy with itraconazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_5_478", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "What are the drugs used in combination in pulse therapy with itraconazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_3_479", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What are the drugs used in the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_3_480", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What is the dosage of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_3_481", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What is the frequency of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_3_482", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What is the route of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_3_483", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "How long has elapsed from the treatment to the occurence of the event in trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_3_484", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "How long did the treatment last in trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_3_485", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What is the disorder targeted by the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_3_486", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "What are the drugs used in combination in trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_2_487", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What are the drugs used in the treatment in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_2_488", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What is the dosage of the treatment in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_2_489", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What is the frequency of the treatment in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_2_490", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What is the route of the treatment in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_2_491", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_2_492", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "How long did the treatment last in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_2_493", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What is the disorder targeted by the treatment in high doses of CCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_2_494", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "What are the drugs used in combination in high doses of CCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_2_495", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the age of the subject in patients with cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_2_496", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the gender of the subject in patients with cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_2_497", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the number of subjects in patients with cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_2_498", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the race of the subject in patients with cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_2_499", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the disorder of the subject in patients with cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_2_500", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What are the drugs used in the treatment in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_2_501", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the dosage of the treatment in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_2_502", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the frequency of the treatment in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_2_503", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the route of the treatment in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_2_504", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_2_505", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "How long did the treatment last in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_2_506", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What is the disorder targeted by the treatment in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_2_507", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "What are the drugs used in combination in 5-fluorouracil (5-FU)-based chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_3_508", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6697887_3_509", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6697887_3_510", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6697887_3_511", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6697887_3_512", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6697887_3_513", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What are the drugs used in the treatment in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_3_514", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the dosage of the treatment in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_3_515", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the frequency of the treatment in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_3_516", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the route of the treatment in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_3_517", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "How long has elapsed from the treatment to the occurence of the event in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_3_518", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "How long did the treatment last in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_3_519", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What is the disorder targeted by the treatment in parenteral verapamil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_3_520", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "What are the drugs used in combination in parenteral verapamil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_4_521", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What are the drugs used in the treatment in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10212021_4_522", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What is the dosage of the treatment in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_4_523", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What is the frequency of the treatment in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10212021_4_524", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What is the route of the treatment in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10212021_4_525", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "How long has elapsed from the treatment to the occurence of the event in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_4_526", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "How long did the treatment last in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10212021_4_527", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What is the disorder targeted by the treatment in Methadone?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10212021_4_528", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "What are the drugs used in combination in Methadone?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21515865_9_529", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21515865_9_530", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21515865_9_531", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21515865_9_532", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21515865_9_533", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21515865_9_534", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What are the drugs used in the treatment in phytonadione?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_9_535", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the dosage of the treatment in phytonadione?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_9_536", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the frequency of the treatment in phytonadione?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_9_537", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the route of the treatment in phytonadione?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_9_538", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "How long has elapsed from the treatment to the occurence of the event in phytonadione?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_9_539", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "How long did the treatment last in phytonadione?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_9_540", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the disorder targeted by the treatment in phytonadione?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_9_541", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What are the drugs used in combination in phytonadione?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_9_542", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What are the drugs used in the treatment in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_9_543", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the dosage of the treatment in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_9_544", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the frequency of the treatment in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_9_545", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the route of the treatment in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_9_546", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "How long has elapsed from the treatment to the occurence of the event in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_9_547", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "How long did the treatment last in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_9_548", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What is the disorder targeted by the treatment in phytonadione?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_9_549", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "What are the drugs used in combination in phytonadione?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22677303_3_550", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the age of the subject in A 70-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22677303_3_551", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the gender of the subject in A 70-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22677303_3_552", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the number of subjects in A 70-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22677303_3_553", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the race of the subject in A 70-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22677303_3_554", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the disorder of the subject in A 70-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22677303_3_555", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22677303_3_556", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_3_557", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22677303_3_558", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the route of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22677303_3_559", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_3_560", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "How long did the treatment last in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22677303_3_561", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_3_562", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1703754_1_563", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the age of the subject in a child with systemic lupus erythematosus?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1703754_1_564", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the gender of the subject in a child with systemic lupus erythematosus?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1703754_1_565", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the number of subjects in a child with systemic lupus erythematosus?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1703754_1_566", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the race of the subject in a child with systemic lupus erythematosus?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1703754_1_567", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the disorder of the subject in a child with systemic lupus erythematosus?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1703754_1_568", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What are the drugs used in the treatment in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1703754_1_569", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the dosage of the treatment in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1703754_1_570", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the frequency of the treatment in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1703754_1_571", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the route of the treatment in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1703754_1_572", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "How long has elapsed from the treatment to the occurence of the event in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1703754_1_573", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "How long did the treatment last in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1703754_1_574", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What is the disorder targeted by the treatment in prednisolone and azathioprine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1703754_1_575", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "What are the drugs used in combination in prednisolone and azathioprine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_1_576", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the age of the subject in a patient with chronic renal failure?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_1_577", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the gender of the subject in a patient with chronic renal failure?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_1_578", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the number of subjects in a patient with chronic renal failure?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_1_579", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the race of the subject in a patient with chronic renal failure?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_1_580", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the disorder of the subject in a patient with chronic renal failure?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_1_581", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What are the drugs used in the treatment in acetazolamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_1_582", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the dosage of the treatment in acetazolamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_1_583", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the frequency of the treatment in acetazolamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_1_584", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the route of the treatment in acetazolamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_1_585", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "How long has elapsed from the treatment to the occurence of the event in acetazolamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_1_586", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "How long did the treatment last in acetazolamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_1_587", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What is the disorder targeted by the treatment in acetazolamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_1_588", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "What are the drugs used in combination in acetazolamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_2_589", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What are the drugs used in the treatment in trazodone alone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_2_590", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What is the dosage of the treatment in trazodone alone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_2_591", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What is the frequency of the treatment in trazodone alone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_2_592", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What is the route of the treatment in trazodone alone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_2_593", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "How long has elapsed from the treatment to the occurence of the event in trazodone alone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_2_594", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "How long did the treatment last in trazodone alone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_2_595", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What is the disorder targeted by the treatment in trazodone alone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_2_596", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "What are the drugs used in combination in trazodone alone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_2_597", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What are the drugs used in the treatment in itraconazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_2_598", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What is the dosage of the treatment in itraconazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_2_599", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What is the frequency of the treatment in itraconazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_2_600", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What is the route of the treatment in itraconazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_2_601", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "How long has elapsed from the treatment to the occurence of the event in itraconazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_2_602", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "How long did the treatment last in itraconazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_2_603", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What is the disorder targeted by the treatment in itraconazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_2_604", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "What are the drugs used in combination in itraconazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "507889_1_605", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the age of the subject in two patients with mycosis fungoides?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "507889_1_606", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the gender of the subject in two patients with mycosis fungoides?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "507889_1_607", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the number of subjects in two patients with mycosis fungoides?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "507889_1_608", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the race of the subject in two patients with mycosis fungoides?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "507889_1_609", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the disorder of the subject in two patients with mycosis fungoides?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "507889_1_610", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What are the drugs used in the treatment in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "507889_1_611", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the dosage of the treatment in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "507889_1_612", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the frequency of the treatment in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "507889_1_613", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the route of the treatment in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "507889_1_614", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "How long has elapsed from the treatment to the occurence of the event in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "507889_1_615", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "How long did the treatment last in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "507889_1_616", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What is the disorder targeted by the treatment in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "507889_1_617", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "What are the drugs used in combination in psoralens plus long-wave ultraviolet radiation (PUVA)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_1_618", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the age of the subject in a patient with acute promyelocytic leukemia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_1_619", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the gender of the subject in a patient with acute promyelocytic leukemia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_1_620", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the number of subjects in a patient with acute promyelocytic leukemia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_1_621", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the race of the subject in a patient with acute promyelocytic leukemia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_1_622", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the disorder of the subject in a patient with acute promyelocytic leukemia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_1_623", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What are the drugs used in the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15663666_1_624", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the dosage of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_1_625", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the frequency of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15663666_1_626", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the route of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15663666_1_627", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_1_628", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "How long did the treatment last in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_1_629", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What is the disorder targeted by the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_1_630", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "What are the drugs used in combination in all-trans retinoic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_1_631", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the age of the subject in A 61 year-old male patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6693840_1_632", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the gender of the subject in A 61 year-old male patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6693840_1_633", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the number of subjects in A 61 year-old male patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6693840_1_634", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the race of the subject in A 61 year-old male patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6693840_1_635", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the disorder of the subject in A 61 year-old male patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6693840_1_636", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What are the drugs used in the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_1_637", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the dosage of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_1_638", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the frequency of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_1_639", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the route of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_1_640", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "How long has elapsed from the treatment to the occurence of the event in theophylline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_1_641", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "How long did the treatment last in theophylline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_1_642", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What is the disorder targeted by the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_1_643", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "What are the drugs used in combination in theophylline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_3_644", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What are the drugs used in the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_3_645", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What is the dosage of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_3_646", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What is the frequency of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_3_647", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What is the route of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_3_648", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "How long has elapsed from the treatment to the occurence of the event in dextran-40?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_3_649", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "How long did the treatment last in dextran-40?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_3_650", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What is the disorder targeted by the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_3_651", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "What are the drugs used in combination in dextran-40?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_2_652", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the age of the subject in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_2_653", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the gender of the subject in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_2_654", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the number of subjects in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_2_655", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the race of the subject in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_2_656", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the disorder of the subject in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_2_657", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What are the drugs used in the treatment in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_2_658", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the dosage of the treatment in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_2_659", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the frequency of the treatment in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_2_660", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the route of the treatment in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_2_661", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "How long has elapsed from the treatment to the occurence of the event in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_2_662", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "How long did the treatment last in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_2_663", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What is the disorder targeted by the treatment in cisplatin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_2_664", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "What are the drugs used in combination in cisplatin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_5_665", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the age of the subject in An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18675768_5_666", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the gender of the subject in An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18675768_5_667", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the number of subjects in An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18675768_5_668", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the race of the subject in An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18675768_5_669", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the disorder of the subject in An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18675768_5_670", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What are the drugs used in the treatment in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18675768_5_671", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the dosage of the treatment in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_5_672", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the frequency of the treatment in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18675768_5_673", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the route of the treatment in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18675768_5_674", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "How long has elapsed from the treatment to the occurence of the event in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_5_675", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "How long did the treatment last in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18675768_5_676", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What is the disorder targeted by the treatment in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_5_677", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "What are the drugs used in combination in propafenone 900 mg/d for >10 years?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_12_678", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the age of the subject in A total of 109 patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_12_679", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the gender of the subject in A total of 109 patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_12_680", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the number of subjects in A total of 109 patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_12_681", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the race of the subject in A total of 109 patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_12_682", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the disorder of the subject in A total of 109 patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_12_683", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What are the drugs used in the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_12_684", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the dosage of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_12_685", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the frequency of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_12_686", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the route of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_12_687", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "How long has elapsed from the treatment to the occurence of the event in omeprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_12_688", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "How long did the treatment last in omeprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_12_689", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What is the disorder targeted by the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_12_690", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "What are the drugs used in combination in omeprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_10_691", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What are the drugs used in the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_10_692", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What is the dosage of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_10_693", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What is the frequency of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_10_694", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What is the route of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_10_695", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "How long has elapsed from the treatment to the occurence of the event in zomepirac?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_10_696", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "How long did the treatment last in zomepirac?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_10_697", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What is the disorder targeted by the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_10_698", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "What are the drugs used in combination in zomepirac?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_1_699", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What are the drugs used in the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_1_700", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What is the dosage of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_1_701", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What is the frequency of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_1_702", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What is the route of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_1_703", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "How long has elapsed from the treatment to the occurence of the event in etanercept?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_1_704", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "How long did the treatment last in etanercept?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_1_705", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What is the disorder targeted by the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_1_706", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "What are the drugs used in combination in etanercept?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_2_707", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What are the drugs used in the treatment in bleomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_2_708", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What is the dosage of the treatment in bleomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_2_709", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What is the frequency of the treatment in bleomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_2_710", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What is the route of the treatment in bleomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_2_711", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in bleomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_2_712", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "How long did the treatment last in bleomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_2_713", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What is the disorder targeted by the treatment in bleomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_2_714", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "What are the drugs used in combination in bleomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24918555_1_715", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the age of the subject in patients with severe recalcitrant nodular acne?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24918555_1_716", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the gender of the subject in patients with severe recalcitrant nodular acne?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24918555_1_717", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the number of subjects in patients with severe recalcitrant nodular acne?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24918555_1_718", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the race of the subject in patients with severe recalcitrant nodular acne?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24918555_1_719", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the disorder of the subject in patients with severe recalcitrant nodular acne?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24918555_1_720", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What are the drugs used in the treatment in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "24918555_1_721", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the dosage of the treatment in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24918555_1_722", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the frequency of the treatment in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24918555_1_723", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the route of the treatment in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24918555_1_724", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "How long has elapsed from the treatment to the occurence of the event in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24918555_1_725", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "How long did the treatment last in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24918555_1_726", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What is the disorder targeted by the treatment in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "24918555_1_727", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "What are the drugs used in combination in isotretinoin-Lidose?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16490518_4_728", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What are the drugs used in the treatment in corticosteroid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_4_729", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What is the dosage of the treatment in corticosteroid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_4_730", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What is the frequency of the treatment in corticosteroid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_4_731", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What is the route of the treatment in corticosteroid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_4_732", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "How long has elapsed from the treatment to the occurence of the event in corticosteroid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_4_733", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "How long did the treatment last in corticosteroid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_4_734", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What is the disorder targeted by the treatment in corticosteroid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_4_735", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "What are the drugs used in combination in corticosteroid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_4_736", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the age of the subject in this patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_4_737", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the gender of the subject in this patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_4_738", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the number of subjects in this patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_4_739", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the race of the subject in this patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_4_740", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the disorder of the subject in this patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_4_741", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What are the drugs used in the treatment in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_4_742", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the dosage of the treatment in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_4_743", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the frequency of the treatment in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_4_744", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the route of the treatment in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_4_745", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "How long has elapsed from the treatment to the occurence of the event in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_4_746", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "How long did the treatment last in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_4_747", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What is the disorder targeted by the treatment in parenteral amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_4_748", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "What are the drugs used in combination in parenteral amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_5_749", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What are the drugs used in the treatment in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_5_750", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What is the dosage of the treatment in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_5_751", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What is the frequency of the treatment in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_5_752", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What is the route of the treatment in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_5_753", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "How long has elapsed from the treatment to the occurence of the event in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_5_754", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "How long did the treatment last in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_5_755", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What is the disorder targeted by the treatment in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_5_756", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "What are the drugs used in combination in Twenty-four hours after the administration of gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_11_757", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What are the drugs used in the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_11_758", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What is the dosage of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_11_759", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What is the frequency of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_11_760", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What is the route of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_11_761", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "How long has elapsed from the treatment to the occurence of the event in omeprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_11_762", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "How long did the treatment last in omeprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_11_763", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What is the disorder targeted by the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_11_764", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "What are the drugs used in combination in omeprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8145359_2_765", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What are the drugs used in the treatment in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8145359_2_766", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What is the dosage of the treatment in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8145359_2_767", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What is the frequency of the treatment in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_2_768", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What is the route of the treatment in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_2_769", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "How long has elapsed from the treatment to the occurence of the event in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_2_770", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "How long did the treatment last in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_2_771", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What is the disorder targeted by the treatment in phenothiazine overdose?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_2_772", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "What are the drugs used in combination in phenothiazine overdose?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6340463_4_773", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the age of the subject in Patients from endemic areas referred to transplant centers?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6340463_4_774", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the gender of the subject in Patients from endemic areas referred to transplant centers?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6340463_4_775", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the number of subjects in Patients from endemic areas referred to transplant centers?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6340463_4_776", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the race of the subject in Patients from endemic areas referred to transplant centers?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6340463_4_777", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the disorder of the subject in Patients from endemic areas referred to transplant centers?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6340463_4_778", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What are the drugs used in the treatment in long-term prednisone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6340463_4_779", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the dosage of the treatment in long-term prednisone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6340463_4_780", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the frequency of the treatment in long-term prednisone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6340463_4_781", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the route of the treatment in long-term prednisone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6340463_4_782", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term prednisone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6340463_4_783", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "How long did the treatment last in long-term prednisone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6340463_4_784", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What is the disorder targeted by the treatment in long-term prednisone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6340463_4_785", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "What are the drugs used in combination in long-term prednisone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_1_786", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What are the drugs used in the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_1_787", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What is the dosage of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_1_788", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What is the frequency of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_1_789", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What is the route of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_1_790", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "How long has elapsed from the treatment to the occurence of the event in tamoxifen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_1_791", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "How long did the treatment last in tamoxifen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_1_792", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What is the disorder targeted by the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_1_793", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "What are the drugs used in combination in tamoxifen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_1_794", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the age of the subject in A 28 year old white schizophrenic male?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9562211_1_795", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the gender of the subject in A 28 year old white schizophrenic male?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9562211_1_796", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the number of subjects in A 28 year old white schizophrenic male?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9562211_1_797", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the race of the subject in A 28 year old white schizophrenic male?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9562211_1_798", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the disorder of the subject in A 28 year old white schizophrenic male?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9562211_1_799", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What are the drugs used in the treatment in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_1_800", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the dosage of the treatment in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_1_801", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the frequency of the treatment in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_1_802", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the route of the treatment in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_1_803", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "How long has elapsed from the treatment to the occurence of the event in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_1_804", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "How long did the treatment last in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_1_805", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What is the disorder targeted by the treatment in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_1_806", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "What are the drugs used in combination in under risperidone monotherapy for about one year?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22047557_8_807", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the age of the subject in Subjects?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22047557_8_808", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the gender of the subject in Subjects?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22047557_8_809", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the number of subjects in Subjects?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22047557_8_810", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the race of the subject in Subjects?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22047557_8_811", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the disorder of the subject in Subjects?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22047557_8_812", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What are the drugs used in the treatment in ivacaftor?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22047557_8_813", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the dosage of the treatment in ivacaftor?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22047557_8_814", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the frequency of the treatment in ivacaftor?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22047557_8_815", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the route of the treatment in ivacaftor?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22047557_8_816", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "How long has elapsed from the treatment to the occurence of the event in ivacaftor?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22047557_8_817", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "How long did the treatment last in ivacaftor?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22047557_8_818", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What is the disorder targeted by the treatment in ivacaftor?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22047557_8_819", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "What are the drugs used in combination in ivacaftor?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10759907_2_820", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10759907_2_821", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10759907_2_822", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10759907_2_823", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10759907_2_824", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10759907_2_825", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What are the drugs used in the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_2_826", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the dosage of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_2_827", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the frequency of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_2_828", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the route of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_2_829", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in zolmitriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_2_830", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "How long did the treatment last in zolmitriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_2_831", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What is the disorder targeted by the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_2_832", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "What are the drugs used in combination in zolmitriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_3_833", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the age of the subject in a 29-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12854039_3_834", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the gender of the subject in a 29-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12854039_3_835", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the number of subjects in a 29-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_3_836", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the race of the subject in a 29-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_3_837", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the disorder of the subject in a 29-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_3_838", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What are the drugs used in the treatment in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_3_839", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the dosage of the treatment in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_3_840", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the frequency of the treatment in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_3_841", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the route of the treatment in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_3_842", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_3_843", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "How long did the treatment last in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_3_844", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What is the disorder targeted by the treatment in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_3_845", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "What are the drugs used in combination in a 22-month use of recombinant interferon alpha-2b?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_3_846", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What are the drugs used in the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_3_847", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What is the dosage of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_3_848", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What is the frequency of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_3_849", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What is the route of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_3_850", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "How long has elapsed from the treatment to the occurence of the event in glibenclamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_3_851", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "How long did the treatment last in glibenclamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_3_852", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What is the disorder targeted by the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_3_853", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "What are the drugs used in combination in glibenclamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_2_854", "context": "Risperidone-induced tardive dyskinesia.", "question": "What are the drugs used in the treatment in Risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_2_855", "context": "Risperidone-induced tardive dyskinesia.", "question": "What is the dosage of the treatment in Risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_2_856", "context": "Risperidone-induced tardive dyskinesia.", "question": "What is the frequency of the treatment in Risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_2_857", "context": "Risperidone-induced tardive dyskinesia.", "question": "What is the route of the treatment in Risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_2_858", "context": "Risperidone-induced tardive dyskinesia.", "question": "How long has elapsed from the treatment to the occurence of the event in Risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_2_859", "context": "Risperidone-induced tardive dyskinesia.", "question": "How long did the treatment last in Risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_2_860", "context": "Risperidone-induced tardive dyskinesia.", "question": "What is the disorder targeted by the treatment in Risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_2_861", "context": "Risperidone-induced tardive dyskinesia.", "question": "What are the drugs used in combination in Risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_2_862", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What are the drugs used in the treatment in pentazocine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_2_863", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What is the dosage of the treatment in pentazocine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_2_864", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What is the frequency of the treatment in pentazocine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_2_865", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What is the route of the treatment in pentazocine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_2_866", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "How long has elapsed from the treatment to the occurence of the event in pentazocine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_2_867", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "How long did the treatment last in pentazocine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_2_868", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What is the disorder targeted by the treatment in pentazocine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_2_869", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "What are the drugs used in combination in pentazocine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_2_870", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What are the drugs used in the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_2_871", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What is the dosage of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_2_872", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What is the frequency of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_2_873", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What is the route of the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_2_874", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine A?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_2_875", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "How long did the treatment last in cyclosporine A?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_2_876", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What is the disorder targeted by the treatment in cyclosporine A?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_2_877", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "What are the drugs used in combination in cyclosporine A?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_2_878", "context": "Niacin maculopathy.", "question": "What are the drugs used in the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_2_879", "context": "Niacin maculopathy.", "question": "What is the dosage of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_2_880", "context": "Niacin maculopathy.", "question": "What is the frequency of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_2_881", "context": "Niacin maculopathy.", "question": "What is the route of the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_2_882", "context": "Niacin maculopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in Niacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_2_883", "context": "Niacin maculopathy.", "question": "How long did the treatment last in Niacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_2_884", "context": "Niacin maculopathy.", "question": "What is the disorder targeted by the treatment in Niacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_2_885", "context": "Niacin maculopathy.", "question": "What are the drugs used in combination in Niacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22293514_5_886", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22293514_5_887", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22293514_5_888", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22293514_5_889", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22293514_5_890", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22293514_5_891", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What are the drugs used in the treatment in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22293514_5_892", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the dosage of the treatment in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22293514_5_893", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the frequency of the treatment in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22293514_5_894", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the route of the treatment in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22293514_5_895", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "How long has elapsed from the treatment to the occurence of the event in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22293514_5_896", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "How long did the treatment last in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22293514_5_897", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the disorder targeted by the treatment in clobazam and etravirine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22293514_5_898", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What are the drugs used in combination in clobazam and etravirine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22293514_5_899", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What are the drugs used in the treatment in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22293514_5_900", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the dosage of the treatment in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22293514_5_901", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the frequency of the treatment in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22293514_5_902", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the route of the treatment in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22293514_5_903", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "How long has elapsed from the treatment to the occurence of the event in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22293514_5_904", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "How long did the treatment last in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22293514_5_905", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What is the disorder targeted by the treatment in clobazam?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22293514_5_906", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "What are the drugs used in combination in clobazam?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11202801_1_907", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11202801_1_908", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11202801_1_909", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11202801_1_910", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11202801_1_911", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11202801_1_912", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What are the drugs used in the treatment in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_1_913", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the dosage of the treatment in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_1_914", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the frequency of the treatment in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_1_915", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the route of the treatment in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_1_916", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_1_917", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "How long did the treatment last in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_1_918", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What is the disorder targeted by the treatment in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_1_919", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "What are the drugs used in combination in long-term cyclophosphamide treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_3_920", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18076602_3_921", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18076602_3_922", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18076602_3_923", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18076602_3_924", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18076602_3_925", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What are the drugs used in the treatment in amphotericin B?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_3_926", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the dosage of the treatment in amphotericin B?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_3_927", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the frequency of the treatment in amphotericin B?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_3_928", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the route of the treatment in amphotericin B?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_3_929", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "How long has elapsed from the treatment to the occurence of the event in amphotericin B?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_3_930", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "How long did the treatment last in amphotericin B?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_3_931", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What is the disorder targeted by the treatment in amphotericin B?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_3_932", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "What are the drugs used in combination in amphotericin B?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_5_933", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_5_934", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_5_935", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_5_936", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_5_937", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_5_938", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_5_939", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_5_940", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_2_941", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_2_942", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_2_943", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_2_944", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_2_945", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_2_946", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What are the drugs used in the treatment in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_2_947", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the dosage of the treatment in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_2_948", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the frequency of the treatment in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_2_949", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the route of the treatment in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_2_950", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "How long has elapsed from the treatment to the occurence of the event in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_2_951", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "How long did the treatment last in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_2_952", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What is the disorder targeted by the treatment in antiretroviral drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_2_953", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "What are the drugs used in combination in antiretroviral drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_2_954", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the age of the subject in the first case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16101941_2_955", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the gender of the subject in the first case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16101941_2_956", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the number of subjects in the first case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16101941_2_957", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the race of the subject in the first case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16101941_2_958", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the disorder of the subject in the first case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16101941_2_959", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What are the drugs used in the treatment in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_2_960", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the dosage of the treatment in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_2_961", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the frequency of the treatment in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_2_962", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the route of the treatment in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_2_963", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "How long has elapsed from the treatment to the occurence of the event in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_2_964", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "How long did the treatment last in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_2_965", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What is the disorder targeted by the treatment in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_2_966", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "What are the drugs used in combination in thiethylperazine maleate (thiethylperazine)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_2_967", "context": "Renal failure associated with the use of dextran-40.", "question": "What are the drugs used in the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_2_968", "context": "Renal failure associated with the use of dextran-40.", "question": "What is the dosage of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_2_969", "context": "Renal failure associated with the use of dextran-40.", "question": "What is the frequency of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_2_970", "context": "Renal failure associated with the use of dextran-40.", "question": "What is the route of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_2_971", "context": "Renal failure associated with the use of dextran-40.", "question": "How long has elapsed from the treatment to the occurence of the event in dextran-40?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_2_972", "context": "Renal failure associated with the use of dextran-40.", "question": "How long did the treatment last in dextran-40?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_2_973", "context": "Renal failure associated with the use of dextran-40.", "question": "What is the disorder targeted by the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_2_974", "context": "Renal failure associated with the use of dextran-40.", "question": "What are the drugs used in combination in dextran-40?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_1_975", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What are the drugs used in the treatment in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_1_976", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What is the dosage of the treatment in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_1_977", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What is the frequency of the treatment in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_1_978", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What is the route of the treatment in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_1_979", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_1_980", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "How long did the treatment last in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_1_981", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What is the disorder targeted by the treatment in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_1_982", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "What are the drugs used in combination in 5-fluorouracil and oxaliplatinum combined chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11155197_3_983", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What are the drugs used in the treatment in heparin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11155197_3_984", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What is the dosage of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_3_985", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What is the frequency of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_3_986", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What is the route of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_3_987", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "How long has elapsed from the treatment to the occurence of the event in heparin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_3_988", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "How long did the treatment last in heparin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_3_989", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What is the disorder targeted by the treatment in heparin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_3_990", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "What are the drugs used in combination in heparin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_3_991", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What are the drugs used in the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_3_992", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What is the dosage of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_3_993", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What is the frequency of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_3_994", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What is the route of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_3_995", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "How long has elapsed from the treatment to the occurence of the event in atovaquone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_3_996", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "How long did the treatment last in atovaquone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_3_997", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What is the disorder targeted by the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_3_998", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "What are the drugs used in combination in atovaquone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_1_999", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What are the drugs used in the treatment in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_1_1000", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What is the dosage of the treatment in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_1_1001", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What is the frequency of the treatment in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_1_1002", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What is the route of the treatment in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_1_1003", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "How long has elapsed from the treatment to the occurence of the event in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_1_1004", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "How long did the treatment last in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_1_1005", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What is the disorder targeted by the treatment in bleomycin and methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_1_1006", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "What are the drugs used in combination in bleomycin and methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_9_1007", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the age of the subject in children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_9_1008", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the gender of the subject in children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_9_1009", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the number of subjects in children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_9_1010", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the race of the subject in children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_9_1011", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the disorder of the subject in children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_9_1012", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What are the drugs used in the treatment in CBZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_9_1013", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the dosage of the treatment in CBZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_9_1014", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the frequency of the treatment in CBZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_9_1015", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the route of the treatment in CBZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_9_1016", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "How long has elapsed from the treatment to the occurence of the event in CBZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_9_1017", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "How long did the treatment last in CBZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_9_1018", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What is the disorder targeted by the treatment in CBZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_9_1019", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "What are the drugs used in combination in CBZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_2_1020", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What are the drugs used in the treatment in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "3964363_2_1021", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What is the dosage of the treatment in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3964363_2_1022", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What is the frequency of the treatment in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3964363_2_1023", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What is the route of the treatment in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3964363_2_1024", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_2_1025", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "How long did the treatment last in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3964363_2_1026", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What is the disorder targeted by the treatment in propranolol overdose?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_2_1027", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "What are the drugs used in combination in propranolol overdose?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9352164_3_1028", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the age of the subject in She?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_3_1029", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the gender of the subject in She?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_3_1030", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the number of subjects in She?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_3_1031", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the race of the subject in She?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_3_1032", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the disorder of the subject in She?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_3_1033", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What are the drugs used in the treatment in AZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_3_1034", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the dosage of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_3_1035", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the frequency of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_3_1036", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the route of the treatment in AZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_3_1037", "context": "She was thus diagnosed as having AZ intoxication.", "question": "How long has elapsed from the treatment to the occurence of the event in AZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_3_1038", "context": "She was thus diagnosed as having AZ intoxication.", "question": "How long did the treatment last in AZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_3_1039", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What is the disorder targeted by the treatment in AZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_3_1040", "context": "She was thus diagnosed as having AZ intoxication.", "question": "What are the drugs used in combination in AZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_3_1041", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What are the drugs used in the treatment in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_3_1042", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What is the dosage of the treatment in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_3_1043", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What is the frequency of the treatment in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_3_1044", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What is the route of the treatment in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_3_1045", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "How long has elapsed from the treatment to the occurence of the event in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_3_1046", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "How long did the treatment last in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_3_1047", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What is the disorder targeted by the treatment in massive ingestion of oolong tea?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_3_1048", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "What are the drugs used in combination in massive ingestion of oolong tea?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_2_1049", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What are the drugs used in the treatment in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15663666_2_1050", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What is the dosage of the treatment in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_2_1051", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What is the frequency of the treatment in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15663666_2_1052", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What is the route of the treatment in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15663666_2_1053", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "How long has elapsed from the treatment to the occurence of the event in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_2_1054", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "How long did the treatment last in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15663666_2_1055", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What is the disorder targeted by the treatment in withholding ATRA?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_2_1056", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "What are the drugs used in combination in withholding ATRA?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9726762_1_1057", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What are the drugs used in the treatment in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_1_1058", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What is the dosage of the treatment in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_1_1059", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What is the frequency of the treatment in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_1_1060", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What is the route of the treatment in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_1_1061", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "How long has elapsed from the treatment to the occurence of the event in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_1_1062", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "How long did the treatment last in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_1_1063", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What is the disorder targeted by the treatment in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_1_1064", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "What are the drugs used in combination in Gemfibrozil-warfarin drug interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_2_1065", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_2_1066", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_2_1067", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_2_1068", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_2_1069", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_2_1070", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_2_1071", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_2_1072", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_4_1073", "context": "Vortex keratopathy associated with atovaquone.", "question": "What are the drugs used in the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_4_1074", "context": "Vortex keratopathy associated with atovaquone.", "question": "What is the dosage of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_4_1075", "context": "Vortex keratopathy associated with atovaquone.", "question": "What is the frequency of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_4_1076", "context": "Vortex keratopathy associated with atovaquone.", "question": "What is the route of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_4_1077", "context": "Vortex keratopathy associated with atovaquone.", "question": "How long has elapsed from the treatment to the occurence of the event in atovaquone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_4_1078", "context": "Vortex keratopathy associated with atovaquone.", "question": "How long did the treatment last in atovaquone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_4_1079", "context": "Vortex keratopathy associated with atovaquone.", "question": "What is the disorder targeted by the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_4_1080", "context": "Vortex keratopathy associated with atovaquone.", "question": "What are the drugs used in combination in atovaquone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_1_1081", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What are the drugs used in the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_1_1082", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What is the dosage of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_1_1083", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What is the frequency of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_1_1084", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What is the route of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_1_1085", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_1_1086", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "How long did the treatment last in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_1_1087", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What is the disorder targeted by the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_1_1088", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "What are the drugs used in combination in thalidomide treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "910864_1_1089", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What are the drugs used in the treatment in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "910864_1_1090", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What is the dosage of the treatment in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "910864_1_1091", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What is the frequency of the treatment in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "910864_1_1092", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What is the route of the treatment in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "910864_1_1093", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "How long has elapsed from the treatment to the occurence of the event in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "910864_1_1094", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "How long did the treatment last in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "910864_1_1095", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What is the disorder targeted by the treatment in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "910864_1_1096", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "What are the drugs used in combination in substitution of acetohexamide for acetazolamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_1_1097", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What are the drugs used in the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_1_1098", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What is the dosage of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_1_1099", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What is the frequency of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_1_1100", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What is the route of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_1_1101", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "How long has elapsed from the treatment to the occurence of the event in Ritalin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_1_1102", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "How long did the treatment last in Ritalin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_1_1103", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What is the disorder targeted by the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_1_1104", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "What are the drugs used in combination in Ritalin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_1_1105", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What are the drugs used in the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_1_1106", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What is the dosage of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_1_1107", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What is the frequency of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_1_1108", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What is the route of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_1_1109", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alpha?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_1_1110", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "How long did the treatment last in interferon alpha?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_1_1111", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What is the disorder targeted by the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_1_1112", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "What are the drugs used in combination in interferon alpha?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25842648_7_1113", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What are the drugs used in the treatment in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25842648_7_1114", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What is the dosage of the treatment in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_7_1115", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What is the frequency of the treatment in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_7_1116", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What is the route of the treatment in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_7_1117", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "How long has elapsed from the treatment to the occurence of the event in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_7_1118", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "How long did the treatment last in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_7_1119", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What is the disorder targeted by the treatment in SSRIs and fentanyl?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_7_1120", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "What are the drugs used in combination in SSRIs and fentanyl?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_4_1121", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What are the drugs used in the treatment in dextran?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_4_1122", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What is the dosage of the treatment in dextran?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_4_1123", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What is the frequency of the treatment in dextran?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_4_1124", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What is the route of the treatment in dextran?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_4_1125", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in dextran?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_4_1126", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "How long did the treatment last in dextran?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_4_1127", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What is the disorder targeted by the treatment in dextran?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_4_1128", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "What are the drugs used in combination in dextran?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_4_1129", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What are the drugs used in the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9865241_4_1130", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What is the dosage of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_4_1131", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What is the frequency of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_4_1132", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What is the route of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_4_1133", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "How long has elapsed from the treatment to the occurence of the event in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_4_1134", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "How long did the treatment last in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_4_1135", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What is the disorder targeted by the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_4_1136", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "What are the drugs used in combination in pamidronate?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14614357_1_1137", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What are the drugs used in the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14614357_1_1138", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What is the dosage of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_1_1139", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What is the frequency of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_1_1140", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What is the route of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_1_1141", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "How long has elapsed from the treatment to the occurence of the event in acenocoumarol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_1_1142", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "How long did the treatment last in acenocoumarol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_1_1143", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What is the disorder targeted by the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14614357_1_1144", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "What are the drugs used in combination in acenocoumarol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8589490_3_1145", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What are the drugs used in the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_3_1146", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What is the dosage of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_3_1147", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What is the frequency of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_3_1148", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What is the route of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_3_1149", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_3_1150", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "How long did the treatment last in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_3_1151", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What is the disorder targeted by the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_3_1152", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "What are the drugs used in combination in CHOP chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_2_1153", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What are the drugs used in the treatment in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12488741_2_1154", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What is the dosage of the treatment in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_2_1155", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What is the frequency of the treatment in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_2_1156", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What is the route of the treatment in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_2_1157", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_2_1158", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "How long did the treatment last in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_2_1159", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What is the disorder targeted by the treatment in metronidazole treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_2_1160", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "What are the drugs used in combination in metronidazole treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_1_1161", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What are the drugs used in the treatment in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_1_1162", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What is the dosage of the treatment in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_1_1163", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What is the frequency of the treatment in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_1_1164", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What is the route of the treatment in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_1_1165", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "How long has elapsed from the treatment to the occurence of the event in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_1_1166", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "How long did the treatment last in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_1_1167", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What is the disorder targeted by the treatment in intravesical alum irrigations?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_1_1168", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "What are the drugs used in combination in intravesical alum irrigations?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_17_1169", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15522120_17_1170", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15522120_17_1171", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15522120_17_1172", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15522120_17_1173", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15522120_17_1174", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What are the drugs used in the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_17_1175", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the dosage of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_17_1176", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the frequency of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_17_1177", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the route of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_17_1178", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "How long has elapsed from the treatment to the occurence of the event in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_17_1179", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "How long did the treatment last in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_17_1180", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What is the disorder targeted by the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_17_1181", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "What are the drugs used in combination in SSRI-drugs?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_3_1182", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the age of the subject in A febrile 36-year-old seaman from Mumbai (Bombay)?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12659609_3_1183", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the gender of the subject in A febrile 36-year-old seaman from Mumbai (Bombay)?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12659609_3_1184", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the number of subjects in A febrile 36-year-old seaman from Mumbai (Bombay)?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12659609_3_1185", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the race of the subject in A febrile 36-year-old seaman from Mumbai (Bombay)?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12659609_3_1186", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the disorder of the subject in A febrile 36-year-old seaman from Mumbai (Bombay)?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12659609_3_1187", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What are the drugs used in the treatment in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12659609_3_1188", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the dosage of the treatment in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_3_1189", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the frequency of the treatment in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12659609_3_1190", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the route of the treatment in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12659609_3_1191", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "How long has elapsed from the treatment to the occurence of the event in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_3_1192", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "How long did the treatment last in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12659609_3_1193", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What is the disorder targeted by the treatment in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_3_1194", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "What are the drugs used in combination in >5 times the usual dose of chloroquine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19266307_2_1195", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19266307_2_1196", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19266307_2_1197", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19266307_2_1198", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19266307_2_1199", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19266307_2_1200", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What are the drugs used in the treatment in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19266307_2_1201", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the dosage of the treatment in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_2_1202", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the frequency of the treatment in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_2_1203", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the route of the treatment in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19266307_2_1204", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "How long has elapsed from the treatment to the occurence of the event in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_2_1205", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "How long did the treatment last in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_2_1206", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What is the disorder targeted by the treatment in two instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_2_1207", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "What are the drugs used in combination in two instillations of epirubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_2_1208", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What are the drugs used in the treatment in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_2_1209", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What is the dosage of the treatment in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_2_1210", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What is the frequency of the treatment in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_2_1211", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What is the route of the treatment in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_2_1212", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_2_1213", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "How long did the treatment last in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_2_1214", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What is the disorder targeted by the treatment in voriconazole therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_2_1215", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "What are the drugs used in combination in voriconazole therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_8_1216", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What are the drugs used in the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_8_1217", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What is the dosage of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_8_1218", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What is the frequency of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_8_1219", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What is the route of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_8_1220", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_8_1221", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "How long did the treatment last in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_8_1222", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What is the disorder targeted by the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_8_1223", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "What are the drugs used in combination in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10435399_2_1224", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10435399_2_1225", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10435399_2_1226", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10435399_2_1227", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10435399_2_1228", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10435399_2_1229", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10435399_2_1230", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_2_1231", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_2_1232", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_2_1233", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_2_1234", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_2_1235", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_2_1236", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_5_1237", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the age of the subject in Five of 70 patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_5_1238", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the gender of the subject in Five of 70 patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_5_1239", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the number of subjects in Five of 70 patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_5_1240", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the race of the subject in Five of 70 patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_5_1241", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the disorder of the subject in Five of 70 patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_5_1242", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What are the drugs used in the treatment in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_5_1243", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the dosage of the treatment in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_5_1244", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the frequency of the treatment in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_5_1245", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the route of the treatment in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_5_1246", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "How long has elapsed from the treatment to the occurence of the event in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_5_1247", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "How long did the treatment last in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_5_1248", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What is the disorder targeted by the treatment in leflunomide therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_5_1249", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "What are the drugs used in combination in leflunomide therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_2_1250", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the age of the subject in a patient with an AVM?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_2_1251", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the gender of the subject in a patient with an AVM?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_2_1252", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the number of subjects in a patient with an AVM?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_2_1253", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the race of the subject in a patient with an AVM?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_2_1254", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the disorder of the subject in a patient with an AVM?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_2_1255", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What are the drugs used in the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_2_1256", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the dosage of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_2_1257", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the frequency of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_2_1258", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the route of the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_2_1259", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "How long has elapsed from the treatment to the occurence of the event in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_2_1260", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "How long did the treatment last in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_2_1261", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What is the disorder targeted by the treatment in phenylpropanolamine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_2_1262", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "What are the drugs used in combination in phenylpropanolamine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_1_1263", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What are the drugs used in the treatment in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_1_1264", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What is the dosage of the treatment in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_1_1265", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What is the frequency of the treatment in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_1_1266", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What is the route of the treatment in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_1_1267", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "How long has elapsed from the treatment to the occurence of the event in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_1_1268", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "How long did the treatment last in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_1_1269", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What is the disorder targeted by the treatment in therapy with thiethylperazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_1_1270", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "What are the drugs used in combination in therapy with thiethylperazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_4_1271", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8430717_4_1272", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8430717_4_1273", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8430717_4_1274", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8430717_4_1275", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8430717_4_1276", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What are the drugs used in the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_4_1277", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the dosage of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_4_1278", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the frequency of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_4_1279", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the route of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_4_1280", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_4_1281", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "How long did the treatment last in acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_4_1282", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What is the disorder targeted by the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_4_1283", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "What are the drugs used in combination in acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_3_1284", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_3_1285", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_3_1286", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_3_1287", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_3_1288", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_3_1289", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_3_1290", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_3_1291", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_3_1292", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_3_1293", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_3_1294", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_3_1295", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_3_1296", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_3_1297", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_3_1298", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_3_1299", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_6_1300", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_6_1301", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_6_1302", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_6_1303", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_6_1304", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_6_1305", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What are the drugs used in the treatment in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_6_1306", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the dosage of the treatment in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_6_1307", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the frequency of the treatment in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_6_1308", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the route of the treatment in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_6_1309", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_6_1310", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "How long did the treatment last in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_6_1311", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What is the disorder targeted by the treatment in Shortly after commencing the drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_6_1312", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "What are the drugs used in combination in Shortly after commencing the drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_3_1313", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What are the drugs used in the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9562211_3_1314", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What is the dosage of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_3_1315", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What is the frequency of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_3_1316", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What is the route of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_3_1317", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "How long has elapsed from the treatment to the occurence of the event in risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_3_1318", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "How long did the treatment last in risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_3_1319", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What is the disorder targeted by the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_3_1320", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "What are the drugs used in combination in risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_4_1321", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the age of the subject in The patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_4_1322", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the gender of the subject in The patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_4_1323", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the number of subjects in The patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_4_1324", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the race of the subject in The patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_4_1325", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the disorder of the subject in The patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_4_1326", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What are the drugs used in the treatment in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_4_1327", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the dosage of the treatment in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_4_1328", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the frequency of the treatment in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_4_1329", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the route of the treatment in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_4_1330", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "How long has elapsed from the treatment to the occurence of the event in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_4_1331", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "How long did the treatment last in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_4_1332", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What is the disorder targeted by the treatment in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_4_1333", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "What are the drugs used in combination in infusion of the first dose of penicillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_4_1334", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What are the drugs used in the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_4_1335", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What is the dosage of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_4_1336", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What is the frequency of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_4_1337", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What is the route of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_4_1338", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in pentamidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_4_1339", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "How long did the treatment last in pentamidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_4_1340", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What is the disorder targeted by the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_4_1341", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "What are the drugs used in combination in pentamidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_1_1342", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What are the drugs used in the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_1_1343", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What is the dosage of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_1_1344", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What is the frequency of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_1_1345", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What is the route of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_1_1346", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "How long has elapsed from the treatment to the occurence of the event in BCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_1_1347", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "How long did the treatment last in BCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_1_1348", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What is the disorder targeted by the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_1_1349", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "What are the drugs used in combination in BCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_1_1350", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the age of the subject in patients with normal renal function?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10492493_1_1351", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the gender of the subject in patients with normal renal function?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10492493_1_1352", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the number of subjects in patients with normal renal function?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10492493_1_1353", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the race of the subject in patients with normal renal function?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10492493_1_1354", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the disorder of the subject in patients with normal renal function?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10492493_1_1355", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What are the drugs used in the treatment in losartan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_1_1356", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the dosage of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_1_1357", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the frequency of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_1_1358", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the route of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_1_1359", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "How long has elapsed from the treatment to the occurence of the event in losartan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_1_1360", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "How long did the treatment last in losartan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_1_1361", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What is the disorder targeted by the treatment in losartan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_1_1362", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "What are the drugs used in combination in losartan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_1_1363", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the age of the subject in Two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3211830_1_1364", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the gender of the subject in Two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3211830_1_1365", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the number of subjects in Two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3211830_1_1366", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the race of the subject in Two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3211830_1_1367", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the disorder of the subject in Two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3211830_1_1368", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What are the drugs used in the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3211830_1_1369", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the dosage of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_1_1370", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the frequency of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_1_1371", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the route of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_1_1372", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "How long has elapsed from the treatment to the occurence of the event in diltiazem?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_1_1373", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "How long did the treatment last in diltiazem?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_1_1374", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What is the disorder targeted by the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_1_1375", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "What are the drugs used in combination in diltiazem?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_4_1376", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What are the drugs used in the treatment in losartan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_4_1377", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What is the dosage of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_4_1378", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What is the frequency of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_4_1379", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What is the route of the treatment in losartan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_4_1380", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "How long has elapsed from the treatment to the occurence of the event in losartan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_4_1381", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "How long did the treatment last in losartan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_4_1382", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What is the disorder targeted by the treatment in losartan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_4_1383", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "What are the drugs used in combination in losartan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_2_1384", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the age of the subject in a young man, affected by rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18347524_2_1385", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the gender of the subject in a young man, affected by rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_2_1386", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the number of subjects in a young man, affected by rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_2_1387", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the race of the subject in a young man, affected by rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_2_1388", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the disorder of the subject in a young man, affected by rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_2_1389", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What are the drugs used in the treatment in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18347524_2_1390", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the dosage of the treatment in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_2_1391", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the frequency of the treatment in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_2_1392", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the route of the treatment in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18347524_2_1393", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "How long has elapsed from the treatment to the occurence of the event in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18347524_2_1394", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "How long did the treatment last in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_2_1395", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What is the disorder targeted by the treatment in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18347524_2_1396", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "What are the drugs used in combination in 2 weeks after the administration of leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_1_1397", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What are the drugs used in the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_1_1398", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What is the dosage of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_1_1399", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What is the frequency of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_1_1400", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What is the route of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_1_1401", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "How long has elapsed from the treatment to the occurence of the event in chloroquine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_1_1402", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "How long did the treatment last in chloroquine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_1_1403", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What is the disorder targeted by the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_1_1404", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "What are the drugs used in combination in chloroquine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_3_1405", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the age of the subject in Patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_3_1406", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the gender of the subject in Patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_3_1407", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the number of subjects in Patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_3_1408", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the race of the subject in Patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_3_1409", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the disorder of the subject in Patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_3_1410", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What are the drugs used in the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_3_1411", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the dosage of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_3_1412", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the frequency of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_3_1413", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the route of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_3_1414", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "How long has elapsed from the treatment to the occurence of the event in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_3_1415", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "How long did the treatment last in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_3_1416", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What is the disorder targeted by the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_3_1417", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "What are the drugs used in combination in nitrous oxide anesthesia?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_2_1418", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the age of the subject in two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15072497_2_1419", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the gender of the subject in two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15072497_2_1420", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the number of subjects in two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15072497_2_1421", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the race of the subject in two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15072497_2_1422", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the disorder of the subject in two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15072497_2_1423", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What are the drugs used in the treatment in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15072497_2_1424", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the dosage of the treatment in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15072497_2_1425", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the frequency of the treatment in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15072497_2_1426", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the route of the treatment in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_2_1427", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "How long has elapsed from the treatment to the occurence of the event in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_2_1428", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "How long did the treatment last in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_2_1429", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What is the disorder targeted by the treatment in high dose colchicine treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_2_1430", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "What are the drugs used in combination in high dose colchicine treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_3_1431", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the age of the subject in two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12786839_3_1432", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the gender of the subject in two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12786839_3_1433", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the number of subjects in two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12786839_3_1434", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the race of the subject in two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12786839_3_1435", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the disorder of the subject in two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12786839_3_1436", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What are the drugs used in the treatment in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_3_1437", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the dosage of the treatment in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_3_1438", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the frequency of the treatment in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_3_1439", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the route of the treatment in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_3_1440", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "How long has elapsed from the treatment to the occurence of the event in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_3_1441", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "How long did the treatment last in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_3_1442", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What is the disorder targeted by the treatment in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_3_1443", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "What are the drugs used in combination in salazosulfapyridine (SASP)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_2_1444", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What are the drugs used in the treatment in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_2_1445", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What is the dosage of the treatment in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_2_1446", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What is the frequency of the treatment in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_2_1447", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What is the route of the treatment in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_2_1448", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_2_1449", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "How long did the treatment last in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_2_1450", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What is the disorder targeted by the treatment in high-dose carmustine infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_2_1451", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "What are the drugs used in combination in high-dose carmustine infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_1_1452", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the age of the subject in a bone marrow transplant patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21802143_1_1453", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the gender of the subject in a bone marrow transplant patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21802143_1_1454", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the number of subjects in a bone marrow transplant patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21802143_1_1455", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the race of the subject in a bone marrow transplant patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21802143_1_1456", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the disorder of the subject in a bone marrow transplant patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21802143_1_1457", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What are the drugs used in the treatment in voriconazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21802143_1_1458", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the dosage of the treatment in voriconazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_1_1459", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the frequency of the treatment in voriconazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21802143_1_1460", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the route of the treatment in voriconazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21802143_1_1461", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "How long has elapsed from the treatment to the occurence of the event in voriconazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_1_1462", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "How long did the treatment last in voriconazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21802143_1_1463", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What is the disorder targeted by the treatment in voriconazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21802143_1_1464", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "What are the drugs used in combination in voriconazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12507063_2_1465", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What are the drugs used in the treatment in Gabapentin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12507063_2_1466", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What is the dosage of the treatment in Gabapentin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12507063_2_1467", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What is the frequency of the treatment in Gabapentin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_2_1468", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What is the route of the treatment in Gabapentin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_2_1469", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "How long has elapsed from the treatment to the occurence of the event in Gabapentin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_2_1470", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "How long did the treatment last in Gabapentin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_2_1471", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What is the disorder targeted by the treatment in Gabapentin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_2_1472", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "What are the drugs used in combination in Gabapentin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_1_1473", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What are the drugs used in the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_1_1474", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What is the dosage of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_1_1475", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What is the frequency of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_1_1476", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What is the route of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_1_1477", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_1_1478", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "How long did the treatment last in amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_1_1479", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What is the disorder targeted by the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_1_1480", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "What are the drugs used in combination in amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_3_1481", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What are the drugs used in the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_3_1482", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What is the dosage of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_3_1483", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What is the frequency of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_3_1484", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What is the route of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_3_1485", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "How long has elapsed from the treatment to the occurence of the event in Colchicine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_3_1486", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "How long did the treatment last in Colchicine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_3_1487", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What is the disorder targeted by the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_3_1488", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "What are the drugs used in combination in Colchicine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_2_1489", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What are the drugs used in the treatment in benzodiazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4075534_2_1490", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What is the dosage of the treatment in benzodiazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_2_1491", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What is the frequency of the treatment in benzodiazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_2_1492", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What is the route of the treatment in benzodiazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_2_1493", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "How long has elapsed from the treatment to the occurence of the event in benzodiazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_2_1494", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "How long did the treatment last in benzodiazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_2_1495", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What is the disorder targeted by the treatment in benzodiazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_2_1496", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "What are the drugs used in combination in benzodiazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_1_1497", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What are the drugs used in the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2483959_1_1498", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What is the dosage of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_1_1499", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What is the frequency of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_1_1500", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What is the route of the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_1_1501", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "How long has elapsed from the treatment to the occurence of the event in dextran-40?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_1_1502", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "How long did the treatment last in dextran-40?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_1_1503", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What is the disorder targeted by the treatment in dextran-40?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_1_1504", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "What are the drugs used in combination in dextran-40?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_1_1505", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15895899_1_1506", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15895899_1_1507", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15895899_1_1508", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15895899_1_1509", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15895899_1_1510", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What are the drugs used in the treatment in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_1_1511", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the dosage of the treatment in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_1_1512", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the frequency of the treatment in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_1_1513", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the route of the treatment in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_1_1514", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "How long has elapsed from the treatment to the occurence of the event in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_1_1515", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "How long did the treatment last in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_1_1516", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What is the disorder targeted by the treatment in second infliximab infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_1_1517", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "What are the drugs used in combination in second infliximab infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_1_1518", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What are the drugs used in the treatment in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7712052_1_1519", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What is the dosage of the treatment in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_1_1520", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What is the frequency of the treatment in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_1_1521", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What is the route of the treatment in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_1_1522", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "How long has elapsed from the treatment to the occurence of the event in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_1_1523", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "How long did the treatment last in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_1_1524", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What is the disorder targeted by the treatment in Lithium?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_1_1525", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "What are the drugs used in combination in Lithium?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14684937_2_1526", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the age of the subject in a case of psoriasis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_2_1527", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the gender of the subject in a case of psoriasis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14684937_2_1528", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the number of subjects in a case of psoriasis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_2_1529", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the race of the subject in a case of psoriasis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_2_1530", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the disorder of the subject in a case of psoriasis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_2_1531", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What are the drugs used in the treatment in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_2_1532", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the dosage of the treatment in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_2_1533", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the frequency of the treatment in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_2_1534", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the route of the treatment in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_2_1535", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "How long has elapsed from the treatment to the occurence of the event in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_2_1536", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "How long did the treatment last in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_2_1537", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What is the disorder targeted by the treatment in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_2_1538", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "What are the drugs used in combination in vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6362443_1_1539", "context": "A case of mania associated with fluoxetine.", "question": "What are the drugs used in the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6362443_1_1540", "context": "A case of mania associated with fluoxetine.", "question": "What is the dosage of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_1_1541", "context": "A case of mania associated with fluoxetine.", "question": "What is the frequency of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_1_1542", "context": "A case of mania associated with fluoxetine.", "question": "What is the route of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_1_1543", "context": "A case of mania associated with fluoxetine.", "question": "How long has elapsed from the treatment to the occurence of the event in fluoxetine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_1_1544", "context": "A case of mania associated with fluoxetine.", "question": "How long did the treatment last in fluoxetine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_1_1545", "context": "A case of mania associated with fluoxetine.", "question": "What is the disorder targeted by the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6362443_1_1546", "context": "A case of mania associated with fluoxetine.", "question": "What are the drugs used in combination in fluoxetine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_3_1547", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What are the drugs used in the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_3_1548", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What is the dosage of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_3_1549", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What is the frequency of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_3_1550", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What is the route of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_3_1551", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in progestin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_3_1552", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "How long did the treatment last in progestin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_3_1553", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What is the disorder targeted by the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_3_1554", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "What are the drugs used in combination in progestin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_1_1555", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What are the drugs used in the treatment in morphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16843118_1_1556", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What is the dosage of the treatment in morphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_1_1557", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What is the frequency of the treatment in morphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_1_1558", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What is the route of the treatment in morphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_1_1559", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "How long has elapsed from the treatment to the occurence of the event in morphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_1_1560", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "How long did the treatment last in morphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_1_1561", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What is the disorder targeted by the treatment in morphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_1_1562", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "What are the drugs used in combination in morphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_1_1563", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9149614_1_1564", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9149614_1_1565", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9149614_1_1566", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9149614_1_1567", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9149614_1_1568", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What are the drugs used in the treatment in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_1_1569", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the dosage of the treatment in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_1_1570", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the frequency of the treatment in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_1_1571", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the route of the treatment in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_1_1572", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "How long has elapsed from the treatment to the occurence of the event in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_1_1573", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "How long did the treatment last in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_1_1574", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What is the disorder targeted by the treatment in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_1_1575", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "What are the drugs used in combination in Eleven days after initiation of therapy with amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_3_1576", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the age of the subject in patients with ET?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_3_1577", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the gender of the subject in patients with ET?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_3_1578", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the number of subjects in patients with ET?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8579054_3_1579", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the race of the subject in patients with ET?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_3_1580", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the disorder of the subject in patients with ET?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_3_1581", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What are the drugs used in the treatment in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8579054_3_1582", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the dosage of the treatment in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_3_1583", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the frequency of the treatment in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8579054_3_1584", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the route of the treatment in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_3_1585", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_3_1586", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "How long did the treatment last in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_3_1587", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What is the disorder targeted by the treatment in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8579054_3_1588", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "What are the drugs used in combination in Prolonged used of hydroxyurea?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "354311_2_1589", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What are the drugs used in the treatment in BCG vaccination?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "354311_2_1590", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What is the dosage of the treatment in BCG vaccination?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_2_1591", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What is the frequency of the treatment in BCG vaccination?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_2_1592", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What is the route of the treatment in BCG vaccination?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_2_1593", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "How long has elapsed from the treatment to the occurence of the event in BCG vaccination?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_2_1594", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "How long did the treatment last in BCG vaccination?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_2_1595", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What is the disorder targeted by the treatment in BCG vaccination?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_2_1596", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "What are the drugs used in combination in BCG vaccination?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_1_1597", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What are the drugs used in the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1414247_1_1598", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What is the dosage of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_1_1599", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What is the frequency of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_1_1600", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What is the route of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_1_1601", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "How long has elapsed from the treatment to the occurence of the event in valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_1_1602", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "How long did the treatment last in valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_1_1603", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What is the disorder targeted by the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_1_1604", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "What are the drugs used in combination in valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_5_1605", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the age of the subject in two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8912599_5_1606", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the gender of the subject in two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8912599_5_1607", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the number of subjects in two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8912599_5_1608", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the race of the subject in two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8912599_5_1609", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the disorder of the subject in two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8912599_5_1610", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_5_1611", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_5_1612", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_5_1613", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_5_1614", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_5_1615", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_5_1616", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_5_1617", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_2_1618", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What are the drugs used in the treatment in Methysergide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9413296_2_1619", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What is the dosage of the treatment in Methysergide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_2_1620", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What is the frequency of the treatment in Methysergide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_2_1621", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What is the route of the treatment in Methysergide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_2_1622", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "How long has elapsed from the treatment to the occurence of the event in Methysergide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_2_1623", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "How long did the treatment last in Methysergide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_2_1624", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What is the disorder targeted by the treatment in Methysergide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_2_1625", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "What are the drugs used in combination in Methysergide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11099623_1_1626", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the age of the subject in 2 children with cerebral palsy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11099623_1_1627", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the gender of the subject in 2 children with cerebral palsy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11099623_1_1628", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the number of subjects in 2 children with cerebral palsy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11099623_1_1629", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the race of the subject in 2 children with cerebral palsy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11099623_1_1630", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the disorder of the subject in 2 children with cerebral palsy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11099623_1_1631", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What are the drugs used in the treatment in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11099623_1_1632", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the dosage of the treatment in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11099623_1_1633", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the frequency of the treatment in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11099623_1_1634", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the route of the treatment in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11099623_1_1635", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "How long has elapsed from the treatment to the occurence of the event in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11099623_1_1636", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "How long did the treatment last in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11099623_1_1637", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What is the disorder targeted by the treatment in hyperbaric oxygen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11099623_1_1638", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "What are the drugs used in combination in hyperbaric oxygen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_2_1639", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the age of the subject in A patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_2_1640", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the gender of the subject in A patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "53128_2_1641", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the number of subjects in A patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_2_1642", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the race of the subject in A patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_2_1643", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the disorder of the subject in A patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_2_1644", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What are the drugs used in the treatment in anticoagulants?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "53128_2_1645", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the dosage of the treatment in anticoagulants?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_2_1646", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the frequency of the treatment in anticoagulants?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_2_1647", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the route of the treatment in anticoagulants?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_2_1648", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "How long has elapsed from the treatment to the occurence of the event in anticoagulants?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_2_1649", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "How long did the treatment last in anticoagulants?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_2_1650", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What is the disorder targeted by the treatment in anticoagulants?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "53128_2_1651", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "What are the drugs used in combination in anticoagulants?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_1_1652", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What are the drugs used in the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_1_1653", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What is the dosage of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_1_1654", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What is the frequency of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_1_1655", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What is the route of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_1_1656", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_1_1657", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "How long did the treatment last in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_1_1658", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What is the disorder targeted by the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_1_1659", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "What are the drugs used in combination in fludarabine phosphate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_3_1660", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What are the drugs used in the treatment in Penicillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_3_1661", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What is the dosage of the treatment in Penicillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_3_1662", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What is the frequency of the treatment in Penicillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_3_1663", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What is the route of the treatment in Penicillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_3_1664", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "How long has elapsed from the treatment to the occurence of the event in Penicillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_3_1665", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "How long did the treatment last in Penicillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_3_1666", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What is the disorder targeted by the treatment in Penicillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_3_1667", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "What are the drugs used in combination in Penicillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_4_1668", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the age of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_4_1669", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the gender of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_4_1670", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the number of subjects in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_4_1671", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the race of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_4_1672", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the disorder of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_4_1673", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What are the drugs used in the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_4_1674", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the dosage of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_4_1675", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the frequency of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_4_1676", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the route of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_4_1677", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "How long has elapsed from the treatment to the occurence of the event in risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_4_1678", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "How long did the treatment last in risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_4_1679", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What is the disorder targeted by the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_4_1680", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "What are the drugs used in combination in risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11315123_1_1681", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "What is the age of the subject in a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11315123_1_1682", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "What is the gender of the subject in a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11315123_1_1683", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "What is the number of subjects in a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11315123_1_1684", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "What is the race of the subject in a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11315123_1_1685", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "What is the disorder of the subject in a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1557089_1_1686", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the age of the subject in postoperative patient with pre-existent myasthenia gravis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1557089_1_1687", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the gender of the subject in postoperative patient with pre-existent myasthenia gravis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1557089_1_1688", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the number of subjects in postoperative patient with pre-existent myasthenia gravis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1557089_1_1689", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the race of the subject in postoperative patient with pre-existent myasthenia gravis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1557089_1_1690", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the disorder of the subject in postoperative patient with pre-existent myasthenia gravis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1557089_1_1691", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What are the drugs used in the treatment in oral verapamil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1557089_1_1692", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the dosage of the treatment in oral verapamil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1557089_1_1693", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the frequency of the treatment in oral verapamil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1557089_1_1694", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the route of the treatment in oral verapamil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1557089_1_1695", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "How long has elapsed from the treatment to the occurence of the event in oral verapamil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1557089_1_1696", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "How long did the treatment last in oral verapamil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1557089_1_1697", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What is the disorder targeted by the treatment in oral verapamil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1557089_1_1698", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "What are the drugs used in combination in oral verapamil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_1_1699", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_1_1700", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_1_1701", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_1_1702", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_1_1703", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_1_1704", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What are the drugs used in the treatment in penicillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_1_1705", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the dosage of the treatment in penicillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_1_1706", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the frequency of the treatment in penicillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_1_1707", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the route of the treatment in penicillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_1_1708", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "How long has elapsed from the treatment to the occurence of the event in penicillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_1_1709", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "How long did the treatment last in penicillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_1_1710", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What is the disorder targeted by the treatment in penicillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_1_1711", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "What are the drugs used in combination in penicillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_2_1712", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the age of the subject in A 34-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16490518_2_1713", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the gender of the subject in A 34-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16490518_2_1714", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the number of subjects in A 34-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_2_1715", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the race of the subject in A 34-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_2_1716", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the disorder of the subject in A 34-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_2_1717", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What are the drugs used in the treatment in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_2_1718", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the dosage of the treatment in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_2_1719", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the frequency of the treatment in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_2_1720", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the route of the treatment in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_2_1721", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_2_1722", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "How long did the treatment last in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_2_1723", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What is the disorder targeted by the treatment in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_2_1724", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "What are the drugs used in combination in intravitreal injection of triamcinolone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_1_1725", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What are the drugs used in the treatment in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16537817_1_1726", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What is the dosage of the treatment in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_1_1727", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What is the frequency of the treatment in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_1_1728", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What is the route of the treatment in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_1_1729", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_1_1730", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "How long did the treatment last in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_1_1731", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What is the disorder targeted by the treatment in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_1_1732", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "What are the drugs used in combination in Simvastatin-amiodarone interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21330680_13_1733", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the age of the subject in A 73-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21330680_13_1734", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the gender of the subject in A 73-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21330680_13_1735", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the number of subjects in A 73-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_13_1736", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the race of the subject in A 73-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_13_1737", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the disorder of the subject in A 73-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_13_1738", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What are the drugs used in the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_13_1739", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the dosage of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_13_1740", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the frequency of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_13_1741", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the route of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_13_1742", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_13_1743", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "How long did the treatment last in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_13_1744", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What is the disorder targeted by the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_13_1745", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "What are the drugs used in combination in high-dosage olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_2_1746", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What are the drugs used in the treatment in paclitaxel?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_2_1747", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What is the dosage of the treatment in paclitaxel?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_2_1748", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What is the frequency of the treatment in paclitaxel?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_2_1749", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What is the route of the treatment in paclitaxel?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_2_1750", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in paclitaxel?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_2_1751", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "How long did the treatment last in paclitaxel?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_2_1752", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What is the disorder targeted by the treatment in paclitaxel?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_2_1753", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "What are the drugs used in combination in paclitaxel?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_1_1754", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What are the drugs used in the treatment in Raltegravir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_1_1755", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What is the dosage of the treatment in Raltegravir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_1_1756", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What is the frequency of the treatment in Raltegravir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_1_1757", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What is the route of the treatment in Raltegravir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_1_1758", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "How long has elapsed from the treatment to the occurence of the event in Raltegravir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_1_1759", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "How long did the treatment last in Raltegravir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_1_1760", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What is the disorder targeted by the treatment in Raltegravir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_1_1761", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "What are the drugs used in combination in Raltegravir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_1_1762", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the age of the subject in A 10-year-old boy with osteosarcoma and normal renal function?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_1_1763", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the gender of the subject in A 10-year-old boy with osteosarcoma and normal renal function?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_1_1764", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the number of subjects in A 10-year-old boy with osteosarcoma and normal renal function?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_1_1765", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the race of the subject in A 10-year-old boy with osteosarcoma and normal renal function?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_1_1766", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the disorder of the subject in A 10-year-old boy with osteosarcoma and normal renal function?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_1_1767", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What are the drugs used in the treatment in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_1_1768", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the dosage of the treatment in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_1_1769", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the frequency of the treatment in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_1_1770", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the route of the treatment in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_1_1771", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "How long has elapsed from the treatment to the occurence of the event in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_1_1772", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "How long did the treatment last in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_1_1773", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What is the disorder targeted by the treatment in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_1_1774", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "What are the drugs used in combination in a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_1_1775", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the age of the subject in three depressed patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2012922_1_1776", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the gender of the subject in three depressed patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2012922_1_1777", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the number of subjects in three depressed patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2012922_1_1778", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the race of the subject in three depressed patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2012922_1_1779", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the disorder of the subject in three depressed patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2012922_1_1780", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What are the drugs used in the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2012922_1_1781", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the dosage of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_1_1782", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the frequency of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_1_1783", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the route of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_1_1784", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "How long has elapsed from the treatment to the occurence of the event in trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_1_1785", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "How long did the treatment last in trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_1_1786", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What is the disorder targeted by the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2012922_1_1787", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "What are the drugs used in combination in trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9886213_4_1788", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What are the drugs used in the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9886213_4_1789", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What is the dosage of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_4_1790", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What is the frequency of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_4_1791", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What is the route of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_4_1792", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "How long has elapsed from the treatment to the occurence of the event in praziquantel?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_4_1793", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "How long did the treatment last in praziquantel?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_4_1794", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What is the disorder targeted by the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_4_1795", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "What are the drugs used in combination in praziquantel?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_2_1796", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the age of the subject in patients who have unexplained high temperatures?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1888256_2_1797", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the gender of the subject in patients who have unexplained high temperatures?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1888256_2_1798", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the number of subjects in patients who have unexplained high temperatures?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1888256_2_1799", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the race of the subject in patients who have unexplained high temperatures?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1888256_2_1800", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the disorder of the subject in patients who have unexplained high temperatures?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1888256_2_1801", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What are the drugs used in the treatment in Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_2_1802", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the dosage of the treatment in Drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_2_1803", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the frequency of the treatment in Drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_2_1804", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the route of the treatment in Drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_2_1805", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in Drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_2_1806", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "How long did the treatment last in Drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_2_1807", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What is the disorder targeted by the treatment in Drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_2_1808", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "What are the drugs used in combination in Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9443627_1_1809", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What are the drugs used in the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9443627_1_1810", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What is the dosage of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9443627_1_1811", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What is the frequency of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9443627_1_1812", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What is the route of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9443627_1_1813", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in ifosfamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9443627_1_1814", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "How long did the treatment last in ifosfamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9443627_1_1815", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What is the disorder targeted by the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9443627_1_1816", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "What are the drugs used in combination in ifosfamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_2_1817", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What are the drugs used in the treatment in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_2_1818", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What is the dosage of the treatment in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_2_1819", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What is the frequency of the treatment in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_2_1820", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What is the route of the treatment in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_2_1821", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_2_1822", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "How long did the treatment last in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_2_1823", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What is the disorder targeted by the treatment in amphotericin B treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_2_1824", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "What are the drugs used in combination in amphotericin B treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_2_1825", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What are the drugs used in the treatment in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6199475_2_1826", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What is the dosage of the treatment in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_2_1827", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What is the frequency of the treatment in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_2_1828", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What is the route of the treatment in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_2_1829", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "How long has elapsed from the treatment to the occurence of the event in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_2_1830", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "How long did the treatment last in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_2_1831", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What is the disorder targeted by the treatment in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6199475_2_1832", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "What are the drugs used in combination in treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3410226_2_1833", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the age of the subject in a 46-yr-old woman with ovarian carcinoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3410226_2_1834", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the gender of the subject in a 46-yr-old woman with ovarian carcinoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3410226_2_1835", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the number of subjects in a 46-yr-old woman with ovarian carcinoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3410226_2_1836", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the race of the subject in a 46-yr-old woman with ovarian carcinoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3410226_2_1837", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the disorder of the subject in a 46-yr-old woman with ovarian carcinoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3410226_2_1838", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What are the drugs used in the treatment in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3410226_2_1839", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the dosage of the treatment in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_2_1840", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the frequency of the treatment in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_2_1841", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the route of the treatment in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_2_1842", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "How long has elapsed from the treatment to the occurence of the event in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_2_1843", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "How long did the treatment last in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_2_1844", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What is the disorder targeted by the treatment in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3410226_2_1845", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "What are the drugs used in combination in cisplatin and cyclophosphamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_2_1846", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the age of the subject in one child?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_2_1847", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the gender of the subject in one child?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_2_1848", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the number of subjects in one child?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_2_1849", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the race of the subject in one child?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_2_1850", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the disorder of the subject in one child?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_2_1851", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What are the drugs used in the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_2_1852", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the dosage of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_2_1853", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the frequency of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_2_1854", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the route of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_2_1855", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_2_1856", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "How long did the treatment last in carbamazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_2_1857", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What is the disorder targeted by the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_2_1858", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "What are the drugs used in combination in carbamazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_1_1859", "context": "Does acyclovir increase serum lithium levels?", "question": "What are the drugs used in the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_1_1860", "context": "Does acyclovir increase serum lithium levels?", "question": "What is the dosage of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_1_1861", "context": "Does acyclovir increase serum lithium levels?", "question": "What is the frequency of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_1_1862", "context": "Does acyclovir increase serum lithium levels?", "question": "What is the route of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_1_1863", "context": "Does acyclovir increase serum lithium levels?", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_1_1864", "context": "Does acyclovir increase serum lithium levels?", "question": "How long did the treatment last in acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_1_1865", "context": "Does acyclovir increase serum lithium levels?", "question": "What is the disorder targeted by the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_1_1866", "context": "Does acyclovir increase serum lithium levels?", "question": "What are the drugs used in combination in acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_2_1867", "context": "Sulfadiazine crystalluria revisited.", "question": "What are the drugs used in the treatment in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_2_1868", "context": "Sulfadiazine crystalluria revisited.", "question": "What is the dosage of the treatment in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_2_1869", "context": "Sulfadiazine crystalluria revisited.", "question": "What is the frequency of the treatment in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_2_1870", "context": "Sulfadiazine crystalluria revisited.", "question": "What is the route of the treatment in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_2_1871", "context": "Sulfadiazine crystalluria revisited.", "question": "How long has elapsed from the treatment to the occurence of the event in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_2_1872", "context": "Sulfadiazine crystalluria revisited.", "question": "How long did the treatment last in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_2_1873", "context": "Sulfadiazine crystalluria revisited.", "question": "What is the disorder targeted by the treatment in Sulfadiazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_2_1874", "context": "Sulfadiazine crystalluria revisited.", "question": "What are the drugs used in combination in Sulfadiazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16472339_1_1875", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the age of the subject in migraine patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16472339_1_1876", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the gender of the subject in migraine patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16472339_1_1877", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the number of subjects in migraine patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16472339_1_1878", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the race of the subject in migraine patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16472339_1_1879", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the disorder of the subject in migraine patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16472339_1_1880", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What are the drugs used in the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16472339_1_1881", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the dosage of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16472339_1_1882", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the frequency of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16472339_1_1883", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the route of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16472339_1_1884", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "How long has elapsed from the treatment to the occurence of the event in sumatriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16472339_1_1885", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "How long did the treatment last in sumatriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16472339_1_1886", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What is the disorder targeted by the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16472339_1_1887", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "What are the drugs used in combination in sumatriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_2_1888", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the age of the subject in Six of 13 outpatients with schizophrenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_2_1889", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the gender of the subject in Six of 13 outpatients with schizophrenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_2_1890", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the number of subjects in Six of 13 outpatients with schizophrenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_2_1891", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the race of the subject in Six of 13 outpatients with schizophrenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_2_1892", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the disorder of the subject in Six of 13 outpatients with schizophrenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_2_1893", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What are the drugs used in the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_2_1894", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the dosage of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_2_1895", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the frequency of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_2_1896", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the route of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_2_1897", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "How long has elapsed from the treatment to the occurence of the event in risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_2_1898", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "How long did the treatment last in risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_2_1899", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What is the disorder targeted by the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_2_1900", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "What are the drugs used in combination in risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_1_1901", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the age of the subject in a patient with pulmonary hypertension and limited scleroderma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10332990_1_1902", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the gender of the subject in a patient with pulmonary hypertension and limited scleroderma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10332990_1_1903", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the number of subjects in a patient with pulmonary hypertension and limited scleroderma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10332990_1_1904", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the race of the subject in a patient with pulmonary hypertension and limited scleroderma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10332990_1_1905", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the disorder of the subject in a patient with pulmonary hypertension and limited scleroderma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10332990_1_1906", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What are the drugs used in the treatment in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10332990_1_1907", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the dosage of the treatment in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_1_1908", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the frequency of the treatment in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10332990_1_1909", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the route of the treatment in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10332990_1_1910", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "How long has elapsed from the treatment to the occurence of the event in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_1_1911", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "How long did the treatment last in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10332990_1_1912", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What is the disorder targeted by the treatment in acute infusion of epoprostenol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10332990_1_1913", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "What are the drugs used in combination in acute infusion of epoprostenol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_3_1914", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What are the drugs used in the treatment in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "3003260_3_1915", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What is the dosage of the treatment in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_3_1916", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What is the frequency of the treatment in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3003260_3_1917", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What is the route of the treatment in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3003260_3_1918", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "How long has elapsed from the treatment to the occurence of the event in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_3_1919", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "How long did the treatment last in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3003260_3_1920", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What is the disorder targeted by the treatment in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_3_1921", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "What are the drugs used in combination in Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16087771_1_1922", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What are the drugs used in the treatment in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16087771_1_1923", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What is the dosage of the treatment in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16087771_1_1924", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What is the frequency of the treatment in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16087771_1_1925", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What is the route of the treatment in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16087771_1_1926", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16087771_1_1927", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "How long did the treatment last in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16087771_1_1928", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What is the disorder targeted by the treatment in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16087771_1_1929", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "What are the drugs used in combination in long-term treatment with the dopamine agonist pergolide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "556126_1_1930", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "What is the age of the subject in An infertile patient with amenorrhea-galactorrhea syndrome lost vision?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "556126_1_1931", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "What is the gender of the subject in An infertile patient with amenorrhea-galactorrhea syndrome lost vision?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "556126_1_1932", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "What is the number of subjects in An infertile patient with amenorrhea-galactorrhea syndrome lost vision?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "556126_1_1933", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "What is the race of the subject in An infertile patient with amenorrhea-galactorrhea syndrome lost vision?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "556126_1_1934", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "What is the disorder of the subject in An infertile patient with amenorrhea-galactorrhea syndrome lost vision?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8430717_2_1935", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What are the drugs used in the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_2_1936", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What is the dosage of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_2_1937", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What is the frequency of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_2_1938", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What is the route of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_2_1939", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_2_1940", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "How long did the treatment last in acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_2_1941", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What is the disorder targeted by the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_2_1942", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "What are the drugs used in combination in acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_5_1943", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the age of the subject in Two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8850251_5_1944", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the gender of the subject in Two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8850251_5_1945", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the number of subjects in Two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8850251_5_1946", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the race of the subject in Two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8850251_5_1947", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the disorder of the subject in Two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8850251_5_1948", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What are the drugs used in the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_5_1949", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the dosage of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_5_1950", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the frequency of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_5_1951", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the route of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_5_1952", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "How long has elapsed from the treatment to the occurence of the event in mequitazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_5_1953", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "How long did the treatment last in mequitazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_5_1954", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What is the disorder targeted by the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_5_1955", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "What are the drugs used in combination in mequitazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_3_1956", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the age of the subject in a patient with decreased calcium-dependent potassium permeability of cell membranes?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_3_1957", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the gender of the subject in a patient with decreased calcium-dependent potassium permeability of cell membranes?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_3_1958", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the number of subjects in a patient with decreased calcium-dependent potassium permeability of cell membranes?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_3_1959", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the race of the subject in a patient with decreased calcium-dependent potassium permeability of cell membranes?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_3_1960", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the disorder of the subject in a patient with decreased calcium-dependent potassium permeability of cell membranes?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_3_1961", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_3_1962", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_3_1963", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_3_1964", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_3_1965", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_3_1966", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_3_1967", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_3_1968", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_1_1969", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the age of the subject in A 47 year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9737132_1_1970", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the gender of the subject in A 47 year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9737132_1_1971", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the number of subjects in A 47 year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9737132_1_1972", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the race of the subject in A 47 year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9737132_1_1973", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the disorder of the subject in A 47 year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9737132_1_1974", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What are the drugs used in the treatment in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_1_1975", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the dosage of the treatment in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_1_1976", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the frequency of the treatment in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_1_1977", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the route of the treatment in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_1_1978", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "How long has elapsed from the treatment to the occurence of the event in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_1_1979", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "How long did the treatment last in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_1_1980", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What is the disorder targeted by the treatment in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_1_1981", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "What are the drugs used in combination in intramuscular pentazocine injections in the lower extremities?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_5_1982", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10592946_5_1983", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_5_1984", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_5_1985", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_5_1986", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10592946_5_1987", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What are the drugs used in the treatment in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_5_1988", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the dosage of the treatment in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_5_1989", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the frequency of the treatment in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_5_1990", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the route of the treatment in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_5_1991", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "How long has elapsed from the treatment to the occurence of the event in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_5_1992", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "How long did the treatment last in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_5_1993", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What is the disorder targeted by the treatment in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_5_1994", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "What are the drugs used in combination in massive ingestion of caffeine-containing beverages?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_3_1995", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the age of the subject in A 25-year-old postpartum white woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_3_1996", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the gender of the subject in A 25-year-old postpartum white woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_3_1997", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the number of subjects in A 25-year-old postpartum white woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_3_1998", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the race of the subject in A 25-year-old postpartum white woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_3_1999", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the disorder of the subject in A 25-year-old postpartum white woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_3_2000", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What are the drugs used in the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_3_2001", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the dosage of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_3_2002", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the frequency of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_3_2003", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the route of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_3_2004", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "How long has elapsed from the treatment to the occurence of the event in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_3_2005", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "How long did the treatment last in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_3_2006", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What is the disorder targeted by the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_3_2007", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "What are the drugs used in combination in clindamycin vaginal cream?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_1_2008", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the age of the subject in three case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_1_2009", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the gender of the subject in three case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_1_2010", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the number of subjects in three case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_1_2011", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the race of the subject in three case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_1_2012", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the disorder of the subject in three case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_1_2013", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What are the drugs used in the treatment in Dose?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_1_2014", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the dosage of the treatment in Dose?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_1_2015", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the frequency of the treatment in Dose?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_1_2016", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the route of the treatment in Dose?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_1_2017", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "How long has elapsed from the treatment to the occurence of the event in Dose?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_1_2018", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "How long did the treatment last in Dose?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_1_2019", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What is the disorder targeted by the treatment in Dose?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_1_2020", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "What are the drugs used in combination in Dose?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_8_2021", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the age of the subject in He?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_8_2022", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the gender of the subject in He?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_8_2023", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the number of subjects in He?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_8_2024", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the race of the subject in He?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_8_2025", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the disorder of the subject in He?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_8_2026", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What are the drugs used in the treatment in administration of levodopa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_8_2027", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the dosage of the treatment in administration of levodopa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_8_2028", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the frequency of the treatment in administration of levodopa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_8_2029", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the route of the treatment in administration of levodopa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_8_2030", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "How long has elapsed from the treatment to the occurence of the event in administration of levodopa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_8_2031", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "How long did the treatment last in administration of levodopa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_8_2032", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What is the disorder targeted by the treatment in administration of levodopa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_8_2033", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "What are the drugs used in combination in administration of levodopa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_2_2034", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What are the drugs used in the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19112808_2_2035", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the dosage of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_2_2036", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the frequency of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_2_2037", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the route of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_2_2038", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "How long has elapsed from the treatment to the occurence of the event in darifenacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_2_2039", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "How long did the treatment last in darifenacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_2_2040", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the disorder targeted by the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_2_2041", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "What are the drugs used in combination in darifenacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_6_2042", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_6_2043", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7056119_6_2044", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_6_2045", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_6_2046", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_6_2047", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What are the drugs used in the treatment in Amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_6_2048", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the dosage of the treatment in Amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_6_2049", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the frequency of the treatment in Amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_6_2050", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the route of the treatment in Amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_6_2051", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "How long has elapsed from the treatment to the occurence of the event in Amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_6_2052", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "How long did the treatment last in Amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_6_2053", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What is the disorder targeted by the treatment in Amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_6_2054", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "What are the drugs used in combination in Amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_1_2055", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the age of the subject in A young diamond dealer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3003260_1_2056", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the gender of the subject in A young diamond dealer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3003260_1_2057", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the number of subjects in A young diamond dealer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3003260_1_2058", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the race of the subject in A young diamond dealer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3003260_1_2059", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the disorder of the subject in A young diamond dealer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3003260_1_2060", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What are the drugs used in the treatment in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3003260_1_2061", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the dosage of the treatment in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_1_2062", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the frequency of the treatment in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_1_2063", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the route of the treatment in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_1_2064", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "How long has elapsed from the treatment to the occurence of the event in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_1_2065", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "How long did the treatment last in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_1_2066", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What is the disorder targeted by the treatment in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_1_2067", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "What are the drugs used in combination in four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_3_2068", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What are the drugs used in the treatment in losartan administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_3_2069", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What is the dosage of the treatment in losartan administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_3_2070", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What is the frequency of the treatment in losartan administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_3_2071", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What is the route of the treatment in losartan administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_3_2072", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "How long has elapsed from the treatment to the occurence of the event in losartan administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_3_2073", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "How long did the treatment last in losartan administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_3_2074", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What is the disorder targeted by the treatment in losartan administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_3_2075", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "What are the drugs used in combination in losartan administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_2_2076", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What are the drugs used in the treatment in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_2_2077", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What is the dosage of the treatment in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_2_2078", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What is the frequency of the treatment in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_2_2079", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What is the route of the treatment in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_2_2080", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "How long has elapsed from the treatment to the occurence of the event in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_2_2081", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "How long did the treatment last in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_2_2082", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What is the disorder targeted by the treatment in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_2_2083", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "What are the drugs used in combination in 3 months after the transurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_1_2084", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the age of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_1_2085", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the gender of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_1_2086", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the number of subjects in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_1_2087", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the race of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_1_2088", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the disorder of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_1_2089", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What are the drugs used in the treatment in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_1_2090", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the dosage of the treatment in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_1_2091", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the frequency of the treatment in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_1_2092", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the route of the treatment in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_1_2093", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_1_2094", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "How long did the treatment last in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_1_2095", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What is the disorder targeted by the treatment in methotrexate and rofecoxib?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_1_2096", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "What are the drugs used in combination in methotrexate and rofecoxib?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_4_2097", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What are the drugs used in the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_4_2098", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What is the dosage of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_4_2099", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What is the frequency of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_4_2100", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What is the route of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_4_2101", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "How long has elapsed from the treatment to the occurence of the event in aspirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_4_2102", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "How long did the treatment last in aspirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_4_2103", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What is the disorder targeted by the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_4_2104", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "What are the drugs used in combination in aspirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_13_2105", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What are the drugs used in the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_13_2106", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What is the dosage of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_13_2107", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What is the frequency of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_13_2108", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What is the route of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_13_2109", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "How long has elapsed from the treatment to the occurence of the event in omeprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_13_2110", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "How long did the treatment last in omeprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_13_2111", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What is the disorder targeted by the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_13_2112", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "What are the drugs used in combination in omeprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_1_2113", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the age of the subject in a patient with severe digitoxin intoxication?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1469187_1_2114", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the gender of the subject in a patient with severe digitoxin intoxication?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1469187_1_2115", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the number of subjects in a patient with severe digitoxin intoxication?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1469187_1_2116", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the race of the subject in a patient with severe digitoxin intoxication?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1469187_1_2117", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the disorder of the subject in a patient with severe digitoxin intoxication?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1469187_1_2118", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What are the drugs used in the treatment in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1469187_1_2119", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the dosage of the treatment in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_1_2120", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the frequency of the treatment in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1469187_1_2121", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the route of the treatment in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1469187_1_2122", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "How long has elapsed from the treatment to the occurence of the event in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_1_2123", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "How long did the treatment last in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1469187_1_2124", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What is the disorder targeted by the treatment in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_1_2125", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "What are the drugs used in combination in Fab fragments of anti-digitalis antibodies?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3410226_1_2126", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What are the drugs used in the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3410226_1_2127", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What is the dosage of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_1_2128", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What is the frequency of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_1_2129", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What is the route of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_1_2130", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_1_2131", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "How long did the treatment last in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_1_2132", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What is the disorder targeted by the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3410226_1_2133", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "What are the drugs used in combination in cyclophosphamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_2_2134", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the age of the subject in a premature infant?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3242521_2_2135", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the gender of the subject in a premature infant?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_2_2136", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the number of subjects in a premature infant?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_2_2137", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the race of the subject in a premature infant?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_2_2138", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the disorder of the subject in a premature infant?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3242521_2_2139", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What are the drugs used in the treatment in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3242521_2_2140", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the dosage of the treatment in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_2_2141", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the frequency of the treatment in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_2_2142", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the route of the treatment in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3242521_2_2143", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "How long has elapsed from the treatment to the occurence of the event in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_2_2144", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "How long did the treatment last in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_2_2145", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What is the disorder targeted by the treatment in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_2_2146", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "What are the drugs used in combination in intraventricular administration of nafcillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_4_2147", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the age of the subject in a single case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_4_2148", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the gender of the subject in a single case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_4_2149", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the number of subjects in a single case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_4_2150", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the race of the subject in a single case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_4_2151", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the disorder of the subject in a single case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_4_2152", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What are the drugs used in the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_4_2153", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the dosage of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_4_2154", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the frequency of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_4_2155", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the route of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_4_2156", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "How long has elapsed from the treatment to the occurence of the event in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_4_2157", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "How long did the treatment last in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_4_2158", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What is the disorder targeted by the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_4_2159", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "What are the drugs used in combination in zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_1_2160", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What are the drugs used in the treatment in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_1_2161", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What is the dosage of the treatment in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_1_2162", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What is the frequency of the treatment in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_1_2163", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What is the route of the treatment in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_1_2164", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_1_2165", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "How long did the treatment last in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_1_2166", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What is the disorder targeted by the treatment in gemcitabine monotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_1_2167", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "What are the drugs used in combination in gemcitabine monotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_1_2168", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What are the drugs used in the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6427463_1_2169", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What is the dosage of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_1_2170", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What is the frequency of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_1_2171", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What is the route of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_1_2172", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "How long has elapsed from the treatment to the occurence of the event in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_1_2173", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "How long did the treatment last in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_1_2174", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What is the disorder targeted by the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_1_2175", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "What are the drugs used in combination in gold sodium thiomalate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_3_2176", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What are the drugs used in the treatment in MTX?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_3_2177", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What is the dosage of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_3_2178", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What is the frequency of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_3_2179", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What is the route of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_3_2180", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in MTX?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_3_2181", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "How long did the treatment last in MTX?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_3_2182", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in MTX?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_3_2183", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "What are the drugs used in combination in MTX?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_9_2184", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What are the drugs used in the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_9_2185", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What is the dosage of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_9_2186", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What is the frequency of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_9_2187", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What is the route of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_9_2188", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "How long has elapsed from the treatment to the occurence of the event in fluoxetine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_9_2189", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "How long did the treatment last in fluoxetine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_9_2190", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What is the disorder targeted by the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_9_2191", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "What are the drugs used in combination in fluoxetine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_2_2192", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What are the drugs used in the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_2_2193", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What is the dosage of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_2_2194", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What is the frequency of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_2_2195", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What is the route of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_2_2196", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "How long has elapsed from the treatment to the occurence of the event in etanercept?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_2_2197", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "How long did the treatment last in etanercept?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_2_2198", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What is the disorder targeted by the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_2_2199", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "What are the drugs used in combination in etanercept?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_3_2200", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What are the drugs used in the treatment in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_3_2201", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What is the dosage of the treatment in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_3_2202", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What is the frequency of the treatment in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_3_2203", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What is the route of the treatment in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_3_2204", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_3_2205", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "How long did the treatment last in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_3_2206", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What is the disorder targeted by the treatment in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_3_2207", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "What are the drugs used in combination in long-term pulse itraconazole treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3824704_1_2208", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What are the drugs used in the treatment in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3824704_1_2209", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What is the dosage of the treatment in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3824704_1_2210", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What is the frequency of the treatment in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3824704_1_2211", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What is the route of the treatment in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3824704_1_2212", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "How long has elapsed from the treatment to the occurence of the event in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3824704_1_2213", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "How long did the treatment last in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3824704_1_2214", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What is the disorder targeted by the treatment in intravesical formalin instillation?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3824704_1_2215", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "What are the drugs used in combination in intravesical formalin instillation?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_3_2216", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What are the drugs used in the treatment in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16101941_3_2217", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What is the dosage of the treatment in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_3_2218", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What is the frequency of the treatment in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_3_2219", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What is the route of the treatment in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_3_2220", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "How long has elapsed from the treatment to the occurence of the event in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_3_2221", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "How long did the treatment last in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_3_2222", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What is the disorder targeted by the treatment in anti-emetic drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_3_2223", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "What are the drugs used in combination in anti-emetic drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_2_2224", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What are the drugs used in the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_2_2225", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What is the dosage of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_2_2226", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What is the frequency of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_2_2227", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What is the route of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_2_2228", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_2_2229", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "How long did the treatment last in cyclosporine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_2_2230", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What is the disorder targeted by the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_2_2231", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "What are the drugs used in combination in cyclosporine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_14_2232", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the age of the subject in patients?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20925534_14_2233", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the gender of the subject in patients?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20925534_14_2234", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the number of subjects in patients?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20925534_14_2235", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the race of the subject in patients?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20925534_14_2236", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the disorder of the subject in patients?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20925534_14_2237", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What are the drugs used in the treatment in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20925534_14_2238", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the dosage of the treatment in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_14_2239", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the frequency of the treatment in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_14_2240", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the route of the treatment in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_14_2241", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "How long has elapsed from the treatment to the occurence of the event in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_14_2242", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "How long did the treatment last in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_14_2243", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What is the disorder targeted by the treatment in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_14_2244", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "What are the drugs used in combination in aspirin and clopidogrel?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11295724_3_2245", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the age of the subject in a pediatric bone marrow transplant recipient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11295724_3_2246", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the gender of the subject in a pediatric bone marrow transplant recipient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11295724_3_2247", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the number of subjects in a pediatric bone marrow transplant recipient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_3_2248", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the race of the subject in a pediatric bone marrow transplant recipient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_3_2249", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the disorder of the subject in a pediatric bone marrow transplant recipient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_3_2250", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What are the drugs used in the treatment in Clofazimine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11295724_3_2251", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the dosage of the treatment in Clofazimine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_3_2252", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the frequency of the treatment in Clofazimine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_3_2253", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the route of the treatment in Clofazimine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_3_2254", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "How long has elapsed from the treatment to the occurence of the event in Clofazimine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11295724_3_2255", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "How long did the treatment last in Clofazimine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_3_2256", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What is the disorder targeted by the treatment in Clofazimine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11295724_3_2257", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "What are the drugs used in combination in Clofazimine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_2_2258", "context": "Anisocoria from transdermal scopolamine.", "question": "What are the drugs used in the treatment in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11696132_2_2259", "context": "Anisocoria from transdermal scopolamine.", "question": "What is the dosage of the treatment in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_2_2260", "context": "Anisocoria from transdermal scopolamine.", "question": "What is the frequency of the treatment in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_2_2261", "context": "Anisocoria from transdermal scopolamine.", "question": "What is the route of the treatment in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11696132_2_2262", "context": "Anisocoria from transdermal scopolamine.", "question": "How long has elapsed from the treatment to the occurence of the event in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_2_2263", "context": "Anisocoria from transdermal scopolamine.", "question": "How long did the treatment last in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_2_2264", "context": "Anisocoria from transdermal scopolamine.", "question": "What is the disorder targeted by the treatment in transdermal scopolamine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11696132_2_2265", "context": "Anisocoria from transdermal scopolamine.", "question": "What are the drugs used in combination in transdermal scopolamine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_4_2266", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_4_2267", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_4_2268", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_4_2269", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_4_2270", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_4_2271", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What are the drugs used in the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_4_2272", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the dosage of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_4_2273", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the frequency of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_4_2274", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the route of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_4_2275", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in chloroquine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_4_2276", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "How long did the treatment last in chloroquine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_4_2277", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What is the disorder targeted by the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_4_2278", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "What are the drugs used in combination in chloroquine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_1_2279", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the age of the subject in A 36-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6199475_1_2280", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the gender of the subject in A 36-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6199475_1_2281", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the number of subjects in A 36-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6199475_1_2282", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the race of the subject in A 36-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6199475_1_2283", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the disorder of the subject in A 36-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6199475_1_2284", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What are the drugs used in the treatment in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6199475_1_2285", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the dosage of the treatment in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_1_2286", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the frequency of the treatment in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_1_2287", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the route of the treatment in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_1_2288", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_1_2289", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "How long did the treatment last in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_1_2290", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What is the disorder targeted by the treatment in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6199475_1_2291", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "What are the drugs used in combination in cisplatinum, vinblastine, and bleomycin for testicular carcinoma?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12410494_2_2292", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12410494_2_2293", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12410494_2_2294", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12410494_2_2295", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12410494_2_2296", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12410494_2_2297", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What are the drugs used in the treatment in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12410494_2_2298", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the dosage of the treatment in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_2_2299", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the frequency of the treatment in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_2_2300", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the route of the treatment in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_2_2301", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "How long has elapsed from the treatment to the occurence of the event in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_2_2302", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "How long did the treatment last in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_2_2303", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What is the disorder targeted by the treatment in a statin and a protease inhibitor?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_2_2304", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "What are the drugs used in combination in a statin and a protease inhibitor?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_2_2305", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the age of the subject in RA patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_2_2306", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the gender of the subject in RA patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_2_2307", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the number of subjects in RA patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_2_2308", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the race of the subject in RA patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_2_2309", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the disorder of the subject in RA patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_2_2310", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What are the drugs used in the treatment in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_2_2311", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the dosage of the treatment in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_2_2312", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the frequency of the treatment in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_2_2313", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the route of the treatment in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_2_2314", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "How long has elapsed from the treatment to the occurence of the event in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_2_2315", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "How long did the treatment last in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_2_2316", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What is the disorder targeted by the treatment in Methotrexate (MTX)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_2_2317", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "What are the drugs used in combination in Methotrexate (MTX)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_2_2318", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18505911_2_2319", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18505911_2_2320", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18505911_2_2321", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18505911_2_2322", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18505911_2_2323", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What are the drugs used in the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_2_2324", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the dosage of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_2_2325", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the frequency of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_2_2326", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the route of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_2_2327", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "How long has elapsed from the treatment to the occurence of the event in azathioprine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_2_2328", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "How long did the treatment last in azathioprine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_2_2329", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What is the disorder targeted by the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_2_2330", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "What are the drugs used in combination in azathioprine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_4_2331", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What are the drugs used in the treatment in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_4_2332", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What is the dosage of the treatment in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_4_2333", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What is the frequency of the treatment in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_4_2334", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What is the route of the treatment in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_4_2335", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "How long has elapsed from the treatment to the occurence of the event in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_4_2336", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "How long did the treatment last in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_4_2337", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What is the disorder targeted by the treatment in paclitaxel therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_4_2338", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "What are the drugs used in combination in paclitaxel therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_2_2339", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the age of the subject in Two patients with adrenal carcinoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "2830062_2_2340", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the gender of the subject in Two patients with adrenal carcinoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "2830062_2_2341", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the number of subjects in Two patients with adrenal carcinoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "2830062_2_2342", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the race of the subject in Two patients with adrenal carcinoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "2830062_2_2343", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the disorder of the subject in Two patients with adrenal carcinoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "2830062_2_2344", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What are the drugs used in the treatment in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "2830062_2_2345", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the dosage of the treatment in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_2_2346", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the frequency of the treatment in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_2_2347", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the route of the treatment in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_2_2348", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "How long has elapsed from the treatment to the occurence of the event in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_2_2349", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "How long did the treatment last in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_2_2350", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What is the disorder targeted by the treatment in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_2_2351", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "What are the drugs used in combination in 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8430717_3_2352", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "What is the age of the subject in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8430717_3_2353", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "What is the gender of the subject in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8430717_3_2354", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "What is the number of subjects in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8430717_3_2355", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "What is the race of the subject in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8430717_3_2356", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "What is the disorder of the subject in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "354311_1_2357", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the age of the subject in An 8-year-old girl?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "354311_1_2358", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the gender of the subject in An 8-year-old girl?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "354311_1_2359", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the number of subjects in An 8-year-old girl?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "354311_1_2360", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the race of the subject in An 8-year-old girl?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "354311_1_2361", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the disorder of the subject in An 8-year-old girl?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "354311_1_2362", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What are the drugs used in the treatment in BCG?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "354311_1_2363", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the dosage of the treatment in BCG?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_1_2364", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the frequency of the treatment in BCG?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_1_2365", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the route of the treatment in BCG?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_1_2366", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "How long has elapsed from the treatment to the occurence of the event in BCG?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_1_2367", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "How long did the treatment last in BCG?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_1_2368", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What is the disorder targeted by the treatment in BCG?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_1_2369", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "What are the drugs used in combination in BCG?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_3_2370", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What are the drugs used in the treatment in DGTX?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1469187_3_2371", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What is the dosage of the treatment in DGTX?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_3_2372", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What is the frequency of the treatment in DGTX?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1469187_3_2373", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What is the route of the treatment in DGTX?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1469187_3_2374", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "How long has elapsed from the treatment to the occurence of the event in DGTX?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_3_2375", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "How long did the treatment last in DGTX?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1469187_3_2376", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What is the disorder targeted by the treatment in DGTX?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_3_2377", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "What are the drugs used in combination in DGTX?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_1_2378", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What are the drugs used in the treatment in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_1_2379", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What is the dosage of the treatment in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_1_2380", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What is the frequency of the treatment in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_1_2381", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What is the route of the treatment in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_1_2382", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "How long has elapsed from the treatment to the occurence of the event in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_1_2383", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "How long did the treatment last in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_1_2384", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What is the disorder targeted by the treatment in quinine amblyopia?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_1_2385", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "What are the drugs used in combination in quinine amblyopia?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1275625_4_2386", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What are the drugs used in the treatment in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1275625_4_2387", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What is the dosage of the treatment in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1275625_4_2388", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What is the frequency of the treatment in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1275625_4_2389", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What is the route of the treatment in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1275625_4_2390", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "How long has elapsed from the treatment to the occurence of the event in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1275625_4_2391", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "How long did the treatment last in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1275625_4_2392", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What is the disorder targeted by the treatment in magnesium sulfate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1275625_4_2393", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "What are the drugs used in combination in magnesium sulfate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_1_2394", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What are the drugs used in the treatment in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8124920_1_2395", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What is the dosage of the treatment in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8124920_1_2396", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What is the frequency of the treatment in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_1_2397", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What is the route of the treatment in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_1_2398", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_1_2399", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "How long did the treatment last in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_1_2400", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8124920_1_2401", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "What are the drugs used in combination in low-dose methotrexate therapy during rheumatoid arthritis?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_3_2402", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the age of the subject in Patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_3_2403", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the gender of the subject in Patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_3_2404", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the number of subjects in Patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_3_2405", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the race of the subject in Patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_3_2406", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the disorder of the subject in Patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_3_2407", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What are the drugs used in the treatment in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_3_2408", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the dosage of the treatment in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_3_2409", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the frequency of the treatment in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_3_2410", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the route of the treatment in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_3_2411", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "How long has elapsed from the treatment to the occurence of the event in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_3_2412", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "How long did the treatment last in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_3_2413", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What is the disorder targeted by the treatment in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_3_2414", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "What are the drugs used in combination in dexamethasone as an antiemetic drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_5_2415", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the age of the subject in a patient with inoperable pancreatic cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_5_2416", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the gender of the subject in a patient with inoperable pancreatic cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_5_2417", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the number of subjects in a patient with inoperable pancreatic cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_5_2418", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the race of the subject in a patient with inoperable pancreatic cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_5_2419", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the disorder of the subject in a patient with inoperable pancreatic cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_5_2420", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_5_2421", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_5_2422", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_5_2423", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_5_2424", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_5_2425", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_5_2426", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_5_2427", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_2_2428", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the age of the subject in a 14-year-old male with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12836099_2_2429", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the gender of the subject in a 14-year-old male with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12836099_2_2430", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the number of subjects in a 14-year-old male with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_2_2431", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the race of the subject in a 14-year-old male with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_2_2432", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the disorder of the subject in a 14-year-old male with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_2_2433", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What are the drugs used in the treatment in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12836099_2_2434", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the dosage of the treatment in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_2_2435", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the frequency of the treatment in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_2_2436", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the route of the treatment in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12836099_2_2437", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "How long has elapsed from the treatment to the occurence of the event in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_2_2438", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "How long did the treatment last in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12836099_2_2439", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What is the disorder targeted by the treatment in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12836099_2_2440", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "What are the drugs used in combination in oral prednisolone for 6 weeks?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_1_2441", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the age of the subject in A 45-year-old woman with thyrotoxicosis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_1_2442", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the gender of the subject in A 45-year-old woman with thyrotoxicosis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_1_2443", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the number of subjects in A 45-year-old woman with thyrotoxicosis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_1_2444", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the race of the subject in A 45-year-old woman with thyrotoxicosis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_1_2445", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the disorder of the subject in A 45-year-old woman with thyrotoxicosis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_1_2446", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What are the drugs used in the treatment in propylthiouracil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_1_2447", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the dosage of the treatment in propylthiouracil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_1_2448", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the frequency of the treatment in propylthiouracil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_1_2449", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the route of the treatment in propylthiouracil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_1_2450", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "How long has elapsed from the treatment to the occurence of the event in propylthiouracil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_1_2451", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "How long did the treatment last in propylthiouracil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_1_2452", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What is the disorder targeted by the treatment in propylthiouracil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_1_2453", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "What are the drugs used in combination in propylthiouracil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_3_2454", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What are the drugs used in the treatment in ACTH?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_3_2455", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What is the dosage of the treatment in ACTH?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_3_2456", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What is the frequency of the treatment in ACTH?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_3_2457", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What is the route of the treatment in ACTH?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_3_2458", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "How long has elapsed from the treatment to the occurence of the event in ACTH?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_3_2459", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "How long did the treatment last in ACTH?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_3_2460", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What is the disorder targeted by the treatment in ACTH?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_3_2461", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "What are the drugs used in combination in ACTH?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_1_2462", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What are the drugs used in the treatment in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6401771_1_2463", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What is the dosage of the treatment in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_1_2464", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What is the frequency of the treatment in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_1_2465", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What is the route of the treatment in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_1_2466", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_1_2467", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "How long did the treatment last in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_1_2468", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What is the disorder targeted by the treatment in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6401771_1_2469", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "What are the drugs used in combination in long-term mitomycin C and 5-fluorouracil therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25842648_6_2470", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What are the drugs used in the treatment in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25842648_6_2471", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What is the dosage of the treatment in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_6_2472", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What is the frequency of the treatment in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_6_2473", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What is the route of the treatment in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_6_2474", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "How long has elapsed from the treatment to the occurence of the event in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_6_2475", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "How long did the treatment last in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_6_2476", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What is the disorder targeted by the treatment in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_6_2477", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "What are the drugs used in combination in selective serotonin reuptake inhibitors (SSRI) and fentanyl?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_1_2478", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the age of the subject in a 61-year-old diabetic patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6794018_1_2479", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the gender of the subject in a 61-year-old diabetic patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6794018_1_2480", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the number of subjects in a 61-year-old diabetic patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6794018_1_2481", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the race of the subject in a 61-year-old diabetic patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6794018_1_2482", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the disorder of the subject in a 61-year-old diabetic patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6794018_1_2483", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What are the drugs used in the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_1_2484", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the dosage of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_1_2485", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the frequency of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_1_2486", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the route of the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_1_2487", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "How long has elapsed from the treatment to the occurence of the event in glibenclamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_1_2488", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "How long did the treatment last in glibenclamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_1_2489", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What is the disorder targeted by the treatment in glibenclamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_1_2490", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "What are the drugs used in combination in glibenclamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_10_2491", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the age of the subject in the presented case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22677303_10_2492", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the gender of the subject in the presented case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22677303_10_2493", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the number of subjects in the presented case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22677303_10_2494", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the race of the subject in the presented case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22677303_10_2495", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the disorder of the subject in the presented case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22677303_10_2496", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What are the drugs used in the treatment in cloxacillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_10_2497", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the dosage of the treatment in cloxacillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_10_2498", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the frequency of the treatment in cloxacillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_10_2499", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the route of the treatment in cloxacillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_10_2500", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "How long has elapsed from the treatment to the occurence of the event in cloxacillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_10_2501", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "How long did the treatment last in cloxacillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_10_2502", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What is the disorder targeted by the treatment in cloxacillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_10_2503", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "What are the drugs used in combination in cloxacillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_2_2504", "context": "Cardiac arrest following use of sumatriptan.", "question": "What are the drugs used in the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_2_2505", "context": "Cardiac arrest following use of sumatriptan.", "question": "What is the dosage of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_2_2506", "context": "Cardiac arrest following use of sumatriptan.", "question": "What is the frequency of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_2_2507", "context": "Cardiac arrest following use of sumatriptan.", "question": "What is the route of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_2_2508", "context": "Cardiac arrest following use of sumatriptan.", "question": "How long has elapsed from the treatment to the occurence of the event in sumatriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_2_2509", "context": "Cardiac arrest following use of sumatriptan.", "question": "How long did the treatment last in sumatriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_2_2510", "context": "Cardiac arrest following use of sumatriptan.", "question": "What is the disorder targeted by the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_2_2511", "context": "Cardiac arrest following use of sumatriptan.", "question": "What are the drugs used in combination in sumatriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_4_2512", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the age of the subject in one patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1422497_4_2513", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the gender of the subject in one patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1422497_4_2514", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the number of subjects in one patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1422497_4_2515", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the race of the subject in one patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1422497_4_2516", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the disorder of the subject in one patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1422497_4_2517", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What are the drugs used in the treatment in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_4_2518", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the dosage of the treatment in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_4_2519", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the frequency of the treatment in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_4_2520", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the route of the treatment in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_4_2521", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "How long has elapsed from the treatment to the occurence of the event in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_4_2522", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "How long did the treatment last in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_4_2523", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What is the disorder targeted by the treatment in elevated aluminum levels?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_4_2524", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "What are the drugs used in combination in elevated aluminum levels?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_5_2525", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the age of the subject in Nine azotemic patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6671350_5_2526", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the gender of the subject in Nine azotemic patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6671350_5_2527", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the number of subjects in Nine azotemic patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6671350_5_2528", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the race of the subject in Nine azotemic patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6671350_5_2529", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the disorder of the subject in Nine azotemic patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6671350_5_2530", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What are the drugs used in the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_5_2531", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the dosage of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_5_2532", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the frequency of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_5_2533", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the route of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_5_2534", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "How long has elapsed from the treatment to the occurence of the event in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_5_2535", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "How long did the treatment last in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_5_2536", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What is the disorder targeted by the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_5_2537", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "What are the drugs used in combination in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_10_2538", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the age of the subject in fetuses?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8442800_10_2539", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the gender of the subject in fetuses?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8442800_10_2540", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the number of subjects in fetuses?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8442800_10_2541", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the race of the subject in fetuses?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8442800_10_2542", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the disorder of the subject in fetuses?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8442800_10_2543", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What are the drugs used in the treatment in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8442800_10_2544", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the dosage of the treatment in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_10_2545", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the frequency of the treatment in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8442800_10_2546", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the route of the treatment in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8442800_10_2547", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_10_2548", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "How long did the treatment last in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8442800_10_2549", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What is the disorder targeted by the treatment in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_10_2550", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "What are the drugs used in combination in disulfiram in the first trimester?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10592946_6_2551", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What are the drugs used in the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_6_2552", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What is the dosage of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_6_2553", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What is the frequency of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_6_2554", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What is the route of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_6_2555", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in caffeine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_6_2556", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "How long did the treatment last in caffeine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_6_2557", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What is the disorder targeted by the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_6_2558", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "What are the drugs used in combination in caffeine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_2_2559", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the age of the subject in an 81-year-old-man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18837734_2_2560", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the gender of the subject in an 81-year-old-man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18837734_2_2561", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the number of subjects in an 81-year-old-man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18837734_2_2562", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the race of the subject in an 81-year-old-man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18837734_2_2563", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the disorder of the subject in an 81-year-old-man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18837734_2_2564", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What are the drugs used in the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18837734_2_2565", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the dosage of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_2_2566", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the frequency of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_2_2567", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the route of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_2_2568", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "How long has elapsed from the treatment to the occurence of the event in erlotinib?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_2_2569", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "How long did the treatment last in erlotinib?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_2_2570", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What is the disorder targeted by the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_2_2571", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "What are the drugs used in combination in erlotinib?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11295724_1_2572", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the age of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11295724_1_2573", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the gender of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11295724_1_2574", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the number of subjects in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_1_2575", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the race of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_1_2576", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the disorder of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_1_2577", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What are the drugs used in the treatment in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11295724_1_2578", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the dosage of the treatment in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_1_2579", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the frequency of the treatment in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_1_2580", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the route of the treatment in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_1_2581", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "How long has elapsed from the treatment to the occurence of the event in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11295724_1_2582", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "How long did the treatment last in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_1_2583", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What is the disorder targeted by the treatment in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11295724_1_2584", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "What are the drugs used in combination in 2 years after initiation of clofazimine treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_3_2585", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_3_2586", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_3_2587", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3174043_3_2588", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_3_2589", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_3_2590", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What are the drugs used in the treatment in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3174043_3_2591", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the dosage of the treatment in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_3_2592", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the frequency of the treatment in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_3_2593", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the route of the treatment in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_3_2594", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "How long has elapsed from the treatment to the occurence of the event in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_3_2595", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "How long did the treatment last in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_3_2596", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What is the disorder targeted by the treatment in taking high doses of oral niacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_3_2597", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "What are the drugs used in combination in taking high doses of oral niacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_2_2598", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the age of the subject in renal transplanted patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_2_2599", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the gender of the subject in renal transplanted patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_2_2600", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the number of subjects in renal transplanted patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_2_2601", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the race of the subject in renal transplanted patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_2_2602", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the disorder of the subject in renal transplanted patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_2_2603", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What are the drugs used in the treatment in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_2_2604", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the dosage of the treatment in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_2_2605", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the frequency of the treatment in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_2_2606", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the route of the treatment in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_2_2607", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "How long has elapsed from the treatment to the occurence of the event in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_2_2608", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "How long did the treatment last in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_2_2609", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What is the disorder targeted by the treatment in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_2_2610", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "What are the drugs used in combination in immunosuppression with tacrolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_2_2611", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the age of the subject in an 11-year-old female treated for mediastinal T-cell lymphoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17387702_2_2612", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the gender of the subject in an 11-year-old female treated for mediastinal T-cell lymphoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17387702_2_2613", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the number of subjects in an 11-year-old female treated for mediastinal T-cell lymphoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_2_2614", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the race of the subject in an 11-year-old female treated for mediastinal T-cell lymphoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_2_2615", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the disorder of the subject in an 11-year-old female treated for mediastinal T-cell lymphoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17387702_2_2616", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What are the drugs used in the treatment in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17387702_2_2617", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the dosage of the treatment in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17387702_2_2618", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the frequency of the treatment in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17387702_2_2619", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the route of the treatment in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_2_2620", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "How long has elapsed from the treatment to the occurence of the event in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_2_2621", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "How long did the treatment last in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_2_2622", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What is the disorder targeted by the treatment in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17387702_2_2623", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "What are the drugs used in combination in the second cycle of high-dose methotrexate (HDMTX)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_3_2624", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the age of the subject in three cases of patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_3_2625", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the gender of the subject in three cases of patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_3_2626", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the number of subjects in three cases of patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_3_2627", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the race of the subject in three cases of patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_3_2628", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the disorder of the subject in three cases of patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_3_2629", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_3_2630", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_3_2631", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_3_2632", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_3_2633", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_3_2634", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_3_2635", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_3_2636", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_2_2637", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What are the drugs used in the treatment in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_2_2638", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What is the dosage of the treatment in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_2_2639", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What is the frequency of the treatment in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_2_2640", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What is the route of the treatment in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_2_2641", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "How long has elapsed from the treatment to the occurence of the event in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_2_2642", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "How long did the treatment last in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_2_2643", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What is the disorder targeted by the treatment in simvastatin and colchicine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_2_2644", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "What are the drugs used in combination in simvastatin and colchicine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_1_2645", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the age of the subject in A 35-year-old man with seropositive rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4063627_1_2646", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the gender of the subject in A 35-year-old man with seropositive rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4063627_1_2647", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the number of subjects in A 35-year-old man with seropositive rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4063627_1_2648", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the race of the subject in A 35-year-old man with seropositive rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4063627_1_2649", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the disorder of the subject in A 35-year-old man with seropositive rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4063627_1_2650", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What are the drugs used in the treatment in fenclofenac?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_1_2651", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the dosage of the treatment in fenclofenac?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_1_2652", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the frequency of the treatment in fenclofenac?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_1_2653", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the route of the treatment in fenclofenac?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_1_2654", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "How long has elapsed from the treatment to the occurence of the event in fenclofenac?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_1_2655", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "How long did the treatment last in fenclofenac?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_1_2656", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What is the disorder targeted by the treatment in fenclofenac?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_1_2657", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "What are the drugs used in combination in fenclofenac?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15461766_1_2658", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the age of the subject in two newborns with congenital heart anomalies?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15461766_1_2659", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the gender of the subject in two newborns with congenital heart anomalies?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15461766_1_2660", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the number of subjects in two newborns with congenital heart anomalies?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15461766_1_2661", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the race of the subject in two newborns with congenital heart anomalies?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15461766_1_2662", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the disorder of the subject in two newborns with congenital heart anomalies?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15461766_1_2663", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What are the drugs used in the treatment in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15461766_1_2664", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the dosage of the treatment in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_1_2665", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the frequency of the treatment in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_1_2666", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the route of the treatment in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_1_2667", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "How long has elapsed from the treatment to the occurence of the event in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_1_2668", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "How long did the treatment last in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_1_2669", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What is the disorder targeted by the treatment in systemic prostaglandin E1?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15461766_1_2670", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "What are the drugs used in combination in systemic prostaglandin E1?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_4_2671", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the age of the subject in infants of women?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8442800_4_2672", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the gender of the subject in infants of women?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_4_2673", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the number of subjects in infants of women?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_4_2674", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the race of the subject in infants of women?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_4_2675", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the disorder of the subject in infants of women?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_4_2676", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What are the drugs used in the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8442800_4_2677", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the dosage of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_4_2678", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the frequency of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_4_2679", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the route of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_4_2680", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_4_2681", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "How long did the treatment last in disulfiram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_4_2682", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What is the disorder targeted by the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_4_2683", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "What are the drugs used in combination in disulfiram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_3_2684", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What are the drugs used in the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_3_2685", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What is the dosage of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_3_2686", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What is the frequency of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_3_2687", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What is the route of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_3_2688", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_3_2689", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "How long did the treatment last in infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_3_2690", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What is the disorder targeted by the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_3_2691", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "What are the drugs used in combination in infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_4_2692", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the age of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12477460_4_2693", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the gender of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12477460_4_2694", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the number of subjects in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_4_2695", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the race of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_4_2696", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the disorder of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_4_2697", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What are the drugs used in the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_4_2698", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the dosage of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_4_2699", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the frequency of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_4_2700", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the route of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_4_2701", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_4_2702", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "How long did the treatment last in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_4_2703", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What is the disorder targeted by the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_4_2704", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "What are the drugs used in combination in tamoxifen therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17123120_1_2705", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What are the drugs used in the treatment in Tacrolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17123120_1_2706", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What is the dosage of the treatment in Tacrolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_1_2707", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What is the frequency of the treatment in Tacrolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_1_2708", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What is the route of the treatment in Tacrolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_1_2709", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in Tacrolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_1_2710", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "How long did the treatment last in Tacrolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_1_2711", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What is the disorder targeted by the treatment in Tacrolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17123120_1_2712", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "What are the drugs used in combination in Tacrolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_2_2713", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the age of the subject in woman with cryptococcal meningitis and no previous cardiac disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_2_2714", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the gender of the subject in woman with cryptococcal meningitis and no previous cardiac disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_2_2715", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the number of subjects in woman with cryptococcal meningitis and no previous cardiac disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_2_2716", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the race of the subject in woman with cryptococcal meningitis and no previous cardiac disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_2_2717", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the disorder of the subject in woman with cryptococcal meningitis and no previous cardiac disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_2_2718", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What are the drugs used in the treatment in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_2_2719", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the dosage of the treatment in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_2_2720", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the frequency of the treatment in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_2_2721", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the route of the treatment in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_2_2722", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_2_2723", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "How long did the treatment last in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_2_2724", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What is the disorder targeted by the treatment in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_2_2725", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "What are the drugs used in combination in an acute overdose of amphotericin B?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3542612_2_2726", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3542612_2_2727", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3542612_2_2728", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3542612_2_2729", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3542612_2_2730", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3542612_2_2731", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What are the drugs used in the treatment in captopril?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3542612_2_2732", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the dosage of the treatment in captopril?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_2_2733", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the frequency of the treatment in captopril?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_2_2734", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the route of the treatment in captopril?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_2_2735", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "How long has elapsed from the treatment to the occurence of the event in captopril?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_2_2736", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "How long did the treatment last in captopril?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_2_2737", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What is the disorder targeted by the treatment in captopril?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_2_2738", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "What are the drugs used in combination in captopril?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_4_2739", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What are the drugs used in the treatment in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "2830062_4_2740", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What is the dosage of the treatment in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_4_2741", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What is the frequency of the treatment in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_4_2742", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What is the route of the treatment in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_4_2743", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_4_2744", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "How long did the treatment last in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_4_2745", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What is the disorder targeted by the treatment in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_4_2746", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "What are the drugs used in combination in increasing steroid replacement therapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16265343_1_2747", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What are the drugs used in the treatment in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16265343_1_2748", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What is the dosage of the treatment in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_1_2749", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What is the frequency of the treatment in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_1_2750", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What is the route of the treatment in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_1_2751", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_1_2752", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "How long did the treatment last in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_1_2753", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What is the disorder targeted by the treatment in Interferon alpha-2b?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_1_2754", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "What are the drugs used in combination in Interferon alpha-2b?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_1_2755", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What are the drugs used in the treatment in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_1_2756", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What is the dosage of the treatment in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_1_2757", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What is the frequency of the treatment in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_1_2758", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What is the route of the treatment in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_1_2759", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "How long has elapsed from the treatment to the occurence of the event in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_1_2760", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "How long did the treatment last in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_1_2761", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What is the disorder targeted by the treatment in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_1_2762", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "What are the drugs used in combination in systemic tissue plasminogen activator?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_1_2763", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the age of the subject in a patient with chronic schizophrenia with suicidal tendencies?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17665812_1_2764", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the gender of the subject in a patient with chronic schizophrenia with suicidal tendencies?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17665812_1_2765", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the number of subjects in a patient with chronic schizophrenia with suicidal tendencies?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17665812_1_2766", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the race of the subject in a patient with chronic schizophrenia with suicidal tendencies?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17665812_1_2767", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the disorder of the subject in a patient with chronic schizophrenia with suicidal tendencies?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17665812_1_2768", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What are the drugs used in the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_1_2769", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the dosage of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_1_2770", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the frequency of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_1_2771", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the route of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_1_2772", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "How long has elapsed from the treatment to the occurence of the event in Clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_1_2773", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "How long did the treatment last in Clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_1_2774", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What is the disorder targeted by the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_1_2775", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "What are the drugs used in combination in Clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_1_2776", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What are the drugs used in the treatment in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_1_2777", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What is the dosage of the treatment in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_1_2778", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What is the frequency of the treatment in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_1_2779", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What is the route of the treatment in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_1_2780", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "How long has elapsed from the treatment to the occurence of the event in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_1_2781", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "How long did the treatment last in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_1_2782", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What is the disorder targeted by the treatment in propafenone; citalopram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_1_2783", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "What are the drugs used in combination in propafenone; citalopram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_2_2784", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the age of the subject in an adult?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7081289_2_2785", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the gender of the subject in an adult?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7081289_2_2786", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the number of subjects in an adult?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7081289_2_2787", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the race of the subject in an adult?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7081289_2_2788", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the disorder of the subject in an adult?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7081289_2_2789", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What are the drugs used in the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_2_2790", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the dosage of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_2_2791", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the frequency of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_2_2792", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the route of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_2_2793", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "How long has elapsed from the treatment to the occurence of the event in cimetidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_2_2794", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "How long did the treatment last in cimetidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_2_2795", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What is the disorder targeted by the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_2_2796", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "What are the drugs used in combination in cimetidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_3_2797", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the age of the subject in 4 patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_3_2798", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the gender of the subject in 4 patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_3_2799", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the number of subjects in 4 patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16609346_3_2800", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the race of the subject in 4 patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_3_2801", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the disorder of the subject in 4 patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_3_2802", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What are the drugs used in the treatment in statin drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_3_2803", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the dosage of the treatment in statin drug?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_3_2804", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the frequency of the treatment in statin drug?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_3_2805", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the route of the treatment in statin drug?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_3_2806", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "How long has elapsed from the treatment to the occurence of the event in statin drug?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_3_2807", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "How long did the treatment last in statin drug?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_3_2808", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What is the disorder targeted by the treatment in statin drug?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_3_2809", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "What are the drugs used in combination in statin drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_1_2810", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_1_2811", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_1_2812", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_1_2813", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_1_2814", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_1_2815", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What are the drugs used in the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_1_2816", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the dosage of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_1_2817", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the frequency of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_1_2818", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the route of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_1_2819", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "How long has elapsed from the treatment to the occurence of the event in pentamidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_1_2820", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "How long did the treatment last in pentamidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_1_2821", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What is the disorder targeted by the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_1_2822", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "What are the drugs used in combination in pentamidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_2_2823", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the age of the subject in A 44-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_2_2824", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the gender of the subject in A 44-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7056119_2_2825", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the number of subjects in A 44-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_2_2826", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the race of the subject in A 44-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_2_2827", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the disorder of the subject in A 44-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_2_2828", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What are the drugs used in the treatment in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_2_2829", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the dosage of the treatment in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_2_2830", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the frequency of the treatment in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_2_2831", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the route of the treatment in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_2_2832", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_2_2833", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "How long did the treatment last in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_2_2834", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What is the disorder targeted by the treatment in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_2_2835", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "What are the drugs used in combination in amiodarone, disopyramide, and quinidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_9_2836", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_9_2837", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_9_2838", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_9_2839", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_9_2840", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_9_2841", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_9_2842", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_9_2843", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_2_2844", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the age of the subject in patients with a history of alcohol abuse?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8442800_2_2845", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the gender of the subject in patients with a history of alcohol abuse?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8442800_2_2846", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the number of subjects in patients with a history of alcohol abuse?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8442800_2_2847", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the race of the subject in patients with a history of alcohol abuse?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8442800_2_2848", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the disorder of the subject in patients with a history of alcohol abuse?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8442800_2_2849", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What are the drugs used in the treatment in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8442800_2_2850", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the dosage of the treatment in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_2_2851", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the frequency of the treatment in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8442800_2_2852", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the route of the treatment in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8442800_2_2853", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "How long has elapsed from the treatment to the occurence of the event in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_2_2854", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "How long did the treatment last in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8442800_2_2855", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What is the disorder targeted by the treatment in Disulfiram?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_2_2856", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "What are the drugs used in combination in Disulfiram?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15507779_2_2857", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the age of the subject in human immunodeficiency virus (HIV)-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15507779_2_2858", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the gender of the subject in human immunodeficiency virus (HIV)-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15507779_2_2859", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the number of subjects in human immunodeficiency virus (HIV)-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15507779_2_2860", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the race of the subject in human immunodeficiency virus (HIV)-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15507779_2_2861", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the disorder of the subject in human immunodeficiency virus (HIV)-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15507779_2_2862", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What are the drugs used in the treatment in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15507779_2_2863", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the dosage of the treatment in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_2_2864", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the frequency of the treatment in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15507779_2_2865", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the route of the treatment in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15507779_2_2866", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_2_2867", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "How long did the treatment last in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15507779_2_2868", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What is the disorder targeted by the treatment in Nevirapine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_2_2869", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "What are the drugs used in combination in Nevirapine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_2_2870", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What are the drugs used in the treatment in ergotamine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8391300_2_2871", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What is the dosage of the treatment in ergotamine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8391300_2_2872", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What is the frequency of the treatment in ergotamine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_2_2873", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What is the route of the treatment in ergotamine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_2_2874", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "How long has elapsed from the treatment to the occurence of the event in ergotamine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_2_2875", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "How long did the treatment last in ergotamine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_2_2876", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What is the disorder targeted by the treatment in ergotamine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_2_2877", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "What are the drugs used in combination in ergotamine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_1_2878", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3359700_1_2879", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3359700_1_2880", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3359700_1_2881", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3359700_1_2882", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3359700_1_2883", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What are the drugs used in the treatment in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3359700_1_2884", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the dosage of the treatment in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_1_2885", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the frequency of the treatment in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_1_2886", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the route of the treatment in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_1_2887", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "How long has elapsed from the treatment to the occurence of the event in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_1_2888", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "How long did the treatment last in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_1_2889", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What is the disorder targeted by the treatment in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_1_2890", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "What are the drugs used in combination in a six-week course of low-dose cyclosporine A?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_4_2891", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What are the drugs used in the treatment in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_4_2892", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What is the dosage of the treatment in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_4_2893", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What is the frequency of the treatment in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_4_2894", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What is the route of the treatment in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_4_2895", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_4_2896", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "How long did the treatment last in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_4_2897", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What is the disorder targeted by the treatment in simvastatin; amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_4_2898", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "What are the drugs used in combination in simvastatin; amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23115227_3_2899", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the age of the subject in a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23115227_3_2900", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the gender of the subject in a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23115227_3_2901", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the number of subjects in a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_3_2902", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the race of the subject in a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_3_2903", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the disorder of the subject in a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_3_2904", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What are the drugs used in the treatment in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23115227_3_2905", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the dosage of the treatment in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23115227_3_2906", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the frequency of the treatment in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23115227_3_2907", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the route of the treatment in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_3_2908", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "How long has elapsed from the treatment to the occurence of the event in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_3_2909", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "How long did the treatment last in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_3_2910", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What is the disorder targeted by the treatment in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23115227_3_2911", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "What are the drugs used in combination in TRIO study regimen?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10870095_7_2912", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What are the drugs used in the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10870095_7_2913", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What is the dosage of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_7_2914", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What is the frequency of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10870095_7_2915", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What is the route of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10870095_7_2916", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "How long has elapsed from the treatment to the occurence of the event in zafirlukast?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_7_2917", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "How long did the treatment last in zafirlukast?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10870095_7_2918", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What is the disorder targeted by the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10870095_7_2919", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "What are the drugs used in combination in zafirlukast?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_6_2920", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18755414_6_2921", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18755414_6_2922", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18755414_6_2923", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18755414_6_2924", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18755414_6_2925", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What are the drugs used in the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_6_2926", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the dosage of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_6_2927", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the frequency of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_6_2928", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the route of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_6_2929", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "How long has elapsed from the treatment to the occurence of the event in aspirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_6_2930", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "How long did the treatment last in aspirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_6_2931", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What is the disorder targeted by the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_6_2932", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "What are the drugs used in combination in aspirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_3_2933", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What are the drugs used in the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_3_2934", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What is the dosage of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_3_2935", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What is the frequency of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_3_2936", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What is the route of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_3_2937", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "How long has elapsed from the treatment to the occurence of the event in IVTA injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_3_2938", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "How long did the treatment last in IVTA injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_3_2939", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What is the disorder targeted by the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_3_2940", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "What are the drugs used in combination in IVTA injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_3_2941", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What are the drugs used in the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_3_2942", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What is the dosage of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_3_2943", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What is the frequency of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_3_2944", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What is the route of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_3_2945", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_3_2946", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "How long did the treatment last in amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_3_2947", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What is the disorder targeted by the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_3_2948", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "What are the drugs used in combination in amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_4_2949", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21658326_4_2950", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21658326_4_2951", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21658326_4_2952", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21658326_4_2953", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21658326_4_2954", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What are the drugs used in the treatment in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_4_2955", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the dosage of the treatment in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_4_2956", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the frequency of the treatment in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_4_2957", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the route of the treatment in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_4_2958", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "How long has elapsed from the treatment to the occurence of the event in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_4_2959", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "How long did the treatment last in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_4_2960", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What is the disorder targeted by the treatment in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_4_2961", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "What are the drugs used in combination in NMSC treatment with imiquimod in the context of infliximab administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_1_2962", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What are the drugs used in the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3964363_1_2963", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What is the dosage of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3964363_1_2964", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What is the frequency of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3964363_1_2965", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What is the route of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3964363_1_2966", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_1_2967", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "How long did the treatment last in propranolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3964363_1_2968", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What is the disorder targeted by the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_1_2969", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "What are the drugs used in combination in propranolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_2_2970", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What are the drugs used in the treatment in Fenclofenac?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_2_2971", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What is the dosage of the treatment in Fenclofenac?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_2_2972", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What is the frequency of the treatment in Fenclofenac?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_2_2973", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What is the route of the treatment in Fenclofenac?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_2_2974", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in Fenclofenac?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_2_2975", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "How long did the treatment last in Fenclofenac?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_2_2976", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in Fenclofenac?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_2_2977", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "What are the drugs used in combination in Fenclofenac?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_2_2978", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the age of the subject in pediatric population?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_2_2979", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the gender of the subject in pediatric population?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_2_2980", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the number of subjects in pediatric population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_2_2981", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the race of the subject in pediatric population?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_2_2982", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the disorder of the subject in pediatric population?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_2_2983", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What are the drugs used in the treatment in Naproxen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_2_2984", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the dosage of the treatment in Naproxen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_2_2985", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the frequency of the treatment in Naproxen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_2_2986", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the route of the treatment in Naproxen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_2_2987", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "How long has elapsed from the treatment to the occurence of the event in Naproxen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_2_2988", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "How long did the treatment last in Naproxen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_2_2989", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What is the disorder targeted by the treatment in Naproxen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_2_2990", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "What are the drugs used in combination in Naproxen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10870095_2_2991", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What are the drugs used in the treatment in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10870095_2_2992", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What is the dosage of the treatment in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_2_2993", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What is the frequency of the treatment in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10870095_2_2994", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What is the route of the treatment in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10870095_2_2995", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "How long has elapsed from the treatment to the occurence of the event in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_2_2996", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "How long did the treatment last in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10870095_2_2997", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What is the disorder targeted by the treatment in Zafirlukast?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10870095_2_2998", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "What are the drugs used in combination in Zafirlukast?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18364401_3_2999", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_3_3000", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_3_3001", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_3_3002", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_3_3003", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_3_3004", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_3_3005", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_3_3006", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_1_3007", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the age of the subject in a 61-year-old man with a 30-year history of fistulizing CD?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_1_3008", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the gender of the subject in a 61-year-old man with a 30-year history of fistulizing CD?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_1_3009", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the number of subjects in a 61-year-old man with a 30-year history of fistulizing CD?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_1_3010", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the race of the subject in a 61-year-old man with a 30-year history of fistulizing CD?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_1_3011", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the disorder of the subject in a 61-year-old man with a 30-year history of fistulizing CD?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_1_3012", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What are the drugs used in the treatment in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_1_3013", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the dosage of the treatment in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_1_3014", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the frequency of the treatment in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_1_3015", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the route of the treatment in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_1_3016", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "How long has elapsed from the treatment to the occurence of the event in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_1_3017", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "How long did the treatment last in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_1_3018", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What is the disorder targeted by the treatment in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_1_3019", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "What are the drugs used in combination in 9 months after treatment with infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7761316_2_3020", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the age of the subject in pediatric oncology patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7761316_2_3021", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the gender of the subject in pediatric oncology patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_2_3022", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the number of subjects in pediatric oncology patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7761316_2_3023", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the race of the subject in pediatric oncology patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_2_3024", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the disorder of the subject in pediatric oncology patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_2_3025", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What are the drugs used in the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7761316_2_3026", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the dosage of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_2_3027", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the frequency of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_2_3028", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the route of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_2_3029", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "How long has elapsed from the treatment to the occurence of the event in ifosfamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_2_3030", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "How long did the treatment last in ifosfamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_2_3031", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What is the disorder targeted by the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7761316_2_3032", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "What are the drugs used in combination in ifosfamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_3_3033", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the age of the subject in a patient with chronic renal failure and ischemic heart disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10225085_3_3034", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the gender of the subject in a patient with chronic renal failure and ischemic heart disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10225085_3_3035", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the number of subjects in a patient with chronic renal failure and ischemic heart disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10225085_3_3036", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the race of the subject in a patient with chronic renal failure and ischemic heart disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10225085_3_3037", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the disorder of the subject in a patient with chronic renal failure and ischemic heart disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10225085_3_3038", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What are the drugs used in the treatment in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_3_3039", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the dosage of the treatment in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_3_3040", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the frequency of the treatment in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_3_3041", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the route of the treatment in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_3_3042", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "How long has elapsed from the treatment to the occurence of the event in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_3_3043", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "How long did the treatment last in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_3_3044", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the disorder targeted by the treatment in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_3_3045", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What are the drugs used in combination in an axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_1_3046", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What are the drugs used in the treatment in Amikacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19884751_1_3047", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What is the dosage of the treatment in Amikacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_1_3048", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What is the frequency of the treatment in Amikacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_1_3049", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What is the route of the treatment in Amikacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_1_3050", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "How long has elapsed from the treatment to the occurence of the event in Amikacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_1_3051", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "How long did the treatment last in Amikacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19884751_1_3052", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What is the disorder targeted by the treatment in Amikacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_1_3053", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "What are the drugs used in combination in Amikacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_2_3054", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15368548_2_3055", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_2_3056", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15368548_2_3057", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15368548_2_3058", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_2_3059", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15368548_2_3060", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_2_3061", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4014301_4_3062", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the age of the subject in a patient without underlying heart disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4014301_4_3063", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the gender of the subject in a patient without underlying heart disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4014301_4_3064", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the number of subjects in a patient without underlying heart disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4014301_4_3065", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the race of the subject in a patient without underlying heart disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4014301_4_3066", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the disorder of the subject in a patient without underlying heart disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4014301_4_3067", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What are the drugs used in the treatment in insulin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_4_3068", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the dosage of the treatment in insulin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_4_3069", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the frequency of the treatment in insulin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_4_3070", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the route of the treatment in insulin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_4_3071", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "How long has elapsed from the treatment to the occurence of the event in insulin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_4_3072", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "How long did the treatment last in insulin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_4_3073", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What is the disorder targeted by the treatment in insulin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_4_3074", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "What are the drugs used in combination in insulin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_4_3075", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_4_3076", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_4_3077", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_4_3078", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_4_3079", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_4_3080", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What are the drugs used in the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_4_3081", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the dosage of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_4_3082", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the frequency of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_4_3083", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the route of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_4_3084", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "How long has elapsed from the treatment to the occurence of the event in leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_4_3085", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "How long did the treatment last in leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_4_3086", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What is the disorder targeted by the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_4_3087", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "What are the drugs used in combination in leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_1_3088", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What are the drugs used in the treatment in INH?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_1_3089", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What is the dosage of the treatment in INH?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_1_3090", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What is the frequency of the treatment in INH?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_1_3091", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What is the route of the treatment in INH?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_1_3092", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "How long has elapsed from the treatment to the occurence of the event in INH?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_1_3093", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "How long did the treatment last in INH?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_1_3094", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What is the disorder targeted by the treatment in INH?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_1_3095", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "What are the drugs used in combination in INH?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19266307_1_3096", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What are the drugs used in the treatment in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19266307_1_3097", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What is the dosage of the treatment in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_1_3098", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What is the frequency of the treatment in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_1_3099", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What is the route of the treatment in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19266307_1_3100", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "How long has elapsed from the treatment to the occurence of the event in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_1_3101", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "How long did the treatment last in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_1_3102", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What is the disorder targeted by the treatment in immediate instillations of epirubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_1_3103", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "What are the drugs used in combination in immediate instillations of epirubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_5_3104", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What are the drugs used in the treatment in Ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_5_3105", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What is the dosage of the treatment in Ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_5_3106", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What is the frequency of the treatment in Ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_5_3107", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What is the route of the treatment in Ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_5_3108", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in Ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_5_3109", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "How long did the treatment last in Ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_5_3110", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What is the disorder targeted by the treatment in Ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_5_3111", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "What are the drugs used in combination in Ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_1_3112", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the age of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16515630_1_3113", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the gender of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16515630_1_3114", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the number of subjects in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16515630_1_3115", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the race of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16515630_1_3116", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the disorder of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16515630_1_3117", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What are the drugs used in the treatment in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_1_3118", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the dosage of the treatment in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_1_3119", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the frequency of the treatment in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_1_3120", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the route of the treatment in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_1_3121", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_1_3122", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "How long did the treatment last in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_1_3123", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What is the disorder targeted by the treatment in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_1_3124", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "What are the drugs used in combination in six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_1_3125", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the age of the subject in A 21-year-old patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_1_3126", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the gender of the subject in A 21-year-old patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_1_3127", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the number of subjects in A 21-year-old patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_1_3128", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the race of the subject in A 21-year-old patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_1_3129", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the disorder of the subject in A 21-year-old patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_1_3130", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_1_3131", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_1_3132", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_1_3133", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_1_3134", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_1_3135", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_1_3136", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_1_3137", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_1_3138", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the age of the subject in a patient with neuroendocrine tumor of the cervix?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_1_3139", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the gender of the subject in a patient with neuroendocrine tumor of the cervix?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_1_3140", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the number of subjects in a patient with neuroendocrine tumor of the cervix?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_1_3141", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the race of the subject in a patient with neuroendocrine tumor of the cervix?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_1_3142", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the disorder of the subject in a patient with neuroendocrine tumor of the cervix?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_1_3143", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What are the drugs used in the treatment in Cisplatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_1_3144", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the dosage of the treatment in Cisplatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_1_3145", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the frequency of the treatment in Cisplatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_1_3146", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the route of the treatment in Cisplatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_1_3147", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in Cisplatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_1_3148", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "How long did the treatment last in Cisplatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_1_3149", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What is the disorder targeted by the treatment in Cisplatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_1_3150", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "What are the drugs used in combination in Cisplatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_1_3151", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What are the drugs used in the treatment in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6610943_1_3152", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What is the dosage of the treatment in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_1_3153", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What is the frequency of the treatment in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_1_3154", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What is the route of the treatment in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6610943_1_3155", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_1_3156", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "How long did the treatment last in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_1_3157", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What is the disorder targeted by the treatment in intravenous vasopressin infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6610943_1_3158", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "What are the drugs used in combination in intravenous vasopressin infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_2_3159", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What are the drugs used in the treatment in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18371508_2_3160", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What is the dosage of the treatment in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_2_3161", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What is the frequency of the treatment in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_2_3162", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What is the route of the treatment in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_2_3163", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "How long has elapsed from the treatment to the occurence of the event in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_2_3164", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "How long did the treatment last in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_2_3165", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What is the disorder targeted by the treatment in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18371508_2_3166", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "What are the drugs used in combination in pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_1_3167", "context": "Catatonia associated with disulfiram therapy.", "question": "What are the drugs used in the treatment in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_1_3168", "context": "Catatonia associated with disulfiram therapy.", "question": "What is the dosage of the treatment in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_1_3169", "context": "Catatonia associated with disulfiram therapy.", "question": "What is the frequency of the treatment in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_1_3170", "context": "Catatonia associated with disulfiram therapy.", "question": "What is the route of the treatment in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_1_3171", "context": "Catatonia associated with disulfiram therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_1_3172", "context": "Catatonia associated with disulfiram therapy.", "question": "How long did the treatment last in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_1_3173", "context": "Catatonia associated with disulfiram therapy.", "question": "What is the disorder targeted by the treatment in disulfiram therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_1_3174", "context": "Catatonia associated with disulfiram therapy.", "question": "What are the drugs used in combination in disulfiram therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_5_3175", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What are the drugs used in the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_5_3176", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What is the dosage of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_5_3177", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What is the frequency of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_5_3178", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What is the route of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_5_3179", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "How long has elapsed from the treatment to the occurence of the event in imiquimod?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_5_3180", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "How long did the treatment last in imiquimod?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_5_3181", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What is the disorder targeted by the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_5_3182", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "What are the drugs used in combination in imiquimod?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_2_3183", "context": "Losartan-induced angioedema.", "question": "What are the drugs used in the treatment in Losartan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10492493_2_3184", "context": "Losartan-induced angioedema.", "question": "What is the dosage of the treatment in Losartan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_2_3185", "context": "Losartan-induced angioedema.", "question": "What is the frequency of the treatment in Losartan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_2_3186", "context": "Losartan-induced angioedema.", "question": "What is the route of the treatment in Losartan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_2_3187", "context": "Losartan-induced angioedema.", "question": "How long has elapsed from the treatment to the occurence of the event in Losartan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_2_3188", "context": "Losartan-induced angioedema.", "question": "How long did the treatment last in Losartan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_2_3189", "context": "Losartan-induced angioedema.", "question": "What is the disorder targeted by the treatment in Losartan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_2_3190", "context": "Losartan-induced angioedema.", "question": "What are the drugs used in combination in Losartan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_1_3191", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What are the drugs used in the treatment in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_1_3192", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What is the dosage of the treatment in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_1_3193", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What is the frequency of the treatment in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_1_3194", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What is the route of the treatment in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_1_3195", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "How long has elapsed from the treatment to the occurence of the event in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_1_3196", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "How long did the treatment last in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_1_3197", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What is the disorder targeted by the treatment in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_1_3198", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "What are the drugs used in combination in mequitazine or other phenothiazine-derivative drugs?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_10_3199", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What are the drugs used in the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_10_3200", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What is the dosage of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_10_3201", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What is the frequency of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_10_3202", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What is the route of the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_10_3203", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "How long has elapsed from the treatment to the occurence of the event in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_10_3204", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "How long did the treatment last in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_10_3205", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What is the disorder targeted by the treatment in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_10_3206", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "What are the drugs used in combination in Oxycodone-gabapentin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11147747_1_3207", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the age of the subject in 2 of the 3 cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_1_3208", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the gender of the subject in 2 of the 3 cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_1_3209", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the number of subjects in 2 of the 3 cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_1_3210", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the race of the subject in 2 of the 3 cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_1_3211", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the disorder of the subject in 2 of the 3 cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_1_3212", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What are the drugs used in the treatment in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_1_3213", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the dosage of the treatment in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_1_3214", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the frequency of the treatment in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_1_3215", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the route of the treatment in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_1_3216", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_1_3217", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "How long did the treatment last in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_1_3218", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What is the disorder targeted by the treatment in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_1_3219", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "What are the drugs used in combination in lithium carbonate and beta-blockers?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_2_3220", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What are the drugs used in the treatment in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_2_3221", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What is the dosage of the treatment in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_2_3222", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What is the frequency of the treatment in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_2_3223", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What is the route of the treatment in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_2_3224", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_2_3225", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "How long did the treatment last in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_2_3226", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What is the disorder targeted by the treatment in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_2_3227", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "What are the drugs used in combination in bis-chloronitrosourea (BCNU) therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_5_3228", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the age of the subject in a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15286697_5_3229", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the gender of the subject in a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15286697_5_3230", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the number of subjects in a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15286697_5_3231", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the race of the subject in a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15286697_5_3232", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the disorder of the subject in a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15286697_5_3233", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What are the drugs used in the treatment in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_5_3234", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the dosage of the treatment in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_5_3235", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the frequency of the treatment in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_5_3236", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the route of the treatment in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_5_3237", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_5_3238", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "How long did the treatment last in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_5_3239", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What is the disorder targeted by the treatment in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_5_3240", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "What are the drugs used in combination in high-dose BCNU (600 mg/m2)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_2_3241", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the age of the subject in The patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_2_3242", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the gender of the subject in The patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_2_3243", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the number of subjects in The patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_2_3244", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the race of the subject in The patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_2_3245", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the disorder of the subject in The patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_2_3246", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What are the drugs used in the treatment in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_2_3247", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the dosage of the treatment in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_2_3248", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the frequency of the treatment in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_2_3249", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the route of the treatment in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_2_3250", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "How long has elapsed from the treatment to the occurence of the event in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_2_3251", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "How long did the treatment last in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_2_3252", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What is the disorder targeted by the treatment in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_2_3253", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "What are the drugs used in combination in methimazole instead of propylthiouracil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_6_3254", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18675768_6_3255", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18675768_6_3256", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18675768_6_3257", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18675768_6_3258", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18675768_6_3259", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What are the drugs used in the treatment in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_6_3260", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the dosage of the treatment in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_6_3261", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the frequency of the treatment in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_6_3262", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the route of the treatment in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_6_3263", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "How long has elapsed from the treatment to the occurence of the event in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_6_3264", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "How long did the treatment last in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_6_3265", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What is the disorder targeted by the treatment in Three months after starting citalopram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_6_3266", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "What are the drugs used in combination in Three months after starting citalopram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_2_3267", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the age of the subject in a small number of patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_2_3268", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the gender of the subject in a small number of patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_2_3269", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the number of subjects in a small number of patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_2_3270", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the race of the subject in a small number of patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_2_3271", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the disorder of the subject in a small number of patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_2_3272", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What are the drugs used in the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_2_3273", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the dosage of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_2_3274", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the frequency of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_2_3275", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the route of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_2_3276", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "How long has elapsed from the treatment to the occurence of the event in vincristine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_2_3277", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "How long did the treatment last in vincristine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_2_3278", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What is the disorder targeted by the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_2_3279", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "What are the drugs used in combination in vincristine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_3_3280", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18042092_3_3281", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18042092_3_3282", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18042092_3_3283", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18042092_3_3284", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18042092_3_3285", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What are the drugs used in the treatment in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18042092_3_3286", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the dosage of the treatment in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_3_3287", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the frequency of the treatment in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_3_3288", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the route of the treatment in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18042092_3_3289", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "How long has elapsed from the treatment to the occurence of the event in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_3_3290", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "How long did the treatment last in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_3_3291", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What is the disorder targeted by the treatment in glatiramer acetate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_3_3292", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "What are the drugs used in combination in glatiramer acetate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_4_3293", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What are the drugs used in the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_4_3294", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What is the dosage of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_4_3295", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What is the frequency of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_4_3296", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What is the route of the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_4_3297", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "How long has elapsed from the treatment to the occurence of the event in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_4_3298", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "How long did the treatment last in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_4_3299", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What is the disorder targeted by the treatment in SSRI-drugs?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_4_3300", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "What are the drugs used in combination in SSRI-drugs?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22552763_1_3301", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the age of the subject in patients undergoing total hip and total knee arthroplasty?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_1_3302", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the gender of the subject in patients undergoing total hip and total knee arthroplasty?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_1_3303", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the number of subjects in patients undergoing total hip and total knee arthroplasty?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_1_3304", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the race of the subject in patients undergoing total hip and total knee arthroplasty?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_1_3305", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the disorder of the subject in patients undergoing total hip and total knee arthroplasty?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_1_3306", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What are the drugs used in the treatment in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22552763_1_3307", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the dosage of the treatment in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_1_3308", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the frequency of the treatment in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_1_3309", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the route of the treatment in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_1_3310", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "How long has elapsed from the treatment to the occurence of the event in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_1_3311", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "How long did the treatment last in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_1_3312", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What is the disorder targeted by the treatment in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22552763_1_3313", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "What are the drugs used in combination in Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_7_3314", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the age of the subject in MS patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_7_3315", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the gender of the subject in MS patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_7_3316", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the number of subjects in MS patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_7_3317", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the race of the subject in MS patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_7_3318", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the disorder of the subject in MS patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_7_3319", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What are the drugs used in the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_7_3320", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the dosage of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_7_3321", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the frequency of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_7_3322", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the route of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_7_3323", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "How long has elapsed from the treatment to the occurence of the event in IFN-beta?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_7_3324", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "How long did the treatment last in IFN-beta?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_7_3325", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What is the disorder targeted by the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_7_3326", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "What are the drugs used in combination in IFN-beta?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_5_3327", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What are the drugs used in the treatment in isoproterenol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_5_3328", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What is the dosage of the treatment in isoproterenol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_5_3329", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What is the frequency of the treatment in isoproterenol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_5_3330", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What is the route of the treatment in isoproterenol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_5_3331", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "How long has elapsed from the treatment to the occurence of the event in isoproterenol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_5_3332", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "How long did the treatment last in isoproterenol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_5_3333", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What is the disorder targeted by the treatment in isoproterenol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_5_3334", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "What are the drugs used in combination in isoproterenol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_3_3335", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the age of the subject in The patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9865241_3_3336", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the gender of the subject in The patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9865241_3_3337", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the number of subjects in The patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9865241_3_3338", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the race of the subject in The patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9865241_3_3339", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the disorder of the subject in The patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9865241_3_3340", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What are the drugs used in the treatment in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9865241_3_3341", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the dosage of the treatment in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_3_3342", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the frequency of the treatment in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_3_3343", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the route of the treatment in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_3_3344", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "How long has elapsed from the treatment to the occurence of the event in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_3_3345", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "How long did the treatment last in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_3_3346", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What is the disorder targeted by the treatment in hydration and furosemide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_3_3347", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "What are the drugs used in combination in hydration and furosemide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_4_3348", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the age of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_4_3349", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the gender of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21729965_4_3350", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the number of subjects in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_4_3351", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the race of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_4_3352", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the disorder of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_4_3353", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What are the drugs used in the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21729965_4_3354", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the dosage of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_4_3355", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the frequency of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_4_3356", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the route of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_4_3357", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "How long has elapsed from the treatment to the occurence of the event in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_4_3358", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "How long did the treatment last in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_4_3359", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What is the disorder targeted by the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21729965_4_3360", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "What are the drugs used in combination in antiretroviral therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_4_3361", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What are the drugs used in the treatment in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15595320_4_3362", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What is the dosage of the treatment in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_4_3363", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What is the frequency of the treatment in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_4_3364", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What is the route of the treatment in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_4_3365", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "How long has elapsed from the treatment to the occurence of the event in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_4_3366", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "How long did the treatment last in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_4_3367", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What is the disorder targeted by the treatment in COX-2 inhibitor?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_4_3368", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "What are the drugs used in combination in COX-2 inhibitor?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_2_3369", "context": "Temsirolimus-induced glomerulopathy.", "question": "What are the drugs used in the treatment in Temsirolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19212144_2_3370", "context": "Temsirolimus-induced glomerulopathy.", "question": "What is the dosage of the treatment in Temsirolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_2_3371", "context": "Temsirolimus-induced glomerulopathy.", "question": "What is the frequency of the treatment in Temsirolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_2_3372", "context": "Temsirolimus-induced glomerulopathy.", "question": "What is the route of the treatment in Temsirolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19212144_2_3373", "context": "Temsirolimus-induced glomerulopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in Temsirolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19212144_2_3374", "context": "Temsirolimus-induced glomerulopathy.", "question": "How long did the treatment last in Temsirolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_2_3375", "context": "Temsirolimus-induced glomerulopathy.", "question": "What is the disorder targeted by the treatment in Temsirolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19212144_2_3376", "context": "Temsirolimus-induced glomerulopathy.", "question": "What are the drugs used in combination in Temsirolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_4_3377", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_4_3378", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_4_3379", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_4_3380", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_4_3381", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_4_3382", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_4_3383", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_4_3384", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_2_3385", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the age of the subject in This patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_2_3386", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the gender of the subject in This patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_2_3387", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the number of subjects in This patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7949255_2_3388", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the race of the subject in This patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_2_3389", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the disorder of the subject in This patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_2_3390", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What are the drugs used in the treatment in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_2_3391", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the dosage of the treatment in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_2_3392", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the frequency of the treatment in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_2_3393", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the route of the treatment in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_2_3394", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "How long has elapsed from the treatment to the occurence of the event in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_2_3395", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "How long did the treatment last in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_2_3396", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What is the disorder targeted by the treatment in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_2_3397", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "What are the drugs used in combination in HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_5_3398", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the age of the subject in Adult and adolescent patients (> or = 12 years old; n = 141)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16685007_5_3399", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the gender of the subject in Adult and adolescent patients (> or = 12 years old; n = 141)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16685007_5_3400", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the number of subjects in Adult and adolescent patients (> or = 12 years old; n = 141)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16685007_5_3401", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the race of the subject in Adult and adolescent patients (> or = 12 years old; n = 141)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16685007_5_3402", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the disorder of the subject in Adult and adolescent patients (> or = 12 years old; n = 141)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16685007_5_3403", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What are the drugs used in the treatment in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685007_5_3404", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the dosage of the treatment in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_5_3405", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the frequency of the treatment in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_5_3406", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the route of the treatment in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685007_5_3407", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "How long has elapsed from the treatment to the occurence of the event in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_5_3408", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "How long did the treatment last in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_5_3409", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What is the disorder targeted by the treatment in oral steroid (prednisone)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_5_3410", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "What are the drugs used in combination in oral steroid (prednisone)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_1_3411", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the age of the subject in children and in adults with preexisting cardiac disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_1_3412", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the gender of the subject in children and in adults with preexisting cardiac disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_1_3413", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the number of subjects in children and in adults with preexisting cardiac disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_1_3414", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the race of the subject in children and in adults with preexisting cardiac disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_1_3415", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the disorder of the subject in children and in adults with preexisting cardiac disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_1_3416", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What are the drugs used in the treatment in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_1_3417", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the dosage of the treatment in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_1_3418", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the frequency of the treatment in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_1_3419", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the route of the treatment in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_1_3420", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "How long has elapsed from the treatment to the occurence of the event in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_1_3421", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "How long did the treatment last in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_1_3422", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What is the disorder targeted by the treatment in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_1_3423", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "What are the drugs used in combination in Amphotericin B deoxycholate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_2_3424", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the age of the subject in a male 60 yrs of age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11510798_2_3425", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the gender of the subject in a male 60 yrs of age?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11510798_2_3426", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the number of subjects in a male 60 yrs of age?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11510798_2_3427", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the race of the subject in a male 60 yrs of age?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11510798_2_3428", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the disorder of the subject in a male 60 yrs of age?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11510798_2_3429", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What are the drugs used in the treatment in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_2_3430", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the dosage of the treatment in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_2_3431", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the frequency of the treatment in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_2_3432", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the route of the treatment in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_2_3433", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "How long has elapsed from the treatment to the occurence of the event in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_2_3434", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "How long did the treatment last in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_2_3435", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What is the disorder targeted by the treatment in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_2_3436", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "What are the drugs used in combination in oxaliplatinum and 5-fluorouracil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18580694_2_3437", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What are the drugs used in the treatment in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18580694_2_3438", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What is the dosage of the treatment in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_2_3439", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What is the frequency of the treatment in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_2_3440", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What is the route of the treatment in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_2_3441", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "How long has elapsed from the treatment to the occurence of the event in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_2_3442", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "How long did the treatment last in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_2_3443", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What is the disorder targeted by the treatment in piperacillin and cefotiam?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_2_3444", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "What are the drugs used in combination in piperacillin and cefotiam?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_1_3445", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the age of the subject in A 55-yr-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6873616_1_3446", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the gender of the subject in A 55-yr-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6873616_1_3447", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the number of subjects in A 55-yr-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6873616_1_3448", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the race of the subject in A 55-yr-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6873616_1_3449", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the disorder of the subject in A 55-yr-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6873616_1_3450", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What are the drugs used in the treatment in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_1_3451", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the dosage of the treatment in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_1_3452", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the frequency of the treatment in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_1_3453", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the route of the treatment in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_1_3454", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_1_3455", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "How long did the treatment last in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_1_3456", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What is the disorder targeted by the treatment in thiabendazole therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_1_3457", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "What are the drugs used in combination in thiabendazole therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_3_3458", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What are the drugs used in the treatment in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_3_3459", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What is the dosage of the treatment in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_3_3460", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What is the frequency of the treatment in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_3_3461", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What is the route of the treatment in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_3_3462", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "How long has elapsed from the treatment to the occurence of the event in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_3_3463", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "How long did the treatment last in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_3_3464", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What is the disorder targeted by the treatment in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_3_3465", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "What are the drugs used in combination in Methylphenidate (Ritalin)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12410494_1_3466", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What are the drugs used in the treatment in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12410494_1_3467", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What is the dosage of the treatment in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_1_3468", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What is the frequency of the treatment in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_1_3469", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What is the route of the treatment in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_1_3470", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "How long has elapsed from the treatment to the occurence of the event in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_1_3471", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "How long did the treatment last in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_1_3472", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What is the disorder targeted by the treatment in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_1_3473", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "What are the drugs used in combination in Simvastatin-nelfinavir interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17955169_2_3474", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What are the drugs used in the treatment in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17955169_2_3475", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What is the dosage of the treatment in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17955169_2_3476", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What is the frequency of the treatment in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17955169_2_3477", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What is the route of the treatment in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17955169_2_3478", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "How long has elapsed from the treatment to the occurence of the event in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17955169_2_3479", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "How long did the treatment last in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17955169_2_3480", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What is the disorder targeted by the treatment in oxcarbazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17955169_2_3481", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "What are the drugs used in combination in oxcarbazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_3_3482", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the age of the subject in kidney transplant recipients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_3_3483", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the gender of the subject in kidney transplant recipients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_3_3484", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the number of subjects in kidney transplant recipients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_3_3485", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the race of the subject in kidney transplant recipients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_3_3486", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the disorder of the subject in kidney transplant recipients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_3_3487", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What are the drugs used in the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_3_3488", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the dosage of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_3_3489", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the frequency of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_3_3490", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the route of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_3_3491", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "How long has elapsed from the treatment to the occurence of the event in tacrolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_3_3492", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "How long did the treatment last in tacrolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_3_3493", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What is the disorder targeted by the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_3_3494", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "What are the drugs used in combination in tacrolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_3_3495", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What are the drugs used in the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_3_3496", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What is the dosage of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_3_3497", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What is the frequency of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_3_3498", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What is the route of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_3_3499", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_3_3500", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "How long did the treatment last in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_3_3501", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What is the disorder targeted by the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_3_3502", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "What are the drugs used in combination in high-dose methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_1_3503", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the age of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22372628_1_3504", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the gender of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22372628_1_3505", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the number of subjects in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22372628_1_3506", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the race of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22372628_1_3507", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the disorder of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22372628_1_3508", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What are the drugs used in the treatment in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22372628_1_3509", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the dosage of the treatment in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_1_3510", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the frequency of the treatment in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_1_3511", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the route of the treatment in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_1_3512", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "How long has elapsed from the treatment to the occurence of the event in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_1_3513", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "How long did the treatment last in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22372628_1_3514", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What is the disorder targeted by the treatment in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22372628_1_3515", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "What are the drugs used in combination in adjunctive lacosamide?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8404753_2_3516", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the age of the subject in adults and children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_2_3517", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the gender of the subject in adults and children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_2_3518", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the number of subjects in adults and children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_2_3519", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the race of the subject in adults and children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_2_3520", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the disorder of the subject in adults and children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_2_3521", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What are the drugs used in the treatment in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_2_3522", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the dosage of the treatment in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_2_3523", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the frequency of the treatment in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_2_3524", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the route of the treatment in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_2_3525", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_2_3526", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "How long did the treatment last in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_2_3527", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What is the disorder targeted by the treatment in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_2_3528", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "What are the drugs used in combination in carbamazepine (CBZ) therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_4_3529", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the age of the subject in he?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21515865_4_3530", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the gender of the subject in he?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21515865_4_3531", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the number of subjects in he?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_4_3532", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the race of the subject in he?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_4_3533", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the disorder of the subject in he?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_4_3534", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What are the drugs used in the treatment in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_4_3535", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the dosage of the treatment in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_4_3536", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the frequency of the treatment in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_4_3537", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the route of the treatment in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_4_3538", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_4_3539", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "How long did the treatment last in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_4_3540", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What is the disorder targeted by the treatment in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_4_3541", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "What are the drugs used in combination in the third of six serial weekly BCG bladder instillations?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7056119_3_3542", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the age of the subject in she?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7056119_3_3543", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the gender of the subject in she?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7056119_3_3544", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the number of subjects in she?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7056119_3_3545", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the race of the subject in she?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7056119_3_3546", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the disorder of the subject in she?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7056119_3_3547", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What are the drugs used in the treatment in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7056119_3_3548", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the dosage of the treatment in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_3_3549", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the frequency of the treatment in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7056119_3_3550", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the route of the treatment in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7056119_3_3551", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "How long has elapsed from the treatment to the occurence of the event in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_3_3552", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "How long did the treatment last in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7056119_3_3553", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What is the disorder targeted by the treatment in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_3_3554", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "What are the drugs used in combination in quinidine, 1.2 g/day, without interruption for 17 years?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3720318_2_3555", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3720318_2_3556", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3720318_2_3557", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3720318_2_3558", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3720318_2_3559", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3720318_2_3560", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What are the drugs used in the treatment in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3720318_2_3561", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the dosage of the treatment in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_2_3562", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the frequency of the treatment in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_2_3563", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the route of the treatment in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3720318_2_3564", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "How long has elapsed from the treatment to the occurence of the event in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_2_3565", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "How long did the treatment last in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_2_3566", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What is the disorder targeted by the treatment in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_2_3567", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "What are the drugs used in combination in intrabiliary infusion of monooctanoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_2_3568", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What are the drugs used in the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12166705_2_3569", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What is the dosage of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_2_3570", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What is the frequency of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_2_3571", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What is the route of the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_2_3572", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_2_3573", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "How long did the treatment last in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_2_3574", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What is the disorder targeted by the treatment in Mitomycin-C?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12166705_2_3575", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "What are the drugs used in combination in Mitomycin-C?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_2_3576", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the age of the subject in an adult patient without a history of metabolic disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1414247_2_3577", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the gender of the subject in an adult patient without a history of metabolic disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1414247_2_3578", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the number of subjects in an adult patient without a history of metabolic disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1414247_2_3579", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the race of the subject in an adult patient without a history of metabolic disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1414247_2_3580", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the disorder of the subject in an adult patient without a history of metabolic disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1414247_2_3581", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What are the drugs used in the treatment in Valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1414247_2_3582", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the dosage of the treatment in Valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_2_3583", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the frequency of the treatment in Valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_2_3584", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the route of the treatment in Valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_2_3585", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "How long has elapsed from the treatment to the occurence of the event in Valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_2_3586", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "How long did the treatment last in Valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_2_3587", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What is the disorder targeted by the treatment in Valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_2_3588", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "What are the drugs used in combination in Valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_4_3589", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the age of the subject in Three patients with no history of asthma or allergy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7355327_4_3590", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the gender of the subject in Three patients with no history of asthma or allergy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7355327_4_3591", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the number of subjects in Three patients with no history of asthma or allergy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7355327_4_3592", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the race of the subject in Three patients with no history of asthma or allergy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7355327_4_3593", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the disorder of the subject in Three patients with no history of asthma or allergy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7355327_4_3594", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What are the drugs used in the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_4_3595", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the dosage of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_4_3596", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the frequency of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_4_3597", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the route of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_4_3598", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_4_3599", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "How long did the treatment last in propranolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_4_3600", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What is the disorder targeted by the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_4_3601", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "What are the drugs used in combination in propranolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_2_3602", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_2_3603", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_2_3604", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_2_3605", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_2_3606", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_2_3607", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What are the drugs used in the treatment in warfarin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_2_3608", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the dosage of the treatment in warfarin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_2_3609", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the frequency of the treatment in warfarin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_2_3610", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the route of the treatment in warfarin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_2_3611", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_2_3612", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "How long did the treatment last in warfarin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_2_3613", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What is the disorder targeted by the treatment in warfarin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_2_3614", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "What are the drugs used in combination in warfarin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_2_3615", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What are the drugs used in the treatment in UV exposure?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_2_3616", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What is the dosage of the treatment in UV exposure?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_2_3617", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What is the frequency of the treatment in UV exposure?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_2_3618", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What is the route of the treatment in UV exposure?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_2_3619", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "How long has elapsed from the treatment to the occurence of the event in UV exposure?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_2_3620", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "How long did the treatment last in UV exposure?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_2_3621", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What is the disorder targeted by the treatment in UV exposure?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_2_3622", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "What are the drugs used in combination in UV exposure?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_1_3623", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What are the drugs used in the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_1_3624", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What is the dosage of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_1_3625", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What is the frequency of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_1_3626", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What is the route of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_1_3627", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "How long has elapsed from the treatment to the occurence of the event in Acetazolamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_1_3628", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "How long did the treatment last in Acetazolamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_1_3629", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What is the disorder targeted by the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_1_3630", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "What are the drugs used in combination in Acetazolamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_2_3631", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the age of the subject in Both patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_2_3632", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the gender of the subject in Both patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_2_3633", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the number of subjects in Both patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_2_3634", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the race of the subject in Both patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_2_3635", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the disorder of the subject in Both patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_2_3636", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What are the drugs used in the treatment in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "129501_2_3637", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the dosage of the treatment in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_2_3638", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the frequency of the treatment in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_2_3639", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the route of the treatment in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "129501_2_3640", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "How long has elapsed from the treatment to the occurence of the event in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_2_3641", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "How long did the treatment last in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_2_3642", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What is the disorder targeted by the treatment in injection of chymopapain into a disk?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_2_3643", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "What are the drugs used in combination in injection of chymopapain into a disk?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_2_3644", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What are the drugs used in the treatment in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_2_3645", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What is the dosage of the treatment in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_2_3646", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What is the frequency of the treatment in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_2_3647", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What is the route of the treatment in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_2_3648", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "How long has elapsed from the treatment to the occurence of the event in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_2_3649", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "How long did the treatment last in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_2_3650", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What is the disorder targeted by the treatment in Large dose of methylphenidate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_2_3651", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "What are the drugs used in combination in Large dose of methylphenidate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_3_3652", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the age of the subject in a 54-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7369302_3_3653", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the gender of the subject in a 54-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7369302_3_3654", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the number of subjects in a 54-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7369302_3_3655", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the race of the subject in a 54-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7369302_3_3656", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the disorder of the subject in a 54-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7369302_3_3657", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What are the drugs used in the treatment in quinine sulfate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_3_3658", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the dosage of the treatment in quinine sulfate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_3_3659", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the frequency of the treatment in quinine sulfate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_3_3660", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the route of the treatment in quinine sulfate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_3_3661", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "How long has elapsed from the treatment to the occurence of the event in quinine sulfate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_3_3662", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "How long did the treatment last in quinine sulfate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_3_3663", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What is the disorder targeted by the treatment in quinine sulfate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_3_3664", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "What are the drugs used in combination in quinine sulfate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_1_3665", "context": "Carbamazepine-induced tics.", "question": "What are the drugs used in the treatment in Carbamazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_1_3666", "context": "Carbamazepine-induced tics.", "question": "What is the dosage of the treatment in Carbamazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_1_3667", "context": "Carbamazepine-induced tics.", "question": "What is the frequency of the treatment in Carbamazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_1_3668", "context": "Carbamazepine-induced tics.", "question": "What is the route of the treatment in Carbamazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_1_3669", "context": "Carbamazepine-induced tics.", "question": "How long has elapsed from the treatment to the occurence of the event in Carbamazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_1_3670", "context": "Carbamazepine-induced tics.", "question": "How long did the treatment last in Carbamazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_1_3671", "context": "Carbamazepine-induced tics.", "question": "What is the disorder targeted by the treatment in Carbamazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_1_3672", "context": "Carbamazepine-induced tics.", "question": "What are the drugs used in combination in Carbamazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_3_3673", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the age of the subject in Three patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1655228_3_3674", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the gender of the subject in Three patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1655228_3_3675", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the number of subjects in Three patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1655228_3_3676", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the race of the subject in Three patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1655228_3_3677", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the disorder of the subject in Three patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1655228_3_3678", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What are the drugs used in the treatment in BCNU infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_3_3679", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the dosage of the treatment in BCNU infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_3_3680", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the frequency of the treatment in BCNU infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_3_3681", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the route of the treatment in BCNU infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_3_3682", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in BCNU infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_3_3683", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "How long did the treatment last in BCNU infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_3_3684", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What is the disorder targeted by the treatment in BCNU infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_3_3685", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "What are the drugs used in combination in BCNU infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25298587_1_3686", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What are the drugs used in the treatment in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "25298587_1_3687", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What is the dosage of the treatment in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25298587_1_3688", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What is the frequency of the treatment in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25298587_1_3689", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What is the route of the treatment in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25298587_1_3690", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "How long has elapsed from the treatment to the occurence of the event in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25298587_1_3691", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "How long did the treatment last in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25298587_1_3692", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What is the disorder targeted by the treatment in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25298587_1_3693", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "What are the drugs used in combination in ranolazine; interaction with clarithromycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_3_3694", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What are the drugs used in the treatment in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_3_3695", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What is the dosage of the treatment in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_3_3696", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What is the frequency of the treatment in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_3_3697", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What is the route of the treatment in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_3_3698", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "How long has elapsed from the treatment to the occurence of the event in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_3_3699", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "How long did the treatment last in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_3_3700", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What is the disorder targeted by the treatment in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_3_3701", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "What are the drugs used in combination in intra-articular hyaluronate injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_3_3702", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What are the drugs used in the treatment in colchicine and statin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_3_3703", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What is the dosage of the treatment in colchicine and statin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_3_3704", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What is the frequency of the treatment in colchicine and statin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_3_3705", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What is the route of the treatment in colchicine and statin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_3_3706", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "How long has elapsed from the treatment to the occurence of the event in colchicine and statin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_3_3707", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "How long did the treatment last in colchicine and statin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_3_3708", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What is the disorder targeted by the treatment in colchicine and statin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_3_3709", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "What are the drugs used in combination in colchicine and statin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_3_3710", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the age of the subject in a patient with propylthiouracil-induced acute hepatic failure?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15588385_3_3711", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the gender of the subject in a patient with propylthiouracil-induced acute hepatic failure?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15588385_3_3712", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the number of subjects in a patient with propylthiouracil-induced acute hepatic failure?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15588385_3_3713", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the race of the subject in a patient with propylthiouracil-induced acute hepatic failure?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15588385_3_3714", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the disorder of the subject in a patient with propylthiouracil-induced acute hepatic failure?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15588385_3_3715", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What are the drugs used in the treatment in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15588385_3_3716", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the dosage of the treatment in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_3_3717", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the frequency of the treatment in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15588385_3_3718", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the route of the treatment in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15588385_3_3719", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_3_3720", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "How long did the treatment last in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15588385_3_3721", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What is the disorder targeted by the treatment in amiodarone?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_3_3722", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "What are the drugs used in combination in amiodarone?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21330680_1_3723", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What are the drugs used in the treatment in Olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_1_3724", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What is the dosage of the treatment in Olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_1_3725", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What is the frequency of the treatment in Olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_1_3726", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What is the route of the treatment in Olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_1_3727", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "How long has elapsed from the treatment to the occurence of the event in Olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_1_3728", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "How long did the treatment last in Olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_1_3729", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What is the disorder targeted by the treatment in Olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_1_3730", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "What are the drugs used in combination in Olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_4_3731", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the age of the subject in an 11-year old male with Budd-Chiari syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20465622_4_3732", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the gender of the subject in an 11-year old male with Budd-Chiari syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20465622_4_3733", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the number of subjects in an 11-year old male with Budd-Chiari syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20465622_4_3734", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the race of the subject in an 11-year old male with Budd-Chiari syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20465622_4_3735", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the disorder of the subject in an 11-year old male with Budd-Chiari syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20465622_4_3736", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What are the drugs used in the treatment in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_4_3737", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the dosage of the treatment in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_4_3738", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the frequency of the treatment in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_4_3739", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the route of the treatment in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_4_3740", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "How long has elapsed from the treatment to the occurence of the event in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_4_3741", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "How long did the treatment last in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_4_3742", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What is the disorder targeted by the treatment in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_4_3743", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "What are the drugs used in combination in immunosuppressive therapy was changed from tacrolimus to sirolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10190739_2_3744", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the age of the subject in two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10190739_2_3745", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the gender of the subject in two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10190739_2_3746", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the number of subjects in two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10190739_2_3747", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the race of the subject in two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10190739_2_3748", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the disorder of the subject in two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10190739_2_3749", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What are the drugs used in the treatment in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10190739_2_3750", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the dosage of the treatment in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10190739_2_3751", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the frequency of the treatment in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10190739_2_3752", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the route of the treatment in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_2_3753", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "How long has elapsed from the treatment to the occurence of the event in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_2_3754", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "How long did the treatment last in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10190739_2_3755", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What is the disorder targeted by the treatment in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_2_3756", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "What are the drugs used in combination in riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_1_3757", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What are the drugs used in the treatment in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20628041_1_3758", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What is the dosage of the treatment in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_1_3759", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What is the frequency of the treatment in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_1_3760", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What is the route of the treatment in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_1_3761", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "How long has elapsed from the treatment to the occurence of the event in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_1_3762", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "How long did the treatment last in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_1_3763", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What is the disorder targeted by the treatment in levodopa and enteral nutrition?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_1_3764", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "What are the drugs used in combination in levodopa and enteral nutrition?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_14_3765", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_14_3766", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_14_3767", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_14_3768", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_14_3769", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_14_3770", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What are the drugs used in the treatment in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_14_3771", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the dosage of the treatment in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_14_3772", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the frequency of the treatment in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_14_3773", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the route of the treatment in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_14_3774", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_14_3775", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "How long did the treatment last in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_14_3776", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What is the disorder targeted by the treatment in tolterodine therapy is initiated?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_14_3777", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "What are the drugs used in combination in tolterodine therapy is initiated?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_13_3778", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the age of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15522120_13_3779", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the gender of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15522120_13_3780", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the number of subjects in the patient?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15522120_13_3781", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the race of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15522120_13_3782", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the disorder of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15522120_13_3783", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What are the drugs used in the treatment in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_13_3784", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the dosage of the treatment in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_13_3785", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the frequency of the treatment in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_13_3786", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the route of the treatment in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_13_3787", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "How long has elapsed from the treatment to the occurence of the event in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_13_3788", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "How long did the treatment last in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_13_3789", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What is the disorder targeted by the treatment in clemastine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_13_3790", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "What are the drugs used in combination in clemastine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_3_3791", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the age of the subject in a 36-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8391300_3_3792", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the gender of the subject in a 36-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8391300_3_3793", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the number of subjects in a 36-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8391300_3_3794", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the race of the subject in a 36-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8391300_3_3795", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the disorder of the subject in a 36-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8391300_3_3796", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What are the drugs used in the treatment in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8391300_3_3797", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the dosage of the treatment in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8391300_3_3798", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the frequency of the treatment in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_3_3799", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the route of the treatment in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_3_3800", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "How long has elapsed from the treatment to the occurence of the event in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_3_3801", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "How long did the treatment last in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_3_3802", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What is the disorder targeted by the treatment in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_3_3803", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "What are the drugs used in combination in erythromycin; ergotamine at normal doses?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_2_3804", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What are the drugs used in the treatment in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_2_3805", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What is the dosage of the treatment in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_2_3806", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What is the frequency of the treatment in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_2_3807", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What is the route of the treatment in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_2_3808", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "How long has elapsed from the treatment to the occurence of the event in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_2_3809", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "How long did the treatment last in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_2_3810", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What is the disorder targeted by the treatment in phenothiazines and clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_2_3811", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "What are the drugs used in combination in phenothiazines and clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_4_3812", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the age of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1695794_4_3813", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the gender of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1695794_4_3814", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the number of subjects in She?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1695794_4_3815", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the race of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1695794_4_3816", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the disorder of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1695794_4_3817", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What are the drugs used in the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1695794_4_3818", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the dosage of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_4_3819", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the frequency of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_4_3820", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the route of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_4_3821", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "How long has elapsed from the treatment to the occurence of the event in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_4_3822", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "How long did the treatment last in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_4_3823", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What is the disorder targeted by the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_4_3824", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "What are the drugs used in combination in rifampin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6572542_3_3825", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What are the drugs used in the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_3_3826", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What is the dosage of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_3_3827", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What is the frequency of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_3_3828", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What is the route of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_3_3829", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "How long has elapsed from the treatment to the occurence of the event in CCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_3_3830", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "How long did the treatment last in CCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_3_3831", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What is the disorder targeted by the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_3_3832", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "What are the drugs used in combination in CCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_1_3833", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_1_3834", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_1_3835", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_1_3836", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_1_3837", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_1_3838", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What are the drugs used in the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_1_3839", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the dosage of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_1_3840", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the frequency of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_1_3841", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the route of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_1_3842", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "How long has elapsed from the treatment to the occurence of the event in raloxifene?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_1_3843", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "How long did the treatment last in raloxifene?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_1_3844", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What is the disorder targeted by the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_1_3845", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "What are the drugs used in combination in raloxifene?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_1_3846", "context": "Fatal overdoses associated with quetiapine.", "question": "What are the drugs used in the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_1_3847", "context": "Fatal overdoses associated with quetiapine.", "question": "What is the dosage of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_1_3848", "context": "Fatal overdoses associated with quetiapine.", "question": "What is the frequency of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_1_3849", "context": "Fatal overdoses associated with quetiapine.", "question": "What is the route of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_1_3850", "context": "Fatal overdoses associated with quetiapine.", "question": "How long has elapsed from the treatment to the occurence of the event in quetiapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_1_3851", "context": "Fatal overdoses associated with quetiapine.", "question": "How long did the treatment last in quetiapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_1_3852", "context": "Fatal overdoses associated with quetiapine.", "question": "What is the disorder targeted by the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_1_3853", "context": "Fatal overdoses associated with quetiapine.", "question": "What are the drugs used in combination in quetiapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_3_3854", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What are the drugs used in the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_3_3855", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What is the dosage of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_3_3856", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What is the frequency of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_3_3857", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What is the route of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_3_3858", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "How long has elapsed from the treatment to the occurence of the event in Gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_3_3859", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "How long did the treatment last in Gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_3_3860", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What is the disorder targeted by the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_3_3861", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "What are the drugs used in combination in Gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_2_3862", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the age of the subject in a severely depressed 55-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19754002_2_3863", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the gender of the subject in a severely depressed 55-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19754002_2_3864", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the number of subjects in a severely depressed 55-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19754002_2_3865", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the race of the subject in a severely depressed 55-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19754002_2_3866", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the disorder of the subject in a severely depressed 55-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19754002_2_3867", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What are the drugs used in the treatment in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_2_3868", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the dosage of the treatment in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_2_3869", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the frequency of the treatment in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_2_3870", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the route of the treatment in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_2_3871", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "How long has elapsed from the treatment to the occurence of the event in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_2_3872", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "How long did the treatment last in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_2_3873", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What is the disorder targeted by the treatment in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_2_3874", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "What are the drugs used in combination in combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_4_3875", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the age of the subject in a 20-year-old woman with Basedow-Graves' disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15588385_4_3876", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the gender of the subject in a 20-year-old woman with Basedow-Graves' disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15588385_4_3877", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the number of subjects in a 20-year-old woman with Basedow-Graves' disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15588385_4_3878", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the race of the subject in a 20-year-old woman with Basedow-Graves' disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15588385_4_3879", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the disorder of the subject in a 20-year-old woman with Basedow-Graves' disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15588385_4_3880", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What are the drugs used in the treatment in PTU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_4_3881", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the dosage of the treatment in PTU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_4_3882", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the frequency of the treatment in PTU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_4_3883", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the route of the treatment in PTU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_4_3884", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in PTU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_4_3885", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "How long did the treatment last in PTU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_4_3886", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What is the disorder targeted by the treatment in PTU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_4_3887", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "What are the drugs used in combination in PTU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_2_3888", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the age of the subject in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_2_3889", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the gender of the subject in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_2_3890", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the number of subjects in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_2_3891", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the race of the subject in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_2_3892", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the disorder of the subject in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_2_3893", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What are the drugs used in the treatment in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_2_3894", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the dosage of the treatment in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_2_3895", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the frequency of the treatment in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_2_3896", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the route of the treatment in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_2_3897", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_2_3898", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "How long did the treatment last in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_2_3899", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What is the disorder targeted by the treatment in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_2_3900", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "What are the drugs used in combination in high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX)-based regimen?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6113770_2_3901", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What are the drugs used in the treatment in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6113770_2_3902", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What is the dosage of the treatment in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_2_3903", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What is the frequency of the treatment in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_2_3904", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What is the route of the treatment in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_2_3905", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_2_3906", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "How long did the treatment last in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_2_3907", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What is the disorder targeted by the treatment in lithium; thioridazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_2_3908", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "What are the drugs used in combination in lithium; thioridazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_1_3909", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What are the drugs used in the treatment in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1711090_1_3910", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What is the dosage of the treatment in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_1_3911", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What is the frequency of the treatment in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_1_3912", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What is the route of the treatment in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1711090_1_3913", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "How long has elapsed from the treatment to the occurence of the event in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_1_3914", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "How long did the treatment last in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_1_3915", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What is the disorder targeted by the treatment in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_1_3916", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "What are the drugs used in combination in lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6693840_2_3917", "context": "Gynecomastia associated with theophylline.", "question": "What are the drugs used in the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_2_3918", "context": "Gynecomastia associated with theophylline.", "question": "What is the dosage of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_2_3919", "context": "Gynecomastia associated with theophylline.", "question": "What is the frequency of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_2_3920", "context": "Gynecomastia associated with theophylline.", "question": "What is the route of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_2_3921", "context": "Gynecomastia associated with theophylline.", "question": "How long has elapsed from the treatment to the occurence of the event in theophylline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_2_3922", "context": "Gynecomastia associated with theophylline.", "question": "How long did the treatment last in theophylline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_2_3923", "context": "Gynecomastia associated with theophylline.", "question": "What is the disorder targeted by the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_2_3924", "context": "Gynecomastia associated with theophylline.", "question": "What are the drugs used in combination in theophylline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_1_3925", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the age of the subject in multiple sclerosis patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_1_3926", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the gender of the subject in multiple sclerosis patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_1_3927", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the number of subjects in multiple sclerosis patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_1_3928", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the race of the subject in multiple sclerosis patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_1_3929", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the disorder of the subject in multiple sclerosis patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_1_3930", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What are the drugs used in the treatment in interferon-beta?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_1_3931", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the dosage of the treatment in interferon-beta?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_1_3932", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the frequency of the treatment in interferon-beta?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_1_3933", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the route of the treatment in interferon-beta?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_1_3934", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon-beta?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_1_3935", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "How long did the treatment last in interferon-beta?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_1_3936", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What is the disorder targeted by the treatment in interferon-beta?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_1_3937", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "What are the drugs used in combination in interferon-beta?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_3_3938", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What are the drugs used in the treatment in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_3_3939", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What is the dosage of the treatment in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_3_3940", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What is the frequency of the treatment in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_3_3941", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What is the route of the treatment in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_3_3942", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "How long has elapsed from the treatment to the occurence of the event in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_3_3943", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "How long did the treatment last in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_3_3944", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What is the disorder targeted by the treatment in diltiazem hydrochloride?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_3_3945", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "What are the drugs used in combination in diltiazem hydrochloride?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11155197_1_3946", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What are the drugs used in the treatment in heparin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11155197_1_3947", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What is the dosage of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_1_3948", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What is the frequency of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_1_3949", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What is the route of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_1_3950", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "How long has elapsed from the treatment to the occurence of the event in heparin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_1_3951", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "How long did the treatment last in heparin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_1_3952", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What is the disorder targeted by the treatment in heparin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_1_3953", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "What are the drugs used in combination in heparin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_2_3954", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the age of the subject in a 41 yr old leprosy patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8316494_2_3955", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the gender of the subject in a 41 yr old leprosy patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8316494_2_3956", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the number of subjects in a 41 yr old leprosy patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8316494_2_3957", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the race of the subject in a 41 yr old leprosy patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8316494_2_3958", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the disorder of the subject in a 41 yr old leprosy patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8316494_2_3959", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What are the drugs used in the treatment in clofazimine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8316494_2_3960", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the dosage of the treatment in clofazimine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8316494_2_3961", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the frequency of the treatment in clofazimine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_2_3962", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the route of the treatment in clofazimine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_2_3963", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "How long has elapsed from the treatment to the occurence of the event in clofazimine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_2_3964", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "How long did the treatment last in clofazimine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8316494_2_3965", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What is the disorder targeted by the treatment in clofazimine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8316494_2_3966", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "What are the drugs used in combination in clofazimine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_2_3967", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What are the drugs used in the treatment in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_2_3968", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What is the dosage of the treatment in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_2_3969", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What is the frequency of the treatment in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_2_3970", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What is the route of the treatment in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_2_3971", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "How long has elapsed from the treatment to the occurence of the event in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_2_3972", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "How long did the treatment last in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_2_3973", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What is the disorder targeted by the treatment in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_2_3974", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "What are the drugs used in combination in antiemetic treatment with dexamethasone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_3_3975", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the age of the subject in a patient with acute promyleocytic leukemia (APL)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_3_3976", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the gender of the subject in a patient with acute promyleocytic leukemia (APL)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_3_3977", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the number of subjects in a patient with acute promyleocytic leukemia (APL)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_3_3978", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the race of the subject in a patient with acute promyleocytic leukemia (APL)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_3_3979", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the disorder of the subject in a patient with acute promyleocytic leukemia (APL)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_3_3980", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What are the drugs used in the treatment in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15663666_3_3981", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the dosage of the treatment in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_3_3982", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the frequency of the treatment in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15663666_3_3983", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the route of the treatment in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15663666_3_3984", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "How long has elapsed from the treatment to the occurence of the event in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_3_3985", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "How long did the treatment last in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_3_3986", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What is the disorder targeted by the treatment in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_3_3987", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "What are the drugs used in combination in 10 days of treatment with ATRA at a dose of 40 mg orally twice daily?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_1_3988", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What are the drugs used in the treatment in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "14684937_1_3989", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What is the dosage of the treatment in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_1_3990", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What is the frequency of the treatment in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "14684937_1_3991", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What is the route of the treatment in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "14684937_1_3992", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "How long has elapsed from the treatment to the occurence of the event in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_1_3993", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "How long did the treatment last in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "14684937_1_3994", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What is the disorder targeted by the treatment in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_1_3995", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "What are the drugs used in combination in topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11485141_6_3996", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What are the drugs used in the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_6_3997", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What is the dosage of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_6_3998", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What is the frequency of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_6_3999", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What is the route of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_6_4000", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "How long has elapsed from the treatment to the occurence of the event in Vancomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_6_4001", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "How long did the treatment last in Vancomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_6_4002", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What is the disorder targeted by the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_6_4003", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "What are the drugs used in combination in Vancomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15623719_1_4004", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What are the drugs used in the treatment in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15623719_1_4005", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What is the dosage of the treatment in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15623719_1_4006", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What is the frequency of the treatment in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15623719_1_4007", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What is the route of the treatment in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15623719_1_4008", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15623719_1_4009", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "How long did the treatment last in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15623719_1_4010", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What is the disorder targeted by the treatment in treatment with methylprednisolone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15623719_1_4011", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "What are the drugs used in combination in treatment with methylprednisolone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_3_4012", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_3_4013", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_3_4014", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_3_4015", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_3_4016", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_3_4017", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What are the drugs used in the treatment in interferon treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_3_4018", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the dosage of the treatment in interferon treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_3_4019", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the frequency of the treatment in interferon treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_3_4020", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the route of the treatment in interferon treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_3_4021", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_3_4022", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "How long did the treatment last in interferon treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_3_4023", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What is the disorder targeted by the treatment in interferon treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_3_4024", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "What are the drugs used in combination in interferon treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_2_4025", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What are the drugs used in the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15895899_2_4026", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What is the dosage of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_2_4027", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What is the frequency of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_2_4028", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What is the route of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_2_4029", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_2_4030", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "How long did the treatment last in infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_2_4031", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What is the disorder targeted by the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_2_4032", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "What are the drugs used in combination in infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_1_4033", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What are the drugs used in the treatment in Aripiprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19555801_1_4034", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What is the dosage of the treatment in Aripiprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_1_4035", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What is the frequency of the treatment in Aripiprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_1_4036", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What is the route of the treatment in Aripiprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_1_4037", "context": "Aripiprazole-induced hiccups: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in Aripiprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_1_4038", "context": "Aripiprazole-induced hiccups: a case report.", "question": "How long did the treatment last in Aripiprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_1_4039", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What is the disorder targeted by the treatment in Aripiprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19555801_1_4040", "context": "Aripiprazole-induced hiccups: a case report.", "question": "What are the drugs used in combination in Aripiprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_3_4041", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What are the drugs used in the treatment in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16728538_3_4042", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What is the dosage of the treatment in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_3_4043", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What is the frequency of the treatment in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16728538_3_4044", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What is the route of the treatment in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16728538_3_4045", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "How long has elapsed from the treatment to the occurence of the event in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_3_4046", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "How long did the treatment last in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16728538_3_4047", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What is the disorder targeted by the treatment in pegvisomant?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_3_4048", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "What are the drugs used in combination in pegvisomant?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9777751_4_4049", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the age of the subject in a 58-year-old female patient with Graves' disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9777751_4_4050", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the gender of the subject in a 58-year-old female patient with Graves' disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9777751_4_4051", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the number of subjects in a 58-year-old female patient with Graves' disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9777751_4_4052", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the race of the subject in a 58-year-old female patient with Graves' disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9777751_4_4053", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the disorder of the subject in a 58-year-old female patient with Graves' disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9777751_4_4054", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What are the drugs used in the treatment in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_4_4055", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the dosage of the treatment in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_4_4056", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the frequency of the treatment in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_4_4057", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the route of the treatment in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_4_4058", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "How long has elapsed from the treatment to the occurence of the event in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_4_4059", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "How long did the treatment last in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_4_4060", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What is the disorder targeted by the treatment in methimazole (MMI)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_4_4061", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "What are the drugs used in combination in methimazole (MMI)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_2_4062", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685112_2_4063", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_2_4064", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_2_4065", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_2_4066", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_2_4067", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_2_4068", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_2_4069", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_2_4070", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the age of the subject in An 80-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16046172_2_4071", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the gender of the subject in An 80-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16046172_2_4072", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the number of subjects in An 80-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_2_4073", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the race of the subject in An 80-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_2_4074", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the disorder of the subject in An 80-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_2_4075", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What are the drugs used in the treatment in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_2_4076", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the dosage of the treatment in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_2_4077", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the frequency of the treatment in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_2_4078", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the route of the treatment in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_2_4079", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "How long has elapsed from the treatment to the occurence of the event in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_2_4080", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "How long did the treatment last in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_2_4081", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What is the disorder targeted by the treatment in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_2_4082", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "What are the drugs used in combination in intraarticular injections of sodium hyaluronate and corticosteroids?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_5_4083", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What are the drugs used in the treatment in zomepirac administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_5_4084", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What is the dosage of the treatment in zomepirac administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_5_4085", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What is the frequency of the treatment in zomepirac administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_5_4086", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What is the route of the treatment in zomepirac administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_5_4087", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "How long has elapsed from the treatment to the occurence of the event in zomepirac administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_5_4088", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "How long did the treatment last in zomepirac administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_5_4089", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What is the disorder targeted by the treatment in zomepirac administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_5_4090", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "What are the drugs used in combination in zomepirac administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_2_4091", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What are the drugs used in the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6427463_2_4092", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What is the dosage of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_2_4093", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What is the frequency of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_2_4094", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What is the route of the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_2_4095", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "How long has elapsed from the treatment to the occurence of the event in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_2_4096", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "How long did the treatment last in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_2_4097", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What is the disorder targeted by the treatment in gold sodium thiomalate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_2_4098", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "What are the drugs used in combination in gold sodium thiomalate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_1_4099", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What are the drugs used in the treatment in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_1_4100", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What is the dosage of the treatment in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_1_4101", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What is the frequency of the treatment in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_1_4102", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What is the route of the treatment in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_1_4103", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_1_4104", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "How long did the treatment last in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_1_4105", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What is the disorder targeted by the treatment in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_1_4106", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "What are the drugs used in combination in Moxifloxacin-acetaminophen-warfarin interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15571949_1_4107", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the age of the subject in four patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15571949_1_4108", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the gender of the subject in four patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15571949_1_4109", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the number of subjects in four patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15571949_1_4110", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the race of the subject in four patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15571949_1_4111", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the disorder of the subject in four patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15571949_1_4112", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What are the drugs used in the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15571949_1_4113", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the dosage of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_1_4114", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the frequency of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_1_4115", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the route of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_1_4116", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "How long has elapsed from the treatment to the occurence of the event in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15571949_1_4117", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "How long did the treatment last in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_1_4118", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What is the disorder targeted by the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_1_4119", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "What are the drugs used in combination in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_1_4120", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the age of the subject in An adolescent male?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7139589_1_4121", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the gender of the subject in An adolescent male?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7139589_1_4122", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the number of subjects in An adolescent male?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7139589_1_4123", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the race of the subject in An adolescent male?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_1_4124", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the disorder of the subject in An adolescent male?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_1_4125", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What are the drugs used in the treatment in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_1_4126", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the dosage of the treatment in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_1_4127", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the frequency of the treatment in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_1_4128", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the route of the treatment in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_1_4129", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "How long has elapsed from the treatment to the occurence of the event in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_1_4130", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "How long did the treatment last in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_1_4131", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What is the disorder targeted by the treatment in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_1_4132", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "What are the drugs used in combination in 16 weeks after cessation of intramuscular L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17205927_1_4133", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What are the drugs used in the treatment in Quinapril?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17205927_1_4134", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What is the dosage of the treatment in Quinapril?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17205927_1_4135", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What is the frequency of the treatment in Quinapril?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17205927_1_4136", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What is the route of the treatment in Quinapril?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17205927_1_4137", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "How long has elapsed from the treatment to the occurence of the event in Quinapril?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17205927_1_4138", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "How long did the treatment last in Quinapril?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17205927_1_4139", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What is the disorder targeted by the treatment in Quinapril?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17205927_1_4140", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "What are the drugs used in combination in Quinapril?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9725786_1_4141", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the age of the subject in a renal transplant recipient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9725786_1_4142", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the gender of the subject in a renal transplant recipient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9725786_1_4143", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the number of subjects in a renal transplant recipient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9725786_1_4144", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the race of the subject in a renal transplant recipient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9725786_1_4145", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the disorder of the subject in a renal transplant recipient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9725786_1_4146", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What are the drugs used in the treatment in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9725786_1_4147", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the dosage of the treatment in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9725786_1_4148", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the frequency of the treatment in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9725786_1_4149", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the route of the treatment in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9725786_1_4150", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9725786_1_4151", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "How long did the treatment last in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9725786_1_4152", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What is the disorder targeted by the treatment in cyclosporine and prednisone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9725786_1_4153", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "What are the drugs used in combination in cyclosporine and prednisone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_2_4154", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the age of the subject in a patient with PTU-induced fulminant hepatitis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15588385_2_4155", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the gender of the subject in a patient with PTU-induced fulminant hepatitis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15588385_2_4156", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the number of subjects in a patient with PTU-induced fulminant hepatitis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15588385_2_4157", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the race of the subject in a patient with PTU-induced fulminant hepatitis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15588385_2_4158", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the disorder of the subject in a patient with PTU-induced fulminant hepatitis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15588385_2_4159", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What are the drugs used in the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15588385_2_4160", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the dosage of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_2_4161", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the frequency of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_2_4162", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the route of the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_2_4163", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_2_4164", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "How long did the treatment last in amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_2_4165", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What is the disorder targeted by the treatment in amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_2_4166", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "What are the drugs used in combination in amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_1_4167", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the age of the subject in the patient's mother?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12042592_1_4168", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the gender of the subject in the patient's mother?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12042592_1_4169", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the number of subjects in the patient's mother?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12042592_1_4170", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the race of the subject in the patient's mother?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12042592_1_4171", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the disorder of the subject in the patient's mother?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12042592_1_4172", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What are the drugs used in the treatment in metamizole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12042592_1_4173", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the dosage of the treatment in metamizole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_1_4174", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the frequency of the treatment in metamizole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_1_4175", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the route of the treatment in metamizole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_1_4176", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "How long has elapsed from the treatment to the occurence of the event in metamizole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_1_4177", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "How long did the treatment last in metamizole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_1_4178", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What is the disorder targeted by the treatment in metamizole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_1_4179", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "What are the drugs used in combination in metamizole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_3_4180", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the age of the subject in a patient with a long-standing history of refractory CLL?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_3_4181", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the gender of the subject in a patient with a long-standing history of refractory CLL?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_3_4182", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the number of subjects in a patient with a long-standing history of refractory CLL?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_3_4183", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the race of the subject in a patient with a long-standing history of refractory CLL?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_3_4184", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the disorder of the subject in a patient with a long-standing history of refractory CLL?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_3_4185", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What are the drugs used in the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_3_4186", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the dosage of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_3_4187", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the frequency of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_3_4188", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the route of the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_3_4189", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "How long has elapsed from the treatment to the occurence of the event in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_3_4190", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "How long did the treatment last in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_3_4191", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What is the disorder targeted by the treatment in fludarabine phosphate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_3_4192", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "What are the drugs used in combination in fludarabine phosphate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_1_4193", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the age of the subject in A 77-year-old woman with no history of epilepsy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10812579_1_4194", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the gender of the subject in A 77-year-old woman with no history of epilepsy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10812579_1_4195", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the number of subjects in A 77-year-old woman with no history of epilepsy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10812579_1_4196", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the race of the subject in A 77-year-old woman with no history of epilepsy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10812579_1_4197", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the disorder of the subject in A 77-year-old woman with no history of epilepsy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10812579_1_4198", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What are the drugs used in the treatment in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_1_4199", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the dosage of the treatment in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_1_4200", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the frequency of the treatment in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_1_4201", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the route of the treatment in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_1_4202", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "How long has elapsed from the treatment to the occurence of the event in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_1_4203", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "How long did the treatment last in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_1_4204", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What is the disorder targeted by the treatment in continuous intravenous morphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_1_4205", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "What are the drugs used in combination in continuous intravenous morphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_2_4206", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What are the drugs used in the treatment in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16685007_2_4207", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What is the dosage of the treatment in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_2_4208", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What is the frequency of the treatment in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_2_4209", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What is the route of the treatment in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685007_2_4210", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "How long has elapsed from the treatment to the occurence of the event in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_2_4211", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "How long did the treatment last in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_2_4212", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What is the disorder targeted by the treatment in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_2_4213", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "What are the drugs used in combination in Oral corticosteroids (OCS)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_1_4214", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What are the drugs used in the treatment in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15072497_1_4215", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What is the dosage of the treatment in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15072497_1_4216", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What is the frequency of the treatment in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15072497_1_4217", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What is the route of the treatment in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_1_4218", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_1_4219", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "How long did the treatment last in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_1_4220", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What is the disorder targeted by the treatment in long-term colchicine treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_1_4221", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "What are the drugs used in combination in long-term colchicine treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_6_4222", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the age of the subject in DPD-deficient patients with severe acute 5-FU reactions?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9007910_6_4223", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the gender of the subject in DPD-deficient patients with severe acute 5-FU reactions?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9007910_6_4224", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the number of subjects in DPD-deficient patients with severe acute 5-FU reactions?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9007910_6_4225", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the race of the subject in DPD-deficient patients with severe acute 5-FU reactions?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9007910_6_4226", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the disorder of the subject in DPD-deficient patients with severe acute 5-FU reactions?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9007910_6_4227", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What are the drugs used in the treatment in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9007910_6_4228", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the dosage of the treatment in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_6_4229", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the frequency of the treatment in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9007910_6_4230", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the route of the treatment in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9007910_6_4231", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_6_4232", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "How long did the treatment last in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9007910_6_4233", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What is the disorder targeted by the treatment in 5-FU?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_6_4234", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "What are the drugs used in combination in 5-FU?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16599252_1_4235", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the age of the subject in a patient with aspirin-induced asthma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16599252_1_4236", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the gender of the subject in a patient with aspirin-induced asthma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16599252_1_4237", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the number of subjects in a patient with aspirin-induced asthma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16599252_1_4238", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the race of the subject in a patient with aspirin-induced asthma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16599252_1_4239", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the disorder of the subject in a patient with aspirin-induced asthma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16599252_1_4240", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What are the drugs used in the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16599252_1_4241", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the dosage of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_1_4242", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the frequency of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_1_4243", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the route of the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_1_4244", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "How long has elapsed from the treatment to the occurence of the event in zafirlukast?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_1_4245", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "How long did the treatment last in zafirlukast?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_1_4246", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What is the disorder targeted by the treatment in zafirlukast?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_1_4247", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "What are the drugs used in combination in zafirlukast?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6788011_4_4248", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6788011_4_4249", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6788011_4_4250", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6788011_4_4251", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6788011_4_4252", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6788011_4_4253", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What are the drugs used in the treatment in therapy with gold?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6788011_4_4254", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the dosage of the treatment in therapy with gold?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_4_4255", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the frequency of the treatment in therapy with gold?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_4_4256", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the route of the treatment in therapy with gold?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_4_4257", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in therapy with gold?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_4_4258", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "How long did the treatment last in therapy with gold?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_4_4259", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in therapy with gold?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6788011_4_4260", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "What are the drugs used in combination in therapy with gold?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_6_4261", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What are the drugs used in the treatment in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_6_4262", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What is the dosage of the treatment in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_6_4263", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What is the frequency of the treatment in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_6_4264", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What is the route of the treatment in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_6_4265", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "How long has elapsed from the treatment to the occurence of the event in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_6_4266", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "How long did the treatment last in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_6_4267", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What is the disorder targeted by the treatment in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_6_4268", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "What are the drugs used in combination in nonsteroidal anti-inflammatory agents, especially zomepirac?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_1_4269", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What are the drugs used in the treatment in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12488741_1_4270", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What is the dosage of the treatment in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_1_4271", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What is the frequency of the treatment in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12488741_1_4272", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What is the route of the treatment in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12488741_1_4273", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "How long has elapsed from the treatment to the occurence of the event in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_1_4274", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "How long did the treatment last in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12488741_1_4275", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What is the disorder targeted by the treatment in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_1_4276", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "What are the drugs used in combination in discontinuation of metronidazole?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20202988_8_4277", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the age of the subject in one?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20202988_8_4278", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the gender of the subject in one?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20202988_8_4279", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the number of subjects in one?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20202988_8_4280", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the race of the subject in one?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20202988_8_4281", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the disorder of the subject in one?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20202988_8_4282", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What are the drugs used in the treatment in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20202988_8_4283", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the dosage of the treatment in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20202988_8_4284", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the frequency of the treatment in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20202988_8_4285", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the route of the treatment in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20202988_8_4286", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "How long has elapsed from the treatment to the occurence of the event in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20202988_8_4287", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "How long did the treatment last in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20202988_8_4288", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What is the disorder targeted by the treatment in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20202988_8_4289", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "What are the drugs used in combination in raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16265343_2_4290", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What are the drugs used in the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16265343_2_4291", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What is the dosage of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_2_4292", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What is the frequency of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_2_4293", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What is the route of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_2_4294", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alpha?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_2_4295", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "How long did the treatment last in interferon alpha?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_2_4296", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What is the disorder targeted by the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_2_4297", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "What are the drugs used in combination in interferon alpha?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8696525_1_4298", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What are the drugs used in the treatment in Metipranolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8696525_1_4299", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What is the dosage of the treatment in Metipranolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8696525_1_4300", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What is the frequency of the treatment in Metipranolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_1_4301", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What is the route of the treatment in Metipranolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8696525_1_4302", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "How long has elapsed from the treatment to the occurence of the event in Metipranolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_1_4303", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "How long did the treatment last in Metipranolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_1_4304", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What is the disorder targeted by the treatment in Metipranolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8696525_1_4305", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "What are the drugs used in combination in Metipranolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_13_4306", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What are the drugs used in the treatment in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12851279_13_4307", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What is the dosage of the treatment in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_13_4308", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What is the frequency of the treatment in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_13_4309", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What is the route of the treatment in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_13_4310", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "How long has elapsed from the treatment to the occurence of the event in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_13_4311", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "How long did the treatment last in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_13_4312", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What is the disorder targeted by the treatment in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_13_4313", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "What are the drugs used in combination in tifacogin and 4.8% placebo for high INR?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3318771_1_4314", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3318771_1_4315", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3318771_1_4316", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3318771_1_4317", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3318771_1_4318", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3318771_1_4319", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What are the drugs used in the treatment in timolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3318771_1_4320", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the dosage of the treatment in timolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3318771_1_4321", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the frequency of the treatment in timolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3318771_1_4322", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the route of the treatment in timolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3318771_1_4323", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "How long has elapsed from the treatment to the occurence of the event in timolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3318771_1_4324", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "How long did the treatment last in timolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3318771_1_4325", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What is the disorder targeted by the treatment in timolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3318771_1_4326", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "What are the drugs used in combination in timolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_1_4327", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the age of the subject in 70-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17016002_1_4328", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the gender of the subject in 70-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17016002_1_4329", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the number of subjects in 70-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_1_4330", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the race of the subject in 70-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_1_4331", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the disorder of the subject in 70-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_1_4332", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What are the drugs used in the treatment in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_1_4333", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the dosage of the treatment in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_1_4334", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the frequency of the treatment in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_1_4335", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the route of the treatment in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_1_4336", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "How long has elapsed from the treatment to the occurence of the event in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_1_4337", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "How long did the treatment last in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_1_4338", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What is the disorder targeted by the treatment in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_1_4339", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "What are the drugs used in combination in taking an antihistaminic agent (homochlorcyclizine hydrochloride)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_1_4340", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What are the drugs used in the treatment in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10212021_1_4341", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What is the dosage of the treatment in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_1_4342", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What is the frequency of the treatment in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10212021_1_4343", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What is the route of the treatment in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10212021_1_4344", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "How long has elapsed from the treatment to the occurence of the event in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_1_4345", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "How long did the treatment last in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10212021_1_4346", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What is the disorder targeted by the treatment in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10212021_1_4347", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "What are the drugs used in combination in antiretroviral regimen including nevirapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_4_4348", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_4_4349", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_4_4350", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_4_4351", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_4_4352", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_4_4353", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What are the drugs used in the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_4_4354", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the dosage of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_4_4355", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the frequency of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_4_4356", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the route of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_4_4357", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "How long has elapsed from the treatment to the occurence of the event in zonisamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_4_4358", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "How long did the treatment last in zonisamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_4_4359", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What is the disorder targeted by the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_4_4360", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "What are the drugs used in combination in zonisamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_4_4361", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_4_4362", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_4_4363", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_4_4364", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_4_4365", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_4_4366", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_4_4367", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_4_4368", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10435399_1_4369", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10435399_1_4370", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_1_4371", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_1_4372", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_1_4373", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_1_4374", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_1_4375", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_1_4376", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17827338_2_4377", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What are the drugs used in the treatment in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17827338_2_4378", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What is the dosage of the treatment in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17827338_2_4379", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What is the frequency of the treatment in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17827338_2_4380", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What is the route of the treatment in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17827338_2_4381", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "How long has elapsed from the treatment to the occurence of the event in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17827338_2_4382", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "How long did the treatment last in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17827338_2_4383", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What is the disorder targeted by the treatment in Vicriviroc?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17827338_2_4384", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "What are the drugs used in combination in Vicriviroc?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9253492_2_4385", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the age of the subject in Children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_2_4386", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the gender of the subject in Children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_2_4387", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the number of subjects in Children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_2_4388", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the race of the subject in Children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_2_4389", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the disorder of the subject in Children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_2_4390", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What are the drugs used in the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_2_4391", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the dosage of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_2_4392", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the frequency of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_2_4393", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the route of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_2_4394", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "How long has elapsed from the treatment to the occurence of the event in zonisamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_2_4395", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "How long did the treatment last in zonisamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_2_4396", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What is the disorder targeted by the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_2_4397", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "What are the drugs used in combination in zonisamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_3_4398", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the age of the subject in 2 male patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_3_4399", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the gender of the subject in 2 male patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_3_4400", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the number of subjects in 2 male patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_3_4401", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the race of the subject in 2 male patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_3_4402", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the disorder of the subject in 2 male patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_3_4403", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What are the drugs used in the treatment in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_3_4404", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the dosage of the treatment in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_3_4405", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the frequency of the treatment in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_3_4406", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the route of the treatment in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_3_4407", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "How long has elapsed from the treatment to the occurence of the event in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_3_4408", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "How long did the treatment last in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_3_4409", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What is the disorder targeted by the treatment in taking venlafaxine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_3_4410", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "What are the drugs used in combination in taking venlafaxine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1087773_2_4411", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What are the drugs used in the treatment in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1087773_2_4412", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What is the dosage of the treatment in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_2_4413", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What is the frequency of the treatment in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_2_4414", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What is the route of the treatment in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_2_4415", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "How long has elapsed from the treatment to the occurence of the event in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1087773_2_4416", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "How long did the treatment last in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_2_4417", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What is the disorder targeted by the treatment in ethambutol and rifampicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1087773_2_4418", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "What are the drugs used in combination in ethambutol and rifampicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15507779_4_4419", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the age of the subject in an HIV-infected woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_4_4420", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the gender of the subject in an HIV-infected woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15507779_4_4421", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the number of subjects in an HIV-infected woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_4_4422", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the race of the subject in an HIV-infected woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_4_4423", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the disorder of the subject in an HIV-infected woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_4_4424", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What are the drugs used in the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15507779_4_4425", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the dosage of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_4_4426", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the frequency of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_4_4427", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the route of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_4_4428", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "How long has elapsed from the treatment to the occurence of the event in nevirapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_4_4429", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "How long did the treatment last in nevirapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_4_4430", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What is the disorder targeted by the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_4_4431", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "What are the drugs used in combination in nevirapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_2_4432", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the age of the subject in a geriatric patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_2_4433", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the gender of the subject in a geriatric patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_2_4434", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the number of subjects in a geriatric patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_2_4435", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the race of the subject in a geriatric patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_2_4436", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the disorder of the subject in a geriatric patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_2_4437", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What are the drugs used in the treatment in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_2_4438", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the dosage of the treatment in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_2_4439", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the frequency of the treatment in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_2_4440", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the route of the treatment in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_2_4441", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "How long has elapsed from the treatment to the occurence of the event in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_2_4442", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "How long did the treatment last in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_2_4443", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What is the disorder targeted by the treatment in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_2_4444", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "What are the drugs used in combination in 3 days after treatment with olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_15_4445", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What are the drugs used in the treatment in Tifacogin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12851279_15_4446", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What is the dosage of the treatment in Tifacogin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_15_4447", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What is the frequency of the treatment in Tifacogin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_15_4448", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What is the route of the treatment in Tifacogin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_15_4449", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "How long has elapsed from the treatment to the occurence of the event in Tifacogin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_15_4450", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "How long did the treatment last in Tifacogin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_15_4451", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What is the disorder targeted by the treatment in Tifacogin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_15_4452", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "What are the drugs used in combination in Tifacogin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6618859_1_4453", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the age of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6618859_1_4454", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the gender of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6618859_1_4455", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the number of subjects in two epileptic patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6618859_1_4456", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the race of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6618859_1_4457", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the disorder of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6618859_1_4458", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What are the drugs used in the treatment in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6618859_1_4459", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the dosage of the treatment in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6618859_1_4460", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the frequency of the treatment in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6618859_1_4461", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the route of the treatment in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6618859_1_4462", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "How long has elapsed from the treatment to the occurence of the event in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6618859_1_4463", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "How long did the treatment last in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_1_4464", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What is the disorder targeted by the treatment in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6618859_1_4465", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "What are the drugs used in combination in oral fluoresone 750 mg daily to the phenobarbital and phenytoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6113770_1_4466", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What are the drugs used in the treatment in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6113770_1_4467", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What is the dosage of the treatment in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_1_4468", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What is the frequency of the treatment in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_1_4469", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What is the route of the treatment in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_1_4470", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_1_4471", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "How long did the treatment last in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_1_4472", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What is the disorder targeted by the treatment in lithium and haloperidol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_1_4473", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "What are the drugs used in combination in lithium and haloperidol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_3_4474", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17665812_3_4475", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_3_4476", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_3_4477", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_3_4478", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_3_4479", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_3_4480", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_3_4481", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_4_4482", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the age of the subject in two women and one man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7139589_4_4483", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the gender of the subject in two women and one man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7139589_4_4484", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the number of subjects in two women and one man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7139589_4_4485", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the race of the subject in two women and one man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_4_4486", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the disorder of the subject in two women and one man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_4_4487", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What are the drugs used in the treatment in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_4_4488", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the dosage of the treatment in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_4_4489", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the frequency of the treatment in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_4_4490", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the route of the treatment in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_4_4491", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_4_4492", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "How long did the treatment last in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_4_4493", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What is the disorder targeted by the treatment in intravenous L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_4_4494", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "What are the drugs used in combination in intravenous L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_4_4495", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What are the drugs used in the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17182354_4_4496", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What is the dosage of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_4_4497", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What is the frequency of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_4_4498", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What is the route of the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_4_4499", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "How long has elapsed from the treatment to the occurence of the event in Ritalin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_4_4500", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "How long did the treatment last in Ritalin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_4_4501", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What is the disorder targeted by the treatment in Ritalin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_4_4502", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "What are the drugs used in combination in Ritalin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_3_4503", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19884751_3_4504", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19884751_3_4505", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19884751_3_4506", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19884751_3_4507", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19884751_3_4508", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What are the drugs used in the treatment in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19884751_3_4509", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the dosage of the treatment in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_3_4510", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the frequency of the treatment in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_3_4511", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the route of the treatment in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_3_4512", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "How long has elapsed from the treatment to the occurence of the event in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_3_4513", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "How long did the treatment last in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19884751_3_4514", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What is the disorder targeted by the treatment in short-term therapy with Amikacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_3_4515", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "What are the drugs used in combination in short-term therapy with Amikacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_1_4516", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What are the drugs used in the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1655228_1_4517", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What is the dosage of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_1_4518", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What is the frequency of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_1_4519", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What is the route of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_1_4520", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "How long has elapsed from the treatment to the occurence of the event in BCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_1_4521", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "How long did the treatment last in BCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_1_4522", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What is the disorder targeted by the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_1_4523", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "What are the drugs used in combination in BCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12891225_2_4524", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What are the drugs used in the treatment in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12891225_2_4525", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What is the dosage of the treatment in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12891225_2_4526", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What is the frequency of the treatment in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12891225_2_4527", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What is the route of the treatment in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12891225_2_4528", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "How long has elapsed from the treatment to the occurence of the event in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12891225_2_4529", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "How long did the treatment last in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12891225_2_4530", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What is the disorder targeted by the treatment in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12891225_2_4531", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "What are the drugs used in combination in Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17123120_2_4532", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What are the drugs used in the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17123120_2_4533", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What is the dosage of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_2_4534", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What is the frequency of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_2_4535", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What is the route of the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_2_4536", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in tacrolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_2_4537", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "How long did the treatment last in tacrolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_2_4538", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What is the disorder targeted by the treatment in tacrolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17123120_2_4539", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "What are the drugs used in combination in tacrolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_3_4540", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_3_4541", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_3_4542", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_3_4543", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_3_4544", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_3_4545", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What are the drugs used in the treatment in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_3_4546", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the dosage of the treatment in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_3_4547", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the frequency of the treatment in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_3_4548", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the route of the treatment in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_3_4549", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_3_4550", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "How long did the treatment last in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_3_4551", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What is the disorder targeted by the treatment in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_3_4552", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "What are the drugs used in combination in pentamidine throughout the duration of therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_3_4553", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What are the drugs used in the treatment in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14684937_3_4554", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What is the dosage of the treatment in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_3_4555", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What is the frequency of the treatment in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_3_4556", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What is the route of the treatment in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14684937_3_4557", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "How long has elapsed from the treatment to the occurence of the event in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_3_4558", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "How long did the treatment last in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_3_4559", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What is the disorder targeted by the treatment in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_3_4560", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "What are the drugs used in combination in vitamin D3 ointment and thiazide simultaneously?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_1_4561", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the age of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_1_4562", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the gender of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_1_4563", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the number of subjects in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_1_4564", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the race of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_1_4565", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the disorder of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_1_4566", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What are the drugs used in the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_1_4567", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the dosage of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_1_4568", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the frequency of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_1_4569", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the route of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_1_4570", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "How long has elapsed from the treatment to the occurence of the event in leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_1_4571", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "How long did the treatment last in leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_1_4572", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What is the disorder targeted by the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_1_4573", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "What are the drugs used in combination in leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7071645_2_4574", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the age of the subject in a man with classic rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7071645_2_4575", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the gender of the subject in a man with classic rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7071645_2_4576", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the number of subjects in a man with classic rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7071645_2_4577", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the race of the subject in a man with classic rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7071645_2_4578", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the disorder of the subject in a man with classic rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7071645_2_4579", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What are the drugs used in the treatment in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7071645_2_4580", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the dosage of the treatment in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_2_4581", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the frequency of the treatment in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7071645_2_4582", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the route of the treatment in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7071645_2_4583", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_2_4584", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "How long did the treatment last in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7071645_2_4585", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What is the disorder targeted by the treatment in gold or penicillamine therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7071645_2_4586", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "What are the drugs used in combination in gold or penicillamine therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24531907_1_4587", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the age of the subject in HIV-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24531907_1_4588", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the gender of the subject in HIV-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24531907_1_4589", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the number of subjects in HIV-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24531907_1_4590", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the race of the subject in HIV-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24531907_1_4591", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the disorder of the subject in HIV-infected patients?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24531907_1_4592", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What are the drugs used in the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "24531907_1_4593", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the dosage of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24531907_1_4594", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the frequency of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24531907_1_4595", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the route of the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24531907_1_4596", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "How long has elapsed from the treatment to the occurence of the event in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24531907_1_4597", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "How long did the treatment last in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24531907_1_4598", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What is the disorder targeted by the treatment in rifampin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "24531907_1_4599", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "What are the drugs used in combination in rifampin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9352164_5_4600", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What are the drugs used in the treatment in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9352164_5_4601", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What is the dosage of the treatment in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_5_4602", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What is the frequency of the treatment in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_5_4603", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What is the route of the treatment in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_5_4604", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "How long has elapsed from the treatment to the occurence of the event in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_5_4605", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "How long did the treatment last in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_5_4606", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What is the disorder targeted by the treatment in an excessive dose of AZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_5_4607", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "What are the drugs used in combination in an excessive dose of AZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_1_4608", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What are the drugs used in the treatment in Acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8430717_1_4609", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What is the dosage of the treatment in Acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_1_4610", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What is the frequency of the treatment in Acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_1_4611", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What is the route of the treatment in Acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_1_4612", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "How long has elapsed from the treatment to the occurence of the event in Acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_1_4613", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "How long did the treatment last in Acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_1_4614", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What is the disorder targeted by the treatment in Acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_1_4615", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "What are the drugs used in combination in Acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1680596_2_4616", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the age of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_2_4617", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the gender of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1680596_2_4618", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the number of subjects in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_2_4619", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the race of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_2_4620", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the disorder of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_2_4621", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What are the drugs used in the treatment in sulphasalazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1680596_2_4622", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the dosage of the treatment in sulphasalazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1680596_2_4623", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the frequency of the treatment in sulphasalazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_2_4624", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the route of the treatment in sulphasalazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_2_4625", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in sulphasalazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_2_4626", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "How long did the treatment last in sulphasalazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_2_4627", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What is the disorder targeted by the treatment in sulphasalazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1680596_2_4628", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "What are the drugs used in combination in sulphasalazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_4_4629", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the age of the subject in 2 patients with Crohn's disease (CD)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_4_4630", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the gender of the subject in 2 patients with Crohn's disease (CD)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_4_4631", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the number of subjects in 2 patients with Crohn's disease (CD)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_4_4632", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the race of the subject in 2 patients with Crohn's disease (CD)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_4_4633", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the disorder of the subject in 2 patients with Crohn's disease (CD)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_4_4634", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What are the drugs used in the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_4_4635", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the dosage of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_4_4636", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the frequency of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_4_4637", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the route of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_4_4638", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_4_4639", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "How long did the treatment last in infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_4_4640", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What is the disorder targeted by the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_4_4641", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "What are the drugs used in combination in infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_2_4642", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What are the drugs used in the treatment in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17275666_2_4643", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What is the dosage of the treatment in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_2_4644", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What is the frequency of the treatment in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17275666_2_4645", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What is the route of the treatment in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17275666_2_4646", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "How long has elapsed from the treatment to the occurence of the event in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_2_4647", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "How long did the treatment last in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17275666_2_4648", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What is the disorder targeted by the treatment in Valproic acid?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_2_4649", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "What are the drugs used in combination in Valproic acid?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14561622_3_4650", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14561622_3_4651", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14561622_3_4652", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14561622_3_4653", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14561622_3_4654", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14561622_3_4655", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What are the drugs used in the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_3_4656", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the dosage of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_3_4657", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the frequency of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_3_4658", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the route of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_3_4659", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_3_4660", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "How long did the treatment last in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_3_4661", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What is the disorder targeted by the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_3_4662", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "What are the drugs used in combination in intrathecal methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_11_4663", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What are the drugs used in the treatment in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_11_4664", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What is the dosage of the treatment in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_11_4665", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What is the frequency of the treatment in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_11_4666", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What is the route of the treatment in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_11_4667", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_11_4668", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "How long did the treatment last in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_11_4669", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What is the disorder targeted by the treatment in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_11_4670", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "What are the drugs used in combination in warfarin-cloxacillin interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_4_4671", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the age of the subject in two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_4_4672", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the gender of the subject in two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_4_4673", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the number of subjects in two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_4_4674", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the race of the subject in two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_4_4675", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the disorder of the subject in two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_4_4676", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What are the drugs used in the treatment in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_4_4677", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the dosage of the treatment in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_4_4678", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the frequency of the treatment in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_4_4679", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the route of the treatment in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_4_4680", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_4_4681", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "How long did the treatment last in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_4_4682", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What is the disorder targeted by the treatment in IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_4_4683", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "What are the drugs used in combination in IFN-beta therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_1_4684", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the age of the subject in brain-damaged children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_1_4685", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the gender of the subject in brain-damaged children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_1_4686", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the number of subjects in brain-damaged children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_1_4687", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the race of the subject in brain-damaged children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_1_4688", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the disorder of the subject in brain-damaged children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_1_4689", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What are the drugs used in the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_1_4690", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the dosage of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_1_4691", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the frequency of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_1_4692", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the route of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_1_4693", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_1_4694", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "How long did the treatment last in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_1_4695", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What is the disorder targeted by the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_1_4696", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "What are the drugs used in combination in carbamazepine administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_10_4697", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the age of the subject in 51 patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_10_4698", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the gender of the subject in 51 patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_10_4699", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the number of subjects in 51 patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_10_4700", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the race of the subject in 51 patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_10_4701", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the disorder of the subject in 51 patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_10_4702", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What are the drugs used in the treatment in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_10_4703", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the dosage of the treatment in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_10_4704", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the frequency of the treatment in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_10_4705", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the route of the treatment in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_10_4706", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "How long has elapsed from the treatment to the occurence of the event in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_10_4707", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "How long did the treatment last in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_10_4708", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What is the disorder targeted by the treatment in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_10_4709", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "What are the drugs used in combination in omeprazole and 2.9% with placebo at 180 days?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_1_4710", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What are the drugs used in the treatment in pamidronate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9865241_1_4711", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the dosage of the treatment in pamidronate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_1_4712", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the frequency of the treatment in pamidronate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_1_4713", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the route of the treatment in pamidronate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_1_4714", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "How long has elapsed from the treatment to the occurence of the event in pamidronate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_1_4715", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "How long did the treatment last in pamidronate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_1_4716", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the disorder targeted by the treatment in pamidronate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_1_4717", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "What are the drugs used in combination in pamidronate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_1_4718", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What are the drugs used in the treatment in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20925534_1_4719", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What is the dosage of the treatment in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_1_4720", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What is the frequency of the treatment in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_1_4721", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What is the route of the treatment in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_1_4722", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "How long has elapsed from the treatment to the occurence of the event in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_1_4723", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "How long did the treatment last in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_1_4724", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What is the disorder targeted by the treatment in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_1_4725", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "What are the drugs used in combination in Clopidogrel with or without omeprazole?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11001600_1_4726", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the age of the subject in patients with dementia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11001600_1_4727", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the gender of the subject in patients with dementia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11001600_1_4728", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the number of subjects in patients with dementia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11001600_1_4729", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the race of the subject in patients with dementia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11001600_1_4730", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the disorder of the subject in patients with dementia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11001600_1_4731", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What are the drugs used in the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11001600_1_4732", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the dosage of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11001600_1_4733", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the frequency of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11001600_1_4734", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the route of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11001600_1_4735", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "How long has elapsed from the treatment to the occurence of the event in risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11001600_1_4736", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "How long did the treatment last in risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11001600_1_4737", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What is the disorder targeted by the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11001600_1_4738", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "What are the drugs used in combination in risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18580694_1_4739", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What are the drugs used in the treatment in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18580694_1_4740", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What is the dosage of the treatment in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_1_4741", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What is the frequency of the treatment in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_1_4742", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What is the route of the treatment in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_1_4743", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "How long has elapsed from the treatment to the occurence of the event in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_1_4744", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "How long did the treatment last in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_1_4745", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What is the disorder targeted by the treatment in ciprofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_1_4746", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "What are the drugs used in combination in ciprofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_2_4747", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What are the drugs used in the treatment in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10592946_2_4748", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What is the dosage of the treatment in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_2_4749", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What is the frequency of the treatment in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10592946_2_4750", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What is the route of the treatment in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10592946_2_4751", "context": "After abstinence from oolong tea his delirium resolved.", "question": "How long has elapsed from the treatment to the occurence of the event in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_2_4752", "context": "After abstinence from oolong tea his delirium resolved.", "question": "How long did the treatment last in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10592946_2_4753", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What is the disorder targeted by the treatment in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_2_4754", "context": "After abstinence from oolong tea his delirium resolved.", "question": "What are the drugs used in combination in abstinence from oolong tea?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16901609_1_4755", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What are the drugs used in the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16901609_1_4756", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What is the dosage of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_1_4757", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What is the frequency of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_1_4758", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What is the route of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16901609_1_4759", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_1_4760", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "How long did the treatment last in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_1_4761", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What is the disorder targeted by the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_1_4762", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "What are the drugs used in combination in intrathecal diamorphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_3_4763", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the age of the subject in This case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8726608_3_4764", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the gender of the subject in This case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8726608_3_4765", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the number of subjects in This case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8726608_3_4766", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the race of the subject in This case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8726608_3_4767", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the disorder of the subject in This case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8726608_3_4768", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What are the drugs used in the treatment in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_3_4769", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the dosage of the treatment in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_3_4770", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the frequency of the treatment in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_3_4771", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the route of the treatment in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_3_4772", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_3_4773", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "How long did the treatment last in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_3_4774", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What is the disorder targeted by the treatment in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_3_4775", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "What are the drugs used in combination in acyclovir when given intravenously in doses of 10 mg/kg?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_12_4776", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15522120_12_4777", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15522120_12_4778", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15522120_12_4779", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15522120_12_4780", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15522120_12_4781", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What are the drugs used in the treatment in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_12_4782", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the dosage of the treatment in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_12_4783", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the frequency of the treatment in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_12_4784", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the route of the treatment in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_12_4785", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "How long has elapsed from the treatment to the occurence of the event in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_12_4786", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "How long did the treatment last in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_12_4787", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What is the disorder targeted by the treatment in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_12_4788", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "What are the drugs used in combination in approximately two weeks of sertraline treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8589490_2_4789", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What are the drugs used in the treatment in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_2_4790", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What is the dosage of the treatment in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_2_4791", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What is the frequency of the treatment in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_2_4792", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What is the route of the treatment in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_2_4793", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "How long has elapsed from the treatment to the occurence of the event in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_2_4794", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "How long did the treatment last in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_2_4795", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What is the disorder targeted by the treatment in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_2_4796", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "What are the drugs used in combination in cytostatic chemotherapeutic agents?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_1_4797", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What are the drugs used in the treatment in Atovaquone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_1_4798", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What is the dosage of the treatment in Atovaquone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_1_4799", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What is the frequency of the treatment in Atovaquone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_1_4800", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What is the route of the treatment in Atovaquone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_1_4801", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "How long has elapsed from the treatment to the occurence of the event in Atovaquone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_1_4802", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "How long did the treatment last in Atovaquone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_1_4803", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What is the disorder targeted by the treatment in Atovaquone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_1_4804", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "What are the drugs used in combination in Atovaquone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_2_4805", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What are the drugs used in the treatment in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_2_4806", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What is the dosage of the treatment in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_2_4807", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What is the frequency of the treatment in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_2_4808", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What is the route of the treatment in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_2_4809", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "How long has elapsed from the treatment to the occurence of the event in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_2_4810", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "How long did the treatment last in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_2_4811", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What is the disorder targeted by the treatment in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_2_4812", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "What are the drugs used in combination in injection of the morphine antagonist naloxone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_1_4813", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the age of the subject in these cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7748076_1_4814", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the gender of the subject in these cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7748076_1_4815", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the number of subjects in these cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7748076_1_4816", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the race of the subject in these cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7748076_1_4817", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the disorder of the subject in these cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7748076_1_4818", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What are the drugs used in the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_1_4819", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the dosage of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_1_4820", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the frequency of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_1_4821", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the route of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_1_4822", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in progestin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_1_4823", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "How long did the treatment last in progestin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_1_4824", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What is the disorder targeted by the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_1_4825", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "What are the drugs used in combination in progestin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_4_4826", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What are the drugs used in the treatment in vasopressin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6610943_4_4827", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What is the dosage of the treatment in vasopressin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_4_4828", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What is the frequency of the treatment in vasopressin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_4_4829", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What is the route of the treatment in vasopressin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6610943_4_4830", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "How long has elapsed from the treatment to the occurence of the event in vasopressin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_4_4831", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "How long did the treatment last in vasopressin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_4_4832", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What is the disorder targeted by the treatment in vasopressin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6610943_4_4833", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "What are the drugs used in combination in vasopressin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_4_4834", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What are the drugs used in the treatment in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "6693840_4_4835", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What is the dosage of the treatment in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_4_4836", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What is the frequency of the treatment in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "6693840_4_4837", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What is the route of the treatment in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "6693840_4_4838", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "How long has elapsed from the treatment to the occurence of the event in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_4_4839", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "How long did the treatment last in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "6693840_4_4840", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What is the disorder targeted by the treatment in theophylline?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_4_4841", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "What are the drugs used in combination in theophylline?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3277077_1_4842", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3277077_1_4843", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3277077_1_4844", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3277077_1_4845", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3277077_1_4846", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3277077_1_4847", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What are the drugs used in the treatment in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3277077_1_4848", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the dosage of the treatment in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3277077_1_4849", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the frequency of the treatment in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3277077_1_4850", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the route of the treatment in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3277077_1_4851", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "How long has elapsed from the treatment to the occurence of the event in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3277077_1_4852", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "How long did the treatment last in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3277077_1_4853", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What is the disorder targeted by the treatment in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3277077_1_4854", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "What are the drugs used in combination in erroneous intake of 1 g doxycycline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2297635_1_4855", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2297635_1_4856", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2297635_1_4857", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2297635_1_4858", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2297635_1_4859", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2297635_1_4860", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What are the drugs used in the treatment in MTX?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2297635_1_4861", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the dosage of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2297635_1_4862", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the frequency of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2297635_1_4863", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the route of the treatment in MTX?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2297635_1_4864", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "How long has elapsed from the treatment to the occurence of the event in MTX?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2297635_1_4865", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "How long did the treatment last in MTX?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2297635_1_4866", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What is the disorder targeted by the treatment in MTX?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2297635_1_4867", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "What are the drugs used in combination in MTX?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1087773_1_4868", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the age of the subject in a nine-year-old boy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1087773_1_4869", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the gender of the subject in a nine-year-old boy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1087773_1_4870", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the number of subjects in a nine-year-old boy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1087773_1_4871", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the race of the subject in a nine-year-old boy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1087773_1_4872", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the disorder of the subject in a nine-year-old boy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1087773_1_4873", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What are the drugs used in the treatment in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1087773_1_4874", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the dosage of the treatment in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_1_4875", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the frequency of the treatment in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_1_4876", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the route of the treatment in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_1_4877", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "How long has elapsed from the treatment to the occurence of the event in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1087773_1_4878", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "How long did the treatment last in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_1_4879", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What is the disorder targeted by the treatment in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1087773_1_4880", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "What are the drugs used in combination in seven months' continuous treatment with rifampicin and ethambutol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_1_4881", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the age of the subject in individual case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_1_4882", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the gender of the subject in individual case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_1_4883", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the number of subjects in individual case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16609346_1_4884", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the race of the subject in individual case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_1_4885", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the disorder of the subject in individual case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_1_4886", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What are the drugs used in the treatment in statin treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_1_4887", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the dosage of the treatment in statin treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_1_4888", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the frequency of the treatment in statin treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_1_4889", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the route of the treatment in statin treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_1_4890", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "How long has elapsed from the treatment to the occurence of the event in statin treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_1_4891", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "How long did the treatment last in statin treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_1_4892", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What is the disorder targeted by the treatment in statin treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_1_4893", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "What are the drugs used in combination in statin treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_2_4894", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What are the drugs used in the treatment in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21658326_2_4895", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What is the dosage of the treatment in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_2_4896", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What is the frequency of the treatment in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21658326_2_4897", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What is the route of the treatment in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21658326_2_4898", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "How long has elapsed from the treatment to the occurence of the event in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_2_4899", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "How long did the treatment last in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21658326_2_4900", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What is the disorder targeted by the treatment in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_2_4901", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "What are the drugs used in combination in Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_1_4902", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What are the drugs used in the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_1_4903", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What is the dosage of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_1_4904", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What is the frequency of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_1_4905", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What is the route of the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_1_4906", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "How long has elapsed from the treatment to the occurence of the event in zomepirac?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_1_4907", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "How long did the treatment last in zomepirac?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_1_4908", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What is the disorder targeted by the treatment in zomepirac?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_1_4909", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "What are the drugs used in combination in zomepirac?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_6_4910", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8850251_6_4911", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8850251_6_4912", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8850251_6_4913", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8850251_6_4914", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8850251_6_4915", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What are the drugs used in the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_6_4916", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the dosage of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_6_4917", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the frequency of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_6_4918", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the route of the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_6_4919", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "How long has elapsed from the treatment to the occurence of the event in mequitazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_6_4920", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "How long did the treatment last in mequitazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_6_4921", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What is the disorder targeted by the treatment in mequitazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_6_4922", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "What are the drugs used in combination in mequitazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_4_4923", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What are the drugs used in the treatment in Carboplatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20349794_4_4924", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What is the dosage of the treatment in Carboplatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_4_4925", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What is the frequency of the treatment in Carboplatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_4_4926", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What is the route of the treatment in Carboplatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_4_4927", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "How long has elapsed from the treatment to the occurence of the event in Carboplatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_4_4928", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "How long did the treatment last in Carboplatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_4_4929", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What is the disorder targeted by the treatment in Carboplatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20349794_4_4930", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "What are the drugs used in combination in Carboplatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_3_4931", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What are the drugs used in the treatment in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_3_4932", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What is the dosage of the treatment in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_3_4933", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What is the frequency of the treatment in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_3_4934", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What is the route of the treatment in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_3_4935", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_3_4936", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "How long did the treatment last in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_3_4937", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What is the disorder targeted by the treatment in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_3_4938", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "What are the drugs used in combination in intravitreal injection of triamcinolone acetonide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_1_4939", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What are the drugs used in the treatment in rituximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16160485_1_4940", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What is the dosage of the treatment in rituximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_1_4941", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What is the frequency of the treatment in rituximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_1_4942", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What is the route of the treatment in rituximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_1_4943", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "How long has elapsed from the treatment to the occurence of the event in rituximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_1_4944", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "How long did the treatment last in rituximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_1_4945", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What is the disorder targeted by the treatment in rituximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16160485_1_4946", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "What are the drugs used in combination in rituximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_2_4947", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the age of the subject in an adult patient with acute lymphoblastic leukemia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10717401_2_4948", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the gender of the subject in an adult patient with acute lymphoblastic leukemia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10717401_2_4949", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the number of subjects in an adult patient with acute lymphoblastic leukemia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10717401_2_4950", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the race of the subject in an adult patient with acute lymphoblastic leukemia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10717401_2_4951", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the disorder of the subject in an adult patient with acute lymphoblastic leukemia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10717401_2_4952", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What are the drugs used in the treatment in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10717401_2_4953", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the dosage of the treatment in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_2_4954", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the frequency of the treatment in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_2_4955", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the route of the treatment in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_2_4956", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "How long has elapsed from the treatment to the occurence of the event in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_2_4957", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "How long did the treatment last in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_2_4958", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What is the disorder targeted by the treatment in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10717401_2_4959", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "What are the drugs used in combination in consolidation treatment with L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_1_4960", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the age of the subject in a patient with pancreatic cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_1_4961", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the gender of the subject in a patient with pancreatic cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_1_4962", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the number of subjects in a patient with pancreatic cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_1_4963", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the race of the subject in a patient with pancreatic cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_1_4964", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the disorder of the subject in a patient with pancreatic cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_1_4965", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What are the drugs used in the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_1_4966", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the dosage of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_1_4967", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the frequency of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_1_4968", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the route of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_1_4969", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "How long has elapsed from the treatment to the occurence of the event in Gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_1_4970", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "How long did the treatment last in Gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_1_4971", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What is the disorder targeted by the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_1_4972", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "What are the drugs used in combination in Gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_7_4973", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What are the drugs used in the treatment in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8404753_7_4974", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What is the dosage of the treatment in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_7_4975", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What is the frequency of the treatment in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8404753_7_4976", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What is the route of the treatment in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8404753_7_4977", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "How long has elapsed from the treatment to the occurence of the event in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_7_4978", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "How long did the treatment last in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8404753_7_4979", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What is the disorder targeted by the treatment in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_7_4980", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "What are the drugs used in combination in CBZ was continued at the same or higher dose?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16978752_4_4981", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_4_4982", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_4_4983", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_4_4984", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_4_4985", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_4_4986", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_4_4987", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_4_4988", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_4_4989", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_4_4990", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_4_4991", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_4_4992", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_4_4993", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_4_4994", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the age of the subject in 3 AS patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18203308_4_4995", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the gender of the subject in 3 AS patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18203308_4_4996", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the number of subjects in 3 AS patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18203308_4_4997", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the race of the subject in 3 AS patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18203308_4_4998", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the disorder of the subject in 3 AS patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18203308_4_4999", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What are the drugs used in the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_4_5000", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the dosage of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_4_5001", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the frequency of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_4_5002", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the route of the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_4_5003", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "How long has elapsed from the treatment to the occurence of the event in etanercept?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_4_5004", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "How long did the treatment last in etanercept?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_4_5005", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What is the disorder targeted by the treatment in etanercept?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_4_5006", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "What are the drugs used in combination in etanercept?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_5_5007", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What are the drugs used in the treatment in chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11510798_5_5008", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What is the dosage of the treatment in chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_5_5009", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What is the frequency of the treatment in chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_5_5010", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What is the route of the treatment in chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_5_5011", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "How long has elapsed from the treatment to the occurence of the event in chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_5_5012", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "How long did the treatment last in chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_5_5013", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What is the disorder targeted by the treatment in chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_5_5014", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "What are the drugs used in combination in chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_2_5015", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What are the drugs used in the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_2_5016", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What is the dosage of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_2_5017", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What is the frequency of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_2_5018", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What is the route of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_2_5019", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "How long has elapsed from the treatment to the occurence of the event in colchicine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_2_5020", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "How long did the treatment last in colchicine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_2_5021", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What is the disorder targeted by the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_2_5022", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "What are the drugs used in combination in colchicine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_4_5023", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What are the drugs used in the treatment in atropine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7056119_4_5024", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What is the dosage of the treatment in atropine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_4_5025", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What is the frequency of the treatment in atropine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_4_5026", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What is the route of the treatment in atropine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_4_5027", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "How long has elapsed from the treatment to the occurence of the event in atropine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_4_5028", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "How long did the treatment last in atropine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_4_5029", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What is the disorder targeted by the treatment in atropine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_4_5030", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "What are the drugs used in combination in atropine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17167851_2_5031", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the age of the subject in Three male patients aged 78-83 years?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17167851_2_5032", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the gender of the subject in Three male patients aged 78-83 years?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17167851_2_5033", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the number of subjects in Three male patients aged 78-83 years?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17167851_2_5034", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the race of the subject in Three male patients aged 78-83 years?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17167851_2_5035", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the disorder of the subject in Three male patients aged 78-83 years?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17167851_2_5036", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What are the drugs used in the treatment in CPA administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17167851_2_5037", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the dosage of the treatment in CPA administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_2_5038", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the frequency of the treatment in CPA administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_2_5039", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the route of the treatment in CPA administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_2_5040", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "How long has elapsed from the treatment to the occurence of the event in CPA administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_2_5041", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "How long did the treatment last in CPA administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_2_5042", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What is the disorder targeted by the treatment in CPA administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_2_5043", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "What are the drugs used in combination in CPA administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_2_5044", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What are the drugs used in the treatment in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "172214_2_5045", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What is the dosage of the treatment in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_2_5046", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What is the frequency of the treatment in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_2_5047", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What is the route of the treatment in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_2_5048", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "How long has elapsed from the treatment to the occurence of the event in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_2_5049", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "How long did the treatment last in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_2_5050", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What is the disorder targeted by the treatment in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_2_5051", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "What are the drugs used in combination in antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_1_5052", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the age of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18347524_1_5053", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the gender of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_1_5054", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the number of subjects in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_1_5055", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the race of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_1_5056", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the disorder of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_1_5057", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What are the drugs used in the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18347524_1_5058", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the dosage of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_1_5059", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the frequency of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_1_5060", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the route of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18347524_1_5061", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18347524_1_5062", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "How long did the treatment last in leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_1_5063", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18347524_1_5064", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "What are the drugs used in combination in leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_2_5065", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the age of the subject in a 64-year-old man with secondary adrenocortical insufficiency?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15836666_2_5066", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the gender of the subject in a 64-year-old man with secondary adrenocortical insufficiency?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15836666_2_5067", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the number of subjects in a 64-year-old man with secondary adrenocortical insufficiency?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15836666_2_5068", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the race of the subject in a 64-year-old man with secondary adrenocortical insufficiency?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15836666_2_5069", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the disorder of the subject in a 64-year-old man with secondary adrenocortical insufficiency?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15836666_2_5070", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What are the drugs used in the treatment in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15836666_2_5071", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the dosage of the treatment in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_2_5072", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the frequency of the treatment in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15836666_2_5073", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the route of the treatment in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15836666_2_5074", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_2_5075", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "How long did the treatment last in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15836666_2_5076", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What is the disorder targeted by the treatment in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15836666_2_5077", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "What are the drugs used in combination in chronic transdermal fentanyl treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6440806_1_5078", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the age of the subject in A 52-year-old, white female; A 52-year-old, white female; rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6440806_1_5079", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the gender of the subject in A 52-year-old, white female; A 52-year-old, white female; rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6440806_1_5080", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the number of subjects in A 52-year-old, white female; A 52-year-old, white female; rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6440806_1_5081", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the race of the subject in A 52-year-old, white female; A 52-year-old, white female; rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6440806_1_5082", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the disorder of the subject in A 52-year-old, white female; A 52-year-old, white female; rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6440806_1_5083", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What are the drugs used in the treatment in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6440806_1_5084", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the dosage of the treatment in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6440806_1_5085", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the frequency of the treatment in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6440806_1_5086", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the route of the treatment in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6440806_1_5087", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6440806_1_5088", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "How long did the treatment last in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6440806_1_5089", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in sodium aurothiomalate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6440806_1_5090", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "What are the drugs used in combination in sodium aurothiomalate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_1_5091", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What are the drugs used in the treatment in SASP?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_1_5092", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What is the dosage of the treatment in SASP?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_1_5093", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What is the frequency of the treatment in SASP?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_1_5094", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What is the route of the treatment in SASP?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_1_5095", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "How long has elapsed from the treatment to the occurence of the event in SASP?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_1_5096", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "How long did the treatment last in SASP?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_1_5097", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What is the disorder targeted by the treatment in SASP?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_1_5098", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "What are the drugs used in combination in SASP?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_2_5099", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What are the drugs used in the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_2_5100", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What is the dosage of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_2_5101", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What is the frequency of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_2_5102", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What is the route of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_2_5103", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "How long has elapsed from the treatment to the occurence of the event in chloroquine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_2_5104", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "How long did the treatment last in chloroquine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_2_5105", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What is the disorder targeted by the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_2_5106", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "What are the drugs used in combination in chloroquine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_4_5107", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the age of the subject in All cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15857283_4_5108", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the gender of the subject in All cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15857283_4_5109", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the number of subjects in All cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15857283_4_5110", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the race of the subject in All cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15857283_4_5111", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the disorder of the subject in All cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15857283_4_5112", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What are the drugs used in the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_4_5113", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the dosage of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_4_5114", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the frequency of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_4_5115", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the route of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_4_5116", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "How long has elapsed from the treatment to the occurence of the event in rifabutin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_4_5117", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "How long did the treatment last in rifabutin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_4_5118", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What is the disorder targeted by the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_4_5119", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "What are the drugs used in combination in rifabutin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_2_5120", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the age of the subject in Two infants?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3136101_2_5121", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the gender of the subject in Two infants?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3136101_2_5122", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the number of subjects in Two infants?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3136101_2_5123", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the race of the subject in Two infants?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3136101_2_5124", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the disorder of the subject in Two infants?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3136101_2_5125", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What are the drugs used in the treatment in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_2_5126", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the dosage of the treatment in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_2_5127", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the frequency of the treatment in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_2_5128", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the route of the treatment in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_2_5129", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "How long has elapsed from the treatment to the occurence of the event in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_2_5130", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "How long did the treatment last in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_2_5131", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What is the disorder targeted by the treatment in prolonged ACTH therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_2_5132", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "What are the drugs used in combination in prolonged ACTH therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_2_5133", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What are the drugs used in the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_2_5134", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What is the dosage of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_2_5135", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What is the frequency of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_2_5136", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What is the route of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_2_5137", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_2_5138", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "How long did the treatment last in cyclosporine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_2_5139", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What is the disorder targeted by the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_2_5140", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "What are the drugs used in combination in cyclosporine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_1_5141", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What are the drugs used in the treatment in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_1_5142", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What is the dosage of the treatment in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_1_5143", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What is the frequency of the treatment in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_1_5144", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What is the route of the treatment in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_1_5145", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_1_5146", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "How long did the treatment last in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_1_5147", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What is the disorder targeted by the treatment in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_1_5148", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "What are the drugs used in combination in intravitreal triamcinolone acetonide injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_2_5149", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What are the drugs used in the treatment in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_2_5150", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What is the dosage of the treatment in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_2_5151", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What is the frequency of the treatment in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_2_5152", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What is the route of the treatment in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_2_5153", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "How long has elapsed from the treatment to the occurence of the event in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_2_5154", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "How long did the treatment last in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_2_5155", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What is the disorder targeted by the treatment in intramuscular L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_2_5156", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "What are the drugs used in combination in intramuscular L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_3_5157", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the age of the subject in a 35-year-old woman with occult coronary artery disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7783891_3_5158", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the gender of the subject in a 35-year-old woman with occult coronary artery disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7783891_3_5159", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the number of subjects in a 35-year-old woman with occult coronary artery disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7783891_3_5160", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the race of the subject in a 35-year-old woman with occult coronary artery disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7783891_3_5161", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the disorder of the subject in a 35-year-old woman with occult coronary artery disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7783891_3_5162", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What are the drugs used in the treatment in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_3_5163", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the dosage of the treatment in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_3_5164", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the frequency of the treatment in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_3_5165", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the route of the treatment in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_3_5166", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "How long has elapsed from the treatment to the occurence of the event in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_3_5167", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "How long did the treatment last in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_3_5168", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What is the disorder targeted by the treatment in subcutaneous sumatriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_3_5169", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "What are the drugs used in combination in subcutaneous sumatriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_2_5170", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What are the drugs used in the treatment in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10332990_2_5171", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What is the dosage of the treatment in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_2_5172", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What is the frequency of the treatment in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10332990_2_5173", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What is the route of the treatment in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10332990_2_5174", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "How long has elapsed from the treatment to the occurence of the event in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_2_5175", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "How long did the treatment last in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10332990_2_5176", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What is the disorder targeted by the treatment in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10332990_2_5177", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "What are the drugs used in combination in Epoprostenol (prostacyclin)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11724089_4_5178", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the age of the subject in a man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11724089_4_5179", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the gender of the subject in a man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11724089_4_5180", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the number of subjects in a man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11724089_4_5181", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the race of the subject in a man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11724089_4_5182", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the disorder of the subject in a man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11724089_4_5183", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What are the drugs used in the treatment in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_4_5184", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the dosage of the treatment in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_4_5185", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the frequency of the treatment in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_4_5186", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the route of the treatment in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_4_5187", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "How long has elapsed from the treatment to the occurence of the event in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_4_5188", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "How long did the treatment last in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_4_5189", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What is the disorder targeted by the treatment in oral ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_4_5190", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "What are the drugs used in combination in oral ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_1_5191", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What are the drugs used in the treatment in heparin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12869178_1_5192", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What is the dosage of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_1_5193", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What is the frequency of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_1_5194", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What is the route of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_1_5195", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "How long has elapsed from the treatment to the occurence of the event in heparin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_1_5196", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "How long did the treatment last in heparin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_1_5197", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What is the disorder targeted by the treatment in heparin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_1_5198", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "What are the drugs used in combination in heparin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_1_5199", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "What is the age of the subject in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_1_5200", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "What is the gender of the subject in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_1_5201", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "What is the number of subjects in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_1_5202", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "What is the race of the subject in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_1_5203", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "What is the disorder of the subject in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11450788_4_5204", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What are the drugs used in the treatment in didanosine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11450788_4_5205", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What is the dosage of the treatment in didanosine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_4_5206", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What is the frequency of the treatment in didanosine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_4_5207", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What is the route of the treatment in didanosine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_4_5208", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "How long has elapsed from the treatment to the occurence of the event in didanosine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_4_5209", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "How long did the treatment last in didanosine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_4_5210", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What is the disorder targeted by the treatment in didanosine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_4_5211", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "What are the drugs used in combination in didanosine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_10_5212", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What are the drugs used in the treatment in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16537817_10_5213", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What is the dosage of the treatment in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_10_5214", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What is the frequency of the treatment in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_10_5215", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What is the route of the treatment in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_10_5216", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_10_5217", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "How long did the treatment last in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_10_5218", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What is the disorder targeted by the treatment in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_10_5219", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "What are the drugs used in combination in amiodarone-simvastatin interaction?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11105373_2_5220", "context": "Nail staining from hydroquinone cream.", "question": "What are the drugs used in the treatment in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11105373_2_5221", "context": "Nail staining from hydroquinone cream.", "question": "What is the dosage of the treatment in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11105373_2_5222", "context": "Nail staining from hydroquinone cream.", "question": "What is the frequency of the treatment in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11105373_2_5223", "context": "Nail staining from hydroquinone cream.", "question": "What is the route of the treatment in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11105373_2_5224", "context": "Nail staining from hydroquinone cream.", "question": "How long has elapsed from the treatment to the occurence of the event in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11105373_2_5225", "context": "Nail staining from hydroquinone cream.", "question": "How long did the treatment last in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11105373_2_5226", "context": "Nail staining from hydroquinone cream.", "question": "What is the disorder targeted by the treatment in hydroquinone cream?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11105373_2_5227", "context": "Nail staining from hydroquinone cream.", "question": "What are the drugs used in combination in hydroquinone cream?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_2_5228", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the age of the subject in an epilepsy patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_2_5229", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the gender of the subject in an epilepsy patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_2_5230", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the number of subjects in an epilepsy patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_2_5231", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the race of the subject in an epilepsy patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_2_5232", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the disorder of the subject in an epilepsy patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_2_5233", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What are the drugs used in the treatment in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_2_5234", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the dosage of the treatment in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_2_5235", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the frequency of the treatment in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_2_5236", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the route of the treatment in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_2_5237", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "How long has elapsed from the treatment to the occurence of the event in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_2_5238", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "How long did the treatment last in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_2_5239", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What is the disorder targeted by the treatment in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_2_5240", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "What are the drugs used in combination in diphenylhydantoin (DILANTIN) therapy for 20 years?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_2_5241", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What are the drugs used in the treatment in Ibuprofen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_2_5242", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What is the dosage of the treatment in Ibuprofen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_2_5243", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What is the frequency of the treatment in Ibuprofen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_2_5244", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What is the route of the treatment in Ibuprofen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_2_5245", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "How long has elapsed from the treatment to the occurence of the event in Ibuprofen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_2_5246", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "How long did the treatment last in Ibuprofen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_2_5247", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What is the disorder targeted by the treatment in Ibuprofen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_2_5248", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "What are the drugs used in combination in Ibuprofen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_5_5249", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What are the drugs used in the treatment in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "20628041_5_5250", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What is the dosage of the treatment in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_5_5251", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What is the frequency of the treatment in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20628041_5_5252", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What is the route of the treatment in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20628041_5_5253", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "How long has elapsed from the treatment to the occurence of the event in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_5_5254", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "How long did the treatment last in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20628041_5_5255", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What is the disorder targeted by the treatment in nasogastric tube?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_5_5256", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "What are the drugs used in combination in nasogastric tube?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18675768_15_5257", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What are the drugs used in the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_15_5258", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the dosage of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_15_5259", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the frequency of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_15_5260", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the route of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_15_5261", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "How long has elapsed from the treatment to the occurence of the event in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_15_5262", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "How long did the treatment last in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_15_5263", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the disorder targeted by the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_15_5264", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What are the drugs used in combination in propafenone and citalopram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14614357_2_5265", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the age of the subject in a young healthy woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14614357_2_5266", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the gender of the subject in a young healthy woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14614357_2_5267", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the number of subjects in a young healthy woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14614357_2_5268", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the race of the subject in a young healthy woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14614357_2_5269", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the disorder of the subject in a young healthy woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14614357_2_5270", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What are the drugs used in the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14614357_2_5271", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the dosage of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_2_5272", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the frequency of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_2_5273", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the route of the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_2_5274", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "How long has elapsed from the treatment to the occurence of the event in acenocoumarol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_2_5275", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "How long did the treatment last in acenocoumarol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_2_5276", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What is the disorder targeted by the treatment in acenocoumarol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14614357_2_5277", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "What are the drugs used in combination in acenocoumarol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_2_5278", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the age of the subject in A patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_2_5279", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the gender of the subject in A patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_2_5280", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the number of subjects in A patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_2_5281", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the race of the subject in A patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_2_5282", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the disorder of the subject in A patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_2_5283", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What are the drugs used in the treatment in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3708949_2_5284", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the dosage of the treatment in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_2_5285", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the frequency of the treatment in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_2_5286", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the route of the treatment in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_2_5287", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "How long has elapsed from the treatment to the occurence of the event in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_2_5288", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "How long did the treatment last in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_2_5289", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What is the disorder targeted by the treatment in parenteral amiodarone administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_2_5290", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "What are the drugs used in combination in parenteral amiodarone administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_4_5291", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_4_5292", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_4_5293", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_4_5294", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_4_5295", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_4_5296", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What are the drugs used in the treatment in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_4_5297", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the dosage of the treatment in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_4_5298", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the frequency of the treatment in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_4_5299", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the route of the treatment in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_4_5300", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_4_5301", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "How long did the treatment last in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_4_5302", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What is the disorder targeted by the treatment in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_4_5303", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "What are the drugs used in combination in olanzapine 2.5 mg twice daily?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_1_5304", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the age of the subject in HIV-infected patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_1_5305", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the gender of the subject in HIV-infected patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_1_5306", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the number of subjects in HIV-infected patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_1_5307", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the race of the subject in HIV-infected patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_1_5308", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the disorder of the subject in HIV-infected patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_1_5309", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What are the drugs used in the treatment in didanosine therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_1_5310", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the dosage of the treatment in didanosine therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_1_5311", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the frequency of the treatment in didanosine therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_1_5312", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the route of the treatment in didanosine therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_1_5313", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in didanosine therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_1_5314", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "How long did the treatment last in didanosine therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_1_5315", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What is the disorder targeted by the treatment in didanosine therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_1_5316", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "What are the drugs used in combination in didanosine therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_4_5317", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What are the drugs used in the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_4_5318", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What is the dosage of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_4_5319", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What is the frequency of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_4_5320", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What is the route of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_4_5321", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_4_5322", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "How long did the treatment last in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_4_5323", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What is the disorder targeted by the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_4_5324", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "What are the drugs used in combination in intravitreal ranibizumab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_4_5325", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the age of the subject in a 31-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14968106_4_5326", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the gender of the subject in a 31-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14968106_4_5327", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the number of subjects in a 31-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14968106_4_5328", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the race of the subject in a 31-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14968106_4_5329", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the disorder of the subject in a 31-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14968106_4_5330", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What are the drugs used in the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_4_5331", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the dosage of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_4_5332", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the frequency of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_4_5333", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the route of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_4_5334", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_4_5335", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "How long did the treatment last in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_4_5336", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What is the disorder targeted by the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_4_5337", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "What are the drugs used in combination in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_4_5338", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18166746_4_5339", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18166746_4_5340", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18166746_4_5341", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18166746_4_5342", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18166746_4_5343", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What are the drugs used in the treatment in paroxetine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_4_5344", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the dosage of the treatment in paroxetine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_4_5345", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the frequency of the treatment in paroxetine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_4_5346", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the route of the treatment in paroxetine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_4_5347", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "How long has elapsed from the treatment to the occurence of the event in paroxetine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_4_5348", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "How long did the treatment last in paroxetine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_4_5349", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What is the disorder targeted by the treatment in paroxetine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_4_5350", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "What are the drugs used in combination in paroxetine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_2_5351", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the age of the subject in patients with defective calcium-activated K+ channels?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_2_5352", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the gender of the subject in patients with defective calcium-activated K+ channels?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_2_5353", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the number of subjects in patients with defective calcium-activated K+ channels?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_2_5354", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the race of the subject in patients with defective calcium-activated K+ channels?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_2_5355", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the disorder of the subject in patients with defective calcium-activated K+ channels?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_2_5356", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What are the drugs used in the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9704170_2_5357", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the dosage of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_2_5358", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the frequency of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_2_5359", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the route of the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_2_5360", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "How long has elapsed from the treatment to the occurence of the event in Clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_2_5361", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "How long did the treatment last in Clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_2_5362", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What is the disorder targeted by the treatment in Clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_2_5363", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "What are the drugs used in combination in Clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_2_5364", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_2_5365", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_2_5366", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_2_5367", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_2_5368", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_2_5369", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_2_5370", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_2_5371", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_1_5372", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10752888_1_5373", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10752888_1_5374", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10752888_1_5375", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10752888_1_5376", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10752888_1_5377", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What are the drugs used in the treatment in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10752888_1_5378", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the dosage of the treatment in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_1_5379", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the frequency of the treatment in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_1_5380", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the route of the treatment in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_1_5381", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "How long has elapsed from the treatment to the occurence of the event in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_1_5382", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "How long did the treatment last in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_1_5383", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What is the disorder targeted by the treatment in Nitrofurantoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_1_5384", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "What are the drugs used in combination in Nitrofurantoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_2_5385", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What are the drugs used in the treatment in Trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2012922_2_5386", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What is the dosage of the treatment in Trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_2_5387", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What is the frequency of the treatment in Trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_2_5388", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What is the route of the treatment in Trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_2_5389", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "How long has elapsed from the treatment to the occurence of the event in Trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_2_5390", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "How long did the treatment last in Trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_2_5391", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What is the disorder targeted by the treatment in Trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2012922_2_5392", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "What are the drugs used in combination in Trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2219619_1_5393", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What are the drugs used in the treatment in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2219619_1_5394", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What is the dosage of the treatment in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2219619_1_5395", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What is the frequency of the treatment in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2219619_1_5396", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What is the route of the treatment in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2219619_1_5397", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "How long has elapsed from the treatment to the occurence of the event in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2219619_1_5398", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "How long did the treatment last in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2219619_1_5399", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What is the disorder targeted by the treatment in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2219619_1_5400", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "What are the drugs used in combination in continuous intravesical alum irrigation?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_1_5401", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What are the drugs used in the treatment in Amphotericin B?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18076602_1_5402", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What is the dosage of the treatment in Amphotericin B?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_1_5403", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What is the frequency of the treatment in Amphotericin B?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_1_5404", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What is the route of the treatment in Amphotericin B?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_1_5405", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "How long has elapsed from the treatment to the occurence of the event in Amphotericin B?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_1_5406", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "How long did the treatment last in Amphotericin B?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_1_5407", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What is the disorder targeted by the treatment in Amphotericin B?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_1_5408", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "What are the drugs used in combination in Amphotericin B?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_5_5409", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What are the drugs used in the treatment in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_5_5410", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What is the dosage of the treatment in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_5_5411", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What is the frequency of the treatment in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_5_5412", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What is the route of the treatment in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_5_5413", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_5_5414", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "How long did the treatment last in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_5_5415", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What is the disorder targeted by the treatment in acyclovir therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_5_5416", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "What are the drugs used in combination in acyclovir therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17504225_3_5417", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the age of the subject in a kidney transplanted woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_3_5418", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the gender of the subject in a kidney transplanted woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17504225_3_5419", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the number of subjects in a kidney transplanted woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_3_5420", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the race of the subject in a kidney transplanted woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_3_5421", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the disorder of the subject in a kidney transplanted woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17504225_3_5422", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What are the drugs used in the treatment in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_3_5423", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the dosage of the treatment in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_3_5424", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the frequency of the treatment in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_3_5425", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the route of the treatment in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_3_5426", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "How long has elapsed from the treatment to the occurence of the event in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_3_5427", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "How long did the treatment last in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_3_5428", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What is the disorder targeted by the treatment in clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_3_5429", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "What are the drugs used in combination in clarithromycin and sirolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12847760_1_5430", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the age of the subject in A 25-year-old man with a history of mid-borderline (BB) Hansen's disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12847760_1_5431", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the gender of the subject in A 25-year-old man with a history of mid-borderline (BB) Hansen's disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12847760_1_5432", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the number of subjects in A 25-year-old man with a history of mid-borderline (BB) Hansen's disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12847760_1_5433", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the race of the subject in A 25-year-old man with a history of mid-borderline (BB) Hansen's disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12847760_1_5434", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the disorder of the subject in A 25-year-old man with a history of mid-borderline (BB) Hansen's disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12847760_1_5435", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What are the drugs used in the treatment in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12847760_1_5436", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the dosage of the treatment in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12847760_1_5437", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the frequency of the treatment in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12847760_1_5438", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the route of the treatment in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12847760_1_5439", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "How long has elapsed from the treatment to the occurence of the event in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12847760_1_5440", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "How long did the treatment last in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12847760_1_5441", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What is the disorder targeted by the treatment in dapsone and rifampin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12847760_1_5442", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "What are the drugs used in combination in dapsone and rifampin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_15_5443", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What are the drugs used in the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_15_5444", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What is the dosage of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_15_5445", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What is the frequency of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_15_5446", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What is the route of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_15_5447", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "How long has elapsed from the treatment to the occurence of the event in quetiapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_15_5448", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "How long did the treatment last in quetiapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_15_5449", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What is the disorder targeted by the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_15_5450", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "What are the drugs used in combination in quetiapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_4_5451", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What are the drugs used in the treatment in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_4_5452", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What is the dosage of the treatment in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_4_5453", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What is the frequency of the treatment in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_4_5454", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What is the route of the treatment in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_4_5455", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "How long has elapsed from the treatment to the occurence of the event in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_4_5456", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "How long did the treatment last in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_4_5457", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What is the disorder targeted by the treatment in antiarrhythmic drugs?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_4_5458", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "What are the drugs used in combination in antiarrhythmic drugs?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_3_5459", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the age of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_3_5460", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the gender of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16192734_3_5461", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the number of subjects in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_3_5462", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the race of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_3_5463", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the disorder of the subject in a pregnant patient with myotonic dystrophy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16192734_3_5464", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What are the drugs used in the treatment in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_3_5465", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the dosage of the treatment in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_3_5466", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the frequency of the treatment in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_3_5467", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the route of the treatment in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_3_5468", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "How long has elapsed from the treatment to the occurence of the event in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_3_5469", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "How long did the treatment last in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_3_5470", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What is the disorder targeted by the treatment in ritodrine-hydrochloride?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_3_5471", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "What are the drugs used in combination in ritodrine-hydrochloride?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_2_5472", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What are the drugs used in the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7748076_2_5473", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What is the dosage of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_2_5474", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What is the frequency of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_2_5475", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What is the route of the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_2_5476", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "How long has elapsed from the treatment to the occurence of the event in progestin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_2_5477", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "How long did the treatment last in progestin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_2_5478", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What is the disorder targeted by the treatment in progestin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_2_5479", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "What are the drugs used in combination in progestin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_8_5480", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the age of the subject in DPD-deficient patients with cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_8_5481", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the gender of the subject in DPD-deficient patients with cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_8_5482", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the number of subjects in DPD-deficient patients with cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_8_5483", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the race of the subject in DPD-deficient patients with cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_8_5484", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the disorder of the subject in DPD-deficient patients with cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_8_5485", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What are the drugs used in the treatment in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_8_5486", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the dosage of the treatment in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_8_5487", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the frequency of the treatment in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_8_5488", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the route of the treatment in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_8_5489", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_8_5490", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "How long did the treatment last in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_8_5491", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What is the disorder targeted by the treatment in 5-FU therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_8_5492", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "What are the drugs used in combination in 5-FU therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_2_5493", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What are the drugs used in the treatment in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8912599_2_5494", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What is the dosage of the treatment in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_2_5495", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What is the frequency of the treatment in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8912599_2_5496", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What is the route of the treatment in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8912599_2_5497", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "How long has elapsed from the treatment to the occurence of the event in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_2_5498", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "How long did the treatment last in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8912599_2_5499", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What is the disorder targeted by the treatment in Methotrexate?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_2_5500", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "What are the drugs used in combination in Methotrexate?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18203308_3_5501", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What are the drugs used in the treatment in etanercept therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18203308_3_5502", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What is the dosage of the treatment in etanercept therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_3_5503", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What is the frequency of the treatment in etanercept therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_3_5504", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What is the route of the treatment in etanercept therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_3_5505", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "How long has elapsed from the treatment to the occurence of the event in etanercept therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_3_5506", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "How long did the treatment last in etanercept therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_3_5507", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What is the disorder targeted by the treatment in etanercept therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_3_5508", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "What are the drugs used in combination in etanercept therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_3_5509", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_3_5510", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "53128_3_5511", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_3_5512", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_3_5513", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_3_5514", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What are the drugs used in the treatment in some aspirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "53128_3_5515", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the dosage of the treatment in some aspirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_3_5516", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the frequency of the treatment in some aspirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_3_5517", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the route of the treatment in some aspirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_3_5518", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "How long has elapsed from the treatment to the occurence of the event in some aspirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_3_5519", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "How long did the treatment last in some aspirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_3_5520", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What is the disorder targeted by the treatment in some aspirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "53128_3_5521", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "What are the drugs used in combination in some aspirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_2_5522", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_2_5523", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_2_5524", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_2_5525", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_2_5526", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_2_5527", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What are the drugs used in the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_2_5528", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the dosage of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_2_5529", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the frequency of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_2_5530", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the route of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_2_5531", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "How long has elapsed from the treatment to the occurence of the event in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_2_5532", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "How long did the treatment last in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_2_5533", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What is the disorder targeted by the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_2_5534", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "What are the drugs used in combination in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_1_5535", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What are the drugs used in the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_1_5536", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What is the dosage of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_1_5537", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What is the frequency of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_1_5538", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What is the route of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_1_5539", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "How long has elapsed from the treatment to the occurence of the event in vancomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_1_5540", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "How long did the treatment last in vancomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_1_5541", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What is the disorder targeted by the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_1_5542", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "What are the drugs used in combination in vancomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8876616_2_5543", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the age of the subject in a 74-year-old female patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8876616_2_5544", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the gender of the subject in a 74-year-old female patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8876616_2_5545", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the number of subjects in a 74-year-old female patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8876616_2_5546", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the race of the subject in a 74-year-old female patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8876616_2_5547", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the disorder of the subject in a 74-year-old female patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8876616_2_5548", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What are the drugs used in the treatment in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8876616_2_5549", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the dosage of the treatment in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8876616_2_5550", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the frequency of the treatment in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8876616_2_5551", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the route of the treatment in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8876616_2_5552", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "How long has elapsed from the treatment to the occurence of the event in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8876616_2_5553", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "How long did the treatment last in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8876616_2_5554", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What is the disorder targeted by the treatment in antide-pressant amitriptyline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8876616_2_5555", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "What are the drugs used in combination in antide-pressant amitriptyline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_2_5556", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What are the drugs used in the treatment in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16192734_2_5557", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What is the dosage of the treatment in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_2_5558", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What is the frequency of the treatment in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_2_5559", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What is the route of the treatment in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_2_5560", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "How long has elapsed from the treatment to the occurence of the event in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_2_5561", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "How long did the treatment last in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_2_5562", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What is the disorder targeted by the treatment in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_2_5563", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "What are the drugs used in combination in tocolytic therapy with ritodrine hydrochloride?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_5_5564", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What are the drugs used in the treatment in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_5_5565", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What is the dosage of the treatment in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_5_5566", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What is the frequency of the treatment in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_5_5567", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What is the route of the treatment in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_5_5568", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "How long has elapsed from the treatment to the occurence of the event in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_5_5569", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "How long did the treatment last in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_5_5570", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What is the disorder targeted by the treatment in Voriconazole (VRC)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_5_5571", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "What are the drugs used in combination in Voriconazole (VRC)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_3_5572", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What are the drugs used in the treatment in Tamoxifen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_3_5573", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What is the dosage of the treatment in Tamoxifen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_3_5574", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What is the frequency of the treatment in Tamoxifen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_3_5575", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What is the route of the treatment in Tamoxifen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_3_5576", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "How long has elapsed from the treatment to the occurence of the event in Tamoxifen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_3_5577", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "How long did the treatment last in Tamoxifen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_3_5578", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What is the disorder targeted by the treatment in Tamoxifen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_3_5579", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "What are the drugs used in combination in Tamoxifen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_5_5580", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the age of the subject in One patient?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_5_5581", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the gender of the subject in One patient?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_5_5582", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the number of subjects in One patient?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10573314_5_5583", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the race of the subject in One patient?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_5_5584", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the disorder of the subject in One patient?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_5_5585", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What are the drugs used in the treatment in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10573314_5_5586", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the dosage of the treatment in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_5_5587", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the frequency of the treatment in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_5_5588", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the route of the treatment in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_5_5589", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "How long has elapsed from the treatment to the occurence of the event in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_5_5590", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "How long did the treatment last in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_5_5591", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What is the disorder targeted by the treatment in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_5_5592", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "What are the drugs used in combination in levofloxacin immediately prior to tolterodine initiation?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16393774_5_5593", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the age of the subject in The first patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_5_5594", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the gender of the subject in The first patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_5_5595", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the number of subjects in The first patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_5_5596", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the race of the subject in The first patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_5_5597", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the disorder of the subject in The first patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_5_5598", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What are the drugs used in the treatment in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_5_5599", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the dosage of the treatment in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_5_5600", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the frequency of the treatment in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_5_5601", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the route of the treatment in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_5_5602", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "How long has elapsed from the treatment to the occurence of the event in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_5_5603", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "How long did the treatment last in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_5_5604", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What is the disorder targeted by the treatment in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_5_5605", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "What are the drugs used in combination in 2 weeks after initiation of IFN-beta?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_9_5606", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the age of the subject in a rare case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_9_5607", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the gender of the subject in a rare case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_9_5608", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the number of subjects in a rare case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_9_5609", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the race of the subject in a rare case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_9_5610", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the disorder of the subject in a rare case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_9_5611", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What are the drugs used in the treatment in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_9_5612", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the dosage of the treatment in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_9_5613", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the frequency of the treatment in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_9_5614", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the route of the treatment in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_9_5615", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_9_5616", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "How long did the treatment last in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_9_5617", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What is the disorder targeted by the treatment in interferon-alpha treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_9_5618", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "What are the drugs used in combination in interferon-alpha treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_1_5619", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What are the drugs used in the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18837734_1_5620", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What is the dosage of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_1_5621", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What is the frequency of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_1_5622", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What is the route of the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_1_5623", "context": "Rosaceiform eruption induced by erlotinib.", "question": "How long has elapsed from the treatment to the occurence of the event in erlotinib?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_1_5624", "context": "Rosaceiform eruption induced by erlotinib.", "question": "How long did the treatment last in erlotinib?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_1_5625", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What is the disorder targeted by the treatment in erlotinib?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_1_5626", "context": "Rosaceiform eruption induced by erlotinib.", "question": "What are the drugs used in combination in erlotinib?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_2_5627", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What are the drugs used in the treatment in oral-verapamil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_2_5628", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What is the dosage of the treatment in oral-verapamil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_2_5629", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What is the frequency of the treatment in oral-verapamil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_2_5630", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What is the route of the treatment in oral-verapamil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_2_5631", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "How long has elapsed from the treatment to the occurence of the event in oral-verapamil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_2_5632", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "How long did the treatment last in oral-verapamil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_2_5633", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What is the disorder targeted by the treatment in oral-verapamil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_2_5634", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "What are the drugs used in combination in oral-verapamil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_4_5635", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What are the drugs used in the treatment in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8726608_4_5636", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What is the dosage of the treatment in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_4_5637", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What is the frequency of the treatment in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8726608_4_5638", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What is the route of the treatment in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8726608_4_5639", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_4_5640", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "How long did the treatment last in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8726608_4_5641", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What is the disorder targeted by the treatment in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_4_5642", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "What are the drugs used in combination in intravenous acyclovir is administered concurrently with lithium?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11283125_9_5643", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What are the drugs used in the treatment in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_9_5644", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What is the dosage of the treatment in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_9_5645", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What is the frequency of the treatment in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_9_5646", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What is the route of the treatment in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_9_5647", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "How long has elapsed from the treatment to the occurence of the event in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_9_5648", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "How long did the treatment last in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_9_5649", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What is the disorder targeted by the treatment in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_9_5650", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "What are the drugs used in combination in HD Ara-C added to HD MTX?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3732375_1_5651", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What are the drugs used in the treatment in viloxazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3732375_1_5652", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What is the dosage of the treatment in viloxazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_1_5653", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What is the frequency of the treatment in viloxazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_1_5654", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What is the route of the treatment in viloxazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_1_5655", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "How long has elapsed from the treatment to the occurence of the event in viloxazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_1_5656", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "How long did the treatment last in viloxazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_1_5657", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What is the disorder targeted by the treatment in viloxazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_1_5658", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "What are the drugs used in combination in viloxazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_3_5659", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What are the drugs used in the treatment in zinc?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_3_5660", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What is the dosage of the treatment in zinc?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_3_5661", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What is the frequency of the treatment in zinc?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_3_5662", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What is the route of the treatment in zinc?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_3_5663", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in zinc?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_3_5664", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "How long did the treatment last in zinc?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_3_5665", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What is the disorder targeted by the treatment in zinc?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_3_5666", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "What are the drugs used in combination in zinc?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_3_5667", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What are the drugs used in the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_3_5668", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What is the dosage of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_3_5669", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What is the frequency of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_3_5670", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What is the route of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_3_5671", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "How long has elapsed from the treatment to the occurence of the event in brimonidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_3_5672", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "How long did the treatment last in brimonidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_3_5673", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What is the disorder targeted by the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_3_5674", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "What are the drugs used in combination in brimonidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_1_5675", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the age of the subject in a child homozygous for MTHFR C677T polymorphism?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17387702_1_5676", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the gender of the subject in a child homozygous for MTHFR C677T polymorphism?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17387702_1_5677", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the number of subjects in a child homozygous for MTHFR C677T polymorphism?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_1_5678", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the race of the subject in a child homozygous for MTHFR C677T polymorphism?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_1_5679", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the disorder of the subject in a child homozygous for MTHFR C677T polymorphism?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17387702_1_5680", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What are the drugs used in the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17387702_1_5681", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the dosage of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17387702_1_5682", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the frequency of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17387702_1_5683", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the route of the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_1_5684", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_1_5685", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "How long did the treatment last in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_1_5686", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What is the disorder targeted by the treatment in high-dose methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17387702_1_5687", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "What are the drugs used in combination in high-dose methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_2_5688", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the age of the subject in his?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_2_5689", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the gender of the subject in his?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_2_5690", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the number of subjects in his?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_2_5691", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the race of the subject in his?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_2_5692", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the disorder of the subject in his?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_2_5693", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What are the drugs used in the treatment in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_2_5694", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the dosage of the treatment in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_2_5695", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the frequency of the treatment in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_2_5696", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the route of the treatment in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_2_5697", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_2_5698", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "How long did the treatment last in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_2_5699", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What is the disorder targeted by the treatment in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_2_5700", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "What are the drugs used in combination in high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_2_5701", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the age of the subject in Ten to 15% of patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10646879_2_5702", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the gender of the subject in Ten to 15% of patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10646879_2_5703", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the number of subjects in Ten to 15% of patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10646879_2_5704", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the race of the subject in Ten to 15% of patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10646879_2_5705", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the disorder of the subject in Ten to 15% of patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10646879_2_5706", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What are the drugs used in the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10646879_2_5707", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the dosage of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_2_5708", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the frequency of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_2_5709", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the route of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_2_5710", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in ifosfamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_2_5711", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "How long did the treatment last in ifosfamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_2_5712", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What is the disorder targeted by the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_2_5713", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "What are the drugs used in combination in ifosfamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_3_5714", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_3_5715", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_3_5716", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_3_5717", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_3_5718", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_3_5719", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What are the drugs used in the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_3_5720", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the dosage of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_3_5721", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the frequency of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_3_5722", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the route of the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_3_5723", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "How long has elapsed from the treatment to the occurence of the event in leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_3_5724", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "How long did the treatment last in leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_3_5725", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What is the disorder targeted by the treatment in leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_3_5726", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "What are the drugs used in combination in leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_3_5727", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "681921_3_5728", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "681921_3_5729", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "681921_3_5730", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "681921_3_5731", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "681921_3_5732", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What are the drugs used in the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_3_5733", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the dosage of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_3_5734", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the frequency of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_3_5735", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the route of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_3_5736", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_3_5737", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "How long did the treatment last in disulfiram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_3_5738", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What is the disorder targeted by the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_3_5739", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "What are the drugs used in combination in disulfiram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_2_5740", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What are the drugs used in the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11096051_2_5741", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What is the dosage of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_2_5742", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What is the frequency of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11096051_2_5743", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What is the route of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11096051_2_5744", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "How long has elapsed from the treatment to the occurence of the event in vancomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_2_5745", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "How long did the treatment last in vancomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11096051_2_5746", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What is the disorder targeted by the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11096051_2_5747", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "What are the drugs used in combination in vancomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_4_5748", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What are the drugs used in the treatment in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_4_5749", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What is the dosage of the treatment in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_4_5750", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What is the frequency of the treatment in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_4_5751", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What is the route of the treatment in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_4_5752", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "How long has elapsed from the treatment to the occurence of the event in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_4_5753", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "How long did the treatment last in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_4_5754", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What is the disorder targeted by the treatment in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_4_5755", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "What are the drugs used in combination in rechallenge with alendronate sodium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16901609_2_5756", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What are the drugs used in the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16901609_2_5757", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What is the dosage of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_2_5758", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What is the frequency of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_2_5759", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What is the route of the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16901609_2_5760", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_2_5761", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "How long did the treatment last in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_2_5762", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What is the disorder targeted by the treatment in intrathecal diamorphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_2_5763", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "What are the drugs used in combination in intrathecal diamorphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_2_5764", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the age of the subject in a patient with cerivastatin-induced rhabdomyolysis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_2_5765", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the gender of the subject in a patient with cerivastatin-induced rhabdomyolysis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_2_5766", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the number of subjects in a patient with cerivastatin-induced rhabdomyolysis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_2_5767", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the race of the subject in a patient with cerivastatin-induced rhabdomyolysis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_2_5768", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the disorder of the subject in a patient with cerivastatin-induced rhabdomyolysis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_2_5769", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What are the drugs used in the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_2_5770", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the dosage of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_2_5771", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the frequency of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_2_5772", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the route of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_2_5773", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in cerivastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_2_5774", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "How long did the treatment last in cerivastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_2_5775", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What is the disorder targeted by the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_2_5776", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "What are the drugs used in combination in cerivastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_13_5777", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the age of the subject in This case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18505911_13_5778", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the gender of the subject in This case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18505911_13_5779", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the number of subjects in This case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18505911_13_5780", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the race of the subject in This case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18505911_13_5781", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the disorder of the subject in This case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18505911_13_5782", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What are the drugs used in the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_13_5783", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the dosage of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_13_5784", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the frequency of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_13_5785", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the route of the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_13_5786", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "How long has elapsed from the treatment to the occurence of the event in azathioprine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_13_5787", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "How long did the treatment last in azathioprine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_13_5788", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What is the disorder targeted by the treatment in azathioprine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_13_5789", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "What are the drugs used in combination in azathioprine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_3_5790", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What are the drugs used in the treatment in alendronate sodium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_3_5791", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What is the dosage of the treatment in alendronate sodium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_3_5792", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What is the frequency of the treatment in alendronate sodium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_3_5793", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What is the route of the treatment in alendronate sodium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_3_5794", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "How long has elapsed from the treatment to the occurence of the event in alendronate sodium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_3_5795", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "How long did the treatment last in alendronate sodium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_3_5796", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What is the disorder targeted by the treatment in alendronate sodium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_3_5797", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "What are the drugs used in combination in alendronate sodium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_2_5798", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the age of the subject in Most cardiac surgical patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12869178_2_5799", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the gender of the subject in Most cardiac surgical patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12869178_2_5800", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the number of subjects in Most cardiac surgical patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12869178_2_5801", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the race of the subject in Most cardiac surgical patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12869178_2_5802", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the disorder of the subject in Most cardiac surgical patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12869178_2_5803", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What are the drugs used in the treatment in heparin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12869178_2_5804", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the dosage of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_2_5805", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the frequency of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_2_5806", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the route of the treatment in heparin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_2_5807", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "How long has elapsed from the treatment to the occurence of the event in heparin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_2_5808", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "How long did the treatment last in heparin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_2_5809", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What is the disorder targeted by the treatment in heparin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_2_5810", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "What are the drugs used in combination in heparin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_2_5811", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7485371_2_5812", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7485371_2_5813", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7485371_2_5814", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7485371_2_5815", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7485371_2_5816", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What are the drugs used in the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7485371_2_5817", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the dosage of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_2_5818", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the frequency of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_2_5819", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the route of the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_2_5820", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "How long has elapsed from the treatment to the occurence of the event in atovaquone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_2_5821", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "How long did the treatment last in atovaquone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_2_5822", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What is the disorder targeted by the treatment in atovaquone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_2_5823", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "What are the drugs used in combination in atovaquone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_2_5824", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16216617_2_5825", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16216617_2_5826", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16216617_2_5827", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16216617_2_5828", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16216617_2_5829", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What are the drugs used in the treatment in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16216617_2_5830", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the dosage of the treatment in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16216617_2_5831", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the frequency of the treatment in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_2_5832", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the route of the treatment in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16216617_2_5833", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "How long has elapsed from the treatment to the occurence of the event in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_2_5834", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "How long did the treatment last in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_2_5835", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What is the disorder targeted by the treatment in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_2_5836", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "What are the drugs used in combination in a maximal dose of phenylephrine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_4_5837", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the age of the subject in Two patients with ocular inflammation of unknown origin?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18751717_4_5838", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the gender of the subject in Two patients with ocular inflammation of unknown origin?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18751717_4_5839", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the number of subjects in Two patients with ocular inflammation of unknown origin?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18751717_4_5840", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the race of the subject in Two patients with ocular inflammation of unknown origin?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18751717_4_5841", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the disorder of the subject in Two patients with ocular inflammation of unknown origin?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18751717_4_5842", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What are the drugs used in the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_4_5843", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the dosage of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_4_5844", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the frequency of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_4_5845", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the route of the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_4_5846", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "How long has elapsed from the treatment to the occurence of the event in IVTA injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_4_5847", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "How long did the treatment last in IVTA injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_4_5848", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What is the disorder targeted by the treatment in IVTA injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_4_5849", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "What are the drugs used in combination in IVTA injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_5_5850", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What are the drugs used in the treatment in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1695794_5_5851", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What is the dosage of the treatment in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_5_5852", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What is the frequency of the treatment in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_5_5853", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What is the route of the treatment in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_5_5854", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "How long has elapsed from the treatment to the occurence of the event in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_5_5855", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "How long did the treatment last in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_5_5856", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What is the disorder targeted by the treatment in Disopyramide?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_5_5857", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "What are the drugs used in combination in Disopyramide?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_1_5858", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the age of the subject in A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10759907_1_5859", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the gender of the subject in A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10759907_1_5860", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the number of subjects in A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10759907_1_5861", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the race of the subject in A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10759907_1_5862", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the disorder of the subject in A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10759907_1_5863", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What are the drugs used in the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_1_5864", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the dosage of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_1_5865", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the frequency of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_1_5866", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the route of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_1_5867", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "How long has elapsed from the treatment to the occurence of the event in zolmitriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_1_5868", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "How long did the treatment last in zolmitriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_1_5869", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What is the disorder targeted by the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_1_5870", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "What are the drugs used in combination in zolmitriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_3_5871", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What are the drugs used in the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_3_5872", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What is the dosage of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_3_5873", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What is the frequency of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_3_5874", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What is the route of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_3_5875", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "How long has elapsed from the treatment to the occurence of the event in pravastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_3_5876", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "How long did the treatment last in pravastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_3_5877", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What is the disorder targeted by the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_3_5878", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "What are the drugs used in combination in pravastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_2_5879", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What are the drugs used in the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_2_5880", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What is the dosage of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_2_5881", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What is the frequency of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_2_5882", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What is the route of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_2_5883", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alfa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_2_5884", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "How long did the treatment last in interferon alfa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_2_5885", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What is the disorder targeted by the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_2_5886", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "What are the drugs used in combination in interferon alfa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_2_5887", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14742791_2_5888", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14742791_2_5889", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14742791_2_5890", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14742791_2_5891", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14742791_2_5892", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What are the drugs used in the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_2_5893", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the dosage of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_2_5894", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the frequency of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_2_5895", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the route of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_2_5896", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "How long has elapsed from the treatment to the occurence of the event in pantoprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_2_5897", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "How long did the treatment last in pantoprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_2_5898", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What is the disorder targeted by the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_2_5899", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "What are the drugs used in combination in pantoprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_5_5900", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What are the drugs used in the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9865241_5_5901", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What is the dosage of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_5_5902", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What is the frequency of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_5_5903", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What is the route of the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_5_5904", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "How long has elapsed from the treatment to the occurence of the event in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_5_5905", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "How long did the treatment last in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_5_5906", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What is the disorder targeted by the treatment in pamidronate?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_5_5907", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "What are the drugs used in combination in pamidronate?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11485141_1_5908", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11485141_1_5909", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11485141_1_5910", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11485141_1_5911", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11485141_1_5912", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11485141_1_5913", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_1_5914", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_1_5915", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_1_5916", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_1_5917", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_1_5918", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_1_5919", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_1_5920", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_3_5921", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the age of the subject in a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18166746_3_5922", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the gender of the subject in a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18166746_3_5923", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the number of subjects in a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18166746_3_5924", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the race of the subject in a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18166746_3_5925", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the disorder of the subject in a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18166746_3_5926", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What are the drugs used in the treatment in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18166746_3_5927", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the dosage of the treatment in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_3_5928", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the frequency of the treatment in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18166746_3_5929", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the route of the treatment in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18166746_3_5930", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "How long has elapsed from the treatment to the occurence of the event in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_3_5931", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "How long did the treatment last in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18166746_3_5932", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What is the disorder targeted by the treatment in Methylene blue?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_3_5933", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "What are the drugs used in combination in Methylene blue?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7712052_3_5934", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the age of the subject in veterans with PTSD?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7712052_3_5935", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the gender of the subject in veterans with PTSD?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7712052_3_5936", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the number of subjects in veterans with PTSD?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7712052_3_5937", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the race of the subject in veterans with PTSD?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7712052_3_5938", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the disorder of the subject in veterans with PTSD?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7712052_3_5939", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7712052_3_5940", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the dosage of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_3_5941", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the frequency of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7712052_3_5942", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the route of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7712052_3_5943", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_3_5944", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "How long did the treatment last in lithium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7712052_3_5945", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_3_5946", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "What are the drugs used in combination in lithium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_2_5947", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What are the drugs used in the treatment in flucloxacillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_2_5948", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What is the dosage of the treatment in flucloxacillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_2_5949", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What is the frequency of the treatment in flucloxacillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_2_5950", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What is the route of the treatment in flucloxacillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_2_5951", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "How long has elapsed from the treatment to the occurence of the event in flucloxacillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_2_5952", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "How long did the treatment last in flucloxacillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_2_5953", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What is the disorder targeted by the treatment in flucloxacillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_2_5954", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "What are the drugs used in combination in flucloxacillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2943526_1_5955", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What are the drugs used in the treatment in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2943526_1_5956", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What is the dosage of the treatment in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2943526_1_5957", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What is the frequency of the treatment in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2943526_1_5958", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What is the route of the treatment in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2943526_1_5959", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "How long has elapsed from the treatment to the occurence of the event in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2943526_1_5960", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "How long did the treatment last in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2943526_1_5961", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What is the disorder targeted by the treatment in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2943526_1_5962", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "What are the drugs used in combination in hepatic artery infusion HAI of FUdR?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_1_5963", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What are the drugs used in the treatment in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3136101_1_5964", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What is the dosage of the treatment in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_1_5965", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What is the frequency of the treatment in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_1_5966", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What is the route of the treatment in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_1_5967", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "How long has elapsed from the treatment to the occurence of the event in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_1_5968", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "How long did the treatment last in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_1_5969", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What is the disorder targeted by the treatment in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_1_5970", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "What are the drugs used in combination in prolonged adrenocorticotropic hormone therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_1_5971", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_1_5972", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_1_5973", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_1_5974", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_1_5975", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_1_5976", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What are the drugs used in the treatment in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10082597_1_5977", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the dosage of the treatment in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_1_5978", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the frequency of the treatment in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_1_5979", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the route of the treatment in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_1_5980", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "How long has elapsed from the treatment to the occurence of the event in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_1_5981", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "How long did the treatment last in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_1_5982", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What is the disorder targeted by the treatment in naproxen and oxaprozin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_1_5983", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "What are the drugs used in combination in naproxen and oxaprozin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_4_5984", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the age of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18505911_4_5985", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the gender of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18505911_4_5986", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the number of subjects in She?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18505911_4_5987", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the race of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18505911_4_5988", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the disorder of the subject in She?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18505911_4_5989", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What are the drugs used in the treatment in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18505911_4_5990", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the dosage of the treatment in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_4_5991", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the frequency of the treatment in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18505911_4_5992", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the route of the treatment in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18505911_4_5993", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_4_5994", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "How long did the treatment last in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18505911_4_5995", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What is the disorder targeted by the treatment in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_4_5996", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "What are the drugs used in combination in an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9279731_1_5997", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What are the drugs used in the treatment in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9279731_1_5998", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What is the dosage of the treatment in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9279731_1_5999", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What is the frequency of the treatment in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9279731_1_6000", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What is the route of the treatment in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9279731_1_6001", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "How long has elapsed from the treatment to the occurence of the event in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9279731_1_6002", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "How long did the treatment last in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9279731_1_6003", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What is the disorder targeted by the treatment in conventional amphotericin B?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9279731_1_6004", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "What are the drugs used in combination in conventional amphotericin B?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_2_6005", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What are the drugs used in the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3211830_2_6006", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What is the dosage of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_2_6007", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What is the frequency of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_2_6008", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What is the route of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_2_6009", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "How long has elapsed from the treatment to the occurence of the event in diltiazem?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_2_6010", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "How long did the treatment last in diltiazem?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_2_6011", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What is the disorder targeted by the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_2_6012", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "What are the drugs used in combination in diltiazem?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_2_6013", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_2_6014", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_2_6015", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_2_6016", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_2_6017", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_2_6018", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_2_6019", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_2_6020", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_2_6021", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_2_6022", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_2_6023", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_2_6024", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_2_6025", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_3_6026", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the age of the subject in a 40-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15773973_3_6027", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the gender of the subject in a 40-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15773973_3_6028", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the number of subjects in a 40-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15773973_3_6029", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the race of the subject in a 40-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15773973_3_6030", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the disorder of the subject in a 40-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15773973_3_6031", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What are the drugs used in the treatment in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_3_6032", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the dosage of the treatment in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_3_6033", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the frequency of the treatment in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_3_6034", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the route of the treatment in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_3_6035", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "How long has elapsed from the treatment to the occurence of the event in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_3_6036", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "How long did the treatment last in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_3_6037", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What is the disorder targeted by the treatment in oral flucloxacillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_3_6038", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "What are the drugs used in combination in oral flucloxacillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_2_6039", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the age of the subject in This case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16697705_2_6040", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the gender of the subject in This case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16697705_2_6041", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the number of subjects in This case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16697705_2_6042", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the race of the subject in This case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16697705_2_6043", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the disorder of the subject in This case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16697705_2_6044", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What are the drugs used in the treatment in Capecitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16697705_2_6045", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the dosage of the treatment in Capecitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_2_6046", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the frequency of the treatment in Capecitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_2_6047", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the route of the treatment in Capecitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_2_6048", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in Capecitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_2_6049", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "How long did the treatment last in Capecitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_2_6050", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What is the disorder targeted by the treatment in Capecitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_2_6051", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "What are the drugs used in combination in Capecitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_2_6052", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7212107_2_6053", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What is the dosage of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_2_6054", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What is the frequency of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_2_6055", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What is the route of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_2_6056", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_2_6057", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "How long did the treatment last in lithium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_2_6058", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_2_6059", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "What are the drugs used in combination in lithium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_2_6060", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What are the drugs used in the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_2_6061", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What is the dosage of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_2_6062", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What is the frequency of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_2_6063", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What is the route of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_2_6064", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_2_6065", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "How long did the treatment last in infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_2_6066", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What is the disorder targeted by the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_2_6067", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "What are the drugs used in combination in infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_7_6068", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What are the drugs used in the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_7_6069", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What is the dosage of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_7_6070", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What is the frequency of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_7_6071", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What is the route of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_7_6072", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "How long has elapsed from the treatment to the occurence of the event in raloxifene?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_7_6073", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "How long did the treatment last in raloxifene?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_7_6074", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What is the disorder targeted by the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_7_6075", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "What are the drugs used in combination in raloxifene?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_3_6076", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19131789_3_6077", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19131789_3_6078", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_3_6079", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_3_6080", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_3_6081", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What are the drugs used in the treatment in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19131789_3_6082", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the dosage of the treatment in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_3_6083", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the frequency of the treatment in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_3_6084", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the route of the treatment in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_3_6085", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_3_6086", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "How long did the treatment last in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_3_6087", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What is the disorder targeted by the treatment in high-dose methotrexate therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_3_6088", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "What are the drugs used in combination in high-dose methotrexate therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_2_6089", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the age of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_2_6090", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the gender of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_2_6091", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the number of subjects in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_2_6092", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the race of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_2_6093", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the disorder of the subject in patients with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_2_6094", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What are the drugs used in the treatment in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8467620_2_6095", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the dosage of the treatment in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_2_6096", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the frequency of the treatment in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_2_6097", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the route of the treatment in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_2_6098", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_2_6099", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "How long did the treatment last in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_2_6100", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What is the disorder targeted by the treatment in methotrexate therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8467620_2_6101", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "What are the drugs used in combination in methotrexate therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_2_6102", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What are the drugs used in the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14561622_2_6103", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What is the dosage of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_2_6104", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What is the frequency of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_2_6105", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What is the route of the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_2_6106", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_2_6107", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "How long did the treatment last in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_2_6108", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What is the disorder targeted by the treatment in intrathecal methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_2_6109", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "What are the drugs used in combination in intrathecal methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_2_6110", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What are the drugs used in the treatment in Morphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16843118_2_6111", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What is the dosage of the treatment in Morphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_2_6112", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What is the frequency of the treatment in Morphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_2_6113", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What is the route of the treatment in Morphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_2_6114", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "How long has elapsed from the treatment to the occurence of the event in Morphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_2_6115", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "How long did the treatment last in Morphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_2_6116", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What is the disorder targeted by the treatment in Morphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_2_6117", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "What are the drugs used in combination in Morphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_1_6118", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What are the drugs used in the treatment in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_1_6119", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What is the dosage of the treatment in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_1_6120", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What is the frequency of the treatment in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_1_6121", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What is the route of the treatment in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_1_6122", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "How long has elapsed from the treatment to the occurence of the event in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_1_6123", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "How long did the treatment last in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_1_6124", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What is the disorder targeted by the treatment in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_1_6125", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "What are the drugs used in combination in oral calcineurin and mTOR inhibitors?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_1_6126", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the age of the subject in A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17619811_1_6127", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the gender of the subject in A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17619811_1_6128", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the number of subjects in A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17619811_1_6129", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the race of the subject in A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17619811_1_6130", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the disorder of the subject in A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17619811_1_6131", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What are the drugs used in the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_1_6132", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the dosage of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_1_6133", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the frequency of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_1_6134", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the route of the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_1_6135", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "How long has elapsed from the treatment to the occurence of the event in colchicine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_1_6136", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "How long did the treatment last in colchicine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_1_6137", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What is the disorder targeted by the treatment in colchicine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_1_6138", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "What are the drugs used in combination in colchicine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_6_6139", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the age of the subject in a child with juvenile absence epilepsy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17275666_6_6140", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the gender of the subject in a child with juvenile absence epilepsy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17275666_6_6141", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the number of subjects in a child with juvenile absence epilepsy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17275666_6_6142", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the race of the subject in a child with juvenile absence epilepsy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17275666_6_6143", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the disorder of the subject in a child with juvenile absence epilepsy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17275666_6_6144", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What are the drugs used in the treatment in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_6_6145", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the dosage of the treatment in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_6_6146", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the frequency of the treatment in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_6_6147", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the route of the treatment in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_6_6148", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_6_6149", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "How long did the treatment last in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_6_6150", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What is the disorder targeted by the treatment in intravenous valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_6_6151", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "What are the drugs used in combination in intravenous valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18277922_1_6152", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the age of the subject in She?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18277922_1_6153", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the gender of the subject in She?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18277922_1_6154", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the number of subjects in She?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18277922_1_6155", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the race of the subject in She?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18277922_1_6156", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the disorder of the subject in She?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18277922_1_6157", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What are the drugs used in the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18277922_1_6158", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the dosage of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18277922_1_6159", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the frequency of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18277922_1_6160", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the route of the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18277922_1_6161", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "How long has elapsed from the treatment to the occurence of the event in acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18277922_1_6162", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "How long did the treatment last in acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18277922_1_6163", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What is the disorder targeted by the treatment in acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18277922_1_6164", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "What are the drugs used in combination in acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_1_6165", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the age of the subject in 3 cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15857283_1_6166", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the gender of the subject in 3 cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15857283_1_6167", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the number of subjects in 3 cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15857283_1_6168", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the race of the subject in 3 cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15857283_1_6169", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the disorder of the subject in 3 cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15857283_1_6170", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What are the drugs used in the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15857283_1_6171", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the dosage of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_1_6172", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the frequency of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_1_6173", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the route of the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_1_6174", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "How long has elapsed from the treatment to the occurence of the event in rifabutin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_1_6175", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "How long did the treatment last in rifabutin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_1_6176", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What is the disorder targeted by the treatment in rifabutin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_1_6177", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "What are the drugs used in combination in rifabutin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_1_6178", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What are the drugs used in the treatment in flumazenil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7978578_1_6179", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What is the dosage of the treatment in flumazenil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_1_6180", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What is the frequency of the treatment in flumazenil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7978578_1_6181", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What is the route of the treatment in flumazenil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7978578_1_6182", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "How long has elapsed from the treatment to the occurence of the event in flumazenil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_1_6183", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "How long did the treatment last in flumazenil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7978578_1_6184", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What is the disorder targeted by the treatment in flumazenil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7978578_1_6185", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "What are the drugs used in combination in flumazenil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_1_6186", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What are the drugs used in the treatment in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_1_6187", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What is the dosage of the treatment in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_1_6188", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What is the frequency of the treatment in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_1_6189", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What is the route of the treatment in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_1_6190", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_1_6191", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "How long did the treatment last in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_1_6192", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What is the disorder targeted by the treatment in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_1_6193", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "What are the drugs used in combination in olanzapine (Zyprexa)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_2_6194", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the age of the subject in patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_2_6195", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the gender of the subject in patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_2_6196", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the number of subjects in patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_2_6197", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the race of the subject in patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_2_6198", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the disorder of the subject in patients with vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_2_6199", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What are the drugs used in the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_2_6200", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the dosage of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_2_6201", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the frequency of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_2_6202", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the route of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_2_6203", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "How long has elapsed from the treatment to the occurence of the event in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_2_6204", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "How long did the treatment last in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_2_6205", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What is the disorder targeted by the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_2_6206", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "What are the drugs used in combination in nitrous oxide anesthesia?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_3_6207", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What are the drugs used in the treatment in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1695794_3_6208", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What is the dosage of the treatment in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_3_6209", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What is the frequency of the treatment in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1695794_3_6210", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What is the route of the treatment in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1695794_3_6211", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "How long has elapsed from the treatment to the occurence of the event in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_3_6212", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "How long did the treatment last in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1695794_3_6213", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What is the disorder targeted by the treatment in antiarrhythmics?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1695794_3_6214", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "What are the drugs used in combination in antiarrhythmics?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6239881_1_6215", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What are the drugs used in the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6239881_1_6216", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What is the dosage of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_1_6217", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What is the frequency of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_1_6218", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What is the route of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_1_6219", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "How long has elapsed from the treatment to the occurence of the event in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_1_6220", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "How long did the treatment last in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_1_6221", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What is the disorder targeted by the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_1_6222", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "What are the drugs used in combination in compound tincture of benzoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_3_6223", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the age of the subject in a 67-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8610807_3_6224", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the gender of the subject in a 67-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8610807_3_6225", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the number of subjects in a 67-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8610807_3_6226", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the race of the subject in a 67-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8610807_3_6227", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the disorder of the subject in a 67-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8610807_3_6228", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What are the drugs used in the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_3_6229", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the dosage of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_3_6230", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the frequency of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_3_6231", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the route of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_3_6232", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "How long has elapsed from the treatment to the occurence of the event in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_3_6233", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "How long did the treatment last in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_3_6234", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What is the disorder targeted by the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_3_6235", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "What are the drugs used in combination in tissue plasminogen activator?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_4_6236", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_4_6237", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_4_6238", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_4_6239", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_4_6240", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_4_6241", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What are the drugs used in the treatment in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_4_6242", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the dosage of the treatment in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_4_6243", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the frequency of the treatment in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_4_6244", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the route of the treatment in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_4_6245", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_4_6246", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "How long did the treatment last in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_4_6247", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What is the disorder targeted by the treatment in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_4_6248", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "What are the drugs used in combination in triamcinolone; her boosted protease inhibitor?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_2_6249", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the age of the subject in five female patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11341670_2_6250", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the gender of the subject in five female patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11341670_2_6251", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the number of subjects in five female patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11341670_2_6252", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the race of the subject in five female patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_2_6253", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the disorder of the subject in five female patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_2_6254", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What are the drugs used in the treatment in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11341670_2_6255", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the dosage of the treatment in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_2_6256", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the frequency of the treatment in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_2_6257", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the route of the treatment in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_2_6258", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "How long has elapsed from the treatment to the occurence of the event in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_2_6259", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "How long did the treatment last in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_2_6260", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What is the disorder targeted by the treatment in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_2_6261", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "What are the drugs used in combination in proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_5_6262", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the age of the subject in a child with metastatic osteosarcoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_5_6263", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the gender of the subject in a child with metastatic osteosarcoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_5_6264", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the number of subjects in a child with metastatic osteosarcoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_5_6265", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the race of the subject in a child with metastatic osteosarcoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_5_6266", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the disorder of the subject in a child with metastatic osteosarcoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_5_6267", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_5_6268", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_5_6269", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_5_6270", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_5_6271", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_5_6272", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_5_6273", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_5_6274", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17823522_5_6275", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What are the drugs used in the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_5_6276", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What is the dosage of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_5_6277", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What is the frequency of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_5_6278", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What is the route of the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_5_6279", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alpha?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_5_6280", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "How long did the treatment last in interferon alpha?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_5_6281", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What is the disorder targeted by the treatment in interferon alpha?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_5_6282", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "What are the drugs used in combination in interferon alpha?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_1_6283", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What are the drugs used in the treatment in Alendronate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_1_6284", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What is the dosage of the treatment in Alendronate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_1_6285", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What is the frequency of the treatment in Alendronate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_1_6286", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What is the route of the treatment in Alendronate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_1_6287", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "How long has elapsed from the treatment to the occurence of the event in Alendronate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_1_6288", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "How long did the treatment last in Alendronate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_1_6289", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What is the disorder targeted by the treatment in Alendronate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_1_6290", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "What are the drugs used in combination in Alendronate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_2_6291", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the age of the subject in a 36-year-old man (35 mg DGTX)?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1469187_2_6292", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the gender of the subject in a 36-year-old man (35 mg DGTX)?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1469187_2_6293", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the number of subjects in a 36-year-old man (35 mg DGTX)?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1469187_2_6294", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the race of the subject in a 36-year-old man (35 mg DGTX)?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1469187_2_6295", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the disorder of the subject in a 36-year-old man (35 mg DGTX)?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1469187_2_6296", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What are the drugs used in the treatment in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1469187_2_6297", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the dosage of the treatment in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_2_6298", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the frequency of the treatment in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1469187_2_6299", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the route of the treatment in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1469187_2_6300", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "How long has elapsed from the treatment to the occurence of the event in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_2_6301", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "How long did the treatment last in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1469187_2_6302", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What is the disorder targeted by the treatment in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_2_6303", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "What are the drugs used in combination in prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6788011_3_6304", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What are the drugs used in the treatment in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6788011_3_6305", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What is the dosage of the treatment in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_3_6306", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What is the frequency of the treatment in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_3_6307", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What is the route of the treatment in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_3_6308", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "How long has elapsed from the treatment to the occurence of the event in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_3_6309", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "How long did the treatment last in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_3_6310", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What is the disorder targeted by the treatment in Gold-salt therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6788011_3_6311", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "What are the drugs used in combination in Gold-salt therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20199429_1_6312", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the age of the subject in children with recalcitrant atopic dermatitis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20199429_1_6313", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the gender of the subject in children with recalcitrant atopic dermatitis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20199429_1_6314", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the number of subjects in children with recalcitrant atopic dermatitis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20199429_1_6315", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the race of the subject in children with recalcitrant atopic dermatitis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20199429_1_6316", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the disorder of the subject in children with recalcitrant atopic dermatitis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20199429_1_6317", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What are the drugs used in the treatment in bisabolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20199429_1_6318", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the dosage of the treatment in bisabolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20199429_1_6319", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the frequency of the treatment in bisabolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20199429_1_6320", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the route of the treatment in bisabolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20199429_1_6321", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in bisabolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20199429_1_6322", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "How long did the treatment last in bisabolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20199429_1_6323", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What is the disorder targeted by the treatment in bisabolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20199429_1_6324", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "What are the drugs used in combination in bisabolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_2_6325", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What are the drugs used in the treatment in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16160485_2_6326", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What is the dosage of the treatment in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_2_6327", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What is the frequency of the treatment in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_2_6328", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What is the route of the treatment in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_2_6329", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_2_6330", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "How long did the treatment last in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_2_6331", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What is the disorder targeted by the treatment in Rituximab therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16160485_2_6332", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "What are the drugs used in combination in Rituximab therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10560960_1_6333", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the age of the subject in A 48-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10560960_1_6334", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the gender of the subject in A 48-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10560960_1_6335", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the number of subjects in A 48-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10560960_1_6336", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the race of the subject in A 48-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10560960_1_6337", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the disorder of the subject in A 48-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10560960_1_6338", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What are the drugs used in the treatment in methimazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10560960_1_6339", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the dosage of the treatment in methimazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10560960_1_6340", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the frequency of the treatment in methimazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10560960_1_6341", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the route of the treatment in methimazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10560960_1_6342", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "How long has elapsed from the treatment to the occurence of the event in methimazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10560960_1_6343", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "How long did the treatment last in methimazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10560960_1_6344", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What is the disorder targeted by the treatment in methimazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10560960_1_6345", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "What are the drugs used in combination in methimazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_1_6346", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What are the drugs used in the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10646879_1_6347", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What is the dosage of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_1_6348", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What is the frequency of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_1_6349", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What is the route of the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_1_6350", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in ifosfamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_1_6351", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "How long did the treatment last in ifosfamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_1_6352", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What is the disorder targeted by the treatment in ifosfamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_1_6353", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "What are the drugs used in combination in ifosfamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_4_6354", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the age of the subject in a woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_4_6355", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the gender of the subject in a woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_4_6356", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the number of subjects in a woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_4_6357", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the race of the subject in a woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_4_6358", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the disorder of the subject in a woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_4_6359", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What are the drugs used in the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_4_6360", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the dosage of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_4_6361", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the frequency of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_4_6362", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the route of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_4_6363", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "How long has elapsed from the treatment to the occurence of the event in raloxifene?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_4_6364", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "How long did the treatment last in raloxifene?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_4_6365", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What is the disorder targeted by the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_4_6366", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "What are the drugs used in combination in raloxifene?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_12_6367", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What are the drugs used in the treatment in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22677303_12_6368", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What is the dosage of the treatment in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_12_6369", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What is the frequency of the treatment in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_12_6370", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What is the route of the treatment in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_12_6371", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_12_6372", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "How long did the treatment last in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_12_6373", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What is the disorder targeted by the treatment in warfarin and cloxacillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_12_6374", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "What are the drugs used in combination in warfarin and cloxacillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_2_6375", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What are the drugs used in the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_2_6376", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What is the dosage of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_2_6377", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What is the frequency of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_2_6378", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What is the route of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_2_6379", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "How long has elapsed from the treatment to the occurence of the event in ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_2_6380", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "How long did the treatment last in ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_2_6381", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What is the disorder targeted by the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_2_6382", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "What are the drugs used in combination in ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_5_6383", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What are the drugs used in the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_5_6384", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What is the dosage of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_5_6385", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What is the frequency of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_5_6386", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What is the route of the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_5_6387", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "How long has elapsed from the treatment to the occurence of the event in Acetazolamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_5_6388", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "How long did the treatment last in Acetazolamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_5_6389", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What is the disorder targeted by the treatment in Acetazolamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_5_6390", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "What are the drugs used in combination in Acetazolamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_1_6391", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_1_6392", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_1_6393", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_1_6394", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_1_6395", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14697943_1_6396", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What are the drugs used in the treatment in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14697943_1_6397", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the dosage of the treatment in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_1_6398", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the frequency of the treatment in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_1_6399", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the route of the treatment in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_1_6400", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "How long has elapsed from the treatment to the occurence of the event in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_1_6401", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "How long did the treatment last in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_1_6402", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What is the disorder targeted by the treatment in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_1_6403", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "What are the drugs used in combination in anticalcineurinic drug (CyA or tacrolimus)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_5_6404", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What are the drugs used in the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_5_6405", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What is the dosage of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_5_6406", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What is the frequency of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_5_6407", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What is the route of the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_5_6408", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "How long has elapsed from the treatment to the occurence of the event in omeprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_5_6409", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "How long did the treatment last in omeprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_5_6410", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What is the disorder targeted by the treatment in omeprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_5_6411", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "What are the drugs used in combination in omeprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_4_6412", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_4_6413", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_4_6414", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_4_6415", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_4_6416", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_4_6417", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9726762_4_6418", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_4_6419", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_4_6420", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_4_6421", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_4_6422", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_4_6423", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_4_6424", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_1_6425", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What are the drugs used in the treatment in Adriamycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1966850_1_6426", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What is the dosage of the treatment in Adriamycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_1_6427", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What is the frequency of the treatment in Adriamycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_1_6428", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What is the route of the treatment in Adriamycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_1_6429", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "How long has elapsed from the treatment to the occurence of the event in Adriamycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_1_6430", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "How long did the treatment last in Adriamycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_1_6431", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What is the disorder targeted by the treatment in Adriamycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_1_6432", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "What are the drugs used in combination in Adriamycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8145359_1_6433", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the age of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8145359_1_6434", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the gender of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8145359_1_6435", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the number of subjects in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8145359_1_6436", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the race of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8145359_1_6437", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the disorder of the subject in An 11-year-old boy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8145359_1_6438", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What are the drugs used in the treatment in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8145359_1_6439", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the dosage of the treatment in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8145359_1_6440", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the frequency of the treatment in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_1_6441", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the route of the treatment in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_1_6442", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_1_6443", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "How long did the treatment last in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_1_6444", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What is the disorder targeted by the treatment in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_1_6445", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "What are the drugs used in combination in a relatively high dose of methotrimeprazine meleate (Levemepromazine)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_1_6446", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the age of the subject in An adult male?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11762672_1_6447", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the gender of the subject in An adult male?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11762672_1_6448", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the number of subjects in An adult male?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11762672_1_6449", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the race of the subject in An adult male?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11762672_1_6450", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the disorder of the subject in An adult male?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11762672_1_6451", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What are the drugs used in the treatment in methanol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11762672_1_6452", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the dosage of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_1_6453", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the frequency of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_1_6454", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the route of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_1_6455", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "How long has elapsed from the treatment to the occurence of the event in methanol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_1_6456", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "How long did the treatment last in methanol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_1_6457", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What is the disorder targeted by the treatment in methanol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_1_6458", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "What are the drugs used in combination in methanol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_1_6459", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What are the drugs used in the treatment in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8523340_1_6460", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What is the dosage of the treatment in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8523340_1_6461", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What is the frequency of the treatment in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8523340_1_6462", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What is the route of the treatment in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8523340_1_6463", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "How long has elapsed from the treatment to the occurence of the event in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8523340_1_6464", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "How long did the treatment last in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8523340_1_6465", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What is the disorder targeted by the treatment in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8523340_1_6466", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "What are the drugs used in combination in 20 weeks of beginning im gold therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_2_6467", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the age of the subject in Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1868481_2_6468", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the gender of the subject in Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_2_6469", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the number of subjects in Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1868481_2_6470", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the race of the subject in Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_2_6471", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the disorder of the subject in Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_2_6472", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What are the drugs used in the treatment in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1868481_2_6473", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the dosage of the treatment in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_2_6474", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the frequency of the treatment in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_2_6475", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the route of the treatment in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1868481_2_6476", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_2_6477", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "How long did the treatment last in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_2_6478", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What is the disorder targeted by the treatment in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1868481_2_6479", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "What are the drugs used in combination in i.v. pulse methylprednisolone (IVPMP) treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_1_6480", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the age of the subject in a boy with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12836099_1_6481", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the gender of the subject in a boy with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12836099_1_6482", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the number of subjects in a boy with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_1_6483", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the race of the subject in a boy with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_1_6484", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the disorder of the subject in a boy with nephrotic syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_1_6485", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What are the drugs used in the treatment in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12836099_1_6486", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the dosage of the treatment in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_1_6487", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the frequency of the treatment in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_1_6488", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the route of the treatment in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12836099_1_6489", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_1_6490", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "How long did the treatment last in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12836099_1_6491", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What is the disorder targeted by the treatment in prednisolone therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12836099_1_6492", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "What are the drugs used in combination in prednisolone therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_4_6493", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What are the drugs used in the treatment in VRC?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_4_6494", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What is the dosage of the treatment in VRC?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_4_6495", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What is the frequency of the treatment in VRC?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_4_6496", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What is the route of the treatment in VRC?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_4_6497", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "How long has elapsed from the treatment to the occurence of the event in VRC?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_4_6498", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "How long did the treatment last in VRC?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_4_6499", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What is the disorder targeted by the treatment in VRC?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_4_6500", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "What are the drugs used in combination in VRC?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_1_6501", "context": "Insulin-induced cardiac failure.", "question": "What are the drugs used in the treatment in Insulin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_1_6502", "context": "Insulin-induced cardiac failure.", "question": "What is the dosage of the treatment in Insulin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_1_6503", "context": "Insulin-induced cardiac failure.", "question": "What is the frequency of the treatment in Insulin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_1_6504", "context": "Insulin-induced cardiac failure.", "question": "What is the route of the treatment in Insulin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_1_6505", "context": "Insulin-induced cardiac failure.", "question": "How long has elapsed from the treatment to the occurence of the event in Insulin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_1_6506", "context": "Insulin-induced cardiac failure.", "question": "How long did the treatment last in Insulin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_1_6507", "context": "Insulin-induced cardiac failure.", "question": "What is the disorder targeted by the treatment in Insulin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_1_6508", "context": "Insulin-induced cardiac failure.", "question": "What are the drugs used in combination in Insulin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_10_6509", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What are the drugs used in the treatment in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_10_6510", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What is the dosage of the treatment in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_10_6511", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What is the frequency of the treatment in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_10_6512", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What is the route of the treatment in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_10_6513", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_10_6514", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "How long did the treatment last in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_10_6515", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What is the disorder targeted by the treatment in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_10_6516", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "What are the drugs used in combination in clemastine and betametasone treatment?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11724089_6_6517", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What are the drugs used in the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_6_6518", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What is the dosage of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_6_6519", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What is the frequency of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_6_6520", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What is the route of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_6_6521", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_6_6522", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "How long did the treatment last in ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_6_6523", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What is the disorder targeted by the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_6_6524", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "What are the drugs used in combination in ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3917429_1_6525", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What are the drugs used in the treatment in lithium therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3917429_1_6526", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What is the dosage of the treatment in lithium therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3917429_1_6527", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What is the frequency of the treatment in lithium therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3917429_1_6528", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What is the route of the treatment in lithium therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3917429_1_6529", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3917429_1_6530", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "How long did the treatment last in lithium therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3917429_1_6531", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What is the disorder targeted by the treatment in lithium therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3917429_1_6532", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "What are the drugs used in combination in lithium therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6738830_1_6533", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the age of the subject in A 56-year-old male parkinsonian patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6738830_1_6534", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the gender of the subject in A 56-year-old male parkinsonian patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6738830_1_6535", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the number of subjects in A 56-year-old male parkinsonian patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6738830_1_6536", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the race of the subject in A 56-year-old male parkinsonian patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6738830_1_6537", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the disorder of the subject in A 56-year-old male parkinsonian patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6738830_1_6538", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What are the drugs used in the treatment in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6738830_1_6539", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the dosage of the treatment in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_1_6540", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the frequency of the treatment in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_1_6541", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the route of the treatment in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6738830_1_6542", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "How long has elapsed from the treatment to the occurence of the event in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_1_6543", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "How long did the treatment last in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_1_6544", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What is the disorder targeted by the treatment in oral administration of cinepazide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6738830_1_6545", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "What are the drugs used in combination in oral administration of cinepazide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_3_6546", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What are the drugs used in the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_3_6547", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What is the dosage of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_3_6548", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What is the frequency of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_3_6549", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What is the route of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_3_6550", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_3_6551", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "How long did the treatment last in carbamazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_3_6552", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What is the disorder targeted by the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_3_6553", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "What are the drugs used in combination in carbamazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_2_6554", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What are the drugs used in the treatment in Metamizole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12042592_2_6555", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What is the dosage of the treatment in Metamizole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_2_6556", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What is the frequency of the treatment in Metamizole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_2_6557", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What is the route of the treatment in Metamizole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_2_6558", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "How long has elapsed from the treatment to the occurence of the event in Metamizole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_2_6559", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "How long did the treatment last in Metamizole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_2_6560", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What is the disorder targeted by the treatment in Metamizole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_2_6561", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "What are the drugs used in combination in Metamizole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_6_6562", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What are the drugs used in the treatment in thionamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_6_6563", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What is the dosage of the treatment in thionamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_6_6564", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What is the frequency of the treatment in thionamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_6_6565", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What is the route of the treatment in thionamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_6_6566", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "How long has elapsed from the treatment to the occurence of the event in thionamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_6_6567", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "How long did the treatment last in thionamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_6_6568", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What is the disorder targeted by the treatment in thionamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_6_6569", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "What are the drugs used in combination in thionamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8696525_2_6570", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the age of the subject in patients with open angle glaucoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8696525_2_6571", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the gender of the subject in patients with open angle glaucoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8696525_2_6572", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the number of subjects in patients with open angle glaucoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8696525_2_6573", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the race of the subject in patients with open angle glaucoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8696525_2_6574", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the disorder of the subject in patients with open angle glaucoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8696525_2_6575", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What are the drugs used in the treatment in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8696525_2_6576", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the dosage of the treatment in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8696525_2_6577", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the frequency of the treatment in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_2_6578", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the route of the treatment in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8696525_2_6579", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "How long has elapsed from the treatment to the occurence of the event in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_2_6580", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "How long did the treatment last in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_2_6581", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What is the disorder targeted by the treatment in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8696525_2_6582", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "What are the drugs used in combination in metripranolol 0.6% eye drops?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_2_6583", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What are the drugs used in the treatment in propranolol therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_2_6584", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What is the dosage of the treatment in propranolol therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_2_6585", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What is the frequency of the treatment in propranolol therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_2_6586", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What is the route of the treatment in propranolol therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_2_6587", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_2_6588", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "How long did the treatment last in propranolol therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_2_6589", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What is the disorder targeted by the treatment in propranolol therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_2_6590", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "What are the drugs used in combination in propranolol therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_2_6591", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the age of the subject in 2 female patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_2_6592", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the gender of the subject in 2 female patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_2_6593", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the number of subjects in 2 female patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_2_6594", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the race of the subject in 2 female patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_2_6595", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the disorder of the subject in 2 female patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_2_6596", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What are the drugs used in the treatment in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11147747_2_6597", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the dosage of the treatment in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_2_6598", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the frequency of the treatment in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_2_6599", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the route of the treatment in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_2_6600", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "How long has elapsed from the treatment to the occurence of the event in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_2_6601", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "How long did the treatment last in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_2_6602", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What is the disorder targeted by the treatment in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_2_6603", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "What are the drugs used in combination in selective serotonin reuptake inhibitors paroxetine and sertraline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1680596_1_6604", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the age of the subject in a woman with classical rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_1_6605", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the gender of the subject in a woman with classical rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1680596_1_6606", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the number of subjects in a woman with classical rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_1_6607", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the race of the subject in a woman with classical rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_1_6608", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the disorder of the subject in a woman with classical rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_1_6609", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What are the drugs used in the treatment in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1680596_1_6610", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the dosage of the treatment in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1680596_1_6611", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the frequency of the treatment in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_1_6612", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the route of the treatment in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_1_6613", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "How long has elapsed from the treatment to the occurence of the event in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_1_6614", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "How long did the treatment last in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_1_6615", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What is the disorder targeted by the treatment in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1680596_1_6616", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "What are the drugs used in combination in sulphasalazine (SASP) therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_1_6617", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What are the drugs used in the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19112808_1_6618", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the dosage of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_1_6619", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the frequency of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_1_6620", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the route of the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_1_6621", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "How long has elapsed from the treatment to the occurence of the event in darifenacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_1_6622", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "How long did the treatment last in darifenacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_1_6623", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What is the disorder targeted by the treatment in darifenacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_1_6624", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "What are the drugs used in combination in darifenacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6625", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What are the drugs used in the treatment in methanol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11762672_2_6626", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the dosage of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6627", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the frequency of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6628", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the route of the treatment in methanol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6629", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "How long has elapsed from the treatment to the occurence of the event in methanol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6630", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "How long did the treatment last in methanol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6631", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the disorder targeted by the treatment in methanol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6632", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What are the drugs used in combination in methanol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6633", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What are the drugs used in the treatment in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11762672_2_6634", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the dosage of the treatment in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6635", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the frequency of the treatment in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6636", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the route of the treatment in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6637", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "How long has elapsed from the treatment to the occurence of the event in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6638", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "How long did the treatment last in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6639", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What is the disorder targeted by the treatment in fomepizole?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6640", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "What are the drugs used in combination in fomepizole?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_3_6641", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_3_6642", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_3_6643", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20925534_3_6644", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_3_6645", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_3_6646", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What are the drugs used in the treatment in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_3_6647", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the dosage of the treatment in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_3_6648", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the frequency of the treatment in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_3_6649", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the route of the treatment in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_3_6650", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_3_6651", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "How long did the treatment last in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_3_6652", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What is the disorder targeted by the treatment in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_3_6653", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "What are the drugs used in combination in Proton-pump inhibitors (PPIs)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_4_6654", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What are the drugs used in the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_4_6655", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What is the dosage of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_4_6656", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What is the frequency of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_4_6657", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What is the route of the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_4_6658", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "How long has elapsed from the treatment to the occurence of the event in caffeine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_4_6659", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "How long did the treatment last in caffeine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_4_6660", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What is the disorder targeted by the treatment in caffeine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_4_6661", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "What are the drugs used in combination in caffeine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_8_6662", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the age of the subject in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_8_6663", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the gender of the subject in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_8_6664", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the number of subjects in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_8_6665", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the race of the subject in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_8_6666", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the disorder of the subject in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_8_6667", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What are the drugs used in the treatment in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_8_6668", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the dosage of the treatment in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_8_6669", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the frequency of the treatment in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_8_6670", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the route of the treatment in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_8_6671", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "How long has elapsed from the treatment to the occurence of the event in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_8_6672", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "How long did the treatment last in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_8_6673", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What is the disorder targeted by the treatment in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_8_6674", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "What are the drugs used in combination in HD IV MTX and intrathecal injections of MTX?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_1_6675", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What are the drugs used in the treatment in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_1_6676", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What is the dosage of the treatment in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_1_6677", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What is the frequency of the treatment in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_1_6678", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What is the route of the treatment in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_1_6679", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_1_6680", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "How long did the treatment last in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_1_6681", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What is the disorder targeted by the treatment in interferon alpha treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_1_6682", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "What are the drugs used in combination in interferon alpha treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_2_6683", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What are the drugs used in the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1422497_2_6684", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What is the dosage of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_2_6685", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What is the frequency of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_2_6686", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What is the route of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_2_6687", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_2_6688", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "How long did the treatment last in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_2_6689", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What is the disorder targeted by the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_2_6690", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "What are the drugs used in combination in cyclophosphamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_1_6691", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the age of the subject in certain patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7212107_1_6692", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the gender of the subject in certain patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7212107_1_6693", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the number of subjects in certain patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7212107_1_6694", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the race of the subject in certain patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7212107_1_6695", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the disorder of the subject in certain patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7212107_1_6696", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7212107_1_6697", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the dosage of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_1_6698", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the frequency of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_1_6699", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the route of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_1_6700", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_1_6701", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "How long did the treatment last in lithium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_1_6702", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_1_6703", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "What are the drugs used in combination in lithium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_2_6704", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What are the drugs used in the treatment in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_2_6705", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What is the dosage of the treatment in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_2_6706", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What is the frequency of the treatment in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_2_6707", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What is the route of the treatment in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_2_6708", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "How long has elapsed from the treatment to the occurence of the event in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_2_6709", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "How long did the treatment last in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_2_6710", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What is the disorder targeted by the treatment in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_2_6711", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "What are the drugs used in combination in internal use of low-dose aspirin for 16 months?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_3_6712", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the age of the subject in five out of six patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_3_6713", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the gender of the subject in five out of six patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_3_6714", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the number of subjects in five out of six patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "589261_3_6715", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the race of the subject in five out of six patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_3_6716", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the disorder of the subject in five out of six patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_3_6717", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What are the drugs used in the treatment in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "589261_3_6718", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the dosage of the treatment in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_3_6719", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the frequency of the treatment in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_3_6720", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the route of the treatment in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_3_6721", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "How long has elapsed from the treatment to the occurence of the event in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_3_6722", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "How long did the treatment last in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_3_6723", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What is the disorder targeted by the treatment in receiving a cardiac glycoside?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_3_6724", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "What are the drugs used in combination in receiving a cardiac glycoside?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_4_6725", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What are the drugs used in the treatment in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_4_6726", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What is the dosage of the treatment in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_4_6727", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What is the frequency of the treatment in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_4_6728", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What is the route of the treatment in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_4_6729", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "How long has elapsed from the treatment to the occurence of the event in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_4_6730", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "How long did the treatment last in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_4_6731", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What is the disorder targeted by the treatment in co-administration of pravastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_4_6732", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "What are the drugs used in combination in co-administration of pravastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_3_6733", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What are the drugs used in the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_3_6734", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What is the dosage of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_3_6735", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What is the frequency of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_3_6736", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What is the route of the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_3_6737", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_3_6738", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "How long did the treatment last in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_3_6739", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What is the disorder targeted by the treatment in cyclophosphamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_3_6740", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "What are the drugs used in combination in cyclophosphamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_2_6741", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What are the drugs used in the treatment in 5-FU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_2_6742", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What is the dosage of the treatment in 5-FU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_2_6743", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What is the frequency of the treatment in 5-FU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_2_6744", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What is the route of the treatment in 5-FU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_2_6745", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-FU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_2_6746", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "How long did the treatment last in 5-FU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_2_6747", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What is the disorder targeted by the treatment in 5-FU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_2_6748", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "What are the drugs used in combination in 5-FU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_2_6749", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the age of the subject in an eight-year old boy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1966850_2_6750", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the gender of the subject in an eight-year old boy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1966850_2_6751", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the number of subjects in an eight-year old boy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1966850_2_6752", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the race of the subject in an eight-year old boy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1966850_2_6753", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the disorder of the subject in an eight-year old boy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1966850_2_6754", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What are the drugs used in the treatment in cisplatinum?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1966850_2_6755", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the dosage of the treatment in cisplatinum?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_2_6756", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the frequency of the treatment in cisplatinum?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_2_6757", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the route of the treatment in cisplatinum?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_2_6758", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in cisplatinum?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_2_6759", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "How long did the treatment last in cisplatinum?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_2_6760", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What is the disorder targeted by the treatment in cisplatinum?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_2_6761", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "What are the drugs used in combination in cisplatinum?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17504225_2_6762", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the age of the subject in renal transplant recipients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_2_6763", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the gender of the subject in renal transplant recipients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17504225_2_6764", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the number of subjects in renal transplant recipients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_2_6765", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the race of the subject in renal transplant recipients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_2_6766", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the disorder of the subject in renal transplant recipients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17504225_2_6767", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What are the drugs used in the treatment in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_2_6768", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the dosage of the treatment in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_2_6769", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the frequency of the treatment in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_2_6770", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the route of the treatment in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_2_6771", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "How long has elapsed from the treatment to the occurence of the event in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_2_6772", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "How long did the treatment last in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_2_6773", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What is the disorder targeted by the treatment in antimicrobial agents?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_2_6774", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "What are the drugs used in combination in antimicrobial agents?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_12_6775", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the age of the subject in patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16685007_12_6776", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the gender of the subject in patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_12_6777", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the number of subjects in patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_12_6778", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the race of the subject in patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_12_6779", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the disorder of the subject in patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_12_6780", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What are the drugs used in the treatment in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16685007_12_6781", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the dosage of the treatment in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_12_6782", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the frequency of the treatment in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_12_6783", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the route of the treatment in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16685007_12_6784", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "How long has elapsed from the treatment to the occurence of the event in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_12_6785", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "How long did the treatment last in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_12_6786", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What is the disorder targeted by the treatment in ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_12_6787", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "What are the drugs used in combination in ciclesonide?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14968106_1_6788", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What are the drugs used in the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_1_6789", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What is the dosage of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_1_6790", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What is the frequency of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_1_6791", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What is the route of the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_1_6792", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_1_6793", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "How long did the treatment last in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_1_6794", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What is the disorder targeted by the treatment in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_1_6795", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "What are the drugs used in combination in intrathecal administration of doxorubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_5_6796", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What are the drugs used in the treatment in alpha interferon?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_5_6797", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What is the dosage of the treatment in alpha interferon?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_5_6798", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What is the frequency of the treatment in alpha interferon?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_5_6799", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What is the route of the treatment in alpha interferon?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_5_6800", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "How long has elapsed from the treatment to the occurence of the event in alpha interferon?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_5_6801", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "How long did the treatment last in alpha interferon?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_5_6802", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What is the disorder targeted by the treatment in alpha interferon?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_5_6803", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "What are the drugs used in combination in alpha interferon?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_4_6804", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the age of the subject in a patient with mild chronic renal insufficiency?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17921794_4_6805", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the gender of the subject in a patient with mild chronic renal insufficiency?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17921794_4_6806", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the number of subjects in a patient with mild chronic renal insufficiency?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17921794_4_6807", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the race of the subject in a patient with mild chronic renal insufficiency?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17921794_4_6808", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the disorder of the subject in a patient with mild chronic renal insufficiency?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17921794_4_6809", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What are the drugs used in the treatment in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_4_6810", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the dosage of the treatment in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_4_6811", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the frequency of the treatment in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_4_6812", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the route of the treatment in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_4_6813", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "How long has elapsed from the treatment to the occurence of the event in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_4_6814", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "How long did the treatment last in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_4_6815", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What is the disorder targeted by the treatment in simvastatin for over a year?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_4_6816", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "What are the drugs used in combination in simvastatin for over a year?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16603845_1_6817", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16603845_1_6818", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16603845_1_6819", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16603845_1_6820", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16603845_1_6821", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16603845_1_6822", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What are the drugs used in the treatment in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16603845_1_6823", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the dosage of the treatment in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16603845_1_6824", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the frequency of the treatment in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16603845_1_6825", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the route of the treatment in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16603845_1_6826", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "How long has elapsed from the treatment to the occurence of the event in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16603845_1_6827", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "How long did the treatment last in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16603845_1_6828", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What is the disorder targeted by the treatment in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16603845_1_6829", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "What are the drugs used in combination in chemotherapy and an injection of pegfilgrastim?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_2_6830", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the age of the subject in a polytrauma patient with Parkinson's disease (PD)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20628041_2_6831", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the gender of the subject in a polytrauma patient with Parkinson's disease (PD)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20628041_2_6832", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the number of subjects in a polytrauma patient with Parkinson's disease (PD)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20628041_2_6833", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the race of the subject in a polytrauma patient with Parkinson's disease (PD)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20628041_2_6834", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the disorder of the subject in a polytrauma patient with Parkinson's disease (PD)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20628041_2_6835", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What are the drugs used in the treatment in levodopa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20628041_2_6836", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the dosage of the treatment in levodopa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_2_6837", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the frequency of the treatment in levodopa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_2_6838", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the route of the treatment in levodopa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_2_6839", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "How long has elapsed from the treatment to the occurence of the event in levodopa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_2_6840", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "How long did the treatment last in levodopa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_2_6841", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What is the disorder targeted by the treatment in levodopa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_2_6842", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "What are the drugs used in combination in levodopa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_3_6843", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the age of the subject in a schizophrenia patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_3_6844", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the gender of the subject in a schizophrenia patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_3_6845", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the number of subjects in a schizophrenia patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_3_6846", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the race of the subject in a schizophrenia patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_3_6847", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the disorder of the subject in a schizophrenia patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_3_6848", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What are the drugs used in the treatment in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16978752_3_6849", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the dosage of the treatment in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_3_6850", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the frequency of the treatment in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_3_6851", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the route of the treatment in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_3_6852", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_3_6853", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "How long did the treatment last in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_3_6854", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What is the disorder targeted by the treatment in olanzapine and thiazide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_3_6855", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "What are the drugs used in combination in olanzapine and thiazide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_3_6856", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What are the drugs used in the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21658326_3_6857", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What is the dosage of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_3_6858", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What is the frequency of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_3_6859", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What is the route of the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_3_6860", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "How long has elapsed from the treatment to the occurence of the event in imiquimod?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_3_6861", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "How long did the treatment last in imiquimod?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_3_6862", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What is the disorder targeted by the treatment in imiquimod?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_3_6863", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "What are the drugs used in combination in imiquimod?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6239881_2_6864", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the age of the subject in Nineteen cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6239881_2_6865", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the gender of the subject in Nineteen cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6239881_2_6866", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the number of subjects in Nineteen cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6239881_2_6867", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the race of the subject in Nineteen cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6239881_2_6868", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the disorder of the subject in Nineteen cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6239881_2_6869", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What are the drugs used in the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6239881_2_6870", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the dosage of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_2_6871", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the frequency of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_2_6872", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the route of the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_2_6873", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "How long has elapsed from the treatment to the occurence of the event in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_2_6874", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "How long did the treatment last in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_2_6875", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What is the disorder targeted by the treatment in compound tincture of benzoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_2_6876", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "What are the drugs used in combination in compound tincture of benzoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_3_6877", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the age of the subject in 3 children with epilepsy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8404753_3_6878", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the gender of the subject in 3 children with epilepsy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_3_6879", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the number of subjects in 3 children with epilepsy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_3_6880", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the race of the subject in 3 children with epilepsy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_3_6881", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the disorder of the subject in 3 children with epilepsy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_3_6882", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What are the drugs used in the treatment in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8404753_3_6883", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the dosage of the treatment in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_3_6884", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the frequency of the treatment in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_3_6885", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the route of the treatment in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_3_6886", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "How long has elapsed from the treatment to the occurence of the event in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_3_6887", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "How long did the treatment last in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_3_6888", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What is the disorder targeted by the treatment in initiation of CBZ?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_3_6889", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "What are the drugs used in combination in initiation of CBZ?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_2_6890", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What are the drugs used in the treatment in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_2_6891", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What is the dosage of the treatment in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_2_6892", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What is the frequency of the treatment in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_2_6893", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What is the route of the treatment in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_2_6894", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "How long has elapsed from the treatment to the occurence of the event in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_2_6895", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "How long did the treatment last in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_2_6896", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What is the disorder targeted by the treatment in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_2_6897", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "What are the drugs used in combination in cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18354950_3_6898", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the age of the subject in a 29-year Nigerian female patient with generalized tonic-elonic seizures?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18354950_3_6899", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the gender of the subject in a 29-year Nigerian female patient with generalized tonic-elonic seizures?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18354950_3_6900", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the number of subjects in a 29-year Nigerian female patient with generalized tonic-elonic seizures?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18354950_3_6901", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the race of the subject in a 29-year Nigerian female patient with generalized tonic-elonic seizures?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18354950_3_6902", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the disorder of the subject in a 29-year Nigerian female patient with generalized tonic-elonic seizures?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18354950_3_6903", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What are the drugs used in the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_3_6904", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the dosage of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_3_6905", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the frequency of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_3_6906", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the route of the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_3_6907", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_3_6908", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "How long did the treatment last in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_3_6909", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What is the disorder targeted by the treatment in carbamazepine administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_3_6910", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "What are the drugs used in combination in carbamazepine administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11310527_2_6911", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the age of the subject in A patient?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11310527_2_6912", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the gender of the subject in A patient?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11310527_2_6913", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the number of subjects in A patient?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11310527_2_6914", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the race of the subject in A patient?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11310527_2_6915", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the disorder of the subject in A patient?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11310527_2_6916", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11310527_2_6917", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11310527_2_6918", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11310527_2_6919", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the route of the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11310527_2_6920", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11310527_2_6921", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "How long did the treatment last in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11310527_2_6922", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11310527_2_6923", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19754002_1_6924", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What are the drugs used in the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19754002_1_6925", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What is the dosage of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_1_6926", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What is the frequency of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_1_6927", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What is the route of the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_1_6928", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "How long has elapsed from the treatment to the occurence of the event in pravastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_1_6929", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "How long did the treatment last in pravastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_1_6930", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What is the disorder targeted by the treatment in pravastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_1_6931", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "What are the drugs used in combination in pravastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1602800_1_6932", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What are the drugs used in the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1602800_1_6933", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What is the dosage of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1602800_1_6934", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What is the frequency of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1602800_1_6935", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What is the route of the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1602800_1_6936", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "How long has elapsed from the treatment to the occurence of the event in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1602800_1_6937", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "How long did the treatment last in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1602800_1_6938", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What is the disorder targeted by the treatment in all-trans retinoic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1602800_1_6939", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "What are the drugs used in combination in all-trans retinoic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_1_6940", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the age of the subject in A 74-year-old hypercholestrerolaemic woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_1_6941", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the gender of the subject in A 74-year-old hypercholestrerolaemic woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_1_6942", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the number of subjects in A 74-year-old hypercholestrerolaemic woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_1_6943", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the race of the subject in A 74-year-old hypercholestrerolaemic woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_1_6944", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the disorder of the subject in A 74-year-old hypercholestrerolaemic woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_1_6945", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What are the drugs used in the treatment in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_1_6946", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the dosage of the treatment in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_1_6947", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the frequency of the treatment in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_1_6948", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the route of the treatment in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_1_6949", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "How long has elapsed from the treatment to the occurence of the event in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_1_6950", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "How long did the treatment last in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_1_6951", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What is the disorder targeted by the treatment in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_1_6952", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "What are the drugs used in combination in cerivastatin (0.15 mg/day) for 22 days?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_3_6953", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What are the drugs used in the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_3_6954", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What is the dosage of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_3_6955", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What is the frequency of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_3_6956", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What is the route of the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_3_6957", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in cimetidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_3_6958", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "How long did the treatment last in cimetidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_3_6959", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What is the disorder targeted by the treatment in cimetidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_3_6960", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "What are the drugs used in combination in cimetidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3732375_2_6961", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What are the drugs used in the treatment in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3732375_2_6962", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What is the dosage of the treatment in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_2_6963", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What is the frequency of the treatment in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_2_6964", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What is the route of the treatment in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_2_6965", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "How long has elapsed from the treatment to the occurence of the event in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_2_6966", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "How long did the treatment last in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_2_6967", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What is the disorder targeted by the treatment in concomitant administration of viloxazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_2_6968", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "What are the drugs used in combination in concomitant administration of viloxazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_1_6969", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What are the drugs used in the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_1_6970", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What is the dosage of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_1_6971", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What is the frequency of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_1_6972", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What is the route of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_1_6973", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alfa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_1_6974", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "How long did the treatment last in interferon alfa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_1_6975", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What is the disorder targeted by the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_1_6976", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "What are the drugs used in combination in interferon alfa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_6_6977", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What are the drugs used in the treatment in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_6_6978", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What is the dosage of the treatment in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_6_6979", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What is the frequency of the treatment in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_6_6980", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What is the route of the treatment in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_6_6981", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "How long has elapsed from the treatment to the occurence of the event in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_6_6982", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "How long did the treatment last in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_6_6983", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What is the disorder targeted by the treatment in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_6_6984", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "What are the drugs used in combination in recombinant and natural interferon alpha administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_2_6985", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What are the drugs used in the treatment in Rofecoxib?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12234159_2_6986", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What is the dosage of the treatment in Rofecoxib?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_2_6987", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What is the frequency of the treatment in Rofecoxib?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_2_6988", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What is the route of the treatment in Rofecoxib?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_2_6989", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "How long has elapsed from the treatment to the occurence of the event in Rofecoxib?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_2_6990", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "How long did the treatment last in Rofecoxib?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_2_6991", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What is the disorder targeted by the treatment in Rofecoxib?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12234159_2_6992", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "What are the drugs used in combination in Rofecoxib?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_2_6993", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What are the drugs used in the treatment in Statin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16609346_2_6994", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What is the dosage of the treatment in Statin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_2_6995", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What is the frequency of the treatment in Statin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_2_6996", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What is the route of the treatment in Statin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_2_6997", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in Statin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_2_6998", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "How long did the treatment last in Statin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_2_6999", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What is the disorder targeted by the treatment in Statin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_2_7000", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "What are the drugs used in combination in Statin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_3_7001", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What are the drugs used in the treatment in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4075534_3_7002", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What is the dosage of the treatment in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_3_7003", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What is the frequency of the treatment in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_3_7004", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What is the route of the treatment in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_3_7005", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "How long has elapsed from the treatment to the occurence of the event in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_3_7006", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "How long did the treatment last in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_3_7007", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What is the disorder targeted by the treatment in alcohol and imipramine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_3_7008", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "What are the drugs used in combination in alcohol and imipramine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_2_7009", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What are the drugs used in the treatment in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3003260_2_7010", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What is the dosage of the treatment in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_2_7011", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What is the frequency of the treatment in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_2_7012", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What is the route of the treatment in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_2_7013", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "How long has elapsed from the treatment to the occurence of the event in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_2_7014", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "How long did the treatment last in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_2_7015", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What is the disorder targeted by the treatment in intermittent Decadron?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_2_7016", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "What are the drugs used in combination in intermittent Decadron?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_2_7017", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the age of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "879939_2_7018", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the gender of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "879939_2_7019", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the number of subjects in two epileptic patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "879939_2_7020", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the race of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "879939_2_7021", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the disorder of the subject in two epileptic patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "879939_2_7022", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What are the drugs used in the treatment in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "879939_2_7023", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the dosage of the treatment in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_2_7024", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the frequency of the treatment in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_2_7025", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the route of the treatment in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_2_7026", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_2_7027", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "How long did the treatment last in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_2_7028", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What is the disorder targeted by the treatment in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_2_7029", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "What are the drugs used in combination in long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3969689_4_7030", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What are the drugs used in the treatment in acetaminophen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3969689_4_7031", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What is the dosage of the treatment in acetaminophen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3969689_4_7032", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What is the frequency of the treatment in acetaminophen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3969689_4_7033", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What is the route of the treatment in acetaminophen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3969689_4_7034", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "How long has elapsed from the treatment to the occurence of the event in acetaminophen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3969689_4_7035", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "How long did the treatment last in acetaminophen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3969689_4_7036", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What is the disorder targeted by the treatment in acetaminophen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3969689_4_7037", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "What are the drugs used in combination in acetaminophen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_6_7038", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_6_7039", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_6_7040", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_6_7041", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_6_7042", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_6_7043", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_6_7044", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_6_7045", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_1_7046", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What are the drugs used in the treatment in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11696132_1_7047", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What is the dosage of the treatment in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_1_7048", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What is the frequency of the treatment in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_1_7049", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What is the route of the treatment in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11696132_1_7050", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "How long has elapsed from the treatment to the occurence of the event in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_1_7051", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "How long did the treatment last in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_1_7052", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What is the disorder targeted by the treatment in transdermal scopolamine patch?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11696132_1_7053", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "What are the drugs used in combination in transdermal scopolamine patch?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_1_7054", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What are the drugs used in the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12851279_1_7055", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What is the dosage of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_1_7056", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What is the frequency of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_1_7057", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What is the route of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_1_7058", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "How long has elapsed from the treatment to the occurence of the event in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_1_7059", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "How long did the treatment last in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_1_7060", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What is the disorder targeted by the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_1_7061", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "What are the drugs used in combination in tifacogin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15863610_5_7062", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the age of the subject in a 64-year-old woman with a bicornuate uterus?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_5_7063", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the gender of the subject in a 64-year-old woman with a bicornuate uterus?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_5_7064", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the number of subjects in a 64-year-old woman with a bicornuate uterus?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_5_7065", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the race of the subject in a 64-year-old woman with a bicornuate uterus?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_5_7066", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the disorder of the subject in a 64-year-old woman with a bicornuate uterus?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_5_7067", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What are the drugs used in the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_5_7068", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the dosage of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_5_7069", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the frequency of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_5_7070", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the route of the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_5_7071", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "How long has elapsed from the treatment to the occurence of the event in raloxifene?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_5_7072", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "How long did the treatment last in raloxifene?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_5_7073", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What is the disorder targeted by the treatment in raloxifene?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_5_7074", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "What are the drugs used in combination in raloxifene?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_1_7075", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What are the drugs used in the treatment in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_1_7076", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What is the dosage of the treatment in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_1_7077", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What is the frequency of the treatment in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_1_7078", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What is the route of the treatment in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_1_7079", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_1_7080", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "How long did the treatment last in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_1_7081", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What is the disorder targeted by the treatment in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_1_7082", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "What are the drugs used in combination in rechallenge with monotherapy pegvisomant?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_2_7083", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the age of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22372628_2_7084", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the gender of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22372628_2_7085", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the number of subjects in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22372628_2_7086", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the race of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22372628_2_7087", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the disorder of the subject in patients with uncontrolled partial-onset seizures?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22372628_2_7088", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What are the drugs used in the treatment in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "22372628_2_7089", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the dosage of the treatment in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_2_7090", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the frequency of the treatment in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_2_7091", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the route of the treatment in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_2_7092", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "How long has elapsed from the treatment to the occurence of the event in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_2_7093", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "How long did the treatment last in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22372628_2_7094", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What is the disorder targeted by the treatment in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22372628_2_7095", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "What are the drugs used in combination in lacosamide as adjunctive therapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7071645_3_7096", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What are the drugs used in the treatment in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7071645_3_7097", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What is the dosage of the treatment in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_3_7098", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What is the frequency of the treatment in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7071645_3_7099", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What is the route of the treatment in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7071645_3_7100", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_3_7101", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "How long did the treatment last in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7071645_3_7102", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What is the disorder targeted by the treatment in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7071645_3_7103", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "What are the drugs used in combination in discontinuation of hydroxychloroquine therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_1_7104", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the age of the subject in elderly patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18364401_1_7105", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the gender of the subject in elderly patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_1_7106", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the number of subjects in elderly patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_1_7107", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the race of the subject in elderly patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_1_7108", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the disorder of the subject in elderly patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_1_7109", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18364401_1_7110", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_1_7111", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_1_7112", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_1_7113", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_1_7114", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_1_7115", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_1_7116", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18661248_2_7117", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the age of the subject in a patient with collapsing focal glomeruloesclerosis (collapsing FGS)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18661248_2_7118", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the gender of the subject in a patient with collapsing focal glomeruloesclerosis (collapsing FGS)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18661248_2_7119", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the number of subjects in a patient with collapsing focal glomeruloesclerosis (collapsing FGS)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18661248_2_7120", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the race of the subject in a patient with collapsing focal glomeruloesclerosis (collapsing FGS)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18661248_2_7121", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the disorder of the subject in a patient with collapsing focal glomeruloesclerosis (collapsing FGS)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18661248_2_7122", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What are the drugs used in the treatment in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18661248_2_7123", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the dosage of the treatment in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18661248_2_7124", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the frequency of the treatment in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18661248_2_7125", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the route of the treatment in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18661248_2_7126", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "How long has elapsed from the treatment to the occurence of the event in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18661248_2_7127", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "How long did the treatment last in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18661248_2_7128", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What is the disorder targeted by the treatment in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18661248_2_7129", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "What are the drugs used in combination in withdrawal of cyclosporine (CSA)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_3_7130", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_3_7131", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_3_7132", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_3_7133", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_3_7134", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_3_7135", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What are the drugs used in the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_3_7136", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the dosage of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_3_7137", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the frequency of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_3_7138", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the route of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_3_7139", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "How long has elapsed from the treatment to the occurence of the event in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_3_7140", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "How long did the treatment last in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_3_7141", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What is the disorder targeted by the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_3_7142", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "What are the drugs used in combination in zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_2_7143", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What are the drugs used in the treatment in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11202801_2_7144", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What is the dosage of the treatment in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_2_7145", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What is the frequency of the treatment in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_2_7146", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What is the route of the treatment in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_2_7147", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_2_7148", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "How long did the treatment last in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_2_7149", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What is the disorder targeted by the treatment in cyclophosphamide therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_2_7150", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "What are the drugs used in combination in cyclophosphamide therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_3_7151", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the age of the subject in children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11283125_3_7152", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the gender of the subject in children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_3_7153", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the number of subjects in children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_3_7154", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the race of the subject in children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_3_7155", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the disorder of the subject in children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_3_7156", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What are the drugs used in the treatment in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_3_7157", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the dosage of the treatment in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_3_7158", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the frequency of the treatment in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_3_7159", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the route of the treatment in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_3_7160", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "How long has elapsed from the treatment to the occurence of the event in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_3_7161", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "How long did the treatment last in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_3_7162", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What is the disorder targeted by the treatment in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_3_7163", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "What are the drugs used in combination in HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7756684_1_7164", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What are the drugs used in the treatment in KW-2149?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7756684_1_7165", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What is the dosage of the treatment in KW-2149?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7756684_1_7166", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What is the frequency of the treatment in KW-2149?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7756684_1_7167", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What is the route of the treatment in KW-2149?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7756684_1_7168", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in KW-2149?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7756684_1_7169", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "How long did the treatment last in KW-2149?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7756684_1_7170", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What is the disorder targeted by the treatment in KW-2149?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7756684_1_7171", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "What are the drugs used in combination in KW-2149?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_1_7172", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What are the drugs used in the treatment in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15773973_1_7173", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What is the dosage of the treatment in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_1_7174", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What is the frequency of the treatment in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_1_7175", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What is the route of the treatment in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_1_7176", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "How long has elapsed from the treatment to the occurence of the event in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_1_7177", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "How long did the treatment last in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_1_7178", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What is the disorder targeted by the treatment in Flucloxacillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_1_7179", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "What are the drugs used in combination in Flucloxacillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_8_7180", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the age of the subject in patients with cancer who experience methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_8_7181", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the gender of the subject in patients with cancer who experience methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_8_7182", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the number of subjects in patients with cancer who experience methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_8_7183", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the race of the subject in patients with cancer who experience methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_8_7184", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the disorder of the subject in patients with cancer who experience methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_8_7185", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_8_7186", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_8_7187", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_8_7188", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_8_7189", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_8_7190", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_8_7191", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_8_7192", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_4_7193", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What are the drugs used in the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_4_7194", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What is the dosage of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_4_7195", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What is the frequency of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_4_7196", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What is the route of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_4_7197", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in BCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_4_7198", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "How long did the treatment last in BCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_4_7199", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What is the disorder targeted by the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_4_7200", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "What are the drugs used in combination in BCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_1_7201", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What are the drugs used in the treatment in sulfonamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_1_7202", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What is the dosage of the treatment in sulfonamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_1_7203", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What is the frequency of the treatment in sulfonamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_1_7204", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What is the route of the treatment in sulfonamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_1_7205", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "How long has elapsed from the treatment to the occurence of the event in sulfonamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_1_7206", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "How long did the treatment last in sulfonamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_1_7207", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What is the disorder targeted by the treatment in sulfonamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_1_7208", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "What are the drugs used in combination in sulfonamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_4_7209", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What are the drugs used in the treatment in Brimonidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_4_7210", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What is the dosage of the treatment in Brimonidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_4_7211", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What is the frequency of the treatment in Brimonidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_4_7212", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What is the route of the treatment in Brimonidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_4_7213", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "How long has elapsed from the treatment to the occurence of the event in Brimonidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_4_7214", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "How long did the treatment last in Brimonidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_4_7215", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What is the disorder targeted by the treatment in Brimonidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_4_7216", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "What are the drugs used in combination in Brimonidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15507779_1_7217", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the age of the subject in an HIV carrier?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_1_7218", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the gender of the subject in an HIV carrier?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15507779_1_7219", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the number of subjects in an HIV carrier?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_1_7220", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the race of the subject in an HIV carrier?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_1_7221", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the disorder of the subject in an HIV carrier?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_1_7222", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What are the drugs used in the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15507779_1_7223", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the dosage of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_1_7224", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the frequency of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_1_7225", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the route of the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_1_7226", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "How long has elapsed from the treatment to the occurence of the event in nevirapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_1_7227", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "How long did the treatment last in nevirapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_1_7228", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What is the disorder targeted by the treatment in nevirapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15507779_1_7229", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "What are the drugs used in combination in nevirapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_2_7230", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the age of the subject in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1711090_2_7231", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the gender of the subject in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1711090_2_7232", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the number of subjects in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1711090_2_7233", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the race of the subject in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1711090_2_7234", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the disorder of the subject in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1711090_2_7235", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What are the drugs used in the treatment in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1711090_2_7236", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the dosage of the treatment in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_2_7237", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the frequency of the treatment in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_2_7238", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the route of the treatment in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1711090_2_7239", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "How long has elapsed from the treatment to the occurence of the event in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_2_7240", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "How long did the treatment last in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_2_7241", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What is the disorder targeted by the treatment in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_2_7242", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "What are the drugs used in combination in Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3806824_1_7243", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What are the drugs used in the treatment in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3806824_1_7244", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What is the dosage of the treatment in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_1_7245", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What is the frequency of the treatment in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_1_7246", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What is the route of the treatment in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3806824_1_7247", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "How long has elapsed from the treatment to the occurence of the event in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_1_7248", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "How long did the treatment last in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_1_7249", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What is the disorder targeted by the treatment in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_1_7250", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "What are the drugs used in combination in intracavernous injection of phentolamine/papaverine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_4_7251", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the age of the subject in three children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "440873_4_7252", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the gender of the subject in three children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_4_7253", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the number of subjects in three children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_4_7254", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the race of the subject in three children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_4_7255", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the disorder of the subject in three children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_4_7256", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What are the drugs used in the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "440873_4_7257", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the dosage of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_4_7258", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the frequency of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_4_7259", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the route of the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_4_7260", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "How long has elapsed from the treatment to the occurence of the event in carbamazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_4_7261", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "How long did the treatment last in carbamazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_4_7262", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What is the disorder targeted by the treatment in carbamazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_4_7263", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "What are the drugs used in combination in carbamazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_1_7264", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What are the drugs used in the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17275666_1_7265", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What is the dosage of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_1_7266", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What is the frequency of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_1_7267", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What is the route of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_1_7268", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "How long has elapsed from the treatment to the occurence of the event in valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_1_7269", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "How long did the treatment last in valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_1_7270", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What is the disorder targeted by the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_1_7271", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "What are the drugs used in combination in valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_10_7272", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the age of the subject in These cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15516308_10_7273", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the gender of the subject in These cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15516308_10_7274", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the number of subjects in These cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15516308_10_7275", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the race of the subject in These cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15516308_10_7276", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the disorder of the subject in These cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15516308_10_7277", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What are the drugs used in the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_10_7278", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the dosage of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_10_7279", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the frequency of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_10_7280", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the route of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_10_7281", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "How long has elapsed from the treatment to the occurence of the event in quetiapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_10_7282", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "How long did the treatment last in quetiapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_10_7283", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What is the disorder targeted by the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_10_7284", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "What are the drugs used in combination in quetiapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16599252_2_7285", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What are the drugs used in the treatment in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16599252_2_7286", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What is the dosage of the treatment in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_2_7287", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What is the frequency of the treatment in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_2_7288", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What is the route of the treatment in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_2_7289", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_2_7290", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "How long did the treatment last in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_2_7291", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What is the disorder targeted by the treatment in zafirlukast therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_2_7292", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "What are the drugs used in combination in zafirlukast therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_3_7293", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the age of the subject in patients with methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_3_7294", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the gender of the subject in patients with methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_3_7295", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the number of subjects in patients with methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_3_7296", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the race of the subject in patients with methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_3_7297", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the disorder of the subject in patients with methotrexate-induced anaphylaxis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_3_7298", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_3_7299", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_3_7300", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_3_7301", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_3_7302", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_3_7303", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_3_7304", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_3_7305", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_3_7306", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What are the drugs used in the treatment in Pentazocine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9737132_3_7307", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What is the dosage of the treatment in Pentazocine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_3_7308", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What is the frequency of the treatment in Pentazocine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_3_7309", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What is the route of the treatment in Pentazocine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_3_7310", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "How long has elapsed from the treatment to the occurence of the event in Pentazocine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_3_7311", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "How long did the treatment last in Pentazocine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_3_7312", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What is the disorder targeted by the treatment in Pentazocine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_3_7313", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "What are the drugs used in combination in Pentazocine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_1_7314", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What are the drugs used in the treatment in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11096051_1_7315", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What is the dosage of the treatment in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_1_7316", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What is the frequency of the treatment in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11096051_1_7317", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What is the route of the treatment in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11096051_1_7318", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_1_7319", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "How long did the treatment last in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11096051_1_7320", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What is the disorder targeted by the treatment in vancomycin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11096051_1_7321", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "What are the drugs used in combination in vancomycin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_3_7322", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the age of the subject in a patient with hepatitis C?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17823522_3_7323", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the gender of the subject in a patient with hepatitis C?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17823522_3_7324", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the number of subjects in a patient with hepatitis C?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17823522_3_7325", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the race of the subject in a patient with hepatitis C?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17823522_3_7326", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the disorder of the subject in a patient with hepatitis C?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17823522_3_7327", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What are the drugs used in the treatment in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17823522_3_7328", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the dosage of the treatment in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_3_7329", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the frequency of the treatment in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_3_7330", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the route of the treatment in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_3_7331", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "How long has elapsed from the treatment to the occurence of the event in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_3_7332", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "How long did the treatment last in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_3_7333", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What is the disorder targeted by the treatment in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_3_7334", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "What are the drugs used in combination in systemic treatment with interferon alpha and ribavirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6810714_1_7335", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the age of the subject in a woman with chronic schizophrenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6810714_1_7336", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the gender of the subject in a woman with chronic schizophrenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6810714_1_7337", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the number of subjects in a woman with chronic schizophrenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6810714_1_7338", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the race of the subject in a woman with chronic schizophrenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6810714_1_7339", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the disorder of the subject in a woman with chronic schizophrenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6810714_1_7340", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What are the drugs used in the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6810714_1_7341", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the dosage of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6810714_1_7342", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the frequency of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6810714_1_7343", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the route of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6810714_1_7344", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6810714_1_7345", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "How long did the treatment last in propranolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6810714_1_7346", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What is the disorder targeted by the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6810714_1_7347", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "What are the drugs used in combination in propranolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_2_7348", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the age of the subject in an infant with complex congenital heart disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16132305_2_7349", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the gender of the subject in an infant with complex congenital heart disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_2_7350", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the number of subjects in an infant with complex congenital heart disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_2_7351", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the race of the subject in an infant with complex congenital heart disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_2_7352", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the disorder of the subject in an infant with complex congenital heart disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16132305_2_7353", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What are the drugs used in the treatment in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16132305_2_7354", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the dosage of the treatment in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_2_7355", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the frequency of the treatment in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_2_7356", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the route of the treatment in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_2_7357", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "How long has elapsed from the treatment to the occurence of the event in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_2_7358", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "How long did the treatment last in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_2_7359", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What is the disorder targeted by the treatment in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_2_7360", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "What are the drugs used in combination in captopril for afterload reduction following cardiac surgery?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_1_7361", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What are the drugs used in the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3084231_1_7362", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What is the dosage of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_1_7363", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What is the frequency of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_1_7364", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What is the route of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_1_7365", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "How long has elapsed from the treatment to the occurence of the event in valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_1_7366", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "How long did the treatment last in valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_1_7367", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What is the disorder targeted by the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_1_7368", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "What are the drugs used in combination in valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19583682_3_7369", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19583682_3_7370", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19583682_3_7371", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19583682_3_7372", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19583682_3_7373", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19583682_3_7374", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What are the drugs used in the treatment in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19583682_3_7375", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the dosage of the treatment in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19583682_3_7376", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the frequency of the treatment in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19583682_3_7377", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the route of the treatment in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19583682_3_7378", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "How long has elapsed from the treatment to the occurence of the event in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19583682_3_7379", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "How long did the treatment last in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19583682_3_7380", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What is the disorder targeted by the treatment in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19583682_3_7381", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "What are the drugs used in combination in pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_1_7382", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What are the drugs used in the treatment in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12218252_1_7383", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What is the dosage of the treatment in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_1_7384", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What is the frequency of the treatment in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_1_7385", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What is the route of the treatment in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_1_7386", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_1_7387", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "How long did the treatment last in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_1_7388", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What is the disorder targeted by the treatment in cyclosporina withdrawal?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_1_7389", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "What are the drugs used in combination in cyclosporina withdrawal?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_1_7390", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the age of the subject in A 36-y-o patient with schizophrenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10592946_1_7391", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the gender of the subject in A 36-y-o patient with schizophrenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_1_7392", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the number of subjects in A 36-y-o patient with schizophrenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_1_7393", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the race of the subject in A 36-y-o patient with schizophrenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_1_7394", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the disorder of the subject in A 36-y-o patient with schizophrenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10592946_1_7395", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What are the drugs used in the treatment in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_1_7396", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the dosage of the treatment in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_1_7397", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the frequency of the treatment in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_1_7398", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the route of the treatment in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_1_7399", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "How long has elapsed from the treatment to the occurence of the event in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_1_7400", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "How long did the treatment last in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_1_7401", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What is the disorder targeted by the treatment in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_1_7402", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "What are the drugs used in combination in gradually increasing quantities of oolong tea that eventually reached 15 L each day,?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_1_7403", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the age of the subject in a neonate?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3242521_1_7404", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the gender of the subject in a neonate?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_1_7405", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the number of subjects in a neonate?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_1_7406", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the race of the subject in a neonate?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_1_7407", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the disorder of the subject in a neonate?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3242521_1_7408", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What are the drugs used in the treatment in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3242521_1_7409", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the dosage of the treatment in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_1_7410", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the frequency of the treatment in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_1_7411", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the route of the treatment in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3242521_1_7412", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "How long has elapsed from the treatment to the occurence of the event in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_1_7413", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "How long did the treatment last in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_1_7414", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What is the disorder targeted by the treatment in Intraventricular nafcillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_1_7415", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "What are the drugs used in combination in Intraventricular nafcillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_4_7416", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What are the drugs used in the treatment in cephalosporin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_4_7417", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What is the dosage of the treatment in cephalosporin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_4_7418", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What is the frequency of the treatment in cephalosporin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_4_7419", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What is the route of the treatment in cephalosporin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_4_7420", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "How long has elapsed from the treatment to the occurence of the event in cephalosporin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_4_7421", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "How long did the treatment last in cephalosporin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_4_7422", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What is the disorder targeted by the treatment in cephalosporin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_4_7423", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "What are the drugs used in combination in cephalosporin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_2_7424", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What are the drugs used in the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_2_7425", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What is the dosage of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_2_7426", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What is the frequency of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_2_7427", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What is the route of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_2_7428", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "How long has elapsed from the treatment to the occurence of the event in thiabendazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_2_7429", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "How long did the treatment last in thiabendazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_2_7430", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What is the disorder targeted by the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_2_7431", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "What are the drugs used in combination in thiabendazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_3_7432", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_3_7433", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_3_7434", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_3_7435", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_3_7436", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_3_7437", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What are the drugs used in the treatment in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "748238_3_7438", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the dosage of the treatment in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_3_7439", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the frequency of the treatment in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_3_7440", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the route of the treatment in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_3_7441", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_3_7442", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "How long did the treatment last in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_3_7443", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What is the disorder targeted by the treatment in diphenylhydantoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_3_7444", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "What are the drugs used in combination in diphenylhydantoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_3_7445", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What are the drugs used in the treatment in Moxalactam?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_3_7446", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What is the dosage of the treatment in Moxalactam?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_3_7447", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What is the frequency of the treatment in Moxalactam?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_3_7448", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What is the route of the treatment in Moxalactam?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_3_7449", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "How long has elapsed from the treatment to the occurence of the event in Moxalactam?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_3_7450", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "How long did the treatment last in Moxalactam?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_3_7451", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What is the disorder targeted by the treatment in Moxalactam?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_3_7452", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "What are the drugs used in combination in Moxalactam?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_2_7453", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the age of the subject in all three AIDS patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_2_7454", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the gender of the subject in all three AIDS patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_2_7455", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the number of subjects in all three AIDS patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_2_7456", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the race of the subject in all three AIDS patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_2_7457", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the disorder of the subject in all three AIDS patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_2_7458", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What are the drugs used in the treatment in ddI?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_2_7459", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the dosage of the treatment in ddI?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_2_7460", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the frequency of the treatment in ddI?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_2_7461", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the route of the treatment in ddI?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_2_7462", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "How long has elapsed from the treatment to the occurence of the event in ddI?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_2_7463", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "How long did the treatment last in ddI?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_2_7464", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What is the disorder targeted by the treatment in ddI?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_2_7465", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "What are the drugs used in combination in ddI?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_3_7466", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the age of the subject in Two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_3_7467", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the gender of the subject in Two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_3_7468", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the number of subjects in Two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_3_7469", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the race of the subject in Two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_3_7470", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the disorder of the subject in Two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_3_7471", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What are the drugs used in the treatment in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_3_7472", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the dosage of the treatment in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_3_7473", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the frequency of the treatment in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_3_7474", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the route of the treatment in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_3_7475", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_3_7476", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "How long did the treatment last in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_3_7477", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What is the disorder targeted by the treatment in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_3_7478", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "What are the drugs used in combination in warfarin for stroke prophylaxis in association with chronic atrial fibrillation?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_2_7479", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the age of the subject in A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_2_7480", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the gender of the subject in A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_2_7481", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the number of subjects in A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_2_7482", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the race of the subject in A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_2_7483", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the disorder of the subject in A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_2_7484", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What are the drugs used in the treatment in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16288069_2_7485", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the dosage of the treatment in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_2_7486", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the frequency of the treatment in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_2_7487", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the route of the treatment in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_2_7488", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "How long has elapsed from the treatment to the occurence of the event in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_2_7489", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "How long did the treatment last in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_2_7490", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What is the disorder targeted by the treatment in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_2_7491", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "What are the drugs used in combination in an initial intravenous dose of penicillin G?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_6_7492", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the age of the subject in The second patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_6_7493", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the gender of the subject in The second patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_6_7494", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the number of subjects in The second patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_6_7495", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the race of the subject in The second patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_6_7496", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the disorder of the subject in The second patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_6_7497", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What are the drugs used in the treatment in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_6_7498", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the dosage of the treatment in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_6_7499", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the frequency of the treatment in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_6_7500", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the route of the treatment in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_6_7501", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_6_7502", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "How long did the treatment last in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_6_7503", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What is the disorder targeted by the treatment in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_6_7504", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "What are the drugs used in combination in 50 months of IFN-beta therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_3_7505", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3156465_3_7506", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3156465_3_7507", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3156465_3_7508", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3156465_3_7509", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3156465_3_7510", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What are the drugs used in the treatment in isotretinoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_3_7511", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the dosage of the treatment in isotretinoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_3_7512", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the frequency of the treatment in isotretinoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_3_7513", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the route of the treatment in isotretinoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_3_7514", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "How long has elapsed from the treatment to the occurence of the event in isotretinoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_3_7515", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "How long did the treatment last in isotretinoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_3_7516", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What is the disorder targeted by the treatment in isotretinoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_3_7517", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "What are the drugs used in combination in isotretinoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "13680140_1_7518", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What are the drugs used in the treatment in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "13680140_1_7519", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What is the dosage of the treatment in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "13680140_1_7520", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What is the frequency of the treatment in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "13680140_1_7521", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What is the route of the treatment in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "13680140_1_7522", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "13680140_1_7523", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "How long did the treatment last in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "13680140_1_7524", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What is the disorder targeted by the treatment in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "13680140_1_7525", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "What are the drugs used in combination in long-term oral isotretinoin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_1_7526", "context": "A case of priapism associated with trazodone is described.", "question": "What is the age of the subject in A case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6725214_1_7527", "context": "A case of priapism associated with trazodone is described.", "question": "What is the gender of the subject in A case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6725214_1_7528", "context": "A case of priapism associated with trazodone is described.", "question": "What is the number of subjects in A case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6725214_1_7529", "context": "A case of priapism associated with trazodone is described.", "question": "What is the race of the subject in A case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6725214_1_7530", "context": "A case of priapism associated with trazodone is described.", "question": "What is the disorder of the subject in A case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6725214_1_7531", "context": "A case of priapism associated with trazodone is described.", "question": "What are the drugs used in the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6725214_1_7532", "context": "A case of priapism associated with trazodone is described.", "question": "What is the dosage of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_1_7533", "context": "A case of priapism associated with trazodone is described.", "question": "What is the frequency of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_1_7534", "context": "A case of priapism associated with trazodone is described.", "question": "What is the route of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_1_7535", "context": "A case of priapism associated with trazodone is described.", "question": "How long has elapsed from the treatment to the occurence of the event in trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_1_7536", "context": "A case of priapism associated with trazodone is described.", "question": "How long did the treatment last in trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_1_7537", "context": "A case of priapism associated with trazodone is described.", "question": "What is the disorder targeted by the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_1_7538", "context": "A case of priapism associated with trazodone is described.", "question": "What are the drugs used in combination in trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_1_7539", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What are the drugs used in the treatment in infliximab infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16678268_1_7540", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What is the dosage of the treatment in infliximab infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_1_7541", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What is the frequency of the treatment in infliximab infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_1_7542", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What is the route of the treatment in infliximab infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16678268_1_7543", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16678268_1_7544", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "How long did the treatment last in infliximab infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_1_7545", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What is the disorder targeted by the treatment in infliximab infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16678268_1_7546", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "What are the drugs used in combination in infliximab infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_3_7547", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What are the drugs used in the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6693840_3_7548", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What is the dosage of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_3_7549", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What is the frequency of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_3_7550", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What is the route of the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_3_7551", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "How long has elapsed from the treatment to the occurence of the event in theophylline?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_3_7552", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "How long did the treatment last in theophylline?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_3_7553", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What is the disorder targeted by the treatment in theophylline?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_3_7554", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "What are the drugs used in combination in theophylline?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_5_7555", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the age of the subject in a patient with an underlying vascular malformation?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_5_7556", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the gender of the subject in a patient with an underlying vascular malformation?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_5_7557", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the number of subjects in a patient with an underlying vascular malformation?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_5_7558", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the race of the subject in a patient with an underlying vascular malformation?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_5_7559", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the disorder of the subject in a patient with an underlying vascular malformation?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_5_7560", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What are the drugs used in the treatment in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_5_7561", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the dosage of the treatment in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_5_7562", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the frequency of the treatment in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_5_7563", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the route of the treatment in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_5_7564", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "How long has elapsed from the treatment to the occurence of the event in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_5_7565", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "How long did the treatment last in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_5_7566", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What is the disorder targeted by the treatment in pseudoephedrine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_5_7567", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "What are the drugs used in combination in pseudoephedrine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6651138_1_7568", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the age of the subject in A 58-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6651138_1_7569", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the gender of the subject in A 58-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6651138_1_7570", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the number of subjects in A 58-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6651138_1_7571", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the race of the subject in A 58-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6651138_1_7572", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the disorder of the subject in A 58-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6651138_1_7573", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What are the drugs used in the treatment in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6651138_1_7574", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the dosage of the treatment in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6651138_1_7575", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the frequency of the treatment in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6651138_1_7576", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the route of the treatment in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6651138_1_7577", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "How long has elapsed from the treatment to the occurence of the event in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6651138_1_7578", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "How long did the treatment last in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6651138_1_7579", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What is the disorder targeted by the treatment in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6651138_1_7580", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "What are the drugs used in combination in transdermal scopolamine delivery system (TRANSDERM-V)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_2_7581", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the age of the subject in a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12218252_2_7582", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the gender of the subject in a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12218252_2_7583", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the number of subjects in a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12218252_2_7584", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the race of the subject in a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12218252_2_7585", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the disorder of the subject in a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12218252_2_7586", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What are the drugs used in the treatment in cyclosporin A?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12218252_2_7587", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the dosage of the treatment in cyclosporin A?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_2_7588", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the frequency of the treatment in cyclosporin A?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_2_7589", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the route of the treatment in cyclosporin A?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_2_7590", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporin A?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_2_7591", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "How long did the treatment last in cyclosporin A?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_2_7592", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What is the disorder targeted by the treatment in cyclosporin A?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_2_7593", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "What are the drugs used in combination in cyclosporin A?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_2_7594", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the age of the subject in she?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8726608_2_7595", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the gender of the subject in she?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8726608_2_7596", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the number of subjects in she?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8726608_2_7597", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the race of the subject in she?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8726608_2_7598", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the disorder of the subject in she?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8726608_2_7599", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What are the drugs used in the treatment in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8726608_2_7600", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the dosage of the treatment in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_2_7601", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the frequency of the treatment in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_2_7602", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the route of the treatment in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_2_7603", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_2_7604", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "How long did the treatment last in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_2_7605", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What is the disorder targeted by the treatment in Six days after starting acyclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_2_7606", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "What are the drugs used in combination in Six days after starting acyclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_1_7607", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What are the drugs used in the treatment in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11197767_1_7608", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What is the dosage of the treatment in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_1_7609", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What is the frequency of the treatment in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_1_7610", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What is the route of the treatment in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_1_7611", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "How long has elapsed from the treatment to the occurence of the event in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_1_7612", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "How long did the treatment last in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_1_7613", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What is the disorder targeted by the treatment in cadmium and zinc?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_1_7614", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "What are the drugs used in combination in cadmium and zinc?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2717661_1_7615", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2717661_1_7616", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What is the dosage of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2717661_1_7617", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What is the frequency of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2717661_1_7618", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What is the route of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2717661_1_7619", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2717661_1_7620", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "How long did the treatment last in lithium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2717661_1_7621", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2717661_1_7622", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "What are the drugs used in combination in lithium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_5_7623", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the age of the subject in One patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_5_7624", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the gender of the subject in One patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_5_7625", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the number of subjects in One patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "589261_5_7626", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the race of the subject in One patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_5_7627", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the disorder of the subject in One patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_5_7628", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What are the drugs used in the treatment in ouabain?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "589261_5_7629", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the dosage of the treatment in ouabain?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_5_7630", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the frequency of the treatment in ouabain?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_5_7631", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the route of the treatment in ouabain?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_5_7632", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in ouabain?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_5_7633", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "How long did the treatment last in ouabain?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_5_7634", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What is the disorder targeted by the treatment in ouabain?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_5_7635", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "What are the drugs used in combination in ouabain?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_3_7636", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What are the drugs used in the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15863610_3_7637", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What is the dosage of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_3_7638", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What is the frequency of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_3_7639", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What is the route of the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_3_7640", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "How long has elapsed from the treatment to the occurence of the event in tamoxifen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_3_7641", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "How long did the treatment last in tamoxifen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_3_7642", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What is the disorder targeted by the treatment in tamoxifen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_3_7643", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "What are the drugs used in combination in tamoxifen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_2_7644", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What are the drugs used in the treatment in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6794018_2_7645", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What is the dosage of the treatment in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_2_7646", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What is the frequency of the treatment in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_2_7647", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What is the route of the treatment in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_2_7648", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_2_7649", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "How long did the treatment last in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_2_7650", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What is the disorder targeted by the treatment in glibenclamide therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_2_7651", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "What are the drugs used in combination in glibenclamide therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_1_7652", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the age of the subject in painful diabetic neuropathy patients?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_1_7653", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the gender of the subject in painful diabetic neuropathy patients?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_1_7654", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the number of subjects in painful diabetic neuropathy patients?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18262450_1_7655", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the race of the subject in painful diabetic neuropathy patients?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_1_7656", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the disorder of the subject in painful diabetic neuropathy patients?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_1_7657", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What are the drugs used in the treatment in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_1_7658", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the dosage of the treatment in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_1_7659", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the frequency of the treatment in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_1_7660", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the route of the treatment in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_1_7661", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "How long has elapsed from the treatment to the occurence of the event in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_1_7662", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "How long did the treatment last in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_1_7663", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What is the disorder targeted by the treatment in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_1_7664", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "What are the drugs used in combination in Prolonged-release oxycodone?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14742791_3_7665", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What are the drugs used in the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_3_7666", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What is the dosage of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_3_7667", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What is the frequency of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_3_7668", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What is the route of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_3_7669", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "How long has elapsed from the treatment to the occurence of the event in pantoprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_3_7670", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "How long did the treatment last in pantoprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_3_7671", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What is the disorder targeted by the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_3_7672", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "What are the drugs used in combination in pantoprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_2_7673", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the age of the subject in a patient of organic bipolar affective disorder?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19555801_2_7674", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the gender of the subject in a patient of organic bipolar affective disorder?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19555801_2_7675", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the number of subjects in a patient of organic bipolar affective disorder?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19555801_2_7676", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the race of the subject in a patient of organic bipolar affective disorder?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19555801_2_7677", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the disorder of the subject in a patient of organic bipolar affective disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19555801_2_7678", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What are the drugs used in the treatment in aripiprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19555801_2_7679", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the dosage of the treatment in aripiprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_2_7680", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the frequency of the treatment in aripiprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_2_7681", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the route of the treatment in aripiprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_2_7682", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "How long has elapsed from the treatment to the occurence of the event in aripiprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_2_7683", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "How long did the treatment last in aripiprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_2_7684", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What is the disorder targeted by the treatment in aripiprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19555801_2_7685", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "What are the drugs used in combination in aripiprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_2_7686", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the age of the subject in A 28 year-old man with chronic hepatitis B?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10682234_2_7687", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the gender of the subject in A 28 year-old man with chronic hepatitis B?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10682234_2_7688", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the number of subjects in A 28 year-old man with chronic hepatitis B?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10682234_2_7689", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the race of the subject in A 28 year-old man with chronic hepatitis B?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10682234_2_7690", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the disorder of the subject in A 28 year-old man with chronic hepatitis B?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10682234_2_7691", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What are the drugs used in the treatment in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_2_7692", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the dosage of the treatment in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_2_7693", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the frequency of the treatment in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_2_7694", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the route of the treatment in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_2_7695", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_2_7696", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "How long did the treatment last in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_2_7697", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What is the disorder targeted by the treatment in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_2_7698", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "What are the drugs used in combination in interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21330680_2_7699", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21330680_2_7700", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21330680_2_7701", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_2_7702", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_2_7703", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_2_7704", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What are the drugs used in the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21330680_2_7705", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the dosage of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21330680_2_7706", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the frequency of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_2_7707", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the route of the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_2_7708", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_2_7709", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "How long did the treatment last in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_2_7710", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What is the disorder targeted by the treatment in high-dosage olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_2_7711", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "What are the drugs used in combination in high-dosage olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_1_7712", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the age of the subject in A 65-year-old woman with bipolar disorder and complicated cardiovascular disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4066620_1_7713", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the gender of the subject in A 65-year-old woman with bipolar disorder and complicated cardiovascular disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4066620_1_7714", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the number of subjects in A 65-year-old woman with bipolar disorder and complicated cardiovascular disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4066620_1_7715", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the race of the subject in A 65-year-old woman with bipolar disorder and complicated cardiovascular disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4066620_1_7716", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the disorder of the subject in A 65-year-old woman with bipolar disorder and complicated cardiovascular disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4066620_1_7717", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What are the drugs used in the treatment in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4066620_1_7718", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the dosage of the treatment in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_1_7719", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the frequency of the treatment in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_1_7720", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the route of the treatment in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_1_7721", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "How long has elapsed from the treatment to the occurence of the event in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_1_7722", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "How long did the treatment last in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_1_7723", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What is the disorder targeted by the treatment in high doses of trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_1_7724", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "What are the drugs used in combination in high doses of trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19354059_1_7725", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19354059_1_7726", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19354059_1_7727", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19354059_1_7728", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19354059_1_7729", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19354059_1_7730", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19354059_1_7731", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19354059_1_7732", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_2_7733", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18166746_2_7734", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18166746_2_7735", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18166746_2_7736", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18166746_2_7737", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18166746_2_7738", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What are the drugs used in the treatment in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_2_7739", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the dosage of the treatment in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_2_7740", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the frequency of the treatment in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_2_7741", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the route of the treatment in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_2_7742", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "How long has elapsed from the treatment to the occurence of the event in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_2_7743", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "How long did the treatment last in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_2_7744", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What is the disorder targeted by the treatment in methylene blue infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_2_7745", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "What are the drugs used in combination in methylene blue infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15571949_2_7746", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the age of the subject in children?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15571949_2_7747", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the gender of the subject in children?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15571949_2_7748", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the number of subjects in children?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15571949_2_7749", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the race of the subject in children?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15571949_2_7750", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the disorder of the subject in children?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15571949_2_7751", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What are the drugs used in the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15571949_2_7752", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the dosage of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_2_7753", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the frequency of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_2_7754", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the route of the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_2_7755", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "How long has elapsed from the treatment to the occurence of the event in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15571949_2_7756", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "How long did the treatment last in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_2_7757", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What is the disorder targeted by the treatment in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_2_7758", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "What are the drugs used in combination in intensive chemotherapy containing busulfan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_3_7759", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What are the drugs used in the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_3_7760", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What is the dosage of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_3_7761", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What is the frequency of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_3_7762", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What is the route of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_3_7763", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "How long has elapsed from the treatment to the occurence of the event in ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_3_7764", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "How long did the treatment last in ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_3_7765", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What is the disorder targeted by the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_3_7766", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "What are the drugs used in combination in ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_1_7767", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What are the drugs used in the treatment in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21630612_1_7768", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What is the dosage of the treatment in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_1_7769", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What is the frequency of the treatment in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_1_7770", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What is the route of the treatment in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_1_7771", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_1_7772", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "How long did the treatment last in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_1_7773", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What is the disorder targeted by the treatment in simvastatin and amiodarone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_1_7774", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "What are the drugs used in combination in simvastatin and amiodarone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_10_7775", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What are the drugs used in the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_10_7776", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What is the dosage of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_10_7777", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What is the frequency of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_10_7778", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What is the route of the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_10_7779", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "How long has elapsed from the treatment to the occurence of the event in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_10_7780", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "How long did the treatment last in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_10_7781", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What is the disorder targeted by the treatment in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_10_7782", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "What are the drugs used in combination in clindamycin phosphate vaginal cream?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_2_7783", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_2_7784", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_2_7785", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_2_7786", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_2_7787", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_2_7788", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_2_7789", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_2_7790", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_3_7791", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the age of the subject in a patient with spinal cord astrocytoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_3_7792", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the gender of the subject in a patient with spinal cord astrocytoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_3_7793", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the number of subjects in a patient with spinal cord astrocytoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_3_7794", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the race of the subject in a patient with spinal cord astrocytoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_3_7795", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the disorder of the subject in a patient with spinal cord astrocytoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_3_7796", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What are the drugs used in the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_3_7797", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the dosage of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_3_7798", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the frequency of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_3_7799", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the route of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_3_7800", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "How long has elapsed from the treatment to the occurence of the event in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_3_7801", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "How long did the treatment last in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_3_7802", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What is the disorder targeted by the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_3_7803", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "What are the drugs used in combination in a single dose of vincristine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_5_7804", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What are the drugs used in the treatment in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_5_7805", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What is the dosage of the treatment in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_5_7806", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What is the frequency of the treatment in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_5_7807", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What is the route of the treatment in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_5_7808", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "How long has elapsed from the treatment to the occurence of the event in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_5_7809", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "How long did the treatment last in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_5_7810", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What is the disorder targeted by the treatment in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_5_7811", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "What are the drugs used in combination in Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7761316_1_7812", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the age of the subject in four of 44 children (9%)?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7761316_1_7813", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the gender of the subject in four of 44 children (9%)?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_1_7814", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the number of subjects in four of 44 children (9%)?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7761316_1_7815", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the race of the subject in four of 44 children (9%)?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_1_7816", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the disorder of the subject in four of 44 children (9%)?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_1_7817", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What are the drugs used in the treatment in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7761316_1_7818", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the dosage of the treatment in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_1_7819", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the frequency of the treatment in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_1_7820", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the route of the treatment in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_1_7821", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "How long has elapsed from the treatment to the occurence of the event in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_1_7822", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "How long did the treatment last in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_1_7823", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What is the disorder targeted by the treatment in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7761316_1_7824", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "What are the drugs used in combination in ifosfamide, a derivative of cyclophosphamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_1_7825", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What are the drugs used in the treatment in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_1_7826", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What is the dosage of the treatment in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_1_7827", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What is the frequency of the treatment in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_1_7828", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What is the route of the treatment in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_1_7829", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_1_7830", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "How long did the treatment last in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_1_7831", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What is the disorder targeted by the treatment in warfarin-like anticoagulant?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_1_7832", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "What are the drugs used in combination in warfarin-like anticoagulant?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_2_7833", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What are the drugs used in the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_2_7834", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What is the dosage of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_2_7835", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What is the frequency of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_2_7836", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What is the route of the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_2_7837", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "How long has elapsed from the treatment to the occurence of the event in Gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_2_7838", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "How long did the treatment last in Gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_2_7839", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What is the disorder targeted by the treatment in Gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_2_7840", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "What are the drugs used in combination in Gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_1_7841", "context": "A paradoxical ocular effect of brimonidine.", "question": "What are the drugs used in the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_1_7842", "context": "A paradoxical ocular effect of brimonidine.", "question": "What is the dosage of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_1_7843", "context": "A paradoxical ocular effect of brimonidine.", "question": "What is the frequency of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_1_7844", "context": "A paradoxical ocular effect of brimonidine.", "question": "What is the route of the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_1_7845", "context": "A paradoxical ocular effect of brimonidine.", "question": "How long has elapsed from the treatment to the occurence of the event in brimonidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_1_7846", "context": "A paradoxical ocular effect of brimonidine.", "question": "How long did the treatment last in brimonidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_1_7847", "context": "A paradoxical ocular effect of brimonidine.", "question": "What is the disorder targeted by the treatment in brimonidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_1_7848", "context": "A paradoxical ocular effect of brimonidine.", "question": "What are the drugs used in combination in brimonidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_1_7849", "context": "Fixed drug eruption to rofecoxib.", "question": "What are the drugs used in the treatment in rofecoxib?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12234159_1_7850", "context": "Fixed drug eruption to rofecoxib.", "question": "What is the dosage of the treatment in rofecoxib?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_1_7851", "context": "Fixed drug eruption to rofecoxib.", "question": "What is the frequency of the treatment in rofecoxib?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_1_7852", "context": "Fixed drug eruption to rofecoxib.", "question": "What is the route of the treatment in rofecoxib?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_1_7853", "context": "Fixed drug eruption to rofecoxib.", "question": "How long has elapsed from the treatment to the occurence of the event in rofecoxib?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_1_7854", "context": "Fixed drug eruption to rofecoxib.", "question": "How long did the treatment last in rofecoxib?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_1_7855", "context": "Fixed drug eruption to rofecoxib.", "question": "What is the disorder targeted by the treatment in rofecoxib?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12234159_1_7856", "context": "Fixed drug eruption to rofecoxib.", "question": "What are the drugs used in combination in rofecoxib?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_8_7857", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9533061_8_7858", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9533061_8_7859", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_8_7860", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9533061_8_7861", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9533061_8_7862", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What are the drugs used in the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9533061_8_7863", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the dosage of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_8_7864", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the frequency of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_8_7865", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the route of the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9533061_8_7866", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "How long has elapsed from the treatment to the occurence of the event in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_8_7867", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "How long did the treatment last in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_8_7868", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What is the disorder targeted by the treatment in clindamycin vaginal cream?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_8_7869", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "What are the drugs used in combination in clindamycin vaginal cream?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_1_7870", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What are the drugs used in the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14742791_1_7871", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What is the dosage of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_1_7872", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What is the frequency of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_1_7873", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What is the route of the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_1_7874", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "How long has elapsed from the treatment to the occurence of the event in pantoprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_1_7875", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "How long did the treatment last in pantoprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_1_7876", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What is the disorder targeted by the treatment in pantoprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_1_7877", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "What are the drugs used in combination in pantoprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_3_7878", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What are the drugs used in the treatment in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16515630_3_7879", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What is the dosage of the treatment in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_3_7880", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What is the frequency of the treatment in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_3_7881", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What is the route of the treatment in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_3_7882", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_3_7883", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "How long did the treatment last in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_3_7884", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What is the disorder targeted by the treatment in taxanes such as paclitaxel?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_3_7885", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "What are the drugs used in combination in taxanes such as paclitaxel?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1238016_1_7886", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the age of the subject in Infant twins?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1238016_1_7887", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the gender of the subject in Infant twins?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1238016_1_7888", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the number of subjects in Infant twins?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1238016_1_7889", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the race of the subject in Infant twins?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1238016_1_7890", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the disorder of the subject in Infant twins?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1238016_1_7891", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What are the drugs used in the treatment in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1238016_1_7892", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the dosage of the treatment in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1238016_1_7893", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the frequency of the treatment in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1238016_1_7894", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the route of the treatment in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1238016_1_7895", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "How long has elapsed from the treatment to the occurence of the event in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1238016_1_7896", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "How long did the treatment last in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1238016_1_7897", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What is the disorder targeted by the treatment in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1238016_1_7898", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "What are the drugs used in combination in a concentrated solution of benzalkonium (Zephiran) chloride?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_2_7899", "context": "Isotretinoin teratogenicity.", "question": "What are the drugs used in the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_2_7900", "context": "Isotretinoin teratogenicity.", "question": "What is the dosage of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_2_7901", "context": "Isotretinoin teratogenicity.", "question": "What is the frequency of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_2_7902", "context": "Isotretinoin teratogenicity.", "question": "What is the route of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_2_7903", "context": "Isotretinoin teratogenicity.", "question": "How long has elapsed from the treatment to the occurence of the event in Isotretinoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_2_7904", "context": "Isotretinoin teratogenicity.", "question": "How long did the treatment last in Isotretinoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_2_7905", "context": "Isotretinoin teratogenicity.", "question": "What is the disorder targeted by the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_2_7906", "context": "Isotretinoin teratogenicity.", "question": "What are the drugs used in combination in Isotretinoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_1_7907", "context": "Hepatitis following cimetidine administration.", "question": "What are the drugs used in the treatment in cimetidine administration?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7081289_1_7908", "context": "Hepatitis following cimetidine administration.", "question": "What is the dosage of the treatment in cimetidine administration?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_1_7909", "context": "Hepatitis following cimetidine administration.", "question": "What is the frequency of the treatment in cimetidine administration?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_1_7910", "context": "Hepatitis following cimetidine administration.", "question": "What is the route of the treatment in cimetidine administration?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_1_7911", "context": "Hepatitis following cimetidine administration.", "question": "How long has elapsed from the treatment to the occurence of the event in cimetidine administration?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_1_7912", "context": "Hepatitis following cimetidine administration.", "question": "How long did the treatment last in cimetidine administration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_1_7913", "context": "Hepatitis following cimetidine administration.", "question": "What is the disorder targeted by the treatment in cimetidine administration?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_1_7914", "context": "Hepatitis following cimetidine administration.", "question": "What are the drugs used in combination in cimetidine administration?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_4_7915", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the age of the subject in an 11-month-old female infant?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10698143_4_7916", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the gender of the subject in an 11-month-old female infant?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10698143_4_7917", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the number of subjects in an 11-month-old female infant?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10698143_4_7918", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the race of the subject in an 11-month-old female infant?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10698143_4_7919", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the disorder of the subject in an 11-month-old female infant?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10698143_4_7920", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What are the drugs used in the treatment in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_4_7921", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the dosage of the treatment in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_4_7922", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the frequency of the treatment in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_4_7923", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the route of the treatment in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_4_7924", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "How long has elapsed from the treatment to the occurence of the event in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_4_7925", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "How long did the treatment last in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_4_7926", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What is the disorder targeted by the treatment in ingestion of ibuprofen?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_4_7927", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "What are the drugs used in combination in ingestion of ibuprofen?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_5_7928", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What are the drugs used in the treatment in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "17619811_5_7929", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What is the dosage of the treatment in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_5_7930", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What is the frequency of the treatment in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17619811_5_7931", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What is the route of the treatment in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17619811_5_7932", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "How long has elapsed from the treatment to the occurence of the event in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_5_7933", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "How long did the treatment last in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17619811_5_7934", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What is the disorder targeted by the treatment in colchicine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_5_7935", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "What are the drugs used in combination in colchicine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7526455_1_7936", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the age of the subject in A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7526455_1_7937", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the gender of the subject in A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7526455_1_7938", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the number of subjects in A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7526455_1_7939", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the race of the subject in A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7526455_1_7940", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the disorder of the subject in A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7526455_1_7941", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What are the drugs used in the treatment in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7526455_1_7942", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the dosage of the treatment in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7526455_1_7943", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the frequency of the treatment in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7526455_1_7944", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the route of the treatment in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7526455_1_7945", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "How long has elapsed from the treatment to the occurence of the event in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7526455_1_7946", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "How long did the treatment last in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7526455_1_7947", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What is the disorder targeted by the treatment in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7526455_1_7948", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "What are the drugs used in combination in 15 days of initiation of flecainide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_11_7949", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What are the drugs used in the treatment in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15522120_11_7950", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What is the dosage of the treatment in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_11_7951", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What is the frequency of the treatment in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_11_7952", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What is the route of the treatment in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_11_7953", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "How long has elapsed from the treatment to the occurence of the event in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_11_7954", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "How long did the treatment last in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_11_7955", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What is the disorder targeted by the treatment in sertraline medication?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_11_7956", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "What are the drugs used in combination in sertraline medication?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8589490_1_7957", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What are the drugs used in the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8589490_1_7958", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What is the dosage of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_1_7959", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What is the frequency of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_1_7960", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What is the route of the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_1_7961", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "How long has elapsed from the treatment to the occurence of the event in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_1_7962", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "How long did the treatment last in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_1_7963", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What is the disorder targeted by the treatment in CHOP chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_1_7964", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "What are the drugs used in combination in CHOP chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11105373_1_7965", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "What is the age of the subject in A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11105373_1_7966", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "What is the gender of the subject in A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11105373_1_7967", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "What is the number of subjects in A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11105373_1_7968", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "What is the race of the subject in A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11105373_1_7969", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "What is the disorder of the subject in A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 33-year-old male; A 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2241449_3_7970", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the age of the subject in patients with acquired immunodeficiency syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2241449_3_7971", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the gender of the subject in patients with acquired immunodeficiency syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2241449_3_7972", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the number of subjects in patients with acquired immunodeficiency syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2241449_3_7973", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the race of the subject in patients with acquired immunodeficiency syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2241449_3_7974", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the disorder of the subject in patients with acquired immunodeficiency syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2241449_3_7975", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What are the drugs used in the treatment in sulfadiazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2241449_3_7976", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the dosage of the treatment in sulfadiazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_3_7977", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the frequency of the treatment in sulfadiazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_3_7978", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the route of the treatment in sulfadiazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_3_7979", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "How long has elapsed from the treatment to the occurence of the event in sulfadiazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_3_7980", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "How long did the treatment last in sulfadiazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_3_7981", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What is the disorder targeted by the treatment in sulfadiazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_3_7982", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "What are the drugs used in combination in sulfadiazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_2_7983", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What are the drugs used in the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_2_7984", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What is the dosage of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_2_7985", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What is the frequency of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_2_7986", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What is the route of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_2_7987", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "How long has elapsed from the treatment to the occurence of the event in calcium stearate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_2_7988", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "How long did the treatment last in calcium stearate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_2_7989", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What is the disorder targeted by the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_2_7990", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "What are the drugs used in combination in calcium stearate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_1_7991", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11563738_1_7992", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_1_7993", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11563738_1_7994", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11563738_1_7995", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_1_7996", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11563738_1_7997", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11563738_1_7998", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2719905_1_7999", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What are the drugs used in the treatment in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2719905_1_8000", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What is the dosage of the treatment in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_1_8001", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What is the frequency of the treatment in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_1_8002", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What is the route of the treatment in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2719905_1_8003", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "How long has elapsed from the treatment to the occurence of the event in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_1_8004", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "How long did the treatment last in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_1_8005", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What is the disorder targeted by the treatment in morphine-6-glucuronide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_1_8006", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "What are the drugs used in combination in morphine-6-glucuronide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "623061_1_8007", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the age of the subject in seven children, 5 years of age and younger?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "623061_1_8008", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the gender of the subject in seven children, 5 years of age and younger?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "623061_1_8009", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the number of subjects in seven children, 5 years of age and younger?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "623061_1_8010", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the race of the subject in seven children, 5 years of age and younger?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "623061_1_8011", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the disorder of the subject in seven children, 5 years of age and younger?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "623061_1_8012", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What are the drugs used in the treatment in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "623061_1_8013", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the dosage of the treatment in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "623061_1_8014", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the frequency of the treatment in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "623061_1_8015", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the route of the treatment in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "623061_1_8016", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "How long has elapsed from the treatment to the occurence of the event in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "623061_1_8017", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "How long did the treatment last in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "623061_1_8018", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What is the disorder targeted by the treatment in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "623061_1_8019", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "What are the drugs used in combination in antiemetic combination of pentobarbital and pyrilamine maleate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_1_8020", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What are the drugs used in the treatment in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_1_8021", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What is the dosage of the treatment in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_1_8022", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What is the frequency of the treatment in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_1_8023", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What is the route of the treatment in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_1_8024", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_1_8025", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "How long did the treatment last in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_1_8026", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What is the disorder targeted by the treatment in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_1_8027", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "What are the drugs used in combination in 5-fluorouracil chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18258513_1_8028", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18258513_1_8029", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18258513_1_8030", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18258513_1_8031", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18258513_1_8032", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18258513_1_8033", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What are the drugs used in the treatment in doxorubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18258513_1_8034", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the dosage of the treatment in doxorubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18258513_1_8035", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the frequency of the treatment in doxorubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18258513_1_8036", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the route of the treatment in doxorubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18258513_1_8037", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "How long has elapsed from the treatment to the occurence of the event in doxorubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18258513_1_8038", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "How long did the treatment last in doxorubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18258513_1_8039", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What is the disorder targeted by the treatment in doxorubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18258513_1_8040", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "What are the drugs used in combination in doxorubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_5_8041", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the age of the subject in An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21802143_5_8042", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the gender of the subject in An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21802143_5_8043", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the number of subjects in An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21802143_5_8044", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the race of the subject in An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21802143_5_8045", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the disorder of the subject in An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21802143_5_8046", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What are the drugs used in the treatment in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21802143_5_8047", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the dosage of the treatment in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_5_8048", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the frequency of the treatment in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21802143_5_8049", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the route of the treatment in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21802143_5_8050", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "How long has elapsed from the treatment to the occurence of the event in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_5_8051", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "How long did the treatment last in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21802143_5_8052", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What is the disorder targeted by the treatment in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21802143_5_8053", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "What are the drugs used in combination in continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10682234_1_8054", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What are the drugs used in the treatment in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_1_8055", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What is the dosage of the treatment in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_1_8056", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What is the frequency of the treatment in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_1_8057", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What is the route of the treatment in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_1_8058", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_1_8059", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "How long did the treatment last in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_1_8060", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What is the disorder targeted by the treatment in interferon-alpha?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_1_8061", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "What are the drugs used in combination in interferon-alpha?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12567347_1_8062", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the age of the subject in Patients with lymphoblastic lymphoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12567347_1_8063", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the gender of the subject in Patients with lymphoblastic lymphoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12567347_1_8064", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the number of subjects in Patients with lymphoblastic lymphoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12567347_1_8065", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the race of the subject in Patients with lymphoblastic lymphoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12567347_1_8066", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the disorder of the subject in Patients with lymphoblastic lymphoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12567347_1_8067", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What are the drugs used in the treatment in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12567347_1_8068", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the dosage of the treatment in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12567347_1_8069", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the frequency of the treatment in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12567347_1_8070", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the route of the treatment in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12567347_1_8071", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12567347_1_8072", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "How long did the treatment last in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12567347_1_8073", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What is the disorder targeted by the treatment in L-asparaginase and steroid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12567347_1_8074", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "What are the drugs used in combination in L-asparaginase and steroid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_1_8075", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the age of the subject in patients with significant risk factors for coronary artery disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7783891_1_8076", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the gender of the subject in patients with significant risk factors for coronary artery disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7783891_1_8077", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the number of subjects in patients with significant risk factors for coronary artery disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7783891_1_8078", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the race of the subject in patients with significant risk factors for coronary artery disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7783891_1_8079", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the disorder of the subject in patients with significant risk factors for coronary artery disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7783891_1_8080", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What are the drugs used in the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7783891_1_8081", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the dosage of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_1_8082", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the frequency of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_1_8083", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the route of the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_1_8084", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "How long has elapsed from the treatment to the occurence of the event in sumatriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_1_8085", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "How long did the treatment last in sumatriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_1_8086", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What is the disorder targeted by the treatment in sumatriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_1_8087", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "What are the drugs used in combination in sumatriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_2_8088", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the age of the subject in a 25-year-old man found dead at home?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11563738_2_8089", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the gender of the subject in a 25-year-old man found dead at home?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11563738_2_8090", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the number of subjects in a 25-year-old man found dead at home?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11563738_2_8091", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the race of the subject in a 25-year-old man found dead at home?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11563738_2_8092", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the disorder of the subject in a 25-year-old man found dead at home?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11563738_2_8093", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11563738_2_8094", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_2_8095", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11563738_2_8096", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11563738_2_8097", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_2_8098", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "How long did the treatment last in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11563738_2_8099", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11563738_2_8100", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7258204_1_8101", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the age of the subject in A 67-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7258204_1_8102", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the gender of the subject in A 67-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7258204_1_8103", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the number of subjects in A 67-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7258204_1_8104", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the race of the subject in A 67-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7258204_1_8105", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the disorder of the subject in A 67-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7258204_1_8106", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What are the drugs used in the treatment in oral ampicillin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7258204_1_8107", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the dosage of the treatment in oral ampicillin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7258204_1_8108", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the frequency of the treatment in oral ampicillin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7258204_1_8109", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the route of the treatment in oral ampicillin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7258204_1_8110", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "How long has elapsed from the treatment to the occurence of the event in oral ampicillin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7258204_1_8111", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "How long did the treatment last in oral ampicillin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7258204_1_8112", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What is the disorder targeted by the treatment in oral ampicillin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7258204_1_8113", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "What are the drugs used in combination in oral ampicillin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_1_8114", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What are the drugs used in the treatment in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16216617_1_8115", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What is the dosage of the treatment in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16216617_1_8116", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What is the frequency of the treatment in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_1_8117", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What is the route of the treatment in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16216617_1_8118", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "How long has elapsed from the treatment to the occurence of the event in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_1_8119", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "How long did the treatment last in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_1_8120", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What is the disorder targeted by the treatment in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_1_8121", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "What are the drugs used in combination in high-dose intravenous phenylephrine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16620273_2_8122", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16620273_2_8123", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16620273_2_8124", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16620273_2_8125", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16620273_2_8126", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16620273_2_8127", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What are the drugs used in the treatment in metformin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16620273_2_8128", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the dosage of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_2_8129", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the frequency of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_2_8130", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the route of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_2_8131", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "How long has elapsed from the treatment to the occurence of the event in metformin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_2_8132", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "How long did the treatment last in metformin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_2_8133", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What is the disorder targeted by the treatment in metformin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16620273_2_8134", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "What are the drugs used in combination in metformin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_1_8135", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the age of the subject in children with primary glomerulonephritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1868481_1_8136", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the gender of the subject in children with primary glomerulonephritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_1_8137", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the number of subjects in children with primary glomerulonephritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1868481_1_8138", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the race of the subject in children with primary glomerulonephritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_1_8139", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the disorder of the subject in children with primary glomerulonephritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_1_8140", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What are the drugs used in the treatment in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1868481_1_8141", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the dosage of the treatment in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_1_8142", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the frequency of the treatment in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_1_8143", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the route of the treatment in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1868481_1_8144", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_1_8145", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "How long did the treatment last in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_1_8146", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What is the disorder targeted by the treatment in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1868481_1_8147", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "What are the drugs used in combination in intravenous pulse methylprednisolone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_4_8148", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the age of the subject in a patient with acromegaly?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_4_8149", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the gender of the subject in a patient with acromegaly?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_4_8150", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the number of subjects in a patient with acromegaly?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_4_8151", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the race of the subject in a patient with acromegaly?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_4_8152", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the disorder of the subject in a patient with acromegaly?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_4_8153", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What are the drugs used in the treatment in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16728538_4_8154", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the dosage of the treatment in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_4_8155", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the frequency of the treatment in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_4_8156", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the route of the treatment in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_4_8157", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "How long has elapsed from the treatment to the occurence of the event in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_4_8158", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "How long did the treatment last in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_4_8159", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What is the disorder targeted by the treatment in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_4_8160", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "What are the drugs used in combination in combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_3_8161", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the age of the subject in a 23-year-old man?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20234160_3_8162", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the gender of the subject in a 23-year-old man?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20234160_3_8163", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the number of subjects in a 23-year-old man?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20234160_3_8164", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the race of the subject in a 23-year-old man?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20234160_3_8165", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the disorder of the subject in a 23-year-old man?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20234160_3_8166", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What are the drugs used in the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_3_8167", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the dosage of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_3_8168", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the frequency of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_3_8169", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the route of the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_3_8170", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "How long has elapsed from the treatment to the occurence of the event in vancomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_3_8171", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "How long did the treatment last in vancomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_3_8172", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What is the disorder targeted by the treatment in vancomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_3_8173", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "What are the drugs used in combination in vancomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_2_8174", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What are the drugs used in the treatment in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "19884751_2_8175", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What is the dosage of the treatment in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_2_8176", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What is the frequency of the treatment in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19884751_2_8177", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What is the route of the treatment in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19884751_2_8178", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "How long has elapsed from the treatment to the occurence of the event in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_2_8179", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "How long did the treatment last in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19884751_2_8180", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What is the disorder targeted by the treatment in Amikacin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_2_8181", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "What are the drugs used in combination in Amikacin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7139589_3_8182", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7139589_3_8183", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_3_8184", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_3_8185", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_3_8186", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_3_8187", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_3_8188", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_3_8189", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_3_8190", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What are the drugs used in the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15286697_3_8191", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What is the dosage of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_3_8192", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What is the frequency of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_3_8193", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What is the route of the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_3_8194", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in BCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_3_8195", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "How long did the treatment last in BCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_3_8196", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What is the disorder targeted by the treatment in BCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_3_8197", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "What are the drugs used in combination in BCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_1_8198", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the age of the subject in A 58-year-old man with advanced renal cell carcinoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19212144_1_8199", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the gender of the subject in A 58-year-old man with advanced renal cell carcinoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19212144_1_8200", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the number of subjects in A 58-year-old man with advanced renal cell carcinoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19212144_1_8201", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the race of the subject in A 58-year-old man with advanced renal cell carcinoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19212144_1_8202", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the disorder of the subject in A 58-year-old man with advanced renal cell carcinoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19212144_1_8203", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What are the drugs used in the treatment in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19212144_1_8204", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the dosage of the treatment in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_1_8205", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the frequency of the treatment in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_1_8206", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the route of the treatment in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19212144_1_8207", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19212144_1_8208", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "How long did the treatment last in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_1_8209", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What is the disorder targeted by the treatment in five days after temsirolimus infusion?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19212144_1_8210", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "What are the drugs used in combination in five days after temsirolimus infusion?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_1_8211", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the age of the subject in A 2-year-old mentally retarded boy with frontal lobe epilepsy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_1_8212", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the gender of the subject in A 2-year-old mentally retarded boy with frontal lobe epilepsy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_1_8213", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the number of subjects in A 2-year-old mentally retarded boy with frontal lobe epilepsy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_1_8214", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the race of the subject in A 2-year-old mentally retarded boy with frontal lobe epilepsy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_1_8215", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the disorder of the subject in A 2-year-old mentally retarded boy with frontal lobe epilepsy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_1_8216", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What are the drugs used in the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_1_8217", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the dosage of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_1_8218", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the frequency of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_1_8219", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the route of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_1_8220", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "How long has elapsed from the treatment to the occurence of the event in zonisamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_1_8221", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "How long did the treatment last in zonisamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_1_8222", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What is the disorder targeted by the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_1_8223", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "What are the drugs used in combination in zonisamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_1_8224", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What are the drugs used in the treatment in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_1_8225", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What is the dosage of the treatment in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_1_8226", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What is the frequency of the treatment in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_1_8227", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What is the route of the treatment in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_1_8228", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "How long has elapsed from the treatment to the occurence of the event in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_1_8229", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "How long did the treatment last in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_1_8230", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What is the disorder targeted by the treatment in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_1_8231", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "What are the drugs used in combination in methylene blue infusion during parathyroidectomy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_3_8232", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the age of the subject in Two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "868978_3_8233", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the gender of the subject in Two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "868978_3_8234", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the number of subjects in Two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "868978_3_8235", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the race of the subject in Two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "868978_3_8236", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the disorder of the subject in Two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "868978_3_8237", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What are the drugs used in the treatment in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "868978_3_8238", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the dosage of the treatment in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_3_8239", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the frequency of the treatment in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_3_8240", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the route of the treatment in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_3_8241", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_3_8242", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "How long did the treatment last in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_3_8243", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What is the disorder targeted by the treatment in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_3_8244", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "What are the drugs used in combination in 5-fluorouracil (5-FU)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_4_8245", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What are the drugs used in the treatment in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11510798_4_8246", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What is the dosage of the treatment in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_4_8247", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What is the frequency of the treatment in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11510798_4_8248", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What is the route of the treatment in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11510798_4_8249", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "How long has elapsed from the treatment to the occurence of the event in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_4_8250", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "How long did the treatment last in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11510798_4_8251", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What is the disorder targeted by the treatment in corticosteroids?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_4_8252", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "What are the drugs used in combination in corticosteroids?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9886213_1_8253", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What are the drugs used in the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9886213_1_8254", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What is the dosage of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_1_8255", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What is the frequency of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_1_8256", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What is the route of the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_1_8257", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in praziquantel?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_1_8258", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "How long did the treatment last in praziquantel?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_1_8259", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What is the disorder targeted by the treatment in praziquantel?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_1_8260", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "What are the drugs used in combination in praziquantel?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_1_8261", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What are the drugs used in the treatment in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "172214_1_8262", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What is the dosage of the treatment in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_1_8263", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What is the frequency of the treatment in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_1_8264", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What is the route of the treatment in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_1_8265", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "How long has elapsed from the treatment to the occurence of the event in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_1_8266", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "How long did the treatment last in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_1_8267", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What is the disorder targeted by the treatment in widely separated courses of adriamycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_1_8268", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "What are the drugs used in combination in widely separated courses of adriamycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_3_8269", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11485141_3_8270", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_3_8271", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_3_8272", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_3_8273", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_3_8274", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_3_8275", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_3_8276", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_12_8277", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the age of the subject in both patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_12_8278", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the gender of the subject in both patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_12_8279", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the number of subjects in both patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_12_8280", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the race of the subject in both patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_12_8281", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the disorder of the subject in both patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_12_8282", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What are the drugs used in the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_12_8283", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the dosage of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_12_8284", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the frequency of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_12_8285", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the route of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_12_8286", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "How long has elapsed from the treatment to the occurence of the event in tolterodine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_12_8287", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "How long did the treatment last in tolterodine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_12_8288", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What is the disorder targeted by the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_12_8289", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "What are the drugs used in combination in tolterodine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15461766_2_8290", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What are the drugs used in the treatment in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15461766_2_8291", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What is the dosage of the treatment in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_2_8292", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What is the frequency of the treatment in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_2_8293", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What is the route of the treatment in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_2_8294", "context": "The harlequin color change and association with prostaglandin E1.", "question": "How long has elapsed from the treatment to the occurence of the event in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_2_8295", "context": "The harlequin color change and association with prostaglandin E1.", "question": "How long did the treatment last in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_2_8296", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What is the disorder targeted by the treatment in prostaglandin E1?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15461766_2_8297", "context": "The harlequin color change and association with prostaglandin E1.", "question": "What are the drugs used in combination in prostaglandin E1?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19336028_1_8298", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19336028_1_8299", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19336028_1_8300", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19336028_1_8301", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19336028_1_8302", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19336028_1_8303", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What are the drugs used in the treatment in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19336028_1_8304", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the dosage of the treatment in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19336028_1_8305", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the frequency of the treatment in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19336028_1_8306", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the route of the treatment in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19336028_1_8307", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19336028_1_8308", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "How long did the treatment last in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19336028_1_8309", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What is the disorder targeted by the treatment in Efalizumab and Etanercept?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19336028_1_8310", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "What are the drugs used in combination in Efalizumab and Etanercept?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_1_8311", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What are the drugs used in the treatment in bupivacaine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_1_8312", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What is the dosage of the treatment in bupivacaine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_1_8313", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What is the frequency of the treatment in bupivacaine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_1_8314", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What is the route of the treatment in bupivacaine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_1_8315", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "How long has elapsed from the treatment to the occurence of the event in bupivacaine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_1_8316", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "How long did the treatment last in bupivacaine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_1_8317", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What is the disorder targeted by the treatment in bupivacaine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_1_8318", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "What are the drugs used in combination in bupivacaine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6851259_1_8319", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the age of the subject in a tolmetin-treated patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6851259_1_8320", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the gender of the subject in a tolmetin-treated patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6851259_1_8321", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the number of subjects in a tolmetin-treated patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6851259_1_8322", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the race of the subject in a tolmetin-treated patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6851259_1_8323", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the disorder of the subject in a tolmetin-treated patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6851259_1_8324", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What are the drugs used in the treatment in tolmetin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6851259_1_8325", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the dosage of the treatment in tolmetin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6851259_1_8326", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the frequency of the treatment in tolmetin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6851259_1_8327", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the route of the treatment in tolmetin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6851259_1_8328", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "How long has elapsed from the treatment to the occurence of the event in tolmetin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6851259_1_8329", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "How long did the treatment last in tolmetin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6851259_1_8330", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What is the disorder targeted by the treatment in tolmetin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6851259_1_8331", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "What are the drugs used in combination in tolmetin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_4_8332", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_4_8333", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_4_8334", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_4_8335", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_4_8336", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_4_8337", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What are the drugs used in the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_4_8338", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the dosage of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_4_8339", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the frequency of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_4_8340", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the route of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_4_8341", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_4_8342", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "How long did the treatment last in cyclosporine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_4_8343", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What is the disorder targeted by the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_4_8344", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "What are the drugs used in combination in cyclosporine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_3_8345", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_3_8346", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_3_8347", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_3_8348", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_3_8349", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_3_8350", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What are the drugs used in the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15811174_3_8351", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the dosage of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_3_8352", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the frequency of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_3_8353", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the route of the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_3_8354", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "How long has elapsed from the treatment to the occurence of the event in cerivastatin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_3_8355", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "How long did the treatment last in cerivastatin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_3_8356", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What is the disorder targeted by the treatment in cerivastatin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_3_8357", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "What are the drugs used in combination in cerivastatin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_2_8358", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the age of the subject in a patient suffering from rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8124920_2_8359", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the gender of the subject in a patient suffering from rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8124920_2_8360", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the number of subjects in a patient suffering from rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8124920_2_8361", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the race of the subject in a patient suffering from rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8124920_2_8362", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the disorder of the subject in a patient suffering from rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8124920_2_8363", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What are the drugs used in the treatment in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8124920_2_8364", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the dosage of the treatment in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8124920_2_8365", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the frequency of the treatment in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_2_8366", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the route of the treatment in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_2_8367", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "How long has elapsed from the treatment to the occurence of the event in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_2_8368", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "How long did the treatment last in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_2_8369", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What is the disorder targeted by the treatment in low-dose methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8124920_2_8370", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "What are the drugs used in combination in low-dose methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_3_8371", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the age of the subject in a 57-year-old man with acral erythrocyanosis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11109149_3_8372", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the gender of the subject in a 57-year-old man with acral erythrocyanosis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11109149_3_8373", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the number of subjects in a 57-year-old man with acral erythrocyanosis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11109149_3_8374", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the race of the subject in a 57-year-old man with acral erythrocyanosis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11109149_3_8375", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the disorder of the subject in a 57-year-old man with acral erythrocyanosis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11109149_3_8376", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What are the drugs used in the treatment in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11109149_3_8377", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the dosage of the treatment in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_3_8378", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the frequency of the treatment in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_3_8379", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the route of the treatment in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_3_8380", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "How long has elapsed from the treatment to the occurence of the event in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_3_8381", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "How long did the treatment last in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_3_8382", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What is the disorder targeted by the treatment in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_3_8383", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "What are the drugs used in combination in combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2719905_2_8384", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the age of the subject in a 7 year old girl with haemolytic uraemic syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2719905_2_8385", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the gender of the subject in a 7 year old girl with haemolytic uraemic syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2719905_2_8386", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the number of subjects in a 7 year old girl with haemolytic uraemic syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2719905_2_8387", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the race of the subject in a 7 year old girl with haemolytic uraemic syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2719905_2_8388", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the disorder of the subject in a 7 year old girl with haemolytic uraemic syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2719905_2_8389", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What are the drugs used in the treatment in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2719905_2_8390", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the dosage of the treatment in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_2_8391", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the frequency of the treatment in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_2_8392", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the route of the treatment in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2719905_2_8393", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_2_8394", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "How long did the treatment last in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_2_8395", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What is the disorder targeted by the treatment in intravenous administration of morphine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_2_8396", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "What are the drugs used in combination in intravenous administration of morphine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18071101_1_8397", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18071101_1_8398", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18071101_1_8399", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18071101_1_8400", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18071101_1_8401", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18071101_1_8402", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What are the drugs used in the treatment in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18071101_1_8403", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the dosage of the treatment in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_1_8404", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the frequency of the treatment in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_1_8405", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the route of the treatment in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_1_8406", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "How long has elapsed from the treatment to the occurence of the event in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_1_8407", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "How long did the treatment last in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_1_8408", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What is the disorder targeted by the treatment in quetiapine treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_1_8409", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "What are the drugs used in combination in quetiapine treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3720318_1_8410", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What are the drugs used in the treatment in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3720318_1_8411", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What is the dosage of the treatment in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_1_8412", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What is the frequency of the treatment in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_1_8413", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What is the route of the treatment in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3720318_1_8414", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "How long has elapsed from the treatment to the occurence of the event in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_1_8415", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "How long did the treatment last in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_1_8416", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What is the disorder targeted by the treatment in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_1_8417", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "What are the drugs used in combination in intrabiliary infusion of mono-octanoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_1_8418", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What are the drugs used in the treatment in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "589261_1_8419", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What is the dosage of the treatment in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "589261_1_8420", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What is the frequency of the treatment in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "589261_1_8421", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What is the route of the treatment in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "589261_1_8422", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "How long has elapsed from the treatment to the occurence of the event in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_1_8423", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "How long did the treatment last in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "589261_1_8424", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What is the disorder targeted by the treatment in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "589261_1_8425", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "What are the drugs used in combination in Cardiac glycosides?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18262450_7_8426", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the age of the subject in Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_7_8427", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the gender of the subject in Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_7_8428", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the number of subjects in Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18262450_7_8429", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the race of the subject in Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_7_8430", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the disorder of the subject in Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_7_8431", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What are the drugs used in the treatment in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_7_8432", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the dosage of the treatment in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_7_8433", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the frequency of the treatment in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_7_8434", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the route of the treatment in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_7_8435", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "How long has elapsed from the treatment to the occurence of the event in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_7_8436", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "How long did the treatment last in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_7_8437", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What is the disorder targeted by the treatment in gabapentin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_7_8438", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "What are the drugs used in combination in gabapentin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22552763_4_8439", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_4_8440", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_4_8441", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_4_8442", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_4_8443", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_4_8444", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What are the drugs used in the treatment in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "22552763_4_8445", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the dosage of the treatment in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_4_8446", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the frequency of the treatment in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_4_8447", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the route of the treatment in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_4_8448", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "How long has elapsed from the treatment to the occurence of the event in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_4_8449", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "How long did the treatment last in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_4_8450", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What is the disorder targeted by the treatment in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22552763_4_8451", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "What are the drugs used in combination in thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2532694_2_8452", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What are the drugs used in the treatment in Dapsone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2532694_2_8453", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What is the dosage of the treatment in Dapsone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_2_8454", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What is the frequency of the treatment in Dapsone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_2_8455", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What is the route of the treatment in Dapsone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_2_8456", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "How long has elapsed from the treatment to the occurence of the event in Dapsone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_2_8457", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "How long did the treatment last in Dapsone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_2_8458", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What is the disorder targeted by the treatment in Dapsone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2532694_2_8459", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "What are the drugs used in combination in Dapsone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_2_8460", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the age of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9870779_2_8461", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the gender of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9870779_2_8462", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the number of subjects in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_2_8463", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the race of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_2_8464", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the disorder of the subject in a patient with rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_2_8465", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What are the drugs used in the treatment in Methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_2_8466", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the dosage of the treatment in Methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_2_8467", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the frequency of the treatment in Methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_2_8468", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the route of the treatment in Methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_2_8469", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in Methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_2_8470", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "How long did the treatment last in Methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_2_8471", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in Methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_2_8472", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "What are the drugs used in combination in Methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_3_8473", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the age of the subject in three cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15516308_3_8474", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the gender of the subject in three cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15516308_3_8475", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the number of subjects in three cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15516308_3_8476", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the race of the subject in three cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15516308_3_8477", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the disorder of the subject in three cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15516308_3_8478", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What are the drugs used in the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15516308_3_8479", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the dosage of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_3_8480", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the frequency of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_3_8481", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the route of the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_3_8482", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "How long has elapsed from the treatment to the occurence of the event in quetiapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_3_8483", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "How long did the treatment last in quetiapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_3_8484", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What is the disorder targeted by the treatment in quetiapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_3_8485", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "What are the drugs used in combination in quetiapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_3_8486", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the age of the subject in Both patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2830062_3_8487", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the gender of the subject in Both patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2830062_3_8488", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the number of subjects in Both patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2830062_3_8489", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the race of the subject in Both patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2830062_3_8490", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the disorder of the subject in Both patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2830062_3_8491", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What are the drugs used in the treatment in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2830062_3_8492", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the dosage of the treatment in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_3_8493", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the frequency of the treatment in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2830062_3_8494", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the route of the treatment in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2830062_3_8495", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_3_8496", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "How long did the treatment last in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2830062_3_8497", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What is the disorder targeted by the treatment in o,p'-DDD?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_3_8498", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "What are the drugs used in combination in o,p'-DDD?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_1_8499", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the age of the subject in a 78-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16046172_1_8500", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the gender of the subject in a 78-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16046172_1_8501", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the number of subjects in a 78-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_1_8502", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the race of the subject in a 78-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_1_8503", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the disorder of the subject in a 78-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_1_8504", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What are the drugs used in the treatment in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16046172_1_8505", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the dosage of the treatment in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_1_8506", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the frequency of the treatment in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_1_8507", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the route of the treatment in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16046172_1_8508", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "How long has elapsed from the treatment to the occurence of the event in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_1_8509", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "How long did the treatment last in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_1_8510", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What is the disorder targeted by the treatment in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_1_8511", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "What are the drugs used in combination in a single sodium hyaluronate injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_1_8512", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the age of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_1_8513", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the gender of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21729965_1_8514", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the number of subjects in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_1_8515", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the race of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_1_8516", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the disorder of the subject in an HIV-positive woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_1_8517", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What are the drugs used in the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21729965_1_8518", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the dosage of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_1_8519", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the frequency of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_1_8520", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the route of the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_1_8521", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "How long has elapsed from the treatment to the occurence of the event in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_1_8522", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "How long did the treatment last in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_1_8523", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What is the disorder targeted by the treatment in antiretroviral therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21729965_1_8524", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "What are the drugs used in combination in antiretroviral therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_1_8525", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What are the drugs used in the treatment in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16341621_1_8526", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What is the dosage of the treatment in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_1_8527", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What is the frequency of the treatment in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_1_8528", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What is the route of the treatment in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16341621_1_8529", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "How long has elapsed from the treatment to the occurence of the event in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_1_8530", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "How long did the treatment last in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_1_8531", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What is the disorder targeted by the treatment in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_1_8532", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "What are the drugs used in combination in periurethral injection of calcium hydroxylapatite?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2532694_1_8533", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the age of the subject in A 35-year-old female with borderline lepromatous (BL) leprosy?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2532694_1_8534", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the gender of the subject in A 35-year-old female with borderline lepromatous (BL) leprosy?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2532694_1_8535", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the number of subjects in A 35-year-old female with borderline lepromatous (BL) leprosy?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2532694_1_8536", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the race of the subject in A 35-year-old female with borderline lepromatous (BL) leprosy?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2532694_1_8537", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the disorder of the subject in A 35-year-old female with borderline lepromatous (BL) leprosy?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2532694_1_8538", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What are the drugs used in the treatment in dapsone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2532694_1_8539", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the dosage of the treatment in dapsone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_1_8540", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the frequency of the treatment in dapsone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_1_8541", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the route of the treatment in dapsone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_1_8542", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "How long has elapsed from the treatment to the occurence of the event in dapsone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_1_8543", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "How long did the treatment last in dapsone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_1_8544", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What is the disorder targeted by the treatment in dapsone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2532694_1_8545", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "What are the drugs used in combination in dapsone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_8_8546", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8912599_8_8547", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_8_8548", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_8_8549", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_8_8550", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_8_8551", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_8_8552", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_8_8553", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_1_8554", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What are the drugs used in the treatment in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_1_8555", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What is the dosage of the treatment in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_1_8556", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What is the frequency of the treatment in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_1_8557", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What is the route of the treatment in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_1_8558", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "How long has elapsed from the treatment to the occurence of the event in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_1_8559", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "How long did the treatment last in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_1_8560", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What is the disorder targeted by the treatment in internal use of low-dose aspirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_1_8561", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "What are the drugs used in combination in internal use of low-dose aspirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_2_8562", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_2_8563", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_2_8564", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_2_8565", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_2_8566", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_2_8567", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What are the drugs used in the treatment in fludarabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9671138_2_8568", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the dosage of the treatment in fludarabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_2_8569", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the frequency of the treatment in fludarabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_2_8570", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the route of the treatment in fludarabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_2_8571", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in fludarabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_2_8572", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "How long did the treatment last in fludarabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_2_8573", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What is the disorder targeted by the treatment in fludarabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_2_8574", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "What are the drugs used in combination in fludarabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_2_8575", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What are the drugs used in the treatment in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9149614_2_8576", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What is the dosage of the treatment in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_2_8577", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What is the frequency of the treatment in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_2_8578", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What is the route of the treatment in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_2_8579", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_2_8580", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "How long did the treatment last in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_2_8581", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What is the disorder targeted by the treatment in amiodarone therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_2_8582", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "What are the drugs used in combination in amiodarone therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_1_8583", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What are the drugs used in the treatment in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8316494_1_8584", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What is the dosage of the treatment in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8316494_1_8585", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What is the frequency of the treatment in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_1_8586", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What is the route of the treatment in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_1_8587", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "How long has elapsed from the treatment to the occurence of the event in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_1_8588", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "How long did the treatment last in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8316494_1_8589", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What is the disorder targeted by the treatment in low dosage clofazimine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8316494_1_8590", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "What are the drugs used in combination in low dosage clofazimine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12908837_1_8591", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What are the drugs used in the treatment in clonazepam?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12908837_1_8592", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What is the dosage of the treatment in clonazepam?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12908837_1_8593", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What is the frequency of the treatment in clonazepam?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12908837_1_8594", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What is the route of the treatment in clonazepam?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12908837_1_8595", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "How long has elapsed from the treatment to the occurence of the event in clonazepam?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12908837_1_8596", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "How long did the treatment last in clonazepam?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12908837_1_8597", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What is the disorder targeted by the treatment in clonazepam?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12908837_1_8598", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "What are the drugs used in combination in clonazepam?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_2_8599", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What are the drugs used in the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_2_8600", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What is the dosage of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_2_8601", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What is the frequency of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_2_8602", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What is the route of the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_2_8603", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "How long has elapsed from the treatment to the occurence of the event in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_2_8604", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "How long did the treatment last in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_2_8605", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What is the disorder targeted by the treatment in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_2_8606", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "What are the drugs used in combination in cephalosporin or moxalactam antibiotics?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_2_8607", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the age of the subject in patients with hypercalcemia secondary to acute vitamin D poisoning?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9865241_2_8608", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the gender of the subject in patients with hypercalcemia secondary to acute vitamin D poisoning?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9865241_2_8609", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the number of subjects in patients with hypercalcemia secondary to acute vitamin D poisoning?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9865241_2_8610", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the race of the subject in patients with hypercalcemia secondary to acute vitamin D poisoning?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9865241_2_8611", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "What is the disorder of the subject in patients with hypercalcemia secondary to acute vitamin D poisoning?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17090724_3_8612", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the age of the subject in this patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_3_8613", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the gender of the subject in this patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_3_8614", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the number of subjects in this patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_3_8615", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the race of the subject in this patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_3_8616", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the disorder of the subject in this patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_3_8617", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What are the drugs used in the treatment in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17090724_3_8618", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the dosage of the treatment in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_3_8619", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the frequency of the treatment in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_3_8620", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the route of the treatment in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_3_8621", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "How long has elapsed from the treatment to the occurence of the event in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_3_8622", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "How long did the treatment last in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_3_8623", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What is the disorder targeted by the treatment in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_3_8624", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "What are the drugs used in combination in amphotericin B deoxycholate therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_1_8625", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the age of the subject in an infant with congenital heart disease?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16132305_1_8626", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the gender of the subject in an infant with congenital heart disease?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_1_8627", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the number of subjects in an infant with congenital heart disease?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_1_8628", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the race of the subject in an infant with congenital heart disease?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_1_8629", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the disorder of the subject in an infant with congenital heart disease?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16132305_1_8630", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What are the drugs used in the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16132305_1_8631", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the dosage of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_1_8632", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the frequency of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_1_8633", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the route of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_1_8634", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "How long has elapsed from the treatment to the occurence of the event in Captopril?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_1_8635", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "How long did the treatment last in Captopril?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_1_8636", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What is the disorder targeted by the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_1_8637", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "What are the drugs used in combination in Captopril?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_1_8638", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What are the drugs used in the treatment in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15836666_1_8639", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What is the dosage of the treatment in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_1_8640", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What is the frequency of the treatment in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15836666_1_8641", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What is the route of the treatment in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15836666_1_8642", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "How long has elapsed from the treatment to the occurence of the event in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_1_8643", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "How long did the treatment last in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15836666_1_8644", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What is the disorder targeted by the treatment in Chronic fentanyl application?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15836666_1_8645", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "What are the drugs used in combination in Chronic fentanyl application?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_5_8646", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the age of the subject in her?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16132305_5_8647", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the gender of the subject in her?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16132305_5_8648", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the number of subjects in her?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16132305_5_8649", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the race of the subject in her?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16132305_5_8650", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the disorder of the subject in her?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16132305_5_8651", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What are the drugs used in the treatment in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16132305_5_8652", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the dosage of the treatment in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_5_8653", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the frequency of the treatment in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16132305_5_8654", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the route of the treatment in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16132305_5_8655", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "How long has elapsed from the treatment to the occurence of the event in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_5_8656", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "How long did the treatment last in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16132305_5_8657", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What is the disorder targeted by the treatment in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_5_8658", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "What are the drugs used in combination in discontinuing captopril and starting systemic steroids?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12927328_1_8659", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the age of the subject in woman schizophrenic patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12927328_1_8660", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the gender of the subject in woman schizophrenic patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12927328_1_8661", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the number of subjects in woman schizophrenic patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12927328_1_8662", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the race of the subject in woman schizophrenic patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12927328_1_8663", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the disorder of the subject in woman schizophrenic patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12927328_1_8664", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What are the drugs used in the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12927328_1_8665", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the dosage of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12927328_1_8666", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the frequency of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12927328_1_8667", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the route of the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12927328_1_8668", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "How long has elapsed from the treatment to the occurence of the event in clozapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12927328_1_8669", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "How long did the treatment last in clozapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12927328_1_8670", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What is the disorder targeted by the treatment in clozapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12927328_1_8671", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "What are the drugs used in combination in clozapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_3_8672", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17016002_3_8673", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17016002_3_8674", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_3_8675", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_3_8676", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_3_8677", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What are the drugs used in the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17016002_3_8678", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the dosage of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_3_8679", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the frequency of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_3_8680", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the route of the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_3_8681", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "How long has elapsed from the treatment to the occurence of the event in calcium stearate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_3_8682", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "How long did the treatment last in calcium stearate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_3_8683", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What is the disorder targeted by the treatment in calcium stearate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_3_8684", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "What are the drugs used in combination in calcium stearate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3343188_2_8685", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the age of the subject in man, dogs, and cats?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3343188_2_8686", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the gender of the subject in man, dogs, and cats?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3343188_2_8687", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the number of subjects in man, dogs, and cats?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3343188_2_8688", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the race of the subject in man, dogs, and cats?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3343188_2_8689", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the disorder of the subject in man, dogs, and cats?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3343188_2_8690", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What are the drugs used in the treatment in Benzocaine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3343188_2_8691", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the dosage of the treatment in Benzocaine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3343188_2_8692", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the frequency of the treatment in Benzocaine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3343188_2_8693", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the route of the treatment in Benzocaine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3343188_2_8694", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "How long has elapsed from the treatment to the occurence of the event in Benzocaine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3343188_2_8695", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "How long did the treatment last in Benzocaine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3343188_2_8696", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What is the disorder targeted by the treatment in Benzocaine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3343188_2_8697", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "What are the drugs used in combination in Benzocaine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_3_8698", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_3_8699", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_3_8700", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_3_8701", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_3_8702", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_3_8703", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What are the drugs used in the treatment in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8151270_3_8704", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the dosage of the treatment in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_3_8705", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the frequency of the treatment in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_3_8706", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the route of the treatment in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_3_8707", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "How long has elapsed from the treatment to the occurence of the event in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_3_8708", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "How long did the treatment last in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_3_8709", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What is the disorder targeted by the treatment in didanosine (ddI)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8151270_3_8710", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "What are the drugs used in combination in didanosine (ddI)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_2_8711", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What are the drugs used in the treatment in Leflunomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_2_8712", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What is the dosage of the treatment in Leflunomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_2_8713", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What is the frequency of the treatment in Leflunomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_2_8714", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What is the route of the treatment in Leflunomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_2_8715", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "How long has elapsed from the treatment to the occurence of the event in Leflunomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_2_8716", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "How long did the treatment last in Leflunomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_2_8717", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What is the disorder targeted by the treatment in Leflunomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_2_8718", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "What are the drugs used in combination in Leflunomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11450788_1_8719", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What are the drugs used in the treatment in Antiretroviral?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11450788_1_8720", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What is the dosage of the treatment in Antiretroviral?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_1_8721", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What is the frequency of the treatment in Antiretroviral?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_1_8722", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What is the route of the treatment in Antiretroviral?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_1_8723", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in Antiretroviral?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_1_8724", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "How long did the treatment last in Antiretroviral?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_1_8725", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What is the disorder targeted by the treatment in Antiretroviral?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_1_8726", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "What are the drugs used in combination in Antiretroviral?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_1_8727", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the age of the subject in A woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1756352_1_8728", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the gender of the subject in A woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1756352_1_8729", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the number of subjects in A woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1756352_1_8730", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the race of the subject in A woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1756352_1_8731", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the disorder of the subject in A woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1756352_1_8732", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What are the drugs used in the treatment in taking phenelzine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1756352_1_8733", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the dosage of the treatment in taking phenelzine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_1_8734", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the frequency of the treatment in taking phenelzine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_1_8735", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the route of the treatment in taking phenelzine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_1_8736", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "How long has elapsed from the treatment to the occurence of the event in taking phenelzine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_1_8737", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "How long did the treatment last in taking phenelzine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_1_8738", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What is the disorder targeted by the treatment in taking phenelzine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_1_8739", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "What are the drugs used in combination in taking phenelzine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_4_8740", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What are the drugs used in the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8308951_4_8741", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What is the dosage of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_4_8742", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What is the frequency of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_4_8743", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What is the route of the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_4_8744", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "How long has elapsed from the treatment to the occurence of the event in warfarin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_4_8745", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "How long did the treatment last in warfarin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_4_8746", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What is the disorder targeted by the treatment in warfarin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_4_8747", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "What are the drugs used in combination in warfarin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_2_8748", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10752888_2_8749", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10752888_2_8750", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10752888_2_8751", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10752888_2_8752", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10752888_2_8753", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What are the drugs used in the treatment in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10752888_2_8754", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the dosage of the treatment in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_2_8755", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the frequency of the treatment in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_2_8756", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the route of the treatment in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_2_8757", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_2_8758", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "How long did the treatment last in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_2_8759", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What is the disorder targeted by the treatment in nitrofurantoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_2_8760", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "What are the drugs used in combination in nitrofurantoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_4_8761", "context": "Colchicine-induced rhabdomyolysis.", "question": "What are the drugs used in the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17619811_4_8762", "context": "Colchicine-induced rhabdomyolysis.", "question": "What is the dosage of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_4_8763", "context": "Colchicine-induced rhabdomyolysis.", "question": "What is the frequency of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_4_8764", "context": "Colchicine-induced rhabdomyolysis.", "question": "What is the route of the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_4_8765", "context": "Colchicine-induced rhabdomyolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in Colchicine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_4_8766", "context": "Colchicine-induced rhabdomyolysis.", "question": "How long did the treatment last in Colchicine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_4_8767", "context": "Colchicine-induced rhabdomyolysis.", "question": "What is the disorder targeted by the treatment in Colchicine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_4_8768", "context": "Colchicine-induced rhabdomyolysis.", "question": "What are the drugs used in combination in Colchicine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_2_8769", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16678268_2_8770", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16678268_2_8771", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16678268_2_8772", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16678268_2_8773", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16678268_2_8774", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What are the drugs used in the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16678268_2_8775", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the dosage of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_2_8776", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the frequency of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_2_8777", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the route of the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16678268_2_8778", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "How long has elapsed from the treatment to the occurence of the event in infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16678268_2_8779", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "How long did the treatment last in infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_2_8780", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What is the disorder targeted by the treatment in infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16678268_2_8781", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "What are the drugs used in combination in infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_7_8782", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_7_8783", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_7_8784", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_7_8785", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_7_8786", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_7_8787", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What are the drugs used in the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10573314_7_8788", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the dosage of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_7_8789", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the frequency of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_7_8790", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the route of the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_7_8791", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "How long has elapsed from the treatment to the occurence of the event in tolterodine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_7_8792", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "How long did the treatment last in tolterodine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_7_8793", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What is the disorder targeted by the treatment in tolterodine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_7_8794", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "What are the drugs used in combination in tolterodine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_4_8795", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the age of the subject in 3% or more of patients with cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_4_8796", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the gender of the subject in 3% or more of patients with cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_4_8797", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the number of subjects in 3% or more of patients with cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_4_8798", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the race of the subject in 3% or more of patients with cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_4_8799", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the disorder of the subject in 3% or more of patients with cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9007910_4_8800", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What are the drugs used in the treatment in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_4_8801", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the dosage of the treatment in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_4_8802", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the frequency of the treatment in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_4_8803", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the route of the treatment in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_4_8804", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "How long has elapsed from the treatment to the occurence of the event in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_4_8805", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "How long did the treatment last in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_4_8806", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What is the disorder targeted by the treatment in standard doses of 5-FU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_4_8807", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "What are the drugs used in combination in standard doses of 5-FU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_11_8808", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What are the drugs used in the treatment in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21515865_11_8809", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What is the dosage of the treatment in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_11_8810", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What is the frequency of the treatment in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_11_8811", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What is the route of the treatment in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_11_8812", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "How long has elapsed from the treatment to the occurence of the event in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_11_8813", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "How long did the treatment last in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_11_8814", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What is the disorder targeted by the treatment in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_11_8815", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "What are the drugs used in combination in acetaminophen and moxifloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_1_8816", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What are the drugs used in the treatment in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17921794_1_8817", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What is the dosage of the treatment in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_1_8818", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What is the frequency of the treatment in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_1_8819", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What is the route of the treatment in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_1_8820", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_1_8821", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "How long did the treatment last in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_1_8822", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What is the disorder targeted by the treatment in colchicine and statin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_1_8823", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "What are the drugs used in combination in colchicine and statin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_1_8824", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What are the drugs used in the treatment in Cephalosporins?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6671350_1_8825", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What is the dosage of the treatment in Cephalosporins?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_1_8826", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What is the frequency of the treatment in Cephalosporins?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_1_8827", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What is the route of the treatment in Cephalosporins?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_1_8828", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "How long has elapsed from the treatment to the occurence of the event in Cephalosporins?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_1_8829", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "How long did the treatment last in Cephalosporins?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_1_8830", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What is the disorder targeted by the treatment in Cephalosporins?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_1_8831", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "What are the drugs used in combination in Cephalosporins?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_2_8832", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What are the drugs used in the treatment in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18042092_2_8833", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What is the dosage of the treatment in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_2_8834", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What is the frequency of the treatment in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_2_8835", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What is the route of the treatment in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18042092_2_8836", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "How long has elapsed from the treatment to the occurence of the event in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_2_8837", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "How long did the treatment last in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_2_8838", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What is the disorder targeted by the treatment in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_2_8839", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "What are the drugs used in combination in subcutaneous injection of glatiramer acetate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_3_8840", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "What is the age of the subject in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3084231_3_8841", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "What is the gender of the subject in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3084231_3_8842", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "What is the number of subjects in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3084231_3_8843", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "What is the race of the subject in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3084231_3_8844", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "What is the disorder of the subject in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17316891_1_8845", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the age of the subject in a 50-year-old woman with advanced non-small cell lung cancer?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17316891_1_8846", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the gender of the subject in a 50-year-old woman with advanced non-small cell lung cancer?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17316891_1_8847", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the number of subjects in a 50-year-old woman with advanced non-small cell lung cancer?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17316891_1_8848", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the race of the subject in a 50-year-old woman with advanced non-small cell lung cancer?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17316891_1_8849", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the disorder of the subject in a 50-year-old woman with advanced non-small cell lung cancer?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17316891_1_8850", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What are the drugs used in the treatment in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17316891_1_8851", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the dosage of the treatment in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17316891_1_8852", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the frequency of the treatment in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17316891_1_8853", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the route of the treatment in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17316891_1_8854", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316891_1_8855", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "How long did the treatment last in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17316891_1_8856", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What is the disorder targeted by the treatment in cisplatin and gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17316891_1_8857", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "What are the drugs used in combination in cisplatin and gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_3_8858", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18628507_3_8859", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18628507_3_8860", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18628507_3_8861", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18628507_3_8862", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18628507_3_8863", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What are the drugs used in the treatment in VRC therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18628507_3_8864", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the dosage of the treatment in VRC therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_3_8865", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the frequency of the treatment in VRC therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_3_8866", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the route of the treatment in VRC therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_3_8867", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in VRC therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_3_8868", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "How long did the treatment last in VRC therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_3_8869", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What is the disorder targeted by the treatment in VRC therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_3_8870", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "What are the drugs used in combination in VRC therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_2_8871", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What are the drugs used in the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_2_8872", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What is the dosage of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_2_8873", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What is the frequency of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_2_8874", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What is the route of the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_2_8875", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "How long has elapsed from the treatment to the occurence of the event in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_2_8876", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "How long did the treatment last in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_2_8877", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What is the disorder targeted by the treatment in thalidomide treatment?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_2_8878", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "What are the drugs used in combination in thalidomide treatment?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_1_8879", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the age of the subject in A 25-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9413296_1_8880", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the gender of the subject in A 25-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9413296_1_8881", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the number of subjects in A 25-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9413296_1_8882", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the race of the subject in A 25-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9413296_1_8883", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the disorder of the subject in A 25-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9413296_1_8884", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What are the drugs used in the treatment in methysergide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9413296_1_8885", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the dosage of the treatment in methysergide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_1_8886", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the frequency of the treatment in methysergide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_1_8887", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the route of the treatment in methysergide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_1_8888", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "How long has elapsed from the treatment to the occurence of the event in methysergide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_1_8889", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "How long did the treatment last in methysergide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_1_8890", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What is the disorder targeted by the treatment in methysergide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_1_8891", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "What are the drugs used in combination in methysergide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_2_8892", "context": "Nodular scleritis following alendronate therapy.", "question": "What are the drugs used in the treatment in alendronate therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18569796_2_8893", "context": "Nodular scleritis following alendronate therapy.", "question": "What is the dosage of the treatment in alendronate therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_2_8894", "context": "Nodular scleritis following alendronate therapy.", "question": "What is the frequency of the treatment in alendronate therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_2_8895", "context": "Nodular scleritis following alendronate therapy.", "question": "What is the route of the treatment in alendronate therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_2_8896", "context": "Nodular scleritis following alendronate therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in alendronate therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_2_8897", "context": "Nodular scleritis following alendronate therapy.", "question": "How long did the treatment last in alendronate therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_2_8898", "context": "Nodular scleritis following alendronate therapy.", "question": "What is the disorder targeted by the treatment in alendronate therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_2_8899", "context": "Nodular scleritis following alendronate therapy.", "question": "What are the drugs used in combination in alendronate therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_8_8900", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the age of the subject in both patients?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_8_8901", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the gender of the subject in both patients?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_8_8902", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the number of subjects in both patients?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10573314_8_8903", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the race of the subject in both patients?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_8_8904", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the disorder of the subject in both patients?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_8_8905", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What are the drugs used in the treatment in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10573314_8_8906", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the dosage of the treatment in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_8_8907", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the frequency of the treatment in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_8_8908", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the route of the treatment in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_8_8909", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "How long has elapsed from the treatment to the occurence of the event in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_8_8910", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "How long did the treatment last in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_8_8911", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What is the disorder targeted by the treatment in tolterodine?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_8_8912", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "What are the drugs used in combination in tolterodine?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2022118_1_8913", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2022118_1_8914", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2022118_1_8915", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2022118_1_8916", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2022118_1_8917", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2022118_1_8918", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "2022118_1_8919", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the dosage of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2022118_1_8920", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the frequency of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2022118_1_8921", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the route of the treatment in lithium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2022118_1_8922", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2022118_1_8923", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "How long did the treatment last in lithium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2022118_1_8924", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2022118_1_8925", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "What are the drugs used in combination in lithium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_2_8926", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What are the drugs used in the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "681921_2_8927", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What is the dosage of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_2_8928", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What is the frequency of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_2_8929", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What is the route of the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_2_8930", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "How long has elapsed from the treatment to the occurence of the event in disulfiram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_2_8931", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "How long did the treatment last in disulfiram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_2_8932", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What is the disorder targeted by the treatment in disulfiram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_2_8933", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "What are the drugs used in combination in disulfiram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_1_8934", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10717401_1_8935", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_1_8936", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_1_8937", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_1_8938", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_1_8939", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_1_8940", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10717401_1_8941", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_3_8942", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What are the drugs used in the treatment in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4063627_3_8943", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What is the dosage of the treatment in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_3_8944", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What is the frequency of the treatment in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_3_8945", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What is the route of the treatment in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_3_8946", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "How long has elapsed from the treatment to the occurence of the event in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_3_8947", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "How long did the treatment last in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_3_8948", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What is the disorder targeted by the treatment in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_3_8949", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "What are the drugs used in combination in fenclofenac as well as aurothiomalate and sulphasalazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_14_8950", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What are the drugs used in the treatment in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "18262450_14_8951", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What is the dosage of the treatment in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_14_8952", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What is the frequency of the treatment in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_14_8953", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What is the route of the treatment in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_14_8954", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "How long has elapsed from the treatment to the occurence of the event in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_14_8955", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "How long did the treatment last in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_14_8956", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What is the disorder targeted by the treatment in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_14_8957", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "What are the drugs used in combination in co-administration of prolonged-release oxycodone and existing gabapentin therapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17504225_4_8958", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What are the drugs used in the treatment in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "17504225_4_8959", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What is the dosage of the treatment in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_4_8960", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What is the frequency of the treatment in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_4_8961", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What is the route of the treatment in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_4_8962", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "How long has elapsed from the treatment to the occurence of the event in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_4_8963", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "How long did the treatment last in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_4_8964", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What is the disorder targeted by the treatment in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_4_8965", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "What are the drugs used in combination in the concomitant administration of clarithromycin and sirolimus?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10190739_1_8966", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the age of the subject in one case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10190739_1_8967", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the gender of the subject in one case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10190739_1_8968", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the number of subjects in one case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10190739_1_8969", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the race of the subject in one case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10190739_1_8970", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the disorder of the subject in one case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10190739_1_8971", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What are the drugs used in the treatment in riluzole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10190739_1_8972", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the dosage of the treatment in riluzole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10190739_1_8973", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the frequency of the treatment in riluzole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10190739_1_8974", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the route of the treatment in riluzole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_1_8975", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in riluzole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_1_8976", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "How long did the treatment last in riluzole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10190739_1_8977", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What is the disorder targeted by the treatment in riluzole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_1_8978", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "What are the drugs used in combination in riluzole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_3_8979", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What are the drugs used in the treatment in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16018164_3_8980", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What is the dosage of the treatment in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_3_8981", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What is the frequency of the treatment in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_3_8982", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What is the route of the treatment in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_3_8983", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "How long has elapsed from the treatment to the occurence of the event in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_3_8984", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "How long did the treatment last in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_3_8985", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What is the disorder targeted by the treatment in Pseudoephedrine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_3_8986", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "What are the drugs used in combination in Pseudoephedrine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_1_8987", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the age of the subject in a 34-year-old man without a history of glaucoma?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16490518_1_8988", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the gender of the subject in a 34-year-old man without a history of glaucoma?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16490518_1_8989", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the number of subjects in a 34-year-old man without a history of glaucoma?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_1_8990", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the race of the subject in a 34-year-old man without a history of glaucoma?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_1_8991", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the disorder of the subject in a 34-year-old man without a history of glaucoma?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_1_8992", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What are the drugs used in the treatment in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16490518_1_8993", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the dosage of the treatment in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_1_8994", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the frequency of the treatment in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_1_8995", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the route of the treatment in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_1_8996", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_1_8997", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "How long did the treatment last in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_1_8998", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What is the disorder targeted by the treatment in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_1_8999", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "What are the drugs used in combination in intravitreal injection of triamcinolone acetate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_2_9000", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What are the drugs used in the treatment in quinine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7369302_2_9001", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What is the dosage of the treatment in quinine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_2_9002", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What is the frequency of the treatment in quinine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_2_9003", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What is the route of the treatment in quinine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_2_9004", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "How long has elapsed from the treatment to the occurence of the event in quinine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_2_9005", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "How long did the treatment last in quinine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_2_9006", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What is the disorder targeted by the treatment in quinine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_2_9007", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "What are the drugs used in combination in quinine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_6_9008", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the age of the subject in he?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_6_9009", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the gender of the subject in he?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10682234_6_9010", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the number of subjects in he?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_6_9011", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the race of the subject in he?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_6_9012", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the disorder of the subject in he?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_6_9013", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What are the drugs used in the treatment in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10682234_6_9014", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the dosage of the treatment in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_6_9015", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the frequency of the treatment in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_6_9016", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the route of the treatment in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_6_9017", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "How long has elapsed from the treatment to the occurence of the event in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_6_9018", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "How long did the treatment last in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_6_9019", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What is the disorder targeted by the treatment in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_6_9020", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "What are the drugs used in combination in Two days' administration of levomepromazine 100 mg?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_1_9021", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What are the drugs used in the treatment in Methimazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9777751_1_9022", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What is the dosage of the treatment in Methimazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_1_9023", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What is the frequency of the treatment in Methimazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_1_9024", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What is the route of the treatment in Methimazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_1_9025", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "How long has elapsed from the treatment to the occurence of the event in Methimazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_1_9026", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "How long did the treatment last in Methimazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_1_9027", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What is the disorder targeted by the treatment in Methimazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_1_9028", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "What are the drugs used in combination in Methimazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_2_9029", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the age of the subject in two cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18751717_2_9030", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the gender of the subject in two cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18751717_2_9031", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the number of subjects in two cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18751717_2_9032", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the race of the subject in two cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18751717_2_9033", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the disorder of the subject in two cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18751717_2_9034", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What are the drugs used in the treatment in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18751717_2_9035", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the dosage of the treatment in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_2_9036", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the frequency of the treatment in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_2_9037", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the route of the treatment in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18751717_2_9038", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_2_9039", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "How long did the treatment last in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_2_9040", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What is the disorder targeted by the treatment in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_2_9041", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "What are the drugs used in combination in intravitreal triamcinolone acetonide (IVTA) injection?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_2_9042", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What are the drugs used in the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14522628_2_9043", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What is the dosage of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_2_9044", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What is the frequency of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_2_9045", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What is the route of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_2_9046", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "How long has elapsed from the treatment to the occurence of the event in ganciclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_2_9047", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "How long did the treatment last in ganciclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_2_9048", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What is the disorder targeted by the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_2_9049", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "What are the drugs used in combination in ganciclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_5_9050", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the age of the subject in a pediatric patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_5_9051", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the gender of the subject in a pediatric patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_5_9052", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the number of subjects in a pediatric patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_5_9053", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the race of the subject in a pediatric patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_5_9054", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the disorder of the subject in a pediatric patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_5_9055", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_5_9056", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_5_9057", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_5_9058", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_5_9059", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_5_9060", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_5_9061", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_5_9062", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_3_9063", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What are the drugs used in the treatment in INH therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11804071_3_9064", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What is the dosage of the treatment in INH therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_3_9065", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What is the frequency of the treatment in INH therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_3_9066", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What is the route of the treatment in INH therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_3_9067", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "How long has elapsed from the treatment to the occurence of the event in INH therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_3_9068", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "How long did the treatment last in INH therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_3_9069", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What is the disorder targeted by the treatment in INH therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_3_9070", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "What are the drugs used in combination in INH therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_3_9071", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What are the drugs used in the treatment in MB?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10646879_3_9072", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What is the dosage of the treatment in MB?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_3_9073", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What is the frequency of the treatment in MB?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10646879_3_9074", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What is the route of the treatment in MB?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10646879_3_9075", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "How long has elapsed from the treatment to the occurence of the event in MB?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_3_9076", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "How long did the treatment last in MB?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10646879_3_9077", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What is the disorder targeted by the treatment in MB?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_3_9078", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "What are the drugs used in combination in MB?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18354950_2_9079", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What are the drugs used in the treatment in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_2_9080", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What is the dosage of the treatment in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_2_9081", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What is the frequency of the treatment in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_2_9082", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What is the route of the treatment in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_2_9083", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_2_9084", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "How long did the treatment last in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_2_9085", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What is the disorder targeted by the treatment in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_2_9086", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "What are the drugs used in combination in low-dose carbamazepine therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_1_9087", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What are the drugs used in the treatment in capecitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16697705_1_9088", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What is the dosage of the treatment in capecitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_1_9089", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What is the frequency of the treatment in capecitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_1_9090", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What is the route of the treatment in capecitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_1_9091", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in capecitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_1_9092", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "How long did the treatment last in capecitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_1_9093", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What is the disorder targeted by the treatment in capecitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_1_9094", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "What are the drugs used in combination in capecitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_1_9095", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the age of the subject in A case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_1_9096", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the gender of the subject in A case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_1_9097", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the number of subjects in A case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_1_9098", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the race of the subject in A case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_1_9099", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the disorder of the subject in A case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_1_9100", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What are the drugs used in the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_1_9101", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the dosage of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_1_9102", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the frequency of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_1_9103", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the route of the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_1_9104", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "How long has elapsed from the treatment to the occurence of the event in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_1_9105", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "How long did the treatment last in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_1_9106", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What is the disorder targeted by the treatment in a single dose of vincristine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_1_9107", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "What are the drugs used in combination in a single dose of vincristine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_3_9108", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the age of the subject in a young woman with SLE and thrombocytopenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16357738_3_9109", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the gender of the subject in a young woman with SLE and thrombocytopenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16357738_3_9110", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the number of subjects in a young woman with SLE and thrombocytopenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16357738_3_9111", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the race of the subject in a young woman with SLE and thrombocytopenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16357738_3_9112", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the disorder of the subject in a young woman with SLE and thrombocytopenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16357738_3_9113", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What are the drugs used in the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_3_9114", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the dosage of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_3_9115", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the frequency of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_3_9116", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the route of the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_3_9117", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "How long has elapsed from the treatment to the occurence of the event in cyclosporine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_3_9118", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "How long did the treatment last in cyclosporine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_3_9119", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What is the disorder targeted by the treatment in cyclosporine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_3_9120", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "What are the drugs used in combination in cyclosporine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12507063_1_9121", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12507063_1_9122", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12507063_1_9123", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12507063_1_9124", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12507063_1_9125", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12507063_1_9126", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What are the drugs used in the treatment in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12507063_1_9127", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the dosage of the treatment in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12507063_1_9128", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the frequency of the treatment in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_1_9129", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the route of the treatment in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_1_9130", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "How long has elapsed from the treatment to the occurence of the event in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_1_9131", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "How long did the treatment last in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_1_9132", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What is the disorder targeted by the treatment in gabapentin withdrawal?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_1_9133", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "What are the drugs used in combination in gabapentin withdrawal?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_2_9134", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What are the drugs used in the treatment in insulin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "4014301_2_9135", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What is the dosage of the treatment in insulin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_2_9136", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What is the frequency of the treatment in insulin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_2_9137", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What is the route of the treatment in insulin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_2_9138", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in insulin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_2_9139", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "How long did the treatment last in insulin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_2_9140", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What is the disorder targeted by the treatment in insulin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_2_9141", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "What are the drugs used in combination in insulin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_1_9142", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the age of the subject in these patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_1_9143", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the gender of the subject in these patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_1_9144", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the number of subjects in these patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_1_9145", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the race of the subject in these patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_1_9146", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the disorder of the subject in these patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_1_9147", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What are the drugs used in the treatment in dexamethasone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15061230_1_9148", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the dosage of the treatment in dexamethasone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_1_9149", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the frequency of the treatment in dexamethasone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_1_9150", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the route of the treatment in dexamethasone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_1_9151", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "How long has elapsed from the treatment to the occurence of the event in dexamethasone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_1_9152", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "How long did the treatment last in dexamethasone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_1_9153", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What is the disorder targeted by the treatment in dexamethasone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_1_9154", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "What are the drugs used in combination in dexamethasone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12397859_1_9155", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12397859_1_9156", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12397859_1_9157", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12397859_1_9158", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12397859_1_9159", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12397859_1_9160", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What are the drugs used in the treatment in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12397859_1_9161", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the dosage of the treatment in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12397859_1_9162", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the frequency of the treatment in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12397859_1_9163", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the route of the treatment in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12397859_1_9164", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "How long has elapsed from the treatment to the occurence of the event in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12397859_1_9165", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "How long did the treatment last in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12397859_1_9166", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What is the disorder targeted by the treatment in discontinuation of nefazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12397859_1_9167", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "What are the drugs used in combination in discontinuation of nefazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_1_9168", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What are the drugs used in the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3156465_1_9169", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What is the dosage of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_1_9170", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What is the frequency of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_1_9171", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What is the route of the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_1_9172", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "How long has elapsed from the treatment to the occurence of the event in Isotretinoin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_1_9173", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "How long did the treatment last in Isotretinoin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_1_9174", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What is the disorder targeted by the treatment in Isotretinoin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_1_9175", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "What are the drugs used in combination in Isotretinoin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_6_9176", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What are the drugs used in the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_6_9177", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What is the dosage of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_6_9178", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What is the frequency of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_6_9179", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What is the route of the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_6_9180", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "How long has elapsed from the treatment to the occurence of the event in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_6_9181", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "How long did the treatment last in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_6_9182", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What is the disorder targeted by the treatment in zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_6_9183", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "What are the drugs used in combination in zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_4_9184", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the age of the subject in Two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_4_9185", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the gender of the subject in Two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_4_9186", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the number of subjects in Two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6572542_4_9187", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the race of the subject in Two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_4_9188", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the disorder of the subject in Two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_4_9189", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What are the drugs used in the treatment in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_4_9190", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the dosage of the treatment in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_4_9191", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the frequency of the treatment in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_4_9192", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the route of the treatment in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_4_9193", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_4_9194", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "How long did the treatment last in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_4_9195", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What is the disorder targeted by the treatment in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_4_9196", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "What are the drugs used in combination in high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_1_9197", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What are the drugs used in the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11724089_1_9198", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What is the dosage of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_1_9199", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What is the frequency of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_1_9200", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What is the route of the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_1_9201", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "How long has elapsed from the treatment to the occurence of the event in ofloxacin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_1_9202", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "How long did the treatment last in ofloxacin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_1_9203", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What is the disorder targeted by the treatment in ofloxacin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_1_9204", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "What are the drugs used in combination in ofloxacin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_3_9205", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What are the drugs used in the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18755414_3_9206", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What is the dosage of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_3_9207", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What is the frequency of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_3_9208", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What is the route of the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_3_9209", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in aspirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_3_9210", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "How long did the treatment last in aspirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_3_9211", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What is the disorder targeted by the treatment in aspirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_3_9212", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "What are the drugs used in combination in aspirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_2_9213", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What are the drugs used in the treatment in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10225085_2_9214", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the dosage of the treatment in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_2_9215", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the frequency of the treatment in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_2_9216", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the route of the treatment in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_2_9217", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "How long has elapsed from the treatment to the occurence of the event in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_2_9218", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "How long did the treatment last in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_2_9219", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What is the disorder targeted by the treatment in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_2_9220", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "What are the drugs used in combination in axillary block with bupivacaine and additional injection of lidocaine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_3_9221", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What are the drugs used in the treatment in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10812579_3_9222", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What is the dosage of the treatment in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_3_9223", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What is the frequency of the treatment in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_3_9224", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What is the route of the treatment in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_3_9225", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "How long has elapsed from the treatment to the occurence of the event in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_3_9226", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "How long did the treatment last in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_3_9227", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What is the disorder targeted by the treatment in morphine and its antagonist?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_3_9228", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "What are the drugs used in combination in morphine and its antagonist?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_1_9229", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the age of the subject in two patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_1_9230", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the gender of the subject in two patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_1_9231", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the number of subjects in two patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8579054_1_9232", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the race of the subject in two patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_1_9233", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the disorder of the subject in two patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_1_9234", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What are the drugs used in the treatment in hydroxyurea?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8579054_1_9235", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the dosage of the treatment in hydroxyurea?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_1_9236", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the frequency of the treatment in hydroxyurea?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8579054_1_9237", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the route of the treatment in hydroxyurea?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_1_9238", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "How long has elapsed from the treatment to the occurence of the event in hydroxyurea?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_1_9239", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "How long did the treatment last in hydroxyurea?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_1_9240", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What is the disorder targeted by the treatment in hydroxyurea?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8579054_1_9241", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "What are the drugs used in combination in hydroxyurea?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_1_9242", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What are the drugs used in the treatment in naloxone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10698143_1_9243", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What is the dosage of the treatment in naloxone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_1_9244", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What is the frequency of the treatment in naloxone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_1_9245", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What is the route of the treatment in naloxone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_1_9246", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "How long has elapsed from the treatment to the occurence of the event in naloxone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_1_9247", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "How long did the treatment last in naloxone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_1_9248", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What is the disorder targeted by the treatment in naloxone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_1_9249", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "What are the drugs used in combination in naloxone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_2_9250", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What are the drugs used in the treatment in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20465622_2_9251", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What is the dosage of the treatment in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_2_9252", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What is the frequency of the treatment in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_2_9253", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What is the route of the treatment in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_2_9254", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_2_9255", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "How long did the treatment last in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_2_9256", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What is the disorder targeted by the treatment in sirolimus therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_2_9257", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "What are the drugs used in combination in sirolimus therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_4_9258", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What are the drugs used in the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_4_9259", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What is the dosage of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_4_9260", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What is the frequency of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_4_9261", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What is the route of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_4_9262", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "How long has elapsed from the treatment to the occurence of the event in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_4_9263", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "How long did the treatment last in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_4_9264", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What is the disorder targeted by the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_4_9265", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "What are the drugs used in combination in propafenone and citalopram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_1_9266", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the age of the subject in one out of 23 patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_1_9267", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the gender of the subject in one out of 23 patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_1_9268", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the number of subjects in one out of 23 patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7949255_1_9269", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the race of the subject in one out of 23 patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_1_9270", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the disorder of the subject in one out of 23 patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_1_9271", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What are the drugs used in the treatment in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7949255_1_9272", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the dosage of the treatment in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7949255_1_9273", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the frequency of the treatment in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_1_9274", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the route of the treatment in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_1_9275", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "How long has elapsed from the treatment to the occurence of the event in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_1_9276", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "How long did the treatment last in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_1_9277", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What is the disorder targeted by the treatment in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_1_9278", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "What are the drugs used in combination in chemotherapy with high-dose methotrexate (HD-MTX)?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_13_9279", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What are the drugs used in the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18675768_13_9280", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the dosage of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_13_9281", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the frequency of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_13_9282", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the route of the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_13_9283", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "How long has elapsed from the treatment to the occurence of the event in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_13_9284", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "How long did the treatment last in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_13_9285", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What is the disorder targeted by the treatment in propafenone and citalopram?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_13_9286", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "What are the drugs used in combination in propafenone and citalopram?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1082426_1_9287", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What are the drugs used in the treatment in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1082426_1_9288", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What is the dosage of the treatment in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1082426_1_9289", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What is the frequency of the treatment in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1082426_1_9290", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What is the route of the treatment in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1082426_1_9291", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1082426_1_9292", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "How long did the treatment last in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1082426_1_9293", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What is the disorder targeted by the treatment in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1082426_1_9294", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "What are the drugs used in combination in intraarterial vasopressin therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_1_9295", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the age of the subject in adult patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16685007_1_9296", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the gender of the subject in adult patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_1_9297", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the number of subjects in adult patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_1_9298", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the race of the subject in adult patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_1_9299", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the disorder of the subject in adult patients with severe, persistent asthma?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_1_9300", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What are the drugs used in the treatment in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16685007_1_9301", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the dosage of the treatment in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_1_9302", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the frequency of the treatment in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_1_9303", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the route of the treatment in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16685007_1_9304", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "How long has elapsed from the treatment to the occurence of the event in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_1_9305", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "How long did the treatment last in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_1_9306", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What is the disorder targeted by the treatment in Ciclesonide?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_1_9307", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "What are the drugs used in combination in Ciclesonide?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8250714_1_9308", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the age of the subject in patients unsuspected of having vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_1_9309", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the gender of the subject in patients unsuspected of having vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_1_9310", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the number of subjects in patients unsuspected of having vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_1_9311", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the race of the subject in patients unsuspected of having vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_1_9312", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the disorder of the subject in patients unsuspected of having vitamin B12 deficiency?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_1_9313", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What are the drugs used in the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8250714_1_9314", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the dosage of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_1_9315", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the frequency of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_1_9316", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the route of the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_1_9317", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "How long has elapsed from the treatment to the occurence of the event in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_1_9318", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "How long did the treatment last in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_1_9319", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What is the disorder targeted by the treatment in nitrous oxide anesthesia?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_1_9320", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "What are the drugs used in combination in nitrous oxide anesthesia?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_1_9321", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the age of the subject in a 31-year-old patient hospitalized due to behavioral alterations?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_1_9322", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the gender of the subject in a 31-year-old patient hospitalized due to behavioral alterations?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_1_9323", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the number of subjects in a 31-year-old patient hospitalized due to behavioral alterations?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_1_9324", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the race of the subject in a 31-year-old patient hospitalized due to behavioral alterations?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_1_9325", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the disorder of the subject in a 31-year-old patient hospitalized due to behavioral alterations?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_1_9326", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What are the drugs used in the treatment in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12022905_1_9327", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the dosage of the treatment in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_1_9328", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the frequency of the treatment in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_1_9329", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the route of the treatment in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_1_9330", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "How long has elapsed from the treatment to the occurence of the event in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_1_9331", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "How long did the treatment last in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_1_9332", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What is the disorder targeted by the treatment in oral zuclopenthixol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_1_9333", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "What are the drugs used in combination in oral zuclopenthixol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_2_9334", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6401771_2_9335", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6401771_2_9336", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6401771_2_9337", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6401771_2_9338", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6401771_2_9339", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What are the drugs used in the treatment in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6401771_2_9340", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the dosage of the treatment in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_2_9341", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the frequency of the treatment in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_2_9342", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the route of the treatment in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_2_9343", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_2_9344", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "How long did the treatment last in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_2_9345", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What is the disorder targeted by the treatment in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6401771_2_9346", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "What are the drugs used in combination in long-term therapy with mitomycin C and 5-fluorouracil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_1_9347", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the age of the subject in 40-year-old man with a long standing history of rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9870779_1_9348", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the gender of the subject in 40-year-old man with a long standing history of rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9870779_1_9349", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the number of subjects in 40-year-old man with a long standing history of rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_1_9350", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the race of the subject in 40-year-old man with a long standing history of rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_1_9351", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the disorder of the subject in 40-year-old man with a long standing history of rheumatoid arthritis?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_1_9352", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What are the drugs used in the treatment in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9870779_1_9353", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the dosage of the treatment in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_1_9354", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the frequency of the treatment in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_1_9355", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the route of the treatment in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_1_9356", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "How long has elapsed from the treatment to the occurence of the event in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_1_9357", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "How long did the treatment last in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_1_9358", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What is the disorder targeted by the treatment in MTX over a 6 month period?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_1_9359", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "What are the drugs used in combination in MTX over a 6 month period?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9627209_1_9360", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What are the drugs used in the treatment in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9627209_1_9361", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What is the dosage of the treatment in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9627209_1_9362", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What is the frequency of the treatment in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9627209_1_9363", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What is the route of the treatment in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9627209_1_9364", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9627209_1_9365", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "How long did the treatment last in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9627209_1_9366", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What is the disorder targeted by the treatment in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9627209_1_9367", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "What are the drugs used in combination in 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_3_9368", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What are the drugs used in the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7355327_3_9369", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What is the dosage of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_3_9370", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What is the frequency of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_3_9371", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What is the route of the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_3_9372", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "How long has elapsed from the treatment to the occurence of the event in propranolol?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_3_9373", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "How long did the treatment last in propranolol?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_3_9374", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What is the disorder targeted by the treatment in propranolol?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_3_9375", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "What are the drugs used in combination in propranolol?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6362443_2_9376", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the age of the subject in A depressed woman with no history of bipolar illness?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6362443_2_9377", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the gender of the subject in A depressed woman with no history of bipolar illness?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6362443_2_9378", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the number of subjects in A depressed woman with no history of bipolar illness?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6362443_2_9379", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the race of the subject in A depressed woman with no history of bipolar illness?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6362443_2_9380", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the disorder of the subject in A depressed woman with no history of bipolar illness?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6362443_2_9381", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What are the drugs used in the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6362443_2_9382", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the dosage of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_2_9383", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the frequency of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_2_9384", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the route of the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_2_9385", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "How long has elapsed from the treatment to the occurence of the event in fluoxetine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_2_9386", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "How long did the treatment last in fluoxetine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_2_9387", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What is the disorder targeted by the treatment in fluoxetine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6362443_2_9388", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "What are the drugs used in combination in fluoxetine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_2_9389", "context": "Priapism associated with trazodone therapy: case report.", "question": "What are the drugs used in the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6725214_2_9390", "context": "Priapism associated with trazodone therapy: case report.", "question": "What is the dosage of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_2_9391", "context": "Priapism associated with trazodone therapy: case report.", "question": "What is the frequency of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_2_9392", "context": "Priapism associated with trazodone therapy: case report.", "question": "What is the route of the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_2_9393", "context": "Priapism associated with trazodone therapy: case report.", "question": "How long has elapsed from the treatment to the occurence of the event in trazodone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_2_9394", "context": "Priapism associated with trazodone therapy: case report.", "question": "How long did the treatment last in trazodone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_2_9395", "context": "Priapism associated with trazodone therapy: case report.", "question": "What is the disorder targeted by the treatment in trazodone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_2_9396", "context": "Priapism associated with trazodone therapy: case report.", "question": "What are the drugs used in combination in trazodone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_3_9397", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What are the drugs used in the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_3_9398", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What is the dosage of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_3_9399", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What is the frequency of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_3_9400", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What is the route of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_3_9401", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alfa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_3_9402", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "How long did the treatment last in interferon alfa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_3_9403", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What is the disorder targeted by the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_3_9404", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "What are the drugs used in combination in interferon alfa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_4_9405", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What are the drugs used in the treatment in Mequitazine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8850251_4_9406", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What is the dosage of the treatment in Mequitazine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_4_9407", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What is the frequency of the treatment in Mequitazine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_4_9408", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What is the route of the treatment in Mequitazine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_4_9409", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "How long has elapsed from the treatment to the occurence of the event in Mequitazine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_4_9410", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "How long did the treatment last in Mequitazine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_4_9411", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What is the disorder targeted by the treatment in Mequitazine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_4_9412", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "What are the drugs used in combination in Mequitazine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_2_9413", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What are the drugs used in the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15927910_2_9414", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What is the dosage of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_2_9415", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What is the frequency of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_2_9416", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What is the route of the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_2_9417", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "How long has elapsed from the treatment to the occurence of the event in pentamidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_2_9418", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "How long did the treatment last in pentamidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_2_9419", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What is the disorder targeted by the treatment in pentamidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_2_9420", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "What are the drugs used in combination in pentamidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23115227_6_9421", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the age of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23115227_6_9422", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the gender of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23115227_6_9423", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the number of subjects in the patient?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_6_9424", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the race of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_6_9425", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the disorder of the subject in the patient?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_6_9426", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What are the drugs used in the treatment in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23115227_6_9427", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the dosage of the treatment in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23115227_6_9428", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the frequency of the treatment in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23115227_6_9429", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the route of the treatment in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_6_9430", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "How long has elapsed from the treatment to the occurence of the event in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_6_9431", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "How long did the treatment last in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_6_9432", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What is the disorder targeted by the treatment in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23115227_6_9433", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "What are the drugs used in combination in emtricitabine monotherapy?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3806824_2_9434", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the age of the subject in a case?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3806824_2_9435", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the gender of the subject in a case?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3806824_2_9436", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the number of subjects in a case?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3806824_2_9437", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the race of the subject in a case?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3806824_2_9438", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the disorder of the subject in a case?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3806824_2_9439", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What are the drugs used in the treatment in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3806824_2_9440", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the dosage of the treatment in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_2_9441", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the frequency of the treatment in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_2_9442", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the route of the treatment in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3806824_2_9443", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "How long has elapsed from the treatment to the occurence of the event in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_2_9444", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "How long did the treatment last in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_2_9445", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What is the disorder targeted by the treatment in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_2_9446", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "What are the drugs used in combination in intracavernous self-injection of a combination of phentolamine and papaverine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_3_9447", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_3_9448", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_3_9449", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_3_9450", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_3_9451", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_3_9452", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What are the drugs used in the treatment in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6865827_3_9453", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the dosage of the treatment in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_3_9454", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the frequency of the treatment in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_3_9455", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the route of the treatment in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_3_9456", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "How long has elapsed from the treatment to the occurence of the event in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_3_9457", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "How long did the treatment last in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_3_9458", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What is the disorder targeted by the treatment in propylthiouracil and methimazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_3_9459", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "What are the drugs used in combination in propylthiouracil and methimazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_1_9460", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What are the drugs used in the treatment in chocolate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15522120_1_9461", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What is the dosage of the treatment in chocolate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_1_9462", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What is the frequency of the treatment in chocolate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_1_9463", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What is the route of the treatment in chocolate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_1_9464", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "How long has elapsed from the treatment to the occurence of the event in chocolate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_1_9465", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "How long did the treatment last in chocolate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_1_9466", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What is the disorder targeted by the treatment in chocolate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_1_9467", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "What are the drugs used in combination in chocolate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_11_9468", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What are the drugs used in the treatment in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18262450_11_9469", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What is the dosage of the treatment in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_11_9470", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What is the frequency of the treatment in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18262450_11_9471", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What is the route of the treatment in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18262450_11_9472", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "How long has elapsed from the treatment to the occurence of the event in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_11_9473", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "How long did the treatment last in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18262450_11_9474", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What is the disorder targeted by the treatment in Oxycodone-gabapentin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_11_9475", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "What are the drugs used in combination in Oxycodone-gabapentin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6618859_2_9476", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the age of the subject in epileptics?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6618859_2_9477", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the gender of the subject in epileptics?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6618859_2_9478", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the number of subjects in epileptics?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6618859_2_9479", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the race of the subject in epileptics?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6618859_2_9480", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the disorder of the subject in epileptics?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6618859_2_9481", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What are the drugs used in the treatment in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6618859_2_9482", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the dosage of the treatment in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6618859_2_9483", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the frequency of the treatment in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6618859_2_9484", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the route of the treatment in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6618859_2_9485", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "How long has elapsed from the treatment to the occurence of the event in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6618859_2_9486", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "How long did the treatment last in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_2_9487", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What is the disorder targeted by the treatment in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6618859_2_9488", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "What are the drugs used in combination in phenobarbital, phenytoin and fluoresone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3542612_1_9489", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What are the drugs used in the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3542612_1_9490", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What is the dosage of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_1_9491", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What is the frequency of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_1_9492", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What is the route of the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_1_9493", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "How long has elapsed from the treatment to the occurence of the event in Captopril?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_1_9494", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "How long did the treatment last in Captopril?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_1_9495", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What is the disorder targeted by the treatment in Captopril?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_1_9496", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "What are the drugs used in combination in Captopril?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_3_9497", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What are the drugs used in the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6873616_3_9498", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What is the dosage of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_3_9499", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What is the frequency of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_3_9500", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What is the route of the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_3_9501", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "How long has elapsed from the treatment to the occurence of the event in thiabendazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_3_9502", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "How long did the treatment last in thiabendazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_3_9503", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What is the disorder targeted by the treatment in thiabendazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_3_9504", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "What are the drugs used in combination in thiabendazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_2_9505", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the age of the subject in patients with mucocutaneous reactions?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8523340_2_9506", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the gender of the subject in patients with mucocutaneous reactions?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8523340_2_9507", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the number of subjects in patients with mucocutaneous reactions?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8523340_2_9508", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the race of the subject in patients with mucocutaneous reactions?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8523340_2_9509", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the disorder of the subject in patients with mucocutaneous reactions?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8523340_2_9510", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What are the drugs used in the treatment in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "8523340_2_9511", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the dosage of the treatment in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8523340_2_9512", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the frequency of the treatment in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8523340_2_9513", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the route of the treatment in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8523340_2_9514", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "How long has elapsed from the treatment to the occurence of the event in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8523340_2_9515", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "How long did the treatment last in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8523340_2_9516", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What is the disorder targeted by the treatment in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8523340_2_9517", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "What are the drugs used in combination in very low dosage of gold?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "23970584_3_9518", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the age of the subject in A 55-year-old HIV-positive African woman?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23970584_3_9519", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the gender of the subject in A 55-year-old HIV-positive African woman?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23970584_3_9520", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the number of subjects in A 55-year-old HIV-positive African woman?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23970584_3_9521", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the race of the subject in A 55-year-old HIV-positive African woman?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23970584_3_9522", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the disorder of the subject in A 55-year-old HIV-positive African woman?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23970584_3_9523", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What are the drugs used in the treatment in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "23970584_3_9524", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the dosage of the treatment in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_3_9525", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the frequency of the treatment in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23970584_3_9526", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the route of the treatment in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23970584_3_9527", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "How long has elapsed from the treatment to the occurence of the event in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_3_9528", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "How long did the treatment last in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23970584_3_9529", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What is the disorder targeted by the treatment in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_3_9530", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "What are the drugs used in combination in a single epidural triamcinolone injection?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_2_9531", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6731466_2_9532", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6731466_2_9533", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6731466_2_9534", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6731466_2_9535", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6731466_2_9536", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What are the drugs used in the treatment in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6731466_2_9537", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the dosage of the treatment in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_2_9538", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the frequency of the treatment in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_2_9539", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the route of the treatment in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_2_9540", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "How long has elapsed from the treatment to the occurence of the event in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_2_9541", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "How long did the treatment last in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_2_9542", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What is the disorder targeted by the treatment in zomepirac sodium?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_2_9543", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "What are the drugs used in combination in zomepirac sodium?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_1_9544", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the age of the subject in three of six young female volunteers?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11341670_1_9545", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the gender of the subject in three of six young female volunteers?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11341670_1_9546", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the number of subjects in three of six young female volunteers?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11341670_1_9547", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the race of the subject in three of six young female volunteers?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_1_9548", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the disorder of the subject in three of six young female volunteers?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_1_9549", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What are the drugs used in the treatment in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11341670_1_9550", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the dosage of the treatment in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_1_9551", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the frequency of the treatment in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_1_9552", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the route of the treatment in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_1_9553", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "How long has elapsed from the treatment to the occurence of the event in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_1_9554", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "How long did the treatment last in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_1_9555", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What is the disorder targeted by the treatment in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_1_9556", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "What are the drugs used in combination in intravenous proton pump inhibitors omeprazole and pantoprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_7_9557", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What are the drugs used in the treatment in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "10682234_7_9558", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What is the dosage of the treatment in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_7_9559", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What is the frequency of the treatment in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_7_9560", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What is the route of the treatment in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_7_9561", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "How long has elapsed from the treatment to the occurence of the event in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_7_9562", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "How long did the treatment last in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_7_9563", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What is the disorder targeted by the treatment in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_7_9564", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "What are the drugs used in combination in Intravenous levodopa 25 mg?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19318596_1_9565", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the age of the subject in a child?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_1_9566", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the gender of the subject in a child?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_1_9567", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the number of subjects in a child?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_1_9568", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the race of the subject in a child?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_1_9569", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the disorder of the subject in a child?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_1_9570", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What are the drugs used in the treatment in Cyclosporine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "19318596_1_9571", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the dosage of the treatment in Cyclosporine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_1_9572", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the frequency of the treatment in Cyclosporine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_1_9573", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the route of the treatment in Cyclosporine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_1_9574", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "How long has elapsed from the treatment to the occurence of the event in Cyclosporine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_1_9575", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "How long did the treatment last in Cyclosporine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_1_9576", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What is the disorder targeted by the treatment in Cyclosporine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_1_9577", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "What are the drugs used in combination in Cyclosporine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_5_9578", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What are the drugs used in the treatment in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_5_9579", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What is the dosage of the treatment in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_5_9580", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What is the frequency of the treatment in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_5_9581", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What is the route of the treatment in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_5_9582", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "How long has elapsed from the treatment to the occurence of the event in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_5_9583", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "How long did the treatment last in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_5_9584", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What is the disorder targeted by the treatment in a single small dose of vincristine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_5_9585", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "What are the drugs used in combination in a single small dose of vincristine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_2_9586", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What are the drugs used in the treatment in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12786839_2_9587", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What is the dosage of the treatment in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_2_9588", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What is the frequency of the treatment in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_2_9589", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What is the route of the treatment in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_2_9590", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "How long has elapsed from the treatment to the occurence of the event in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_2_9591", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "How long did the treatment last in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_2_9592", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What is the disorder targeted by the treatment in salazosulfapyridine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_2_9593", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "What are the drugs used in combination in salazosulfapyridine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_8_9594", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What are the drugs used in the treatment in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_8_9595", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What is the dosage of the treatment in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_8_9596", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What is the frequency of the treatment in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_8_9597", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What is the route of the treatment in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_8_9598", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "How long has elapsed from the treatment to the occurence of the event in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_8_9599", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "How long did the treatment last in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_8_9600", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What is the disorder targeted by the treatment in protease inhibitor-based therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_8_9601", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "What are the drugs used in combination in protease inhibitor-based therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_2_9602", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the age of the subject in patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12504711_2_9603", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the gender of the subject in patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12504711_2_9604", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the number of subjects in patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12504711_2_9605", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the race of the subject in patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12504711_2_9606", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the disorder of the subject in patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12504711_2_9607", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What are the drugs used in the treatment in topical brimonidine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12504711_2_9608", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the dosage of the treatment in topical brimonidine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_2_9609", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the frequency of the treatment in topical brimonidine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_2_9610", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the route of the treatment in topical brimonidine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_2_9611", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "How long has elapsed from the treatment to the occurence of the event in topical brimonidine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_2_9612", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "How long did the treatment last in topical brimonidine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_2_9613", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What is the disorder targeted by the treatment in topical brimonidine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_2_9614", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "What are the drugs used in combination in topical brimonidine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_9_9615", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the age of the subject in patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_9_9616", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the gender of the subject in patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_9_9617", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the number of subjects in patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_9_9618", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the race of the subject in patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_9_9619", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the disorder of the subject in patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_9_9620", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What are the drugs used in the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12659609_9_9621", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the dosage of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_9_9622", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the frequency of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_9_9623", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the route of the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_9_9624", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "How long has elapsed from the treatment to the occurence of the event in chloroquine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_9_9625", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "How long did the treatment last in chloroquine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_9_9626", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What is the disorder targeted by the treatment in chloroquine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_9_9627", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "What are the drugs used in combination in chloroquine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_15_9628", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What are the drugs used in the treatment in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20925534_15_9629", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What is the dosage of the treatment in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_15_9630", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What is the frequency of the treatment in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_15_9631", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What is the route of the treatment in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_15_9632", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "How long has elapsed from the treatment to the occurence of the event in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_15_9633", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "How long did the treatment last in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_15_9634", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What is the disorder targeted by the treatment in clopidogrel and omeprazole?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_15_9635", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "What are the drugs used in combination in clopidogrel and omeprazole?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_2_9636", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What are the drugs used in the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_2_9637", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What is the dosage of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_2_9638", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What is the frequency of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_2_9639", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What is the route of the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_2_9640", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "How long has elapsed from the treatment to the occurence of the event in methotrexate?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_2_9641", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "How long did the treatment last in methotrexate?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_2_9642", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What is the disorder targeted by the treatment in methotrexate?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_2_9643", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "What are the drugs used in combination in methotrexate?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_3_9644", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What are the drugs used in the treatment in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1422497_3_9645", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What is the dosage of the treatment in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_3_9646", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What is the frequency of the treatment in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1422497_3_9647", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What is the route of the treatment in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1422497_3_9648", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "How long has elapsed from the treatment to the occurence of the event in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_3_9649", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "How long did the treatment last in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1422497_3_9650", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What is the disorder targeted by the treatment in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_3_9651", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "What are the drugs used in combination in Continuous bladder irrigation of a 1% alum solution?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_3_9652", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What are the drugs used in the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10759907_3_9653", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What is the dosage of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_3_9654", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What is the frequency of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_3_9655", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What is the route of the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_3_9656", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "How long has elapsed from the treatment to the occurence of the event in zolmitriptan?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_3_9657", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "How long did the treatment last in zolmitriptan?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_3_9658", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What is the disorder targeted by the treatment in zolmitriptan?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_3_9659", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "What are the drugs used in combination in zolmitriptan?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_2_9660", "context": "Delusional parasitosis associated with phenelzine.", "question": "What are the drugs used in the treatment in phenelzine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1756352_2_9661", "context": "Delusional parasitosis associated with phenelzine.", "question": "What is the dosage of the treatment in phenelzine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_2_9662", "context": "Delusional parasitosis associated with phenelzine.", "question": "What is the frequency of the treatment in phenelzine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_2_9663", "context": "Delusional parasitosis associated with phenelzine.", "question": "What is the route of the treatment in phenelzine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_2_9664", "context": "Delusional parasitosis associated with phenelzine.", "question": "How long has elapsed from the treatment to the occurence of the event in phenelzine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_2_9665", "context": "Delusional parasitosis associated with phenelzine.", "question": "How long did the treatment last in phenelzine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_2_9666", "context": "Delusional parasitosis associated with phenelzine.", "question": "What is the disorder targeted by the treatment in phenelzine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_2_9667", "context": "Delusional parasitosis associated with phenelzine.", "question": "What are the drugs used in combination in phenelzine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_2_9668", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What are the drugs used in the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "8610807_2_9669", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What is the dosage of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_2_9670", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What is the frequency of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_2_9671", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What is the route of the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_2_9672", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "How long has elapsed from the treatment to the occurence of the event in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_2_9673", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "How long did the treatment last in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_2_9674", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What is the disorder targeted by the treatment in tissue plasminogen activator?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_2_9675", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "What are the drugs used in combination in tissue plasminogen activator?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_1_9676", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What are the drugs used in the treatment in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9007910_1_9677", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What is the dosage of the treatment in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_1_9678", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What is the frequency of the treatment in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_1_9679", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What is the route of the treatment in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_1_9680", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "How long has elapsed from the treatment to the occurence of the event in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_1_9681", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "How long did the treatment last in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_1_9682", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What is the disorder targeted by the treatment in 5-fluorouracil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_1_9683", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "What are the drugs used in combination in 5-fluorouracil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_2_9684", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What are the drugs used in the treatment in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "16393774_2_9685", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What is the dosage of the treatment in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_2_9686", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What is the frequency of the treatment in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16393774_2_9687", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What is the route of the treatment in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16393774_2_9688", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "How long has elapsed from the treatment to the occurence of the event in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_2_9689", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "How long did the treatment last in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16393774_2_9690", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What is the disorder targeted by the treatment in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_2_9691", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "What are the drugs used in combination in Interferon-beta (IFN-beta)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18071101_2_9692", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What are the drugs used in the treatment in Quetiapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18071101_2_9693", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What is the dosage of the treatment in Quetiapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_2_9694", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What is the frequency of the treatment in Quetiapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_2_9695", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What is the route of the treatment in Quetiapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_2_9696", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "How long has elapsed from the treatment to the occurence of the event in Quetiapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_2_9697", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "How long did the treatment last in Quetiapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_2_9698", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What is the disorder targeted by the treatment in Quetiapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_2_9699", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "What are the drugs used in combination in Quetiapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_2_9700", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What are the drugs used in the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_2_9701", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What is the dosage of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_2_9702", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What is the frequency of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_2_9703", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What is the route of the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_2_9704", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "How long has elapsed from the treatment to the occurence of the event in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_2_9705", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "How long did the treatment last in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_2_9706", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What is the disorder targeted by the treatment in intravitreal ranibizumab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_2_9707", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "What are the drugs used in combination in intravitreal ranibizumab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_1_9708", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the age of the subject in four patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_1_9709", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the gender of the subject in four patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_1_9710", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the number of subjects in four patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18425523_1_9711", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the race of the subject in four patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_1_9712", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the disorder of the subject in four patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_1_9713", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What are the drugs used in the treatment in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18425523_1_9714", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the dosage of the treatment in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_1_9715", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the frequency of the treatment in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_1_9716", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the route of the treatment in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_1_9717", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "How long has elapsed from the treatment to the occurence of the event in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_1_9718", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "How long did the treatment last in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_1_9719", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What is the disorder targeted by the treatment in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_1_9720", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "What are the drugs used in combination in injection of ranibizumab intravitreally?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_2_9721", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What are the drugs used in the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "20234160_2_9722", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What is the dosage of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_2_9723", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What is the frequency of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_2_9724", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What is the route of the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_2_9725", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "How long has elapsed from the treatment to the occurence of the event in Vancomycin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_2_9726", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "How long did the treatment last in Vancomycin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_2_9727", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What is the disorder targeted by the treatment in Vancomycin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_2_9728", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "What are the drugs used in combination in Vancomycin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15093850_2_9729", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the age of the subject in a patient with Sjogren's syndrome?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15093850_2_9730", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the gender of the subject in a patient with Sjogren's syndrome?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15093850_2_9731", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the number of subjects in a patient with Sjogren's syndrome?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15093850_2_9732", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the race of the subject in a patient with Sjogren's syndrome?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15093850_2_9733", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the disorder of the subject in a patient with Sjogren's syndrome?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15093850_2_9734", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What are the drugs used in the treatment in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15093850_2_9735", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the dosage of the treatment in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15093850_2_9736", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the frequency of the treatment in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15093850_2_9737", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the route of the treatment in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15093850_2_9738", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15093850_2_9739", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "How long did the treatment last in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15093850_2_9740", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What is the disorder targeted by the treatment in oral pilocarpine tablets?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15093850_2_9741", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "What are the drugs used in combination in oral pilocarpine tablets?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_1_9742", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What are the drugs used in the treatment in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16357738_1_9743", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What is the dosage of the treatment in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_1_9744", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What is the frequency of the treatment in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_1_9745", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What is the route of the treatment in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_1_9746", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "How long has elapsed from the treatment to the occurence of the event in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_1_9747", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "How long did the treatment last in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_1_9748", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What is the disorder targeted by the treatment in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_1_9749", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "What are the drugs used in combination in immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_2_9750", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the age of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12854039_2_9751", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the gender of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12854039_2_9752", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the number of subjects in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_2_9753", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the race of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_2_9754", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the disorder of the subject in a 62-year-old woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_2_9755", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What are the drugs used in the treatment in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12854039_2_9756", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the dosage of the treatment in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_2_9757", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the frequency of the treatment in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_2_9758", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the route of the treatment in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_2_9759", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "How long has elapsed from the treatment to the occurence of the event in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_2_9760", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "How long did the treatment last in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_2_9761", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What is the disorder targeted by the treatment in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_2_9762", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "What are the drugs used in combination in a seven-month use of recombinant interferon alpha-2a?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_1_9763", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the age of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_1_9764", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the gender of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_1_9765", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the number of subjects in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_1_9766", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the race of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_1_9767", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the disorder of the subject in patients with schizophrenia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_1_9768", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What are the drugs used in the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9550246_1_9769", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the dosage of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_1_9770", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the frequency of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_1_9771", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the route of the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_1_9772", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "How long has elapsed from the treatment to the occurence of the event in risperidone?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_1_9773", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "How long did the treatment last in risperidone?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_1_9774", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What is the disorder targeted by the treatment in risperidone?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9550246_1_9775", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "What are the drugs used in combination in risperidone?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_3_9776", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What are the drugs used in the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16393774_3_9777", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What is the dosage of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_3_9778", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What is the frequency of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_3_9779", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What is the route of the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_3_9780", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "How long has elapsed from the treatment to the occurence of the event in IFN-beta?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_3_9781", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "How long did the treatment last in IFN-beta?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_3_9782", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What is the disorder targeted by the treatment in IFN-beta?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_3_9783", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "What are the drugs used in combination in IFN-beta?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18977778_1_9784", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the age of the subject in the patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18977778_1_9785", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the gender of the subject in the patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18977778_1_9786", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the number of subjects in the patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18977778_1_9787", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the race of the subject in the patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18977778_1_9788", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the disorder of the subject in the patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18977778_1_9789", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What are the drugs used in the treatment in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18977778_1_9790", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the dosage of the treatment in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18977778_1_9791", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the frequency of the treatment in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18977778_1_9792", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the route of the treatment in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18977778_1_9793", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "How long has elapsed from the treatment to the occurence of the event in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18977778_1_9794", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "How long did the treatment last in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18977778_1_9795", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What is the disorder targeted by the treatment in low-molecular-weight heparin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18977778_1_9796", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "What are the drugs used in combination in low-molecular-weight heparin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18354950_1_9797", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What are the drugs used in the treatment in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18354950_1_9798", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What is the dosage of the treatment in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_1_9799", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What is the frequency of the treatment in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_1_9800", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What is the route of the treatment in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_1_9801", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "How long has elapsed from the treatment to the occurence of the event in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_1_9802", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "How long did the treatment last in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_1_9803", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What is the disorder targeted by the treatment in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_1_9804", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "What are the drugs used in combination in rechallenge with controlled release carbamazepine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_1_9805", "context": "Azathioprine-induced warfarin resistance.", "question": "What are the drugs used in the treatment in Azathioprine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18505911_1_9806", "context": "Azathioprine-induced warfarin resistance.", "question": "What is the dosage of the treatment in Azathioprine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_1_9807", "context": "Azathioprine-induced warfarin resistance.", "question": "What is the frequency of the treatment in Azathioprine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_1_9808", "context": "Azathioprine-induced warfarin resistance.", "question": "What is the route of the treatment in Azathioprine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_1_9809", "context": "Azathioprine-induced warfarin resistance.", "question": "How long has elapsed from the treatment to the occurence of the event in Azathioprine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_1_9810", "context": "Azathioprine-induced warfarin resistance.", "question": "How long did the treatment last in Azathioprine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_1_9811", "context": "Azathioprine-induced warfarin resistance.", "question": "What is the disorder targeted by the treatment in Azathioprine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_1_9812", "context": "Azathioprine-induced warfarin resistance.", "question": "What are the drugs used in combination in Azathioprine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_2_9813", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What are the drugs used in the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3084231_2_9814", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What is the dosage of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_2_9815", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What is the frequency of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_2_9816", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What is the route of the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_2_9817", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "How long has elapsed from the treatment to the occurence of the event in valproic acid?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_2_9818", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "How long did the treatment last in valproic acid?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_2_9819", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What is the disorder targeted by the treatment in valproic acid?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_2_9820", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "What are the drugs used in combination in valproic acid?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_1_9821", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What are the drugs used in the treatment in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6697887_1_9822", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What is the dosage of the treatment in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_1_9823", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What is the frequency of the treatment in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_1_9824", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What is the route of the treatment in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_1_9825", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "How long has elapsed from the treatment to the occurence of the event in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_1_9826", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "How long did the treatment last in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_1_9827", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What is the disorder targeted by the treatment in Parenteral-verapamil?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_1_9828", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "What are the drugs used in combination in Parenteral-verapamil?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_6_9829", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What are the drugs used in the treatment in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1711090_6_9830", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What is the dosage of the treatment in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_6_9831", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What is the frequency of the treatment in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1711090_6_9832", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What is the route of the treatment in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1711090_6_9833", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "How long has elapsed from the treatment to the occurence of the event in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_6_9834", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "How long did the treatment last in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1711090_6_9835", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What is the disorder targeted by the treatment in Lp-TAE combined with HT?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_6_9836", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "What are the drugs used in combination in Lp-TAE combined with HT?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6738830_2_9837", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What are the drugs used in the treatment in cinepazide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6738830_2_9838", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What is the dosage of the treatment in cinepazide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_2_9839", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What is the frequency of the treatment in cinepazide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_2_9840", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What is the route of the treatment in cinepazide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6738830_2_9841", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "How long has elapsed from the treatment to the occurence of the event in cinepazide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_2_9842", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "How long did the treatment last in cinepazide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_2_9843", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What is the disorder targeted by the treatment in cinepazide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6738830_2_9844", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "What are the drugs used in combination in cinepazide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_4_9845", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What are the drugs used in the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "3171334_4_9846", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What is the dosage of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_4_9847", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What is the frequency of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_4_9848", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What is the route of the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_4_9849", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "How long has elapsed from the treatment to the occurence of the event in vincristine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_4_9850", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "How long did the treatment last in vincristine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_4_9851", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What is the disorder targeted by the treatment in vincristine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_4_9852", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "What are the drugs used in combination in vincristine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_4_9853", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the age of the subject in Two patients, ages 40 and 51 years?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7639655_4_9854", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the gender of the subject in Two patients, ages 40 and 51 years?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7639655_4_9855", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the number of subjects in Two patients, ages 40 and 51 years?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7639655_4_9856", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the race of the subject in Two patients, ages 40 and 51 years?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7639655_4_9857", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the disorder of the subject in Two patients, ages 40 and 51 years?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7639655_4_9858", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What are the drugs used in the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "7639655_4_9859", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the dosage of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_4_9860", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the frequency of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_4_9861", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the route of the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_4_9862", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "How long has elapsed from the treatment to the occurence of the event in interferon alfa?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_4_9863", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "How long did the treatment last in interferon alfa?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_4_9864", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What is the disorder targeted by the treatment in interferon alfa?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_4_9865", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "What are the drugs used in combination in interferon alfa?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_2_9866", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What are the drugs used in the treatment in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14968106_2_9867", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What is the dosage of the treatment in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_2_9868", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What is the frequency of the treatment in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_2_9869", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What is the route of the treatment in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14968106_2_9870", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "How long has elapsed from the treatment to the occurence of the event in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_2_9871", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "How long did the treatment last in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_2_9872", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What is the disorder targeted by the treatment in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_2_9873", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "What are the drugs used in combination in intrathecal injection of doxorubicin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_1_9874", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What are the drugs used in the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "14522628_1_9875", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What is the dosage of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_1_9876", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What is the frequency of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_1_9877", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What is the route of the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_1_9878", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "How long has elapsed from the treatment to the occurence of the event in ganciclovir?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_1_9879", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "How long did the treatment last in ganciclovir?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_1_9880", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What is the disorder targeted by the treatment in ganciclovir?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_1_9881", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "What are the drugs used in combination in ganciclovir?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_1_9882", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the age of the subject in 1% of such cases?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_1_9883", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the gender of the subject in 1% of such cases?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_1_9884", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the number of subjects in 1% of such cases?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_1_9885", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the race of the subject in 1% of such cases?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_1_9886", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the disorder of the subject in 1% of such cases?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_1_9887", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What are the drugs used in the treatment in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "129501_1_9888", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the dosage of the treatment in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_1_9889", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the frequency of the treatment in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_1_9890", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the route of the treatment in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "129501_1_9891", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "How long has elapsed from the treatment to the occurence of the event in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_1_9892", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "How long did the treatment last in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_1_9893", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What is the disorder targeted by the treatment in injection of chymopapain?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_1_9894", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "What are the drugs used in combination in injection of chymopapain?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_3_9895", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the age of the subject in a child?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9253492_3_9896", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the gender of the subject in a child?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_3_9897", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the number of subjects in a child?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_3_9898", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the race of the subject in a child?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_3_9899", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the disorder of the subject in a child?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_3_9900", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What are the drugs used in the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "9253492_3_9901", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the dosage of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_3_9902", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the frequency of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_3_9903", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the route of the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_3_9904", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "How long has elapsed from the treatment to the occurence of the event in zonisamide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_3_9905", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "How long did the treatment last in zonisamide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_3_9906", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What is the disorder targeted by the treatment in zonisamide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_3_9907", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "What are the drugs used in combination in zonisamide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_7_9908", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What are the drugs used in the treatment in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18166746_7_9909", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What is the dosage of the treatment in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_7_9910", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What is the frequency of the treatment in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_7_9911", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What is the route of the treatment in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_7_9912", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "How long has elapsed from the treatment to the occurence of the event in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_7_9913", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "How long did the treatment last in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_7_9914", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What is the disorder targeted by the treatment in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_7_9915", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "What are the drugs used in combination in methylene blue; serotonergic agents?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_2_9916", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the age of the subject in some patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_2_9917", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the gender of the subject in some patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_2_9918", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the number of subjects in some patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_2_9919", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the race of the subject in some patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_2_9920", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the disorder of the subject in some patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_2_9921", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What are the drugs used in the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11236070_2_9922", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the dosage of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_2_9923", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the frequency of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_2_9924", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the route of the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_2_9925", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "How long has elapsed from the treatment to the occurence of the event in olanzapine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_2_9926", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "How long did the treatment last in olanzapine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_2_9927", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What is the disorder targeted by the treatment in olanzapine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_2_9928", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "What are the drugs used in combination in olanzapine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_1_9929", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What are the drugs used in the treatment in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18371508_1_9930", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What is the dosage of the treatment in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_1_9931", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What is the frequency of the treatment in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_1_9932", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What is the route of the treatment in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_1_9933", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "How long has elapsed from the treatment to the occurence of the event in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_1_9934", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "How long did the treatment last in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_1_9935", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What is the disorder targeted by the treatment in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18371508_1_9936", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "What are the drugs used in combination in pegylated interferon alpha-2a and ribavirin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16620273_1_9937", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What are the drugs used in the treatment in metformin?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16620273_1_9938", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What is the dosage of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_1_9939", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What is the frequency of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_1_9940", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What is the route of the treatment in metformin?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_1_9941", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "How long has elapsed from the treatment to the occurence of the event in metformin?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_1_9942", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "How long did the treatment last in metformin?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_1_9943", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What is the disorder targeted by the treatment in metformin?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16620273_1_9944", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "What are the drugs used in combination in metformin?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_3_9945", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the age of the subject in patient with primary plasma-cell leukemia?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18037876_3_9946", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the gender of the subject in patient with primary plasma-cell leukemia?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18037876_3_9947", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the number of subjects in patient with primary plasma-cell leukemia?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18037876_3_9948", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the race of the subject in patient with primary plasma-cell leukemia?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18037876_3_9949", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the disorder of the subject in patient with primary plasma-cell leukemia?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18037876_3_9950", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What are the drugs used in the treatment in thalidomide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18037876_3_9951", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the dosage of the treatment in thalidomide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_3_9952", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the frequency of the treatment in thalidomide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_3_9953", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the route of the treatment in thalidomide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_3_9954", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in thalidomide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_3_9955", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "How long did the treatment last in thalidomide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_3_9956", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What is the disorder targeted by the treatment in thalidomide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_3_9957", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "What are the drugs used in combination in thalidomide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_3_9958", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the age of the subject in a 29-year-old man with CD?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_3_9959", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the gender of the subject in a 29-year-old man with CD?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_3_9960", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the number of subjects in a 29-year-old man with CD?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_3_9961", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the race of the subject in a 29-year-old man with CD?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_3_9962", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the disorder of the subject in a 29-year-old man with CD?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_3_9963", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What are the drugs used in the treatment in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10579985_3_9964", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the dosage of the treatment in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_3_9965", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the frequency of the treatment in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_3_9966", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the route of the treatment in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_3_9967", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "How long has elapsed from the treatment to the occurence of the event in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_3_9968", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "How long did the treatment last in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_3_9969", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What is the disorder targeted by the treatment in infusion with infliximab?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10579985_3_9970", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "What are the drugs used in combination in infusion with infliximab?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_6_9971", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What are the drugs used in the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "16317298_6_9972", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What is the dosage of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_6_9973", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What is the frequency of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_6_9974", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What is the route of the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_6_9975", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "How long has elapsed from the treatment to the occurence of the event in gemcitabine?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_6_9976", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "How long did the treatment last in gemcitabine?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_6_9977", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What is the disorder targeted by the treatment in gemcitabine?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_6_9978", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "What are the drugs used in combination in gemcitabine?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_4_9979", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the age of the subject in a patient?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_4_9980", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the gender of the subject in a patient?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_4_9981", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the number of subjects in a patient?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_4_9982", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the race of the subject in a patient?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_4_9983", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the disorder of the subject in a patient?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_4_9984", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What are the drugs used in the treatment in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18523232_4_9985", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the dosage of the treatment in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_4_9986", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the frequency of the treatment in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_4_9987", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the route of the treatment in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_4_9988", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "How long has elapsed from the treatment to the occurence of the event in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_4_9989", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "How long did the treatment last in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_4_9990", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What is the disorder targeted by the treatment in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_4_9991", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "What are the drugs used in combination in pulse itraconazole therapy for 24 weeks?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_6_9992", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the age of the subject in patients with PTSD?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7712052_6_9993", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the gender of the subject in patients with PTSD?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7712052_6_9994", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the number of subjects in patients with PTSD?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7712052_6_9995", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the race of the subject in patients with PTSD?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7712052_6_9996", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the disorder of the subject in patients with PTSD?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7712052_6_9997", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What are the drugs used in the treatment in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "7712052_6_9998", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the dosage of the treatment in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_6_9999", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the frequency of the treatment in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_6_10000", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the route of the treatment in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_6_10001", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "How long has elapsed from the treatment to the occurence of the event in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_6_10002", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "How long did the treatment last in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_6_10003", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What is the disorder targeted by the treatment in lithium?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7712052_6_10004", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "What are the drugs used in combination in lithium?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6928097_1_10005", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the age of the subject in She?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6928097_1_10006", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the gender of the subject in She?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6928097_1_10007", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the number of subjects in She?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6928097_1_10008", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the race of the subject in She?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6928097_1_10009", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the disorder of the subject in She?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6928097_1_10010", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What are the drugs used in the treatment in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6928097_1_10011", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the dosage of the treatment in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6928097_1_10012", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the frequency of the treatment in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6928097_1_10013", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the route of the treatment in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6928097_1_10014", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "How long has elapsed from the treatment to the occurence of the event in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6928097_1_10015", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "How long did the treatment last in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6928097_1_10016", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What is the disorder targeted by the treatment in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6928097_1_10017", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "What are the drugs used in combination in adjuvant Adriamycin (doxorubicin) chemotherapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_2_10018", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the age of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12477460_2_10019", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the gender of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12477460_2_10020", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the number of subjects in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_2_10021", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the race of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_2_10022", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the disorder of the subject in a postmenopausal woman?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_2_10023", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What are the drugs used in the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "12477460_2_10024", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the dosage of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_2_10025", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the frequency of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_2_10026", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the route of the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_2_10027", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "How long has elapsed from the treatment to the occurence of the event in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_2_10028", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "How long did the treatment last in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_2_10029", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What is the disorder targeted by the treatment in tamoxifen therapy?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_2_10030", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "What are the drugs used in combination in tamoxifen therapy?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_1_10031", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What are the drugs used in the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_1_10032", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What is the dosage of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_1_10033", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What is the frequency of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_1_10034", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What is the route of the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_1_10035", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "How long has elapsed from the treatment to the occurence of the event in L-asparaginase?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_1_10036", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "How long did the treatment last in L-asparaginase?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_1_10037", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What is the disorder targeted by the treatment in L-asparaginase?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_1_10038", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "What are the drugs used in combination in L-asparaginase?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_3_10039", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the age of the subject in An 89-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21515865_3_10040", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the gender of the subject in An 89-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21515865_3_10041", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the number of subjects in An 89-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_3_10042", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the race of the subject in An 89-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_3_10043", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the disorder of the subject in An 89-year-old man?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_3_10044", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What are the drugs used in the treatment in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "21515865_3_10045", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the dosage of the treatment in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_3_10046", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the frequency of the treatment in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21515865_3_10047", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the route of the treatment in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_3_10048", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "How long has elapsed from the treatment to the occurence of the event in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_3_10049", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "How long did the treatment last in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_3_10050", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What is the disorder targeted by the treatment in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_3_10051", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "What are the drugs used in combination in long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg)?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12851279_14_10052", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the age of the subject in patients with severe sepsis and high INR?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "12851279_14_10053", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the gender of the subject in patients with severe sepsis and high INR?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12851279_14_10054", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the number of subjects in patients with severe sepsis and high INR?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12851279_14_10055", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the race of the subject in patients with severe sepsis and high INR?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12851279_14_10056", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the disorder of the subject in patients with severe sepsis and high INR?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12851279_14_10057", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What are the drugs used in the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "12851279_14_10058", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the dosage of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_14_10059", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the frequency of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_14_10060", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the route of the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_14_10061", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "How long has elapsed from the treatment to the occurence of the event in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_14_10062", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "How long did the treatment last in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_14_10063", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What is the disorder targeted by the treatment in tifacogin?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_14_10064", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "What are the drugs used in combination in tifacogin?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6572542_1_10065", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the age of the subject in three patients?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_1_10066", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the gender of the subject in three patients?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_1_10067", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the number of subjects in three patients?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6572542_1_10068", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the race of the subject in three patients?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_1_10069", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the disorder of the subject in three patients?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_1_10070", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What are the drugs used in the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "6572542_1_10071", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the dosage of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_1_10072", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the frequency of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_1_10073", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the route of the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_1_10074", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "How long has elapsed from the treatment to the occurence of the event in CCNU?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_1_10075", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "How long did the treatment last in CCNU?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_1_10076", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What is the disorder targeted by the treatment in CCNU?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_1_10077", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "What are the drugs used in combination in CCNU?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11452245_11_10078", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What are the drugs used in the treatment in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11452245_11_10079", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What is the dosage of the treatment in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11452245_11_10080", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What is the frequency of the treatment in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11452245_11_10081", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What is the route of the treatment in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11452245_11_10082", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "How long has elapsed from the treatment to the occurence of the event in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11452245_11_10083", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "How long did the treatment last in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11452245_11_10084", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What is the disorder targeted by the treatment in clarithromycin; repaglinide?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11452245_11_10085", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "What are the drugs used in combination in clarithromycin; repaglinide?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_1_10086", "context": "Drug-induced fever due to diltiazem.", "question": "What are the drugs used in the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1888256_1_10087", "context": "Drug-induced fever due to diltiazem.", "question": "What is the dosage of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_1_10088", "context": "Drug-induced fever due to diltiazem.", "question": "What is the frequency of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_1_10089", "context": "Drug-induced fever due to diltiazem.", "question": "What is the route of the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_1_10090", "context": "Drug-induced fever due to diltiazem.", "question": "How long has elapsed from the treatment to the occurence of the event in diltiazem?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_1_10091", "context": "Drug-induced fever due to diltiazem.", "question": "How long did the treatment last in diltiazem?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_1_10092", "context": "Drug-induced fever due to diltiazem.", "question": "What is the disorder targeted by the treatment in diltiazem?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_1_10093", "context": "Drug-induced fever due to diltiazem.", "question": "What are the drugs used in combination in diltiazem?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}]}